Dossier zur Nutzenbewertung gemäß § 35a SGB V

Zolbetuximab (VYLOY™)

Astellas Pharma GmbH

Modul 4A, Anhang 4-G

In Kombination mit Fluoropyrimidin- und Platin-haltiger Chemotherapie zur Erstlinienbehandlung von erwachsenen Patienten mit lokal fortgeschrittenem inoperablem oder metastasiertem HER2-negativem Adenokarzinom des Magens oder des GEJ, deren Tumore Claudin18.2 positiv sind

Studie GLOW

Finaler Datenschnitt vom 12.01.2024

Stand: 11.05.2026

Inhaltsverzeichnis

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024 4
Anhang 4-G mITT (CPS < 1) 4
Anhang 4-G Baseline Charakteristika 4
Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben 24
Anhang 4-G Gesamtüberleben 24
1. Time-to-Event-Analyse 24
2. Kaplan-Meier-Plots 29

Anhang 4-G Sensitivitätsanalysen zum Gesamtüberleben: REI-Analysen 31
Anhang 4-G Sensitivitätsanalysen zum Gesamtüberleben: Steroid-Behandlung 36
1. Time-to-Event-Analyse 36
2. Kaplan-Meier-Plots 38

Anhang 4-G Progressionsfreies Überleben (IRC und INV) 40
1. Time-to-Event-Analysen 40
2. Kaplan-Meier-Plots 47

Anhang 4-G Patientenberichtete Endpunkte 50
Anhang 4-G Symptomatik und Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ-C30 50
1. Rücklaufquoten 50
2. Verlauf über die Zeit (Observed Means and Change from Baseline) 99
3. Time-to-Event-Analysen - Zeit bis zur ersten Verschlechterung 145
4. Graphische Darstellung des Verlaufs (Mean Change from Baseline) 191
5. Kaplan-Meier-Plots 207

Anhang 4-G Symptomatik anhand des EORTC QLQ-OG25 239
1. Rücklaufquoten 239
2. Verlauf über die Zeit (Observed Means and Change from Baseline) 291
3. Time-to-Event-Analysen - Zeit bis zur ersten Verschlechterung 339
4. Graphische Darstellung des Verlaufs (Mean Change from Baseline) 388
5. Kaplan-Meier-Plots 405

Anhang 4-G Symptomatik anhand d. EORTC QLQ-STO22 (Belching-Skala) . 429
1. Rücklaufquoten 429
2. Verlauf über die Zeit (Observed Means and Change from Baseline) 433
3. Time-to-Event-Analysen - Zeit bis zur ersten Verschlechterung 437
4. Graphische Darstellung des Verlaufs (Mean Change from Baseline) 441
5. Kaplan-Meier-Plots 443

Anhang 4-G Schmerzintensität anhand der NRS ... 449
1. Rücklaufquoten ... 449
2. Verlauf über die Zeit (Observed Means and Change from Baseline) ... 453
3. Time-to-Event-Analysen - Zeit bis zur ersten Verschlechterung ... 457
4. Graphische Darstellung des Verlaufs (Mean Change from Baseline) ... 461
5. Kaplan-Meier-Plots ... 463

Anhang 4-G Symptomatik anhand des EQ-5D VAS ... 465
1. Rücklaufquoten ... 465
2. Verlauf über die Zeit (Observed Means and Change from Baseline) ... 469
3. Time-to-Event-Analysen - Zeit bis zur ersten Verschlechterung ... 473
4. Graphische Darstellung des Verlaufs (Mean Change from Baseline) ... 477
5. Kaplan-Meier-Plots ... 479

Anhang 4-G Zusammenfassung MMRM-Analysen ... 483

Anhang 4-G Sicherheit ... 488
Anhang 4-G Unerwünschte Ereignisse ... 488
Anhang 4-G Schwere unerwünschte Ereignisse ... 491
Anhang 4-G Schwerwiegende unerwünschte Ereignisse ... 494
Anhang 4-G Abbruch der Studienmedikation aufgrund UE ... 497
Anhang 4-G Unerwünschte Ereignisse - SOC und PT ... 500
Anhang 4-G Schwere unerwünschte Ereignisse - SOC und PT ... 555
Anhang 4-G Schwerwiegende unerwünschte Ereignisse - SOC und PT ... 574
Anhang 4-G Abbruchgründe – SOC und PT ... 589

Anhang 4-G Weitere Analysen ... 594
Anhang 4-G Beobachtungsdauern ... 594
Anhang 4-G Begleitmedikationen ... 605
Anhang 4-G Studienmedikation – Exposition ... 609
Anhang 4-G Patientenfluss ... 611
Anhang 4-G Folgetherapien ... 614
1. Erste Folgetherapie ... 614
2. Alle Folgetherapien ... 617

Anhang 4-G CPS < 1 / unknown ... 620
Anhang 4-G Baseline Charakteristika ... 620
Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben ... 625
Anhang 4-G Gesamtüberleben ... 625
1. Time-to-Event-Analyse ... 625
2. Kaplan-Meier-Plots ... 630

Anhang 4-G Progressionsfreies Überleben (IRC und INV) ... 632
1. Time-to-Event-Analysen ... 632
2. Kaplan-Meier-Plots ... 639

Anhang 4-G Sicherheit ... 642
Anhang 4-G Schwere unerwünschte Ereignisse ... 642

Anhang 4-G Schwerwiegende unerwünschte Ereignisse ... 645
Anhang 4-G Abbruch der Studienmedikation aufgrund UE ... 648
Anhang 4-G Weitere Analysen ... 651
Anhang 4-G Beobachtungsdauern ... 651
Anhang 4-G Begleitmedikationen ... 657
Anhang 4-G Studienmedikation - Exposition ... 661
Anhang 4-G Patientenfluss ... 663
Anhang 4-G ITT ... 666
Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben ... 666
Anhang 4-G Gesamtüberleben ... 666
1. Time-to-Event-Analyse ... 666
2. Kaplan-Meier-Plots ... 671

Anhang 4-G Progressionsfreies Überleben (IRC und INV) ... 675
1. Time-to-Event-Analysen ... 675
2. Kaplan-Meier-Plots ... 682

Anhang 4-G Weitere Analysen: Patientenfluss ... 685
Anhang 4-G CPS unknown ... 688
Anhang 4-G Baseline Charakteristika ... 688
Anhang 4-G Ergänzende Analysen zur Studie GLOW - Gesamtüberleben ... **693**
Anhang 4-G *Post hoc* Meta-Analyse aus den beiden Studien GLOW (finaler Datenschnitt 12.01.2024) und SPOTLIGHT (finaler Datenschnitt 08.09.2023) ... 693
1. Time-to-Event-Analyse ... 693
2. Forest-Plot ... 698

Anhang 4-G *Post hoc* Analysen für die Studie SPOTLIGHT, finaler Datenschnitt 08.09.2023) ... 700
1. Time-to-Event-Analyse ... 700
2. Kaplan-Meier-Plots ... 705

Anhang 4-G *Post hoc* Analysen für die Studien GLOW und SPOTLIGHT
1. Übersicht zum Gesamtüberleben ... 707
2. Übersicht zum CPS Status ... 709

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Baseline Charakteristika

Table 302.3.1001.1.2: Summary of Baseline Demographics
Modified Full Analysis Set (CPS < 1)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N= 84)	Placebo + CAPOX (N= 88)
Sex		
Male	52 (61.9%)	46 (52.3%)
Female	32 (38.1%)	42 (47.7%)
Unknown	0	0
Age (years)		
n	84	88
Mean (SD)	57.31 (12.24)	56.89 (12.93)
Median	59.0	58.0
Range	22.0 - 81.0	29.0 - 81.0
Age (years)		
>=18 to <=64	56 (66.7%)	57 (64.8%)
>=65 to <85	28 (33.3%)	31 (35.2%)
Age Group 1 (years)		
<=65	60 (71.4%)	60 (68.2%)
>65	24 (28.6%)	28 (31.8%)
Age Group 2 (years)		
<=75	81 (96.4%)	81 (92.0%)
>75	3 (3.6%)	7 (8.0%)
Race		
White	44 (53.7%)	43 (51.2%)
Black or African American	0	0
Asian	38 (46.3%)	41 (48.8%)
American Indian or Alaska Native	0	0

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.1.2: Summary of Baseline Demographics
Modified Full Analysis Set (CPS < 1)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N= 84)	Placebo + CAPOX (N= 88)
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Missing	2	4
Ethnicity		
Hispanic or Latino	6 (7.3%)	3 (3.6%)
Not Hispanic or Latino	76 (92.7%)	81 (96.4%)
Missing	2	4
Country 1		
Japan	12 (14.3%)	13 (14.8%)
Non-Japan	72 (85.7%)	75 (85.2%)
Country 2		
Non-China	84 (100.0%)	88 (100.0%)
Height (cm)		
n	83	87
Mean (SD)	165.73 (9.26)	164.82 (9.07)
Median	164.7	163.0
Range	145.0 - 189.0	141.5 - 188.4
Weight (kg)		
n	83	87
Mean (SD)	63.51 (14.74)	61.57 (13.15)
Median	61.8	60.0
Range	40.0 - 111.2	29.1 - 91.3

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.1.2: Summary of Baseline Demographics
Modified Full Analysis Set (CPS < 1)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N= 84)	Placebo + CAPOX (N= 88)
BMI (kg/m^2)		
<18.5	11 (13.3%)	9 (10.3%)
>=18.5 to <25	47 (56.6%)	53 (60.9%)
>=25 to <30	21 (25.3%)	23 (26.4%)
>=30	4 (4.8%)	2 (2.3%)
Missing	1	1
BSA (m^2)		
n	83	87
Mean (SD)	1.69 (0.22)	1.67 (0.21)
Median	1.7	1.7
Range	1.3 - 2.3	1.1 - 2.2
BSA (m^2)		
<1.7	41 (49.4%)	50 (57.5%)
>=1.7	42 (50.6%)	37 (42.5%)
Missing	1	1
Tobacco History		
Never	32 (39.0%)	44 (51.8%)
Current	15 (18.3%)	8 (9.4%)
Former	35 (42.7%)	33 (38.8%)
Missing	2	3
Baseline ECOG Status		
0	37 (44.6%)	39 (44.8%)
>=1	46 (55.4%)	48 (55.2%)
Missing	1	1

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.1.2: Summary of Baseline Demographics
Modified Full Analysis Set (CPS < 1)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N= 84)	Placebo + CAPOX (N= 88)
Region (IRT)		
Asia	38 (45.2%)	41 (46.6%)
Non-Asia	46 (54.8%)	47 (53.4%)
Region (eCRF)		
Asia	38 (45.2%)	41 (46.6%)
Non-Asia	46 (54.8%)	47 (53.4%)
Number of Organs with Metastatic Sites (IRT)		
0-2	64 (76.2%)	64 (72.7%)
>=3	20 (23.8%)	24 (27.3%)
Number of Organs with Metastatic Sites (eCRF)		
0-2	60 (71.4%)	63 (71.6%)
>=3	24 (28.6%)	25 (28.4%)
Prior Gastrectomy (IRT)		
Yes	24 (28.6%)	22 (25.0%)
No	60 (71.4%)	66 (75.0%)
Prior Gastrectomy (eCRF)		
Yes	25 (29.8%)	19 (21.6%)
No	59 (70.2%)	69 (78.4%)

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.3.2: Summary of Primary Diagnosis
Modified Full Analysis Set (CPS < 1)

Parameter	Category/Statistic	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)
Medical Condition	Gastric Adenocarcinoma	73 (86.9%)	75 (85.2%)
	Gastro-Esophageal Junction Adenocarcinoma	11 (13.1%)	13 (14.8%)
Duration Since Initial Diagnosis (days)	n	79	85
	Mean (SD)	227.14 (422.51)	217.62 (523.27)
	Median	51.0	50.0
	Range	14 - 2139	2 - 3846
Tumor Location			
All	Proximal	32 (38.1%)	34 (38.6%)
	Distal	35 (41.7%)	36 (40.9%)
	Unknown	17 (20.2%)	18 (20.5%)
Gastric	n	73	75
	Proximal	28 (38.4%)	29 (38.7%)
	Distal	30 (41.1%)	30 (40.0%)
	Unknown	15 (20.5%)	16 (21.3%)
GEJ	n	11	13
	Proximal	4 (36.4%)	5 (38.5%)
	Distal	5 (45.5%)	6 (46.2%)
	Unknown	2 (18.2%)	2 (15.4%)
Tumor Type	Diffuse	37 (44.6%)	44 (50.0%)
	Intestinal	13 (15.7%)	12 (13.6%)
	Mixed	5 (6.0%)	3 (3.4%)
	Other	11 (13.3%)	10 (11.4%)

Abbreviations: CPS=combined positive score; GEJ=gastro-esophageal junction; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
[1] Distant metastases (M1) and Tumor Metastasic (Yes) may differ depending on date of initial diagnosis.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.3.2: Summary of Primary Diagnosis
Modified Full Analysis Set (CPS < 1)

Parameter	Category/Statistic	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)
	Unknown	17 (20.5%)	19 (21.6%)
	Missing	1	0
Primary Tumor	TX	24 (28.6%)	14 (15.9%)
	T0	0	0
	Tis	0	0
	T1	1 (1.2%)	1 (1.1%)
	T1a	0	1 (1.1%)
	T1b	1 (1.2%)	2 (2.3%)
	T2	8 (9.5%)	6 (6.8%)
	T3	20 (23.8%)	26 (29.5%)
	T4	8 (9.5%)	13 (14.8%)
	T4a	19 (22.6%)	18 (20.5%)
	T4b	3 (3.6%)	7 (8.0%)
Regional Lymph Nodes	NX	24 (28.6%)	19 (21.6%)
	N0	5 (6.0%)	15 (17.0%)
	N1	28 (33.3%)	16 (18.2%)
	N2	10 (11.9%)	12 (13.6%)
	N3	10 (11.9%)	17 (19.3%)
	N3a	4 (4.8%)	5 (5.7%)
	N3b	3 (3.6%)	4 (4.5%)
Distant Metastasis [1]	M0	20 (24.1%)	16 (18.2%)
	M1	63 (75.9%)	72 (81.8%)
	Missing	1	0
Tumor Metastatic [1]	Yes	74 (88.1%)	82 (93.2%)

Abbreviations: CPS=combined positive score; GEJ=gastro-esophageal junction; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
[1] Distant metastases (M1) and Tumor Metastasic (Yes) may differ depending on date of initial diagnosis.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.3.2: Summary of Primary Diagnosis
Modified Full Analysis Set (CPS < 1)

Parameter	Category/Statistic	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)
	No	10 (11.9%)	6 (6.8%)
Metastasis Location	Abdominal Cavity	6 (7.1%)	6 (6.8%)
	Adrenal Gland	6 (7.1%)	3 (3.4%)
	Bile Duct	0	1 (1.1%)
	Bladder	1 (1.2%)	0
	Bone	6 (7.1%)	11 (12.5%)
	Colon	4 (4.8%)	0
	Liver	21 (25.0%)	21 (23.9%)
	Lung	5 (6.0%)	9 (10.2%)
	Lymph Node	36 (42.9%)	37 (42.0%)
	Mediastinum	2 (2.4%)	1 (1.1%)
	Neck	0	1 (1.1%)
	Omentum	3 (3.6%)	2 (2.3%)
	Other	3 (3.6%)	6 (6.8%)
	Ovary	9 (10.7%)	9 (10.2%)
	Pancreas	0	1 (1.1%)
	Pelvis	3 (3.6%)	0
	Pericardium	1 (1.2%)	1 (1.1%)
	Peritoneum	33 (39.3%)	44 (50.0%)
	Pleura	4 (4.8%)	3 (3.4%)
	Rectum	0	1 (1.1%)
	Retroperitoneum	0	1 (1.1%)
	Skin	0	1 (1.1%)
	Small Intestine	1 (1.2%)	0
	Spleen	0	2 (2.3%)
	Stomach	2 (2.4%)	2 (2.3%)

Abbreviations: CPS=combined positive score; GEJ=gastro-esophageal junction; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
[1] Distant metastases (M1) and Tumor Metastasic (Yes) may differ depending on date of initial diagnosis.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.3.2: Summary of Primary Diagnosis
Modified Full Analysis Set (CPS < 1)

Parameter	Category/Statistic	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)
History of Helicobacter pylori Infection	Yes	19 (22.6%)	17 (19.3%)
	No	35 (41.7%)	43 (48.9%)
	Unknown	30 (35.7%)	28 (31.8%)
Barrett's Esophagus Diagnosed	Yes	1 (1.2%)	3 (3.4%)
	No	55 (65.5%)	64 (72.7%)
	Unknown	28 (33.3%)	21 (23.9%)
CLDN18.2 Testing Result	<75%	0	0
	>=75%	84 (100.0%)	88 (100.0%)
	Not Applicable	0	0
HER2 Status	Positive	0	0
	Negative	84 (100.0%)	88 (100.0%)
	Not Applicable	0	0
Measurable Disease based on Central	Yes	58 (69.0%)	63 (71.6%)
	No	26 (31.0%)	25 (28.4%)
Measurable Disease based on Local	Yes	66 (78.6%)	71 (80.7%)
	No	18 (21.4%)	17 (19.3%)

Abbreviations: CPS=combined positive score; GEJ=gastro-esophageal junction; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
[1] Distant metastases (M1) and Tumor Metastasic (Yes) may differ depending on date of initial diagnosis.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Overall	69 (82.1%)	73 (83.0%)	142 (82.6%)
Blood And Lymphatic System Disorders	14 (16.7%)	11 (12.5%)	25 (14.5%)
Anaemia	10 (11.9%)	10 (11.4%)	20 (11.6%)
Iron Deficiency Anaemia	2 (2.4%)	1 (1.1%)	3 (1.7%)
Thrombocytopenia	2 (2.4%)	0	2 (1.2%)
Lymphadenopathy	1 (1.2%)	0	1 (0.6%)
Pernicious Anaemia	1 (1.2%)	0	1 (0.6%)
Splenomegaly	1 (1.2%)	0	1 (0.6%)
Cardiac Disorders	10 (11.9%)	4 (4.5%)	14 (8.1%)
Angina Pectoris	1 (1.2%)	2 (2.3%)	3 (1.7%)
Coronary Artery Disease	3 (3.6%)	0	3 (1.7%)
Arrhythmia	2 (2.4%)	0	2 (1.2%)
Cardiac Failure Chronic	1 (1.2%)	1 (1.1%)	2 (1.2%)
Myocardial Ischaemia	0	2 (2.3%)	2 (1.2%)
Tachycardia	2 (2.4%)	0	2 (1.2%)
Cardiomyopathy	1 (1.2%)	0	1 (0.6%)
Pericardial Effusion	1 (1.2%)	0	1 (0.6%)
Congenital, Familial And Genetic Disorders	2 (2.4%)	1 (1.1%)	3 (1.7%)
Adrenogenital Syndrome	1 (1.2%)	0	1 (0.6%)
Albinism	1 (1.2%)	0	1 (0.6%)
Cataract Congenital	0	1 (1.1%)	1 (0.6%)
Endocrine Disorders	2 (2.4%)	1 (1.1%)	3 (1.7%)
Goitre	0	1 (1.1%)	1 (0.6%)
Hyperthyroidism	1 (1.2%)	0	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Hypothyroidism	1 (1.2%)	0	1 (0.6%)
Eye Disorders	3 (3.6%)	5 (5.7%)	8 (4.7%)
Cataract	1 (1.2%)	2 (2.3%)	3 (1.7%)
Glaucoma	1 (1.2%)	1 (1.1%)	2 (1.2%)
Age-Related Macular Degeneration	0	1 (1.1%)	1 (0.6%)
Lacrimation Increased	1 (1.2%)	0	1 (0.6%)
Narrow Anterior Chamber Angle	0	1 (1.1%)	1 (0.6%)
Gastrointestinal Disorders	39 (46.4%)	36 (40.9%)	75 (43.6%)
Constipation	11 (13.1%)	10 (11.4%)	21 (12.2%)
Abdominal Pain	15 (17.9%)	5 (5.7%)	20 (11.6%)
Nausea	4 (4.8%)	8 (9.1%)	12 (7.0%)
Gastrooesophageal Reflux Disease	6 (7.1%)	5 (5.7%)	11 (6.4%)
Abdominal Distension	5 (6.0%)	4 (4.5%)	9 (5.2%)
Abdominal Pain Upper	6 (7.1%)	3 (3.4%)	9 (5.2%)
Dyspepsia	3 (3.6%)	5 (5.7%)	8 (4.7%)
Dysphagia	2 (2.4%)	5 (5.7%)	7 (4.1%)
Ascites	3 (3.6%)	2 (2.3%)	5 (2.9%)
Vomiting	1 (1.2%)	3 (3.4%)	4 (2.3%)
Diarrhoea	3 (3.6%)	0	3 (1.7%)
Duodenal Ulcer	0	3 (3.4%)	3 (1.7%)
Haemorrhoids	2 (2.4%)	1 (1.1%)	3 (1.7%)
Chronic Gastritis	2 (2.4%)	0	2 (1.2%)
Gastric Ulcer	2 (2.4%)	0	2 (1.2%)
Gastritis	1 (1.2%)	1 (1.1%)	2 (1.2%)
Hiatus Hernia	2 (2.4%)	0	2 (1.2%)
Inguinal Hernia	1 (1.2%)	1 (1.1%)	2 (1.2%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Large Intestine Polyp	1 (1.2%)	1 (1.1%)	2 (1.2%)
Abdominal Discomfort	1 (1.2%)	0	1 (0.6%)
Abdominal Pain Lower	1 (1.2%)	0	1 (0.6%)
Abdominal Wall Mass	0	1 (1.1%)	1 (0.6%)
Barrett's Oesophagus	0	1 (1.1%)	1 (0.6%)
Bezoar	0	1 (1.1%)	1 (0.6%)
Eructation	1 (1.2%)	0	1 (0.6%)
Flatulence	1 (1.2%)	0	1 (0.6%)
Gastric Perforation	1 (1.2%)	0	1 (0.6%)
Intestinal Obstruction	0	1 (1.1%)	1 (0.6%)
Large Intestinal Obstruction	0	1 (1.1%)	1 (0.6%)
Large Intestinal Stenosis	0	1 (1.1%)	1 (0.6%)
Periodontal Disease	0	1 (1.1%)	1 (0.6%)
Proctalgia	1 (1.2%)	0	1 (0.6%)
Rectal Prolapse	0	1 (1.1%)	1 (0.6%)
General Disorders And Administration Site Conditions	14 (16.7%)	3 (3.4%)	17 (9.9%)
Asthenia	5 (6.0%)	1 (1.1%)	6 (3.5%)
Pain	2 (2.4%)	2 (2.3%)	4 (2.3%)
Oedema Peripheral	3 (3.6%)	0	3 (1.7%)
Early Satiety	2 (2.4%)	0	2 (1.2%)
Fatigue	1 (1.2%)	1 (1.1%)	2 (1.2%)
Drug Intolerance	1 (1.2%)	0	1 (0.6%)
Mucosal Inflammation	1 (1.2%)	0	1 (0.6%)
Hepatobiliary Disorders	3 (3.6%)	4 (4.5%)	7 (4.1%)
Biliary Obstruction	1 (1.2%)	1 (1.1%)	2 (1.2%)
Hepatic Cyst	1 (1.2%)	1 (1.1%)	2 (1.2%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Cholelithiasis	1 (1.2%)	0	1 (0.6%)
Jaundice	0	1 (1.1%)	1 (0.6%)
Portal Vein Thrombosis	0	1 (1.1%)	1 (0.6%)
Immune System Disorders	4 (4.8%)	4 (4.5%)	8 (4.7%)
Drug Hypersensitivity	3 (3.6%)	1 (1.1%)	4 (2.3%)
Seasonal Allergy	1 (1.2%)	3 (3.4%)	4 (2.3%)
Infections And Infestations	7 (8.3%)	3 (3.4%)	10 (5.8%)
Appendicitis	1 (1.2%)	1 (1.1%)	2 (1.2%)
Biliary Tract Infection	1 (1.2%)	0	1 (0.6%)
Covid-19	1 (1.2%)	0	1 (0.6%)
Diverticulitis	1 (1.2%)	0	1 (0.6%)
Helicobacter Gastritis	0	1 (1.1%)	1 (0.6%)
Oral Herpes	1 (1.2%)	0	1 (0.6%)
Periodontitis	1 (1.2%)	0	1 (0.6%)
Pulmonary Tuberculosis	1 (1.2%)	0	1 (0.6%)
Viral Hepatitis Carrier	0	1 (1.1%)	1 (0.6%)
Injury, Poisoning And Procedural Complications	2 (2.4%)	2 (2.3%)	4 (2.3%)
Chest Injury	1 (1.2%)	0	1 (0.6%)
Fall	1 (1.2%)	0	1 (0.6%)
Head Injury	1 (1.2%)	0	1 (0.6%)
Meniscus Injury	1 (1.2%)	0	1 (0.6%)
Radiation Injury	0	1 (1.1%)	1 (0.6%)
Stoma Site Pain	0	1 (1.1%)	1 (0.6%)
Upper Limb Fracture	1 (1.2%)	0	1 (0.6%)
Wrist Fracture	1 (1.2%)	0	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Investigations	13 (15.5%)	8 (9.1%)	21 (12.2%)
Weight Decreased	5 (6.0%)	4 (4.5%)	9 (5.2%)
Blood Cholesterol Increased	4 (4.8%)	1 (1.1%)	5 (2.9%)
Blood Alkaline Phosphatase Increased	0	2 (2.3%)	2 (1.2%)
Alanine Aminotransferase Increased	1 (1.2%)	0	1 (0.6%)
Blood Bilirubin Increased	1 (1.2%)	0	1 (0.6%)
Blood Glucose Increased	1 (1.2%)	0	1 (0.6%)
Gamma-Glutamyltransferase Increased	1 (1.2%)	0	1 (0.6%)
Gastric Ph Decreased	0	1 (1.1%)	1 (0.6%)
Neutrophil Count Decreased	1 (1.2%)	0	1 (0.6%)
Paracentesis	1 (1.2%)	0	1 (0.6%)
Vitamin D Decreased	1 (1.2%)	0	1 (0.6%)
Metabolism And Nutrition Disorders	25 (29.8%)	25 (28.4%)	50 (29.1%)
Diabetes Mellitus	9 (10.7%)	7 (8.0%)	16 (9.3%)
Dyslipidaemia	7 (8.3%)	5 (5.7%)	12 (7.0%)
Decreased Appetite	4 (4.8%)	7 (8.0%)	11 (6.4%)
Type 2 Diabetes Mellitus	8 (9.5%)	3 (3.4%)	11 (6.4%)
Hyperlipidaemia	3 (3.6%)	1 (1.1%)	4 (2.3%)
Hypercholesterolaemia	0	3 (3.4%)	3 (1.7%)
Gout	0	2 (2.3%)	2 (1.2%)
Hyperuricaemia	0	2 (2.3%)	2 (1.2%)
Hypoalbuminaemia	1 (1.2%)	1 (1.1%)	2 (1.2%)
Vitamin B12 Deficiency	1 (1.2%)	1 (1.1%)	2 (1.2%)
Hyponatraemia	1 (1.2%)	0	1 (0.6%)
Iron Deficiency	0	1 (1.1%)	1 (0.6%)
Malnutrition	1 (1.2%)	0	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Obesity	1 (1.2%)	0	1 (0.6%)
Type 1 Diabetes Mellitus	0	1 (1.1%)	1 (0.6%)
Musculoskeletal And Connective Tissue Disorders	11 (13.1%)	10 (11.4%)	21 (12.2%)
Back Pain	5 (6.0%)	5 (5.7%)	10 (5.8%)
Arthralgia	1 (1.2%)	3 (3.4%)	4 (2.3%)
Osteoarthritis	3 (3.6%)	0	3 (1.7%)
Intervertebral Disc Protrusion	1 (1.2%)	1 (1.1%)	2 (1.2%)
Spinal Stenosis	1 (1.2%)	1 (1.1%)	2 (1.2%)
Fibromyalgia	1 (1.2%)	0	1 (0.6%)
Intervertebral Disc Degeneration	1 (1.2%)	0	1 (0.6%)
Musculoskeletal Chest Pain	0	1 (1.1%)	1 (0.6%)
Psoriatic Arthropathy	0	1 (1.1%)	1 (0.6%)
Rotator Cuff Syndrome	1 (1.2%)	0	1 (0.6%)
Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps)	12 (14.3%)	11 (12.5%)	23 (13.4%)
Cancer Pain	2 (2.4%)	5 (5.7%)	7 (4.1%)
Uterine Leiomyoma	3 (3.6%)	2 (2.3%)	5 (2.9%)
Breast Cancer	2 (2.4%)	0	2 (1.2%)
Benign Neoplasm Of Thyroid Gland	0	1 (1.1%)	1 (0.6%)
Bowen's Disease	0	1 (1.1%)	1 (0.6%)
Breast Cancer In Situ	1 (1.2%)	0	1 (0.6%)
Colorectal Adenoma	1 (1.2%)	0	1 (0.6%)
Essential Thrombocythaemia	1 (1.2%)	0	1 (0.6%)
Gastric Cancer	0	1 (1.1%)	1 (0.6%)
Gastrointestinal Tract Adenoma	1 (1.2%)	0	1 (0.6%)
Intraductal Papillary Mucinous Neoplasm	1 (1.2%)	0	1 (0.6%)
Lipoma	0	1 (1.1%)	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Metastases To Bone	1 (1.2%)	0	1 (0.6%)
Metastases To Peritoneum	1 (1.2%)	0	1 (0.6%)
Oropharyngeal Neoplasm	1 (1.2%)	0	1 (0.6%)
Ovarian Cancer	1 (1.2%)	0	1 (0.6%)
Prostate Cancer	1 (1.2%)	0	1 (0.6%)
Tongue Neoplasm Benign	0	1 (1.1%)	1 (0.6%)
Nervous System Disorders	7 (8.3%)	7 (8.0%)	14 (8.1%)
Lethargy	0	2 (2.3%)	2 (1.2%)
Restless Legs Syndrome	1 (1.2%)	1 (1.1%)	2 (1.2%)
Cerebellar Haemorrhage	1 (1.2%)	0	1 (0.6%)
Cerebral Infarction	1 (1.2%)	0	1 (0.6%)
Diabetic Neuropathy	0	1 (1.1%)	1 (0.6%)
Essential Tremor	1 (1.2%)	0	1 (0.6%)
Intracranial Aneurysm	1 (1.2%)	0	1 (0.6%)
Migraine	0	1 (1.1%)	1 (0.6%)
Neuropathy Peripheral	1 (1.2%)	0	1 (0.6%)
Optic Neuritis	0	1 (1.1%)	1 (0.6%)
Parkinson's Disease	0	1 (1.1%)	1 (0.6%)
Peripheral Sensorimotor Neuropathy	0	1 (1.1%)	1 (0.6%)
Sensory Disturbance	1 (1.2%)	0	1 (0.6%)
Psychiatric Disorders	7 (8.3%)	7 (8.0%)	14 (8.1%)
Insomnia	3 (3.6%)	2 (2.3%)	5 (2.9%)
Anxiety	2 (2.4%)	1 (1.1%)	3 (1.7%)
Depression	1 (1.2%)	1 (1.1%)	2 (1.2%)
Adjustment Disorder	0	1 (1.1%)	1 (0.6%)
Bipolar Disorder	0	1 (1.1%)	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Sleep Disorder	1 (1.2%)	0	1 (0.6%)
Stress	0	1 (1.1%)	1 (0.6%)
Renal And Urinary Disorders	5 (6.0%)	6 (6.8%)	11 (6.4%)
Nephrolithiasis	3 (3.6%)	1 (1.1%)	4 (2.3%)
Chronic Kidney Disease	1 (1.2%)	2 (2.3%)	3 (1.7%)
Renal Cyst	1 (1.2%)	1 (1.1%)	2 (1.2%)
Acute Kidney Injury	0	1 (1.1%)	1 (0.6%)
Hydronephrosis	0	1 (1.1%)	1 (0.6%)
Hypertonic Bladder	0	1 (1.1%)	1 (0.6%)
Lower Urinary Tract Symptoms	0	1 (1.1%)	1 (0.6%)
Renal Atrophy	0	1 (1.1%)	1 (0.6%)
Reproductive System And Breast Disorders	9 (10.7%)	6 (6.8%)	15 (8.7%)
Benign Prostatic Hyperplasia	5 (6.0%)	2 (2.3%)	7 (4.1%)
Ovarian Cyst	0	2 (2.3%)	2 (1.2%)
Breast Fibrosis	0	1 (1.1%)	1 (0.6%)
Genital Haemorrhage	1 (1.2%)	0	1 (0.6%)
Menstruation Irregular	0	1 (1.1%)	1 (0.6%)
Ovarian Mass	1 (1.2%)	0	1 (0.6%)
Prostatitis	0	1 (1.1%)	1 (0.6%)
Uterine Polyp	1 (1.2%)	0	1 (0.6%)
Uterine Prolapse	1 (1.2%)	0	1 (0.6%)
Respiratory, Thoracic And Mediastinal Disorders	8 (9.5%)	11 (12.5%)	19 (11.0%)
Chronic Obstructive Pulmonary Disease	2 (2.4%)	2 (2.3%)	4 (2.3%)
Emphysema	2 (2.4%)	1 (1.1%)	3 (1.7%)
Cough	1 (1.2%)	1 (1.1%)	2 (1.2%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Pleural Effusion	0	2 (2.3%)	2 (1.2%)
Sleep Apnoea Syndrome	1 (1.2%)	1 (1.1%)	2 (1.2%)
Asthma	1 (1.2%)	0	1 (0.6%)
Atelectasis	0	1 (1.1%)	1 (0.6%)
Bronchiectasis	0	1 (1.1%)	1 (0.6%)
Dyspnoea	0	1 (1.1%)	1 (0.6%)
Obstructive Airways Disorder	0	1 (1.1%)	1 (0.6%)
Pneumothorax Spontaneous	0	1 (1.1%)	1 (0.6%)
Pulmonary Embolism	0	1 (1.1%)	1 (0.6%)
Rhinitis Allergic	1 (1.2%)	0	1 (0.6%)
Skin And Subcutaneous Tissue Disorders	2 (2.4%)	4 (4.5%)	6 (3.5%)
Chronic Spontaneous Urticaria	0	1 (1.1%)	1 (0.6%)
Dry Skin	1 (1.2%)	0	1 (0.6%)
Eczema	0	1 (1.1%)	1 (0.6%)
Eczema Asteatotic	0	1 (1.1%)	1 (0.6%)
Pruritus	1 (1.2%)	0	1 (0.6%)
Seborrhoeic Dermatitis	0	1 (1.1%)	1 (0.6%)
Social Circumstances	1 (1.2%)	0	1 (0.6%)
Ex-Tobacco User	1 (1.2%)	0	1 (0.6%)
Surgical And Medical Procedures	9 (10.7%)	12 (13.6%)	21 (12.2%)
Coronary Arterial Stent Insertion	2 (2.4%)	1 (1.1%)	3 (1.7%)
Inguinal Hernia Repair	0	3 (3.4%)	3 (1.7%)
Appendicectomy	2 (2.4%)	0	2 (1.2%)
Cholecystectomy	2 (2.4%)	0	2 (1.2%)
Radical Prostatectomy	0	2 (2.3%)	2 (1.2%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Adenoidectomy	0	1 (1.1%)	1 (0.6%)
Breast Conserving Surgery	0	1 (1.1%)	1 (0.6%)
Caesarean Section	0	1 (1.1%)	1 (0.6%)
Cardiac Ablation	1 (1.2%)	0	1 (0.6%)
Central Venous Catheterisation	1 (1.2%)	0	1 (0.6%)
Cyst Removal	1 (1.2%)	0	1 (0.6%)
Endometriosis Ablation	0	1 (1.1%)	1 (0.6%)
Enterostomy	1 (1.2%)	0	1 (0.6%)
Gastric Stent Insertion	1 (1.2%)	0	1 (0.6%)
Gastrointestinal Tube Insertion	0	1 (1.1%)	1 (0.6%)
Mastectomy	1 (1.2%)	0	1 (0.6%)
Meniscus Operation	0	1 (1.1%)	1 (0.6%)
Meniscus Removal	1 (1.2%)	0	1 (0.6%)
Nephrostomy	1 (1.2%)	0	1 (0.6%)
Oesophagogastric Fundoplasty	0	1 (1.1%)	1 (0.6%)
Papilloma Excision	0	1 (1.1%)	1 (0.6%)
Peritoneal Lavage	1 (1.2%)	0	1 (0.6%)
Prophylaxis Of Nausea And Vomiting	0	1 (1.1%)	1 (0.6%)
Renal Stone Removal	1 (1.2%)	0	1 (0.6%)
Salpingo-Oophorectomy Unilateral	1 (1.2%)	0	1 (0.6%)
Spinal Operation	0	1 (1.1%)	1 (0.6%)
Splenectomy	0	1 (1.1%)	1 (0.6%)
Thyroidectomy	1 (1.2%)	0	1 (0.6%)
Umbilical Hernia Repair	0	1 (1.1%)	1 (0.6%)
Vascular Disorders	27 (32.1%)	23 (26.1%)	50 (29.1%)
Hypertension	23 (27.4%)	22 (25.0%)	45 (26.2%)
Angiopathy	1 (1.2%)	0	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.4.2: Summary of Medical History by SOC/PT
Modified Full Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Leriche Syndrome	0	1 (1.1%)	1 (0.6%)
Peripheral Venous Disease	1 (1.2%)	0	1 (0.6%)
Subclavian Vein Thrombosis	1 (1.2%)	0	1 (0.6%)
Thrombosis	0	1 (1.1%)	1 (0.6%)
Varicose Vein	1 (1.2%)	0	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: alphabetical order by SOC and descending order by the number of subjects of overall group by PT. In case of ties, alphabetical order by PT is applied.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben

Anhang 4-G Gesamtüberleben

1. Time-to-Event-Analyse

Table 302.3.1002.1.2.1: Summary of Overall Survival
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	54 (64.3%)	67 (76.1%)	
Number of patients censored	30 (35.7%)	21 (23.9%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	85.91 [76.00, 91.94]	72.41 [61.43, 80.74]	
Month 12	57.18 [45.13, 67.52]	50.44 [39.02, 60.80]	
Month 18	39.84 [28.51, 50.92]	25.92 [16.67, 36.15]	
Month 24	31.59 [20.97, 42.75]	20.16 [11.92, 29.95]	
Month 30	25.40 [15.30, 36.76]	15.60 [8.33, 24.93]	
Month 36	23.09 [13.27, 34.51]	11.70 [5.31, 20.84]	
Month 42	17.32 [6.94, 31.57]	11.70 [5.31, 20.84]	
Month 48	NC [NC, NC]	NC [NC, NC]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	15.51 [11.76, 19.29]	12.06 [7.75, 15.41]	
Difference in median			3.45
Cox proportional hazards model			
Stratified HR, 95% CI			0.680 [0.467, 0.990]
Log-rank test			
Two-sided stratified log-rank p-value			0.0451

Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.1.2.2: Type of Events and Censoring of Overall Survival
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	54 (64.3%)	67 (76.1%)
Death before analysis cutoff date	54 (64.3%)	67 (76.1%)
Number of patients censored	30 (35.7%)	21 (23.9%)
Last known alive date is before cutoff date	28 (33.3%)	19 (21.6%)
Censored at cutoff date	2 (2.4%)	2 (2.3%)

Abbreviations: CPS=combined positive score; N=number of patients.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.1.2.2a: Breakdown of Reasons for Censoring
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX	Placebo + CAPOX	Total
Number of patients censored	30	21	51
1 Censored at Cutoff Date	2	2	4
2 Last known alive date is before cutoff date	28	19	47
2.a Not in survival follow-up	17	12	29
2.a.1 Lost To Follow-Up	2	2	4
2.a.2 Withdrawal By Subject	14	10	24
2.a.3 Other	1	0	1
2.b In survival follow-up	11	7	18
Timepoint of censoring relative to cutoff date			
2.b.1 < 4 weeks	6 (54.5%)	4 (57.1%)	10 (55.6%)
2.b.2 4-8 weeks	5 (45.5%)	2 (28.6%)	7 (38.9%)
2.b.3 8-12 weeks	0 (0.0%)	1 (14.3%)	1 (5.6%)

Abbreviations: CPS = combined positive score
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.1.2.3: Summary of Overall Survival by Subgroups
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	**N**	**n (%)**	**KME [95% CI](a)**	**N**	**n (%)**	**KME [95% CI](a)**	**HR [95% CI](b)**	**Log-rank p-value(c)**	**Test for Interaction p-value(d)**
Age Group 1									
<=65 years	60	34 (56.7)	16.36 [11.76, 23.06]	60	45 (75.0)	12.94 [7.49, 15.80]	0.614 [0.393, 0.960]	0.0308	0.2816
>65 years	24	20 (83.3)	11.93 [7.26, 17.84]	28	22 (78.6)	9.76 [3.65, 17.74]	0.912 [0.497, 1.673]	0.7749	
Age Group 2									
<=75 years	81	51 (63.0)	14.32 [11.10, 19.29]	81	61 (75.3)	11.53 [7.69, 15.41]	0.692 [0.477, 1.005]	0.0523	0.8961
>75 years	3	3 (100.0)	28.48 [16.49, NC]	7	6 (85.7)	14.23 [0.69, 17.74]	0.611 [0.148, 2.517]	0.5316	
Sex									
Male	52	36 (69.2)	14.32 [9.36, 19.29]	46	37 (80.4)	10.58 [5.82, 15.80]	0.709 [0.447, 1.123]	0.1424	0.7226
Female	32	18 (56.3)	16.49 [11.10, 30.13]	42	30 (71.4)	13.67 [7.75, 16.56]	0.615 [0.342, 1.106]	0.1010	
Region									
Asia	38	21 (55.3)	20.17 [14.32, 28.48]	41	26 (63.4)	13.90 [7.20, 17.08]	0.616 [0.346, 1.098]	0.0989	0.4308
Non-Asia	46	33 (71.7)	11.07 [8.71, 16.00]	47	41 (87.2)	11.53 [7.20, 15.41]	0.783 [0.493, 1.245]	0.3028	
Number of Organs with Metastatic Sites									
0-2	64	37 (57.8)	17.18 [13.67, 27.04]	64	48 (75.0)	13.90 [8.77, 15.80]	0.623 [0.405, 0.958]	0.0300	0.3545
>=3	20	17 (85.0)	11.10 [7.79, 12.35]	24	19 (79.2)	7.49 [4.50, 13.67]	0.896 [0.463, 1.735]	0.7470	
Prior Gastrectomy (total or partial)									
Yes	24	13 (54.2)	23.06 [10.35, 28.48]	22	12 (54.5)	19.25 [9.89, NC]	1.039 [0.473, 2.282]	0.9238	0.1791
No	60	41 (68.3)	13.67 [10.84, 17.18]	66	55 (83.3)	9.23 [6.80, 13.67]	0.583 [0.387, 0.877]	0.0093	


Abbreviations: CI=confidence interval; CPS=combined positive score; GEJ=gastro-esophageal junction; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method, (b) Calculated from Cox proportional hazards model, (c) Based on 2-sided log-rank test, unadjusted for multiplicity, and (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben
Anhang 4-G Gesamtüberleben

2. Kaplan-Meier-Plots

Figure 302.3.1002.1.2: Kaplan-Meier Plot of Overall Survival - Modified Full Analysis Set (CPS < 1)



	# at Risk								
1	84 (0.0)	65 (9.5)	41 (13.1)	26 (16.7)	19 (19.0)	11 (25.0)	5 (31.0)	2 (33.3)	0 (35.7)
2	88 (0.0)	58 (8.0)	38 (11.4)	19 (12.5)	14 (13.6)	9 (15.9)	3 (20.5)	1 (22.7)	0 (23.9)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; N=number of patients.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben

Anhang 4-G Sensitivitätsanalysen zum Gesamtüberleben: REI-Analysen

Table 302.3.1002.4.2.1: Overall survival by censoring Nausea or Vomiting Leading to Dose Interruption of any Study Drug with < 75% REI of Zolbetuximab or Nausea or Vomiting Leading to Withdrawal of any Study Drug with Zolbetuximab Treatment Discontinued within 180 days
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N=84)	**Placebo + CAPOX (N=88)**
Deaths, n(%)	48 (57.1%)	64 (72.7%)
Censored, n(%)	36 (42.9%)	24 (27.3%)
Censored at Cutoff Date, n (%)	2 (2.4%)	2 (2.3%)
Duration of Overall Survival (Months) (a)		
1st Quartile (95% CI)	10.32 (6.97, 11.93)	5.75 (3.68, 7.33)
Median (95% CI)	16.36 (11.99, 22.28)	12.94 (7.75, 15.80)
3rd Quartile (95% CI)	37.49 (23.06, NE)	21.42 (15.80, 30.49)
Range (b)	0.03+, 45.83+	0.03+, 45.57+
Stratified Analysis (c)		
1-sided P-value (d)	0.0112	
Hazard Ratio (95% CI) (e)	0.633 (0.427, 0.938)	
Stratified Analysis #2 (f)		
1-sided P-value (d)	0.0103	
Hazard Ratio (95% CI) (e)	0.632 (0.427, 0.935)	
Overall Survival Rate, % (95% CI) (g)		
At 12 months	61.30% (48.95%, 71.52%)	52.14% (40.54%, 62.52%)
At 18 months	44.13% (32.07%, 55.53%)	28.21% (18.47%, 38.74%)
At 24 months	35.00% (23.49%, 46.73%)	21.94% (13.15%, 32.16%)
At 30 months	29.79% (18.41%, 42.05%)	16.98% (9.17%, 26.81%)
At 36 months	27.08% (15.91%, 39.53%)	12.73% (5.82%, 22.44%)
Median Follow-Up Time, Months (95% CI) (h)	25.79 (19.35, 33.28)	33.22 (26.02, 36.90)

Abbreviations: CI=confidence interval; CPS=combined positive score; N=number of patients; n=number of patients with events; REI=relative exposure intensity; TEAE=treatment emergent adverse event.
(a) Based on Kaplan-Meier estimate; (b) + indicates censoring; (c) stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No); (d) based on 1-sided log-rank test; (e) Based on Cox proportional hazards model with treatment as the only explanatory variable; (f) stratification factors are region, number of metastatic sites and prior gastrectomy from eCRF; (g) survival rate and 95% CI are estimated using Kaplan-Meier method and Greenwood formula; (h) based on reverse Kaplan-Meier estimate.
Note: REI is calculated as (actual cumulative dose/planned cumulative dose)* 100%. Planned cumulative dose is defined as 800 + 600 * (number of planned dosing - 1). The number of planned dosing is defined as ceiling up integer value of (the duration of zolbetuximab/placebo)/ 21 (days) of dose interval.
Censoring status of patients with TEAEs nausea or vomiting leading to dose interruption of any study drug with < 75 REI of zolbetuximab or nausea or vomiting TEAE leading to withdrawal of any study drug with zolbetuximab treatment discontinued within 180 days was set to censored regardless of original censoring status. Censoring date was not changed.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.4.2.2: Overall survival by censoring Nausea or Vomiting Leading to Dose Interruption of any Study Drug with < 75% REI of Zolbetuximab or Nausea or Vomiting Leading to Withdrawal of any Study Drug with Zolbetuximab Treatment Discontinued within 63 days
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N=84)	**Placebo + CAPOX (N=88)**
Deaths, n(%)	48 (57.1%)	65 (73.9%)
Censored, n(%)	36 (42.9%)	23 (26.1%)
Censored at Cutoff Date, n (%)	2 (2.4%)	2 (2.3%)
Duration of Overall Survival (Months) (a)		
1st Quartile (95% CI)	10.32 (6.97, 11.93)	5.75 (3.68, 7.33)
Median (95% CI)	16.36 (11.99, 22.28)	12.06 (7.75, 15.41)
3rd Quartile (95% CI)	37.49 (23.06, NE)	19.25 (15.80, 30.49)
Range (b)	0.03+, 45.83+	0.03+, 45.57+
Stratified Analysis (c)		
1-sided P-value (d)	0.0086	
Hazard Ratio (95% CI) (e)	0.622 (0.421, 0.920)	
Stratified Analysis #2 (f)		
1-sided P-value (d)	0.0078	
Hazard Ratio (95% CI) (e)	0.620 (0.420, 0.916)	
Overall Survival Rate, % (95% CI) (g)		
At 12 months	61.30% (48.95%, 71.52%)	51.03% (39.51%, 61.43%)
At 18 months	44.13% (32.07%, 55.53%)	27.61% (18.04%, 38.01%)
At 24 months	35.00% (23.49%, 46.73%)	21.47% (12.85%, 31.55%)
At 30 months	29.79% (18.41%, 42.05%)	16.61% (8.96%, 26.30%)
At 36 months	27.08% (15.91%, 39.53%)	12.46% (5.70%, 22.01%)
Median Follow-Up Time, Months (95% CI) (h)	25.79 (19.35, 33.28)	33.22 (26.02, 36.90)

Abbreviations: CI=confidence interval; CPS=combined positive score; N=number of patients; n=number of patients with events; REI=relative exposure intensity; TEAE=treatment emergent adverse event.
(a) Based on Kaplan-Meier estimate; (b) + indicates censoring; (c) stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No); (d) based on 1-sided log-rank test; (e) Based on Cox proportional hazards model with treatment as the only explanatory variable; (f) stratification factors are region, number of metastatic sites and prior gastrectomy from eCRF; (g) survival rate and 95% CI are estimated using Kaplan-Meier method and Greenwood formula; (h) based on reverse Kaplan-Meier estimate.
Note: REI is calculated as (actual cumulative dose/planned cumulative dose)* 100%. Planned cumulative dose is defined as 800 + 600 * (number of planned dosing - 1). The number of planned dosing is defined as ceiling up integer value of (the duration of zolbetuximab/placebo)/ 21 (days) of dose interval.
Censoring status of patients with TEAEs nausea or vomiting leading to dose interruption of any study drug with < 75 REI of zolbetuximab or nausea or vomiting TEAE leading to withdrawal of any study drug with zolbetuximab treatment discontinued within 63 days was set to censored regardless of original censoring status. Censoring date was not changed.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.4.2.3: Overall survival by censoring Nausea or Vomiting Leading to Dose Interruption of any Study Drug with < 80% REI of Zolbetuximab or Nausea or Vomiting Leading to Withdrawal of any Study Drug with Zolbetuximab Treatment Discontinued within 63 days
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N=84)	**Placebo + CAPOX (N=88)**
Deaths, n(%)	48 (57.1%)	65 (73.9%)
Censored, n(%)	36 (42.9%)	23 (26.1%)
Censored at Cutoff Date, n (%)	2 (2.4%)	2 (2.3%)
Duration of Overall Survival (Months) (a)		
1st Quartile (95% CI)	10.32 (6.97, 11.93)	5.75 (3.68, 7.33)
Median (95% CI)	16.36 (11.99, 22.28)	12.06 (7.75, 15.41)
3rd Quartile (95% CI)	37.49 (23.06, NE)	19.25 (15.80, 30.49)
Range (b)	0.03+, 45.83+	0.03+, 45.57+
Stratified Analysis (c)		
1-sided P-value (d)	0.0086	
Hazard Ratio (95% CI) (e)	0.622 (0.421, 0.920)	
Stratified Analysis #2 (f)		
1-sided P-value (d)	0.0078	
Hazard Ratio (95% CI) (e)	0.620 (0.420, 0.916)	
Overall Survival Rate, % (95% CI) (g)		
At 12 months	61.30% (48.95%, 71.52%)	51.03% (39.51%, 61.43%)
At 18 months	44.13% (32.07%, 55.53%)	27.61% (18.04%, 38.01%)
At 24 months	35.00% (23.49%, 46.73%)	21.47% (12.85%, 31.55%)
At 30 months	29.79% (18.41%, 42.05%)	16.61% (8.96%, 26.30%)
At 36 months	27.08% (15.91%, 39.53%)	12.46% (5.70%, 22.01%)
Median Follow-Up Time, Months (95% CI) (h)	25.79 (19.35, 33.28)	33.22 (26.02, 36.90)

Abbreviations: CI=confidence interval; CPS=combined positive score; N=number of patients; n=number of patients with events; REI=relative exposure intensity; TEAE=treatment emergent adverse event.
(a) Based on Kaplan-Meier estimate; (b) + indicates censoring; (c) stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No); (d) based on 1-sided log-rank test; (e) Based on Cox proportional hazards model with treatment as the only explanatory variable; (f) stratification factors are region, number of metastatic sites and prior gastrectomy from eCRF; (g) survival rate and 95% CI are estimated using Kaplan-Meier method and Greenwood formula; (h) based on reverse Kaplan-Meier estimate.
Note: REI is calculated as (actual cumulative dose/planned cumulative dose)* 100%. Planned cumulative dose is defined as 800 + 600 * (number of planned dosing - 1). The number of planned dosing is defined as ceiling up integer value of (the duration of zolbetuximab/placebo)/ 21 (days) of dose interval.
Censoring status of patients with TEAEs nausea or vomiting leading to dose interruption of any study drug with < 80 REI of zolbetuximab or nausea or vomiting TEAE leading to withdrawal of any study drug with zolbetuximab treatment discontinued within 180 days was set to censored regardless of original censoring status. Censoring date was not changed.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.4.2.4: Overall survival by censoring Nausea or Vomiting Leading to Dose Interruption of any Study Drug with < 80% REI of Zolbetuximab or Nausea or Vomiting Leading to Withdrawal of any Study Drug with Zolbetuximab Treatment Discontinued within 180 days
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N=84)	**Placebo + CAPOX (N=88)**
Deaths, n(%)	48 (57.1%)	64 (72.7%)
Censored, n(%)	36 (42.9%)	24 (27.3%)
Censored at Cutoff Date, n (%)	2 (2.4%)	2 (2.3%)
Duration of Overall Survival (Months) (a)		
1st Quartile (95% CI)	10.32 (6.97, 11.93)	5.75 (3.68, 7.33)
Median (95% CI)	16.36 (11.99, 22.28)	12.94 (7.75, 15.80)
3rd Quartile (95% CI)	37.49 (23.06, NE)	21.42 (15.80, 30.49)
Range (b)	0.03+, 45.83+	0.03+, 45.57+
Stratified Analysis (c)		
1-sided P-value (d)	0.0112	
Hazard Ratio (95% CI) (e)	0.633 (0.427, 0.938)	
Stratified Analysis #2 (f)		
1-sided P-value (d)	0.0103	
Hazard Ratio (95% CI) (e)	0.632 (0.427, 0.935)	
Overall Survival Rate, % (95% CI) (g)		
At 12 months	61.30% (48.95%, 71.52%)	52.14% (40.54%, 62.52%)
At 18 months	44.13% (32.07%, 55.53%)	28.21% (18.47%, 38.74%)
At 24 months	35.00% (23.49%, 46.73%)	21.94% (13.15%, 32.16%)
At 30 months	29.79% (18.41%, 42.05%)	16.98% (9.17%, 26.81%)
At 36 months	27.08% (15.91%, 39.53%)	12.73% (5.82%, 22.44%)
Median Follow-Up Time, Months (95% CI) (h)	25.79 (19.35, 33.28)	33.22 (26.02, 36.90)

Abbreviations: CI=confidence interval; CPS=combined positive score; N=number of patients; n=number of patients with events; REI=relative exposure intensity; TEAE=treatment emergent adverse event.
(a) Based on Kaplan-Meier estimate; (b) + indicates censoring; (c) stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No); (d) based on 1-sided log-rank test; (e) Based on Cox proportional hazards model with treatment as the only explanatory variable; (f) stratification factors are region, number of metastatic sites and prior gastrectomy from eCRF; (g) survival rate and 95% CI are estimated using Kaplan-Meier method and Greenwood formula; (h) based on reverse Kaplan-Meier estimate.
Note: REI is calculated as (actual cumulative dose/planned cumulative dose)* 100%. Planned cumulative dose is defined as 800 + 600 * (number of planned dosing - 1). The number of planned dosing is defined as ceiling up integer value of (the duration of zolbetuximab/placebo)/ 21 (days) of dose interval.
Censoring status of patients with TEAEs nausea or vomiting leading to dose interruption of any study drug with < 80 REI of zolbetuximab or nausea or vomiting TEAE leading to withdrawal of any study drug with zolbetuximab treatment discontinued within 63 days was set to censored regardless of original censoring status. Censoring date was not changed.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben

Anhang 4-G Sensitivitätsanalysen zum Gesamtüberleben: Steroid-Behandlung

1. Time-to-Event-Analyse

Table 302.3.1003.1.2: Summary of Overall Survival in Patients Receiving Corticosteroids as Antiemetic or Concomitant Medication
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 59)	**Placebo + CAPOX (N= 50)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	59 (100.0%)	50 (100.0%)	
Number of patients with events	38 (64.4%)	41 (82.0%)	
Number of patients censored	21 (35.6%)	9 (18.0%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	91.21 [80.16, 96.25]	69.55 [54.64, 80.39]	
Month 12	62.92 [48.56, 74.29]	42.95 [28.99, 56.17]	
Month 18	41.86 [28.51, 54.65]	21.53 [11.22, 34.03]	
Month 24	35.35 [22.62, 48.31]	16.75 [7.69, 28.80]	
Month 30	27.22 [15.28, 40.60]	14.35 [6.06, 26.07]	
Month 36	24.19 [12.71, 37.67]	14.35 [6.06, 26.07]	
Month 42	24.19 [12.71, 37.67]	NC [NC, NC]	
Month 48	NC [NC, NC]	NC [NC, NC]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	16.36 [11.99, 23.06]	9.23 [7.20, 13.67]	
Difference in median			7.13
Cox proportional hazards model			
Stratified HR, 95% CI			0.549 [0.339, 0.889]
Log-rank test			
Two-sided stratified log-rank p-value			0.0143


Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben
Anhang 4-G Sensitivitätsanalysen zum Gesamtüberleben: Steroid-Behandlung

2. Kaplan-Meier-Plots

Figure 302.3.1003.1.2: Kaplan-Meier Plot of Overall Survival in Patients Receiving Corticosteroids as Antiemetic or Concomitant Medication
Modified Full Analysis Set (CPS < 1)



Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; N=number of patients.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben
Anhang 4-G Progressionsfreies Überleben (IRC und INV)

1. Time-to-Event-Analysen

Table 302.3.1002.2.2.1: Summary of Progression-Free Survival (IRC)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	50 (59.5%)	62 (70.5%)	
Number of patients censored	34 (40.5%)	26 (29.5%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	71.90 [59.45, 81.12]	62.89 [51.12, 72.58]	
Month 12	37.26 [25.16, 49.34]	23.52 [13.96, 34.51]	
Month 18	25.78 [15.22, 37.67]	13.06 [5.75, 23.45]	
Month 24	14.10 [6.01, 25.54]	10.89 [4.29, 20.97]	
Month 30	14.10 [6.01, 25.54]	7.26 [1.81, 18.01]	
Month 36	14.10 [6.01, 25.54]	0.00 [NC, NC]	
Month 42	14.10 [6.01, 25.54]	0.00 [NC, NC]	
Month 48	NC [NC, NC]	0.00 [NC, NC]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	8.80 [6.97, 11.99]	7.33 [6.05, 8.51]	
Difference in median			1.48
Cox proportional hazards model			
Stratified HR, 95% CI			0.686 [0.460, 1.021]
Log-rank test			
Two-sided stratified log-rank p-value			0.0628

Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; IRC=independent review committee; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.2.2.2: Type of Events and Censoring of Progression-Free Survival (IRC)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	50 (59.5%)	62 (70.5%)
rPD	28 (33.3%)	29 (33.0%)
No rPD, but death recorded on eCRF	22 (26.2%)	33 (37.5%)
Number of patients censored	34 (40.5%)	26 (29.5%)

Abbreviations: CPS=combined positive score; eCRF=electronic case report form; IRC=independent review committee; N=number of patients; rPD=radiological progressive disease.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.2.2.3: Summary of Progression-Free Survival (IRC) by Subgroups
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	**N**	**n (%)**	**KME [95% CI](a)**	**N**	**n (%)**	**KME [95% CI](a)**	**HR [95% CI](b)**	**Log-rank p-value(c)**	**Test for Interaction p-value(d)**
Age Group 1									
<=65 years	60	34 (56.7)	8.51 [6.44, 13.04]	60	41 (68.3)	7.33 [6.24, 9.23]	0.709 [0.447, 1.124]	0.1416	0.8720
>65 years	24	16 (66.7)	9.17 [6.01, 15.51]	28	21 (75.0)	7.69 [2.23, 10.38]	0.601 [0.307, 1.176]	0.1349	
Age Group 2									
<=75 years	81	50 (61.7)	8.80 [6.83, 11.76]	81	58 (71.6)	7.33 [6.05, 8.51]	0.717 [0.489, 1.050]	0.0876	0.9790
>75 years	3	0 (0.0)	NC [NC, NC]	7	4 (57.1)	8.21 [0.69, NC]	0.000 [0.000, NC]	0.1345	
Sex									
Male	52	35 (67.3)	8.51 [5.06, 11.76]	46	35 (76.1)	6.28 [3.65, 8.25]	0.634 [0.394, 1.020]	0.0581	0.8461
Female	32	15 (46.9)	9.17 [6.83, 19.06]	42	27 (64.3)	8.08 [6.05, 10.38]	0.694 [0.367, 1.311]	0.2612	
Region									
Asia	38	21 (55.3)	10.58 [7.13, 20.80]	41	28 (68.3)	8.08 [6.05, 11.07]	0.593 [0.335, 1.048]	0.0708	0.4708
Non-Asia	46	29 (63.0)	8.08 [5.06, 9.30]	47	34 (72.3)	6.37 [5.19, 8.25]	0.778 [0.471, 1.286]	0.3274	
Number of Organs with Metastatic Sites									
0-2	64	37 (57.8)	8.51 [6.83, 15.38]	64	45 (70.3)	8.08 [6.28, 9.23]	0.702 [0.452, 1.089]	0.1147	0.8237
>=3	20	13 (65.0)	8.80 [3.98, 12.35]	24	17 (70.8)	6.05 [2.23, 11.07]	0.633 [0.304, 1.317]	0.2209	
Prior Gastrectomy (total or partial)									
Yes	24	14 (58.3)	11.99 [6.83, 22.28]	22	14 (63.6)	8.51 [6.05, 26.02]	0.935 [0.443, 1.973]	0.8608	0.3080
No	60	36 (60.0)	8.48 [6.08, 10.58]	66	48 (72.7)	6.80 [5.42, 8.25]	0.606 [0.387, 0.949]	0.0274	

Abbreviations: CI=confidence interval; CPS=combined positive score; GEJ=gastro-esophageal junction; HR=hazard ratio; IRC=independent review committee; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method, (b) Calculated from Cox proportional hazards model, (c) Based on 2-sided log-rank test, unadjusted for multiplicity, and (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.3.2.1: Summary of Progression-Free Survival (INV)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	57 (67.9%)	75 (85.2%)	
Number of patients censored	27 (32.1%)	13 (14.8%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	64.90 [52.30, 74.95]	48.59 [37.22, 59.02]	
Month 12	32.99 [21.84, 44.56]	17.10 [9.62, 26.39]	
Month 18	22.87 [13.36, 33.93]	7.13 [2.67, 14.57]	
Month 24	15.25 [7.43, 25.65]	4.28 [1.15, 10.81]	
Month 30	10.17 [3.73, 20.40]	NC [NC, NC]	
Month 36	6.78 [1.61, 17.32]	NC [NC, NC]	
Month 42	NC [NC, NC]	NC [NC, NC]	
Month 48	NC [NC, NC]	NC [NC, NC]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	8.44 [6.31, 10.41]	5.72 [4.21, 7.33]	
Difference in median			2.73
Cox proportional hazards model			
Stratified HR, 95% CI			0.621 [0.428, 0.902]
Log-rank test			
Two-sided stratified log-rank p-value			0.0120

Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; INV=investigator; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.3.2.2: Type of Events and Censoring of Progression-Free Survival (INV)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	57 (67.9%)	75 (85.2%)
rPD	41 (48.8%)	60 (68.2%)
No rPD, but death recorded on eCRF	16 (19.0%)	15 (17.0%)
Number of patients censored	27 (32.1%)	13 (14.8%)

Abbreviations: CPS=combined positive score; eCRF= electronic case report form; INV=investigator; N=number of patients; rPD=radiological progressive disease.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.3.2.3: Summary of Progression-Free Survival (INV) by Subgroups
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	**N**	**n (%)**	**KME [95% CI](a)**	**N**	**n (%)**	**KME [95% CI](a)**	**HR [95% CI](b)**	**Log-rank p-value(c)**	**Test for Interaction p-value(d)**
Age Group 1									
<=65 years	60	41 (68.3)	8.48 [6.24, 11.99]	60	50 (83.3)	6.21 [4.30, 7.62]	0.618 [0.406, 0.940]	0.0236	0.8039
>65 years	24	16 (66.7)	7.89 [4.17, 11.96]	28	25 (89.3)	4.27 [2.56, 8.28]	0.504 [0.261, 0.974]	0.0377	
Age Group 2									
<=75 years	81	56 (69.1)	8.44 [6.31, 10.41]	81	70 (86.4)	5.98 [4.27, 7.33]	0.606 [0.424, 0.866]	0.0054	0.4592
>75 years	3	1 (33.3)	NC [5.55, NC]	7	5 (71.4)	2.56 [0.69, NC]	0.317 [0.036, 2.782]	0.2763	
Sex									
Male	52	37 (71.2)	7.89 [5.06, 10.38]	46	41 (89.1)	4.30 [3.94, 8.11]	0.586 [0.374, 0.918]	0.0180	0.9403
Female	32	20 (62.5)	9.17 [5.98, 15.21]	42	34 (81.0)	6.05 [4.21, 7.82]	0.565 [0.320, 0.998]	0.0460	
Region									
Asia	38	26 (68.4)	10.41 [5.55, 15.51]	41	32 (78.0)	6.24 [4.27, 9.66]	0.592 [0.349, 1.001]	0.0486	0.8231
Non-Asia	46	31 (67.4)	7.89 [5.06, 9.17]	47	43 (91.5)	4.44 [4.01, 6.37]	0.609 [0.380, 0.977]	0.0378	
Number of Organs with Metastatic Sites									
0-2	64	42 (65.6)	8.48 [6.24, 11.99]	64	53 (82.8)	5.98 [4.17, 8.08]	0.609 [0.405, 0.917]	0.0164	0.9973
>=3	20	15 (75.0)	8.28 [4.17, 11.10]	24	22 (91.7)	5.19 [2.56, 7.82]	0.605 [0.308, 1.190]	0.1419	
Prior Gastrectomy (total or partial)									
Yes	24	14 (58.3)	11.99 [5.55, 20.80]	22	16 (72.7)	7.82 [4.21, 15.44]	0.661 [0.322, 1.359]	0.2567	0.7169
No	60	43 (71.7)	7.79 [5.06, 10.38]	66	59 (89.4)	4.44 [3.94, 6.28]	0.555 [0.368, 0.836]	0.0042	


Abbreviations: CI=confidence interval; CPS=combined positive score; GEJ=gastro-esophageal junction; HR=hazard ratio; INV=investigator; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method, (b) Calculated from Cox proportional hazards model, (c) Based on 2-sided log-rank test, unadjusted for multiplicity, and (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben
Anhang 4-G Progressionsfreies Überleben (IRC und INV)

2. Kaplan-Meier-Plots

Figure 302.3.1002.2.2: Kaplan-Meier Plot of Progression-Free Survival (IRC) - Modified Full Analysis Set (CPS < 1)




at Risk

1	84 (0.0)	43 (26.2)	21 (28.6)	12 (32.1)	5 (34.5)	4 (35.7)	2 (38.1)	1 (39.3)	0 (40.5)
2	88 (0.0)	45 (15.9)	13 (23.9)	6 (26.1)	3 (28.4)	1 (29.5)	0 (29.5)	0 (29.5)	0 (29.5)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; IRC=independent review committee; N=number of patients.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.1002.3.2: Kaplan-Meier Plot of Progression-Free Survival (INV) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	42 (21.4)	20 (23.8)	12 (26.2)	6 (28.6)	4 (28.6)	1 (31.0)	0 (32.1)	0 (32.1)
2	88 (0.0)	38 (10.2)	12 (12.5)	5 (12.5)	2 (13.6)	0 (14.8)	0 (14.8)	0 (14.8)	0 (14.8)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; INV=investigator; N=number of patients.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte

Anhang 4-G Symptomatik und Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ-C30

1. Rücklaufquoten

Table 302.3.3001.1.2: EORTC QLQ-C30 v3.0 - Completion Status
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.1.2: EORTC QLQ-C30 v3.0 - Completion Status
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.1.2: EORTC QLQ-C30 v3.0 - Completion Status
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.5.2: EORTC QLQ-C30 v3.0 - Completion Status of Global Health Status
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.5.2: EORTC QLQ-C30 v3.0 - Completion Status of Global Health Status
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.5.2: EORTC QLQ-C30 v3.0 - Completion Status of Global Health Status
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.6.2: EORTC QLQ-C30 v3.0 - Completion Status of Physical Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.6.2: EORTC QLQ-C30 v3.0 - Completion Status of Physical Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.6.2: EORTC QLQ-C30 v3.0 - Completion Status of Physical Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.7.2: EORTC QLQ-C30 v3.0 - Completion Status of Role Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.7.2: EORTC QLQ-C30 v3.0 - Completion Status of Role Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.7.2: EORTC QLQ-C30 v3.0 - Completion Status of Role Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.8.2: EORTC QLQ-C30 v3.0 - Completion Status of Emotional Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.8.2: EORTC QLQ-C30 v3.0 - Completion Status of Emotional Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.8.2: EORTC QLQ-C30 v3.0 - Completion Status of Emotional Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.9.2: EORTC QLQ-C30 v3.0 - Completion Status of Cognitive Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.9.2: EORTC QLQ-C30 v3.0 - Completion Status of Cognitive Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.9.2: EORTC QLQ-C30 v3.0 - Completion Status of Cognitive Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.10.2: EORTC QLQ-C30 v3.0 - Completion Status of Social Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.10.2: EORTC QLQ-C30 v3.0 - Completion Status of Social Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.10.2: EORTC QLQ-C30 v3.0 - Completion Status of Social Functioning
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.11.2: EORTC QLQ-C30 v3.0 - Completion Status of Fatigue
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.11.2: EORTC QLQ-C30 v3.0 - Completion Status of Fatigue
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.11.2: EORTC QLQ-C30 v3.0 - Completion Status of Fatigue
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.12.2: EORTC QLQ-C30 v3.0 - Completion Status of Nausea and Vomiting
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.12.2: EORTC QLQ-C30 v3.0 - Completion Status of Nausea and Vomiting
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.12.2: EORTC QLQ-C30 v3.0 - Completion Status of Nausea and Vomiting
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.13.2: EORTC QLQ-C30 v3.0 - Completion Status of Pain
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.13.2: EORTC QLQ-C30 v3.0 - Completion Status of Pain
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.13.2: EORTC QLQ-C30 v3.0 - Completion Status of Pain
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.14.2: EORTC QLQ-C30 v3.0 - Completion Status of Dyspnoea
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.14.2: EORTC QLQ-C30 v3.0 - Completion Status of Dyspnoea
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.14.2: EORTC QLQ-C30 v3.0 - Completion Status of Dyspnoea
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.15.2: EORTC QLQ-C30 v3.0 - Completion Status of Insomnia
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.15.2: EORTC QLQ-C30 v3.0 - Completion Status of Insomnia
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.15.2: EORTC QLQ-C30 v3.0 - Completion Status of Insomnia
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.16.2: EORTC QLQ-C30 v3.0 - Completion Status of Appetite Loss
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.16.2: EORTC QLQ-C30 v3.0 - Completion Status of Appetite Loss
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.16.2: EORTC QLQ-C30 v3.0 - Completion Status of Appetite Loss
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.17.2: EORTC QLQ-C30 v3.0 - Completion Status of Constipation
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.17.2: EORTC QLQ-C30 v3.0 - Completion Status of Constipation
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.17.2: EORTC QLQ-C30 v3.0 - Completion Status of Constipation
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.18.2: EORTC QLQ-C30 v3.0 - Completion Status of Diarrhoea
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.18.2: EORTC QLQ-C30 v3.0 - Completion Status of Diarrhoea
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.18.2: EORTC QLQ-C30 v3.0 - Completion Status of Diarrhoea
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.19.2: EORTC QLQ-C30 v3.0 - Completion Status of Financial Difficulties
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.19.2: EORTC QLQ-C30 v3.0 - Completion Status of Financial Difficulties
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.19.2: EORTC QLQ-C30 v3.0 - Completion Status of Financial Difficulties
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	55/ 75 (73.3%)	55/ 76 (72.4%)	55/ 88 (62.5%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik und Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ-C30

2. Verlauf über die Zeit (Observed Means and Change from Baseline)

Table 302.3.3002.5.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Global Health Status
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	66.77	17.74	25.0	66.67	100.0						
Cycle 2 Day 1	69	66.55	20.13	0.0	75.00	100.0	68	-0.61	20.12	-83.3	0.00	41.7
Cycle 3 Day 1	61	71.72	16.26	33.3	75.00	100.0	60	3.61	16.41	-33.3	0.00	41.7
Cycle 4 Day 1	57	73.10	18.90	16.7	83.33	100.0	57	4.24	19.68	-50.0	0.00	41.7
Cycle 5 Day 1	55	70.15	21.38	0.0	83.33	100.0	54	2.31	19.59	-66.7	0.00	41.7
Cycle 6 Day 1	55	71.82	18.87	0.0	75.00	100.0	55	2.88	21.11	-83.3	0.00	41.7
Cycle 7 Day 1	44	71.59	18.44	16.7	83.33	100.0	44	1.33	19.52	-50.0	0.00	41.7
Cycle 8 Day 1	41	73.78	16.41	16.7	83.33	100.0	39	2.99	15.59	-16.7	0.00	33.3
Cycle 9 Day 1	38	73.46	17.10	16.7	83.33	100.0	37	3.38	19.88	-50.0	0.00	33.3
Cycle 10 Day 1	34	73.28	16.89	41.7	75.00	100.0	33	2.53	20.25	-41.7	0.00	41.7
Cycle 11 Day 1	32	72.14	17.14	41.7	79.17	100.0	31	1.08	23.05	-41.7	8.33	41.7
Cycle 12 Day 1	31	72.31	20.34	0.0	75.00	100.0	30	1.67	25.84	-83.3	0.00	50.0
Cycle 13 Day 1	26	75.00	15.63	41.7	83.33	100.0	25	5.00	21.65	-33.3	8.33	58.3
Cycle 14 Day 1	22	75.76	16.65	41.7	83.33	100.0	21	5.16	20.83	-33.3	0.00	41.7
Cycle 15 Day 1	23	77.90	15.20	50.0	83.33	100.0	22	7.20	21.41	-25.0	0.00	50.0
Cycle 16 Day 1	24	77.08	18.10	33.3	83.33	100.0	23	6.52	24.35	-41.7	0.00	50.0
Cycle 17 Day 1	21	77.78	12.45	50.0	83.33	100.0	20	7.50	20.57	-33.3	0.00	41.7
Cycle 18 Day 1	21	76.19	15.43	50.0	75.00	100.0	20	4.17	20.68	-33.3	0.00	41.7
Cycle 19 Day 1	21	77.38	15.62	50.0	83.33	100.0	20	5.42	19.36	-33.3	0.00	41.7
Cycle 20 Day 1	19	73.68	19.50	25.0	83.33	100.0	18	1.85	18.86	-25.0	0.00	41.7
Cycle 21 Day 1	18	74.54	18.18	41.7	75.00	100.0	17	3.43	21.05	-25.0	0.00	50.0
Cycle 22 Day 1	15	76.11	18.86	50.0	75.00	100.0	14	4.17	23.29	-33.3	8.33	50.0
Cycle 23 Day 1	15	77.78	17.16	50.0	83.33	100.0	14	2.98	21.34	-25.0	0.00	50.0
Cycle 24 Day 1	14	79.76	13.36	50.0	83.33	100.0	13	4.49	21.14	-16.7	0.00	50.0
Cycle 25 Day 1	14	76.19	15.63	50.0	83.33	100.0	13	0.64	21.10	-16.7	0.00	50.0

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.5.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Global Health Status
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	83.33	12.31	50.0	83.33	100.0	11	7.58	17.26	-16.7	0.00	33.3
Cycle 27 Day 1	13	82.05	18.59	50.0	83.33	100.0	12	6.94	22.98	-16.7	16.67	50.0
Cycle 28 Day 1	11	78.03	15.93	50.0	83.33	100.0	10	0.83	16.87	-16.7	0.00	33.3
Cycle 29 Day 1	11	77.27	11.24	50.0	83.33	83.3	10	1.67	16.57	-16.7	0.00	33.3
Cycle 30 Day 1	10	80.00	15.32	50.0	83.33	100.0	9	3.70	18.22	-16.7	0.00	33.3
Cycle 31 Day 1	10	78.33	19.33	50.0	83.33	100.0	9	1.85	22.74	-33.3	16.67	33.3
Cycle 32 Day 1	10	79.17	18.94	50.0	83.33	100.0	9	2.78	19.54	-25.0	0.00	33.3
Study Disc 1	48	58.16	26.44	0.0	62.50	100.0	48	-8.51	27.85	-100.0	-4.17	50.0
30 D SFU Z/P	22	64.02	23.48	0.0	66.67	100.0	22	-7.95	24.19	-75.0	0.00	16.7
90 D SFU Z/P	23	69.20	20.63	25.0	66.67	100.0	23	-3.99	23.69	-50.0	0.00	50.0
Placebo + CAPOX (N= 88)												
Baseline	81	64.51	21.96	0.0	66.67	100.0						
Cycle 2 Day 1	73	67.35	20.35	0.0	66.67	100.0	70	2.74	23.94	-100.0	0.00	50.0
Cycle 3 Day 1	64	70.57	18.06	33.3	66.67	100.0	63	6.75	21.05	-50.0	0.00	58.3
Cycle 4 Day 1	56	69.94	15.62	8.3	66.67	100.0	56	6.25	21.86	-58.3	8.33	58.3
Cycle 5 Day 1	57	68.27	19.38	0.0	66.67	100.0	57	4.09	22.05	-50.0	0.00	58.3
Cycle 6 Day 1	48	68.58	18.29	0.0	66.67	100.0	48	3.82	23.00	-50.0	0.00	58.3
Cycle 7 Day 1	42	71.23	18.24	33.3	70.83	100.0	42	5.36	22.07	-50.0	8.33	58.3
Cycle 8 Day 1	37	69.59	21.80	0.0	66.67	100.0	37	6.31	23.02	-41.7	8.33	66.7
Cycle 9 Day 1	35	70.24	18.67	33.3	66.67	100.0	35	3.81	23.16	-41.7	8.33	66.7
Cycle 10 Day 1	30	71.11	15.12	33.3	66.67	100.0	29	3.74	22.89	-50.0	0.00	58.3
Cycle 11 Day 1	27	70.68	19.11	33.3	66.67	100.0	27	5.25	27.85	-50.0	0.00	75.0
Cycle 12 Day 1	26	70.19	22.51	33.3	75.00	100.0	25	4.00	26.91	-50.0	0.00	75.0
Cycle 13 Day 1	22	69.32	20.15	25.0	70.83	100.0	21	3.17	22.43	-41.7	0.00	50.0
Cycle 14 Day 1	21	69.84	24.08	16.7	66.67	100.0	20	2.08	23.24	-66.7	0.00	41.7
Cycle 15 Day 1	18	68.98	27.83	8.3	70.83	100.0	17	-0.98	22.42	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.5.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Global Health Status
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	74.02	24.63	0.0	83.33	100.0	16	3.65	16.93	-25.0	0.00	33.3
Cycle 17 Day 1	13	80.13	17.19	50.0	83.33	100.0	11	4.55	18.01	-16.7	0.00	33.3
Cycle 18 Day 1	10	70.83	28.93	0.0	79.17	100.0	9	-5.56	40.82	-100.0	0.00	33.3
Study Disc 1	52	55.13	24.60	0.0	58.33	100.0	47	-8.51	26.78	-66.7	0.00	41.7
30 D SFU Z/P	29	57.47	22.86	0.0	50.00	100.0	27	-7.10	30.29	-83.3	0.00	41.7
90 D SFU Z/P	30	64.44	21.55	33.3	66.67	100.0	29	2.59	23.48	-41.7	8.33	58.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.6.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Physical Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	79.06	17.78	26.7	86.67	100.0						
Cycle 2 Day 1	69	78.16	18.29	33.3	80.00	100.0	68	-1.18	17.24	-60.0	0.00	40.0
Cycle 3 Day 1	61	78.36	20.82	6.7	80.00	100.0	60	-0.22	15.62	-66.7	0.00	40.0
Cycle 4 Day 1	57	79.06	19.78	20.0	86.67	100.0	57	-0.70	14.12	-53.3	0.00	33.3
Cycle 5 Day 1	55	82.30	17.79	13.3	86.67	100.0	54	3.21	14.29	-26.7	0.00	46.7
Cycle 6 Day 1	55	80.73	19.86	20.0	86.67	100.0	55	1.45	14.89	-53.3	0.00	33.3
Cycle 7 Day 1	44	78.18	22.01	6.7	83.33	100.0	44	-1.21	20.40	-80.0	0.00	46.7
Cycle 8 Day 1	41	80.00	19.94	13.3	80.00	100.0	39	-0.17	18.26	-33.3	0.00	60.0
Cycle 9 Day 1	38	80.35	18.66	20.0	80.00	100.0	37	0.18	17.74	-40.0	0.00	46.7
Cycle 10 Day 1	34	79.41	19.02	20.0	86.67	100.0	33	-0.40	15.54	-40.0	0.00	40.0
Cycle 11 Day 1	32	80.21	15.29	40.0	80.00	100.0	31	-0.65	18.41	-33.3	0.00	40.0
Cycle 12 Day 1	31	81.94	14.00	46.7	80.00	100.0	30	1.33	20.45	-26.7	0.00	46.7
Cycle 13 Day 1	26	85.13	10.38	60.0	86.67	100.0	25	5.60	21.32	-33.3	6.67	60.0
Cycle 14 Day 1	22	81.52	13.48	60.0	80.00	100.0	21	2.22	19.36	-26.7	6.67	46.7
Cycle 15 Day 1	23	83.48	14.34	60.0	86.67	100.0	22	3.94	16.54	-20.0	3.33	40.0
Cycle 16 Day 1	24	82.78	12.26	53.3	86.67	100.0	23	2.03	14.83	-26.7	6.67	33.3
Cycle 17 Day 1	21	86.35	13.41	53.3	86.67	100.0	20	6.67	18.23	-26.7	6.67	53.3
Cycle 18 Day 1	21	84.13	11.45	60.0	86.67	100.0	20	2.33	13.56	-20.0	0.00	33.3
Cycle 19 Day 1	21	86.67	13.98	53.3	86.67	100.0	20	5.00	11.00	-13.3	6.67	33.3
Cycle 20 Day 1	19	83.86	13.76	53.3	86.67	100.0	18	1.48	13.44	-20.0	3.33	33.3
Cycle 21 Day 1	18	85.93	15.32	53.3	90.00	100.0	17	3.53	14.55	-20.0	0.00	33.3
Cycle 22 Day 1	15	88.00	16.17	53.3	93.33	100.0	14	4.76	12.10	-20.0	6.67	26.7
Cycle 23 Day 1	15	87.56	11.78	60.0	86.67	100.0	14	1.90	18.93	-20.0	0.00	53.3
Cycle 24 Day 1	14	91.90	8.34	73.3	93.33	100.0	13	6.15	18.55	-20.0	6.67	53.3
Cycle 25 Day 1	14	90.48	9.68	73.3	93.33	100.0	13	4.62	21.84	-20.0	6.67	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.6.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Physical Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	91.11	9.57	73.3	93.33	100.0	11	4.85	23.87	-26.7	0.00	66.7
Cycle 27 Day 1	13	89.23	8.41	73.3	86.67	100.0	12	3.33	21.37	-20.0	3.33	60.0
Cycle 28 Day 1	11	84.24	11.26	66.7	80.00	100.0	10	2.67	19.42	-20.0	3.33	46.7
Cycle 29 Day 1	11	77.58	28.64	0.0	86.67	100.0	10	-6.67	33.85	-73.3	0.00	60.0
Cycle 30 Day 1	10	89.33	8.43	80.0	86.67	100.0	9	8.15	20.49	-13.3	6.67	60.0
Cycle 31 Day 1	10	88.67	10.91	66.7	90.00	100.0	9	8.15	21.02	-13.3	6.67	60.0
Cycle 32 Day 1	10	89.33	9.00	80.0	90.00	100.0	9	8.15	20.49	-13.3	6.67	60.0
Study Disc 1	48	69.58	28.18	0.0	73.33	100.0	48	-9.17	24.43	-100.0	-6.67	40.0
30 D SFU Z/P	22	75.15	23.29	6.7	80.00	100.0	22	-6.06	22.90	-66.7	0.00	33.3
90 D SFU Z/P	23	75.07	21.58	33.3	80.00	100.0	23	-9.86	22.73	-66.7	-6.67	33.3
Placebo + CAPOX (N= 88)												
Baseline	81	80.66	20.43	0.0	86.67	100.0						
Cycle 2 Day 1	73	80.64	18.40	0.0	86.67	100.0	70	-0.38	14.08	-46.7	0.00	33.3
Cycle 3 Day 1	64	83.44	19.95	13.3	86.67	100.0	63	2.22	15.19	-46.7	0.00	46.7
Cycle 4 Day 1	56	82.26	16.97	20.0	86.67	100.0	56	1.19	16.04	-53.3	0.00	46.7
Cycle 5 Day 1	57	80.12	19.42	13.3	86.67	100.0	57	-1.52	18.30	-66.7	0.00	40.0
Cycle 6 Day 1	48	80.83	23.48	0.0	86.67	100.0	48	-0.42	19.71	-46.7	0.00	46.7
Cycle 7 Day 1	42	86.19	15.12	20.0	86.67	100.0	42	3.17	16.87	-33.3	0.00	46.7
Cycle 8 Day 1	37	83.96	20.46	6.7	86.67	100.0	37	1.26	14.47	-26.7	0.00	33.3
Cycle 9 Day 1	35	83.05	19.36	13.3	86.67	100.0	35	-1.14	20.61	-73.3	0.00	46.7
Cycle 10 Day 1	30	85.11	17.57	13.3	86.67	100.0	29	-0.92	17.06	-33.3	0.00	40.0
Cycle 11 Day 1	27	87.16	13.83	40.0	93.33	100.0	27	4.44	13.84	-20.0	6.67	33.3
Cycle 12 Day 1	26	85.38	17.18	20.0	86.67	100.0	25	2.67	18.56	-33.3	6.67	46.7
Cycle 13 Day 1	22	85.76	17.00	33.3	90.00	100.0	21	1.59	17.37	-46.7	0.00	40.0
Cycle 14 Day 1	21	84.44	20.04	6.7	86.67	100.0	20	0.67	14.97	-26.7	0.00	33.3
Cycle 15 Day 1	18	82.22	22.75	6.7	86.67	100.0	17	-2.75	16.51	-40.0	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.6.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Physical Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	86.67	21.34	13.3	93.33	100.0	16	2.50	13.53	-20.0	0.00	33.3
Cycle 17 Day 1	13	89.74	16.01	40.0	93.33	100.0	11	7.27	12.09	-13.3	6.67	33.3
Cycle 18 Day 1	10	97.33	3.44	93.3	100.00	100.0	9	11.11	15.28	-6.7	6.67	46.7
Study Disc 1	52	70.26	30.58	0.0	80.00	100.0	47	-12.62	31.06	-100.0	0.00	33.3
30 D SFU Z/P	29	76.32	23.47	0.0	80.00	100.0	27	-5.43	21.00	-66.7	0.00	20.0
90 D SFU Z/P	30	81.78	20.78	20.0	86.67	100.0	29	-2.53	17.40	-53.3	0.00	20.0

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.7.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Role Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	76.50	24.68	0.0	75.00	100.0						
Cycle 2 Day 1	69	72.71	25.40	16.7	66.67	100.0	68	-4.17	23.64	-66.7	0.00	66.7
Cycle 3 Day 1	61	72.95	24.94	0.0	66.67	100.0	60	-4.17	23.50	-83.3	0.00	33.3
Cycle 4 Day 1	57	76.90	25.54	0.0	83.33	100.0	57	-0.88	17.08	-33.3	0.00	33.3
Cycle 5 Day 1	55	80.00	21.85	0.0	83.33	100.0	54	2.78	21.17	-33.3	0.00	66.7
Cycle 6 Day 1	55	74.55	26.62	0.0	83.33	100.0	55	-2.73	24.17	-100.0	0.00	66.7
Cycle 7 Day 1	44	75.76	26.03	0.0	75.00	100.0	44	-1.89	24.70	-66.7	0.00	50.0
Cycle 8 Day 1	41	74.80	26.65	0.0	66.67	100.0	39	-2.99	20.55	-33.3	0.00	66.7
Cycle 9 Day 1	38	78.07	23.92	0.0	75.00	100.0	37	0.00	22.91	-33.3	0.00	66.7
Cycle 10 Day 1	34	77.94	28.93	0.0	91.67	100.0	33	-1.52	28.37	-66.7	0.00	50.0
Cycle 11 Day 1	32	78.65	17.06	50.0	66.67	100.0	31	-1.61	22.51	-33.3	0.00	66.7
Cycle 12 Day 1	31	79.03	20.17	33.3	83.33	100.0	30	-1.67	28.82	-66.7	0.00	66.7
Cycle 13 Day 1	26	83.33	17.00	66.7	83.33	100.0	25	2.67	29.53	-33.3	0.00	66.7
Cycle 14 Day 1	22	82.58	17.43	50.0	83.33	100.0	21	3.17	26.68	-50.0	0.00	66.7
Cycle 15 Day 1	23	83.33	19.46	33.3	100.00	100.0	22	3.79	24.09	-33.3	0.00	66.7
Cycle 16 Day 1	24	84.03	16.65	66.7	91.67	100.0	23	3.62	25.10	-33.3	0.00	66.7
Cycle 17 Day 1	21	89.68	17.06	50.0	100.00	100.0	20	10.83	24.94	-33.3	0.00	66.7
Cycle 18 Day 1	21	83.33	16.67	66.7	83.33	100.0	20	0.83	21.27	-33.3	0.00	33.3
Cycle 19 Day 1	21	88.89	18.51	33.3	100.00	100.0	20	6.67	21.22	-33.3	0.00	33.3
Cycle 20 Day 1	19	86.84	19.70	33.3	100.00	100.0	18	4.63	23.44	-33.3	0.00	33.3
Cycle 21 Day 1	18	85.19	19.71	33.3	100.00	100.0	17	2.94	21.44	-33.3	0.00	33.3
Cycle 22 Day 1	15	88.89	20.57	33.3	100.00	100.0	14	5.95	16.80	-33.3	0.00	33.3
Cycle 23 Day 1	15	94.44	12.06	66.7	100.00	100.0	14	7.14	18.16	-33.3	0.00	33.3
Cycle 24 Day 1	14	89.29	14.03	66.7	100.00	100.0	13	1.28	20.93	-33.3	0.00	33.3
Cycle 25 Day 1	14	94.05	12.42	66.7	100.00	100.0	13	6.41	22.09	-33.3	0.00	50.0

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.7.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Role Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	88.89	16.41	66.7	100.00	100.0	11	3.03	22.13	-33.3	0.00	33.3
Cycle 27 Day 1	13	89.74	14.50	66.7	100.00	100.0	12	2.78	18.58	-33.3	0.00	33.3
Cycle 28 Day 1	11	86.36	14.56	66.7	83.33	100.0	10	3.33	20.49	-33.3	0.00	33.3
Cycle 29 Day 1	11	77.27	30.07	0.0	83.33	100.0	10	-6.67	31.62	-66.7	0.00	50.0
Cycle 30 Day 1	10	88.33	15.81	66.7	100.00	100.0	9	7.41	23.73	-33.3	0.00	50.0
Cycle 31 Day 1	10	93.33	14.05	66.7	100.00	100.0	9	12.96	24.69	-33.3	16.67	50.0
Cycle 32 Day 1	10	90.00	16.10	66.7	100.00	100.0	9	9.26	26.50	-33.3	0.00	50.0
Study Disc 1	48	64.58	34.32	0.0	66.67	100.0	48	-12.85	29.02	-100.0	0.00	66.7
30 D SFU Z/P	22	70.45	25.68	0.0	66.67	100.0	22	-9.09	27.57	-66.7	0.00	33.3
90 D SFU Z/P	23	78.99	23.69	33.3	83.33	100.0	23	-5.07	25.34	-66.7	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	81	77.98	24.27	0.0	83.33	100.0						
Cycle 2 Day 1	73	77.40	27.27	0.0	83.33	100.0	70	-0.48	22.16	-66.7	0.00	66.7
Cycle 3 Day 1	64	79.69	26.31	0.0	100.00	100.0	63	2.65	25.79	-66.7	0.00	66.7
Cycle 4 Day 1	56	80.95	24.08	0.0	91.67	100.0	56	2.68	28.39	-66.7	0.00	66.7
Cycle 5 Day 1	57	79.82	24.95	0.0	83.33	100.0	57	0.88	27.53	-83.3	0.00	66.7
Cycle 6 Day 1	48	77.08	26.32	0.0	83.33	100.0	48	-2.43	28.35	-66.7	0.00	66.7
Cycle 7 Day 1	42	83.73	19.99	33.3	100.00	100.0	42	2.38	25.12	-50.0	0.00	66.7
Cycle 8 Day 1	37	74.77	30.59	0.0	83.33	100.0	37	-5.41	31.93	-100.0	0.00	33.3
Cycle 9 Day 1	35	77.62	23.89	0.0	83.33	100.0	35	-4.29	25.03	-66.7	0.00	33.3
Cycle 10 Day 1	30	77.78	25.27	0.0	83.33	100.0	29	-6.90	24.20	-66.7	0.00	33.3
Cycle 11 Day 1	27	79.63	28.99	0.0	100.00	100.0	27	-0.62	30.13	-100.0	0.00	33.3
Cycle 12 Day 1	26	78.21	23.93	16.7	83.33	100.0	25	-2.67	28.33	-66.7	0.00	33.3
Cycle 13 Day 1	22	81.06	28.31	0.0	100.00	100.0	21	-1.59	32.02	-66.7	0.00	33.3
Cycle 14 Day 1	21	79.37	25.22	0.0	83.33	100.0	20	-1.67	23.51	-50.0	0.00	33.3
Cycle 15 Day 1	18	80.56	29.29	0.0	91.67	100.0	17	-2.94	29.01	-100.0	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.7.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Role Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	81.37	25.61	0.0	83.33	100.0	16	-1.04	23.94	-33.3	0.00	33.3
Cycle 17 Day 1	13	87.18	21.68	33.3	100.00	100.0	11	6.06	29.13	-33.3	0.00	33.3
Cycle 18 Day 1	10	91.67	11.79	66.7	100.00	100.0	9	11.11	27.64	-33.3	33.33	33.3
Study Disc 1	52	64.74	33.28	0.0	66.67	100.0	47	-13.12	36.93	-100.0	0.00	66.7
30 D SFU Z/P	29	64.37	28.43	0.0	66.67	100.0	27	-13.58	35.82	-100.0	-16.67	50.0
90 D SFU Z/P	30	78.33	24.43	33.3	83.33	100.0	29	0.57	26.90	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.8.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Emotional Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	75.64	20.80	8.3	75.00	100.0						
Cycle 2 Day 1	69	78.74	21.79	16.7	83.33	100.0	68	1.72	16.64	-41.7	0.00	58.3
Cycle 3 Day 1	61	78.69	17.97	16.7	75.00	100.0	60	-0.28	17.42	-41.7	0.00	66.7
Cycle 4 Day 1	57	80.26	20.08	8.3	83.33	100.0	57	1.02	16.67	-50.0	0.00	50.0
Cycle 5 Day 1	55	82.27	18.57	0.0	83.33	100.0	54	3.09	19.71	-100.0	4.17	33.3
Cycle 6 Day 1	55	80.30	18.80	16.7	83.33	100.0	55	2.27	16.15	-58.3	0.00	50.0
Cycle 7 Day 1	44	82.39	15.69	41.7	83.33	100.0	44	3.60	18.27	-50.0	0.00	58.3
Cycle 8 Day 1	41	80.28	22.73	8.3	91.67	100.0	39	4.91	18.90	-50.0	0.00	50.0
Cycle 9 Day 1	38	80.92	18.57	16.7	87.50	100.0	37	5.18	21.73	-58.3	8.33	75.0
Cycle 10 Day 1	34	85.29	13.30	66.7	87.50	100.0	33	10.35	20.94	-25.0	8.33	83.3
Cycle 11 Day 1	32	82.55	16.44	50.0	87.50	100.0	31	8.06	21.46	-33.3	0.00	83.3
Cycle 12 Day 1	31	85.22	13.73	66.7	91.67	100.0	30	10.28	21.07	-16.7	8.33	83.3
Cycle 13 Day 1	26	84.94	16.16	50.0	91.67	100.0	25	7.00	20.65	-33.3	0.00	58.3
Cycle 14 Day 1	22	85.23	14.53	58.3	91.67	100.0	21	6.35	17.66	-33.3	0.00	41.7
Cycle 15 Day 1	23	85.87	13.16	66.7	83.33	100.0	22	7.58	18.35	-33.3	4.17	41.7
Cycle 16 Day 1	24	84.38	15.98	50.0	87.50	100.0	23	5.07	17.72	-33.3	0.00	41.7
Cycle 17 Day 1	21	83.33	16.67	50.0	91.67	100.0	20	6.25	17.07	-16.7	0.00	41.7
Cycle 18 Day 1	21	80.95	17.11	41.7	83.33	100.0	20	3.33	16.31	-25.0	0.00	41.7
Cycle 19 Day 1	21	86.11	13.78	58.3	91.67	100.0	20	9.17	13.49	-8.3	8.33	41.7
Cycle 20 Day 1	19	85.53	13.84	66.7	83.33	100.0	18	7.41	13.67	-16.7	4.17	41.7
Cycle 21 Day 1	18	86.57	15.95	50.0	91.67	100.0	17	8.82	16.26	-16.7	0.00	41.7
Cycle 22 Day 1	15	85.56	15.58	58.3	91.67	100.0	14	5.95	11.98	-16.7	4.17	25.0
Cycle 23 Day 1	15	85.56	15.89	58.3	91.67	100.0	14	2.98	8.40	-8.3	0.00	25.0
Cycle 24 Day 1	14	83.93	17.44	41.7	87.50	100.0	13	0.00	11.79	-25.0	0.00	25.0
Cycle 25 Day 1	14	88.10	14.51	66.7	95.83	100.0	13	4.49	9.39	-8.3	0.00	25.0

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.8.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Emotional Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	87.50	15.69	66.7	95.83	100.0	11	5.30	11.35	-8.3	0.00	33.3
Cycle 27 Day 1	13	84.62	18.59	33.3	91.67	100.0	12	1.39	15.42	-33.3	0.00	25.0
Cycle 28 Day 1	11	79.55	17.23	58.3	75.00	100.0	10	1.67	13.49	-16.7	0.00	25.0
Cycle 29 Day 1	11	78.79	17.62	41.7	83.33	100.0	10	0.00	15.21	-25.0	0.00	25.0
Cycle 30 Day 1	10	82.50	16.41	50.0	87.50	100.0	9	4.63	16.20	-16.7	0.00	25.0
Cycle 31 Day 1	10	77.50	20.05	41.7	79.17	100.0	9	-1.85	14.89	-25.0	0.00	25.0
Cycle 32 Day 1	10	82.50	18.19	50.0	91.67	100.0	9	4.63	13.89	-16.7	0.00	25.0
Study Disc 1	48	73.61	25.23	0.0	79.17	100.0	48	-5.21	23.73	-100.0	0.00	25.0
30 D SFU Z/P	22	71.59	22.81	0.0	75.00	100.0	22	-6.06	24.15	-66.7	0.00	41.7
90 D SFU Z/P	23	79.35	19.44	33.3	83.33	100.0	23	-3.26	15.23	-50.0	0.00	16.7
Placebo + CAPOX (N= 88)												
Baseline	81	76.85	23.57	0.0	83.33	100.0						
Cycle 2 Day 1	73	80.82	21.81	0.0	83.33	100.0	70	4.29	17.01	-33.3	0.00	50.0
Cycle 3 Day 1	64	81.38	20.07	0.0	87.50	100.0	63	5.56	20.90	-50.0	0.00	66.7
Cycle 4 Day 1	56	79.17	17.70	33.3	83.33	100.0	56	2.53	18.86	-33.3	0.00	41.7
Cycle 5 Day 1	57	78.80	17.68	41.7	75.00	100.0	57	1.75	20.09	-50.0	0.00	41.7
Cycle 6 Day 1	48	76.91	21.28	16.7	75.00	100.0	48	0.52	23.09	-58.3	0.00	66.7
Cycle 7 Day 1	42	78.37	20.66	25.0	79.17	100.0	42	0.99	24.50	-66.7	0.00	58.3
Cycle 8 Day 1	37	75.23	22.26	16.7	75.00	100.0	37	0.68	19.78	-41.7	0.00	33.3
Cycle 9 Day 1	35	77.14	19.84	33.3	83.33	100.0	35	0.24	20.36	-41.7	0.00	33.3
Cycle 10 Day 1	30	76.11	19.78	25.0	83.33	100.0	29	-0.86	20.81	-50.0	0.00	33.3
Cycle 11 Day 1	27	80.86	23.77	16.7	83.33	100.0	27	3.40	21.96	-50.0	0.00	58.3
Cycle 12 Day 1	26	77.24	21.80	25.0	75.00	100.0	25	-0.67	23.31	-50.0	0.00	41.7
Cycle 13 Day 1	22	78.41	22.37	25.0	83.33	100.0	21	-1.59	25.09	-50.0	0.00	50.0
Cycle 14 Day 1	21	74.60	21.97	25.0	75.00	100.0	20	-7.50	18.91	-50.0	0.00	25.0
Cycle 15 Day 1	18	77.78	23.22	25.0	83.33	100.0	17	-8.82	19.87	-50.0	-8.33	25.0

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.8.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Emotional Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	83.82	19.65	33.3	91.67	100.0	16	-3.65	21.51	-50.0	0.00	33.3
Cycle 17 Day 1	13	94.23	7.12	83.3	100.00	100.0	11	3.79	15.97	-16.7	0.00	33.3
Cycle 18 Day 1	10	91.67	8.78	75.0	91.67	100.0	9	0.00	13.18	-25.0	0.00	16.7
Study Disc 1	52	66.99	25.93	0.0	70.83	100.0	47	-9.40	26.22	-66.7	0.00	41.7
30 D SFU Z/P	29	68.97	29.96	0.0	75.00	100.0	27	-1.85	28.99	-66.7	0.00	41.7
90 D SFU Z/P	30	76.11	24.54	0.0	83.33	100.0	29	7.18	22.24	-41.7	8.33	58.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.9.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Cognitive Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	86.32	17.97	33.3	100.00	100.0						
Cycle 2 Day 1	69	86.23	18.29	33.3	100.00	100.0	68	-0.25	14.54	-33.3	0.00	66.7
Cycle 3 Day 1	61	85.79	15.47	50.0	83.33	100.0	60	-1.94	15.06	-33.3	0.00	50.0
Cycle 4 Day 1	57	86.84	15.35	50.0	100.00	100.0	57	-0.88	13.15	-33.3	0.00	33.3
Cycle 5 Day 1	55	86.97	17.77	0.0	83.33	100.0	54	-0.62	18.59	-83.3	0.00	50.0
Cycle 6 Day 1	55	87.27	18.13	16.7	100.00	100.0	55	-0.91	17.40	-50.0	0.00	50.0
Cycle 7 Day 1	44	88.64	16.77	33.3	100.00	100.0	44	2.27	21.74	-66.7	0.00	66.7
Cycle 8 Day 1	41	87.40	15.71	50.0	100.00	100.0	39	0.85	18.71	-50.0	0.00	50.0
Cycle 9 Day 1	38	86.84	16.51	33.3	100.00	100.0	37	0.00	16.20	-33.3	0.00	33.3
Cycle 10 Day 1	34	90.20	13.05	66.7	100.00	100.0	33	5.05	21.03	-16.7	0.00	66.7
Cycle 11 Day 1	32	88.54	14.93	50.0	100.00	100.0	31	2.69	20.23	-33.3	0.00	50.0
Cycle 12 Day 1	31	86.56	14.54	66.7	83.33	100.0	30	1.11	19.04	-33.3	0.00	50.0
Cycle 13 Day 1	26	87.82	14.57	66.7	100.00	100.0	25	3.33	21.52	-33.3	0.00	66.7
Cycle 14 Day 1	22	91.67	13.36	66.7	100.00	100.0	21	4.76	22.45	-33.3	0.00	66.7
Cycle 15 Day 1	23	89.13	13.86	66.7	100.00	100.0	22	2.27	20.12	-33.3	0.00	50.0
Cycle 16 Day 1	24	91.67	13.00	66.7	100.00	100.0	23	5.07	21.58	-16.7	0.00	66.7
Cycle 17 Day 1	21	91.27	13.56	66.7	100.00	100.0	20	4.17	16.99	-16.7	0.00	50.0
Cycle 18 Day 1	21	90.48	12.44	66.7	100.00	100.0	20	5.00	17.18	-16.7	0.00	50.0
Cycle 19 Day 1	21	90.48	12.44	66.7	100.00	100.0	20	5.00	21.01	-33.3	0.00	50.0
Cycle 20 Day 1	19	90.35	12.81	66.7	100.00	100.0	18	5.56	23.57	-16.7	0.00	66.7
Cycle 21 Day 1	18	87.96	15.97	50.0	100.00	100.0	17	2.94	24.46	-33.3	0.00	50.0
Cycle 22 Day 1	15	94.44	8.13	83.3	100.00	100.0	14	10.71	20.26	-16.7	0.00	50.0
Cycle 23 Day 1	15	94.44	10.29	66.7	100.00	100.0	14	5.95	21.29	-16.7	0.00	66.7
Cycle 24 Day 1	14	95.24	10.19	66.7	100.00	100.0	13	6.41	24.09	-33.3	0.00	66.7
Cycle 25 Day 1	14	95.24	7.81	83.3	100.00	100.0	13	6.41	23.11	-16.7	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.9.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Cognitive Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	97.22	6.49	83.3	100.00	100.0	11	10.61	22.70	-16.7	0.00	66.7
Cycle 27 Day 1	13	94.87	8.01	83.3	100.00	100.0	12	6.94	22.98	-16.7	0.00	66.7
Cycle 28 Day 1	11	92.42	11.46	66.7	100.00	100.0	10	8.33	25.15	-16.7	0.00	66.7
Cycle 29 Day 1	11	89.39	13.48	66.7	100.00	100.0	10	5.00	27.27	-16.7	0.00	66.7
Cycle 30 Day 1	10	93.33	11.65	66.7	100.00	100.0	9	7.41	23.73	-16.7	0.00	66.7
Cycle 31 Day 1	10	90.00	14.05	66.7	100.00	100.0	9	3.70	26.06	-16.7	0.00	66.7
Cycle 32 Day 1	10	91.67	14.16	66.7	100.00	100.0	9	5.56	26.35	-16.7	0.00	66.7
Study Disc 1	48	81.60	23.63	0.0	83.33	100.0	48	-3.82	22.34	-100.0	0.00	50.0
30 D SFU Z/P	22	86.36	18.99	33.3	100.00	100.0	22	-1.52	18.48	-33.3	0.00	50.0
90 D SFU Z/P	23	85.51	16.90	50.0	100.00	100.0	23	-7.97	15.79	-50.0	0.00	16.7
Placebo + CAPOX (N= 88)												
Baseline	81	84.36	21.46	0.0	100.00	100.0						
Cycle 2 Day 1	73	84.70	21.11	0.0	100.00	100.0	70	0.00	17.49	-50.0	0.00	50.0
Cycle 3 Day 1	64	86.20	20.26	0.0	100.00	100.0	63	1.85	17.22	-50.0	0.00	33.3
Cycle 4 Day 1	56	87.80	16.96	16.7	100.00	100.0	56	2.38	18.38	-50.0	0.00	50.0
Cycle 5 Day 1	57	90.35	16.35	16.7	100.00	100.0	57	4.39	17.40	-50.0	0.00	50.0
Cycle 6 Day 1	48	87.15	20.12	0.0	100.00	100.0	48	1.39	20.87	-66.7	0.00	66.7
Cycle 7 Day 1	42	83.73	20.98	33.3	91.67	100.0	42	-2.38	20.68	-66.7	0.00	33.3
Cycle 8 Day 1	37	84.68	21.65	16.7	100.00	100.0	37	0.00	17.57	-50.0	0.00	33.3
Cycle 9 Day 1	35	86.19	19.17	16.7	100.00	100.0	35	0.48	17.84	-50.0	0.00	33.3
Cycle 10 Day 1	30	85.00	19.74	33.3	100.00	100.0	29	-1.15	20.86	-66.7	0.00	33.3
Cycle 11 Day 1	27	87.04	17.50	50.0	100.00	100.0	27	1.85	17.50	-50.0	0.00	33.3
Cycle 12 Day 1	26	86.54	19.45	16.7	100.00	100.0	25	1.33	18.58	-50.0	0.00	33.3
Cycle 13 Day 1	22	83.33	21.82	16.7	91.67	100.0	21	-3.97	23.51	-50.0	0.00	33.3
Cycle 14 Day 1	21	83.33	25.28	16.7	100.00	100.0	20	-5.00	23.63	-66.7	0.00	16.7
Cycle 15 Day 1	18	83.33	20.61	33.3	91.67	100.0	17	-6.86	18.69	-50.0	0.00	16.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.9.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Cognitive Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	84.31	23.91	16.7	100.00	100.0	16	-5.21	20.83	-50.0	0.00	16.7
Cycle 17 Day 1	13	89.74	21.01	33.3	100.00	100.0	11	1.52	13.85	-33.3	0.00	16.7
Cycle 18 Day 1	10	95.00	11.25	66.7	100.00	100.0	9	0.00	14.43	-33.3	0.00	16.7
Study Disc 1	52	76.28	28.27	0.0	83.33	100.0	47	-7.45	25.01	-83.3	0.00	66.7
30 D SFU Z/P	29	76.44	30.38	0.0	100.00	100.0	27	-2.47	26.84	-100.0	0.00	50.0
90 D SFU Z/P	30	82.78	23.77	0.0	100.00	100.0	29	3.45	21.99	-33.3	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.10.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Social Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	76.07	23.66	0.0	66.67	100.0						
Cycle 2 Day 1	69	77.78	25.67	16.7	83.33	100.0	68	1.47	26.51	-66.7	0.00	66.7
Cycle 3 Day 1	61	72.68	25.46	0.0	66.67	100.0	60	-3.33	24.70	-66.7	0.00	33.3
Cycle 4 Day 1	57	79.53	21.83	33.3	83.33	100.0	57	3.22	22.81	-66.7	0.00	33.3
Cycle 5 Day 1	55	78.48	24.36	0.0	83.33	100.0	54	4.63	25.58	-83.3	0.00	50.0
Cycle 6 Day 1	55	77.58	23.40	33.3	83.33	100.0	55	2.42	24.72	-66.7	0.00	33.3
Cycle 7 Day 1	44	75.38	26.53	0.0	75.00	100.0	44	-2.65	30.06	-100.0	0.00	50.0
Cycle 8 Day 1	41	80.49	23.54	33.3	100.00	100.0	39	3.42	28.14	-66.7	0.00	66.7
Cycle 9 Day 1	38	75.44	24.43	0.0	75.00	100.0	37	-2.25	25.20	-66.7	0.00	33.3
Cycle 10 Day 1	34	81.86	20.25	33.3	83.33	100.0	33	5.05	28.41	-66.7	0.00	66.7
Cycle 11 Day 1	32	83.33	18.45	33.3	91.67	100.0	31	5.91	24.55	-33.3	0.00	66.7
Cycle 12 Day 1	31	83.33	19.72	33.3	83.33	100.0	30	6.67	23.81	-33.3	0.00	50.0
Cycle 13 Day 1	26	82.05	21.56	33.3	100.00	100.0	25	6.67	30.43	-66.7	0.00	66.7
Cycle 14 Day 1	22	82.58	16.65	66.7	75.00	100.0	21	3.97	22.92	-33.3	0.00	66.7
Cycle 15 Day 1	23	81.88	19.41	33.3	83.33	100.0	22	5.30	27.40	-66.7	0.00	66.7
Cycle 16 Day 1	24	84.72	21.38	16.7	100.00	100.0	23	6.52	23.96	-50.0	0.00	50.0
Cycle 17 Day 1	21	86.51	17.17	50.0	100.00	100.0	20	10.00	22.56	-33.3	0.00	66.7
Cycle 18 Day 1	21	79.37	21.67	33.3	83.33	100.0	20	2.50	27.19	-66.7	0.00	66.7
Cycle 19 Day 1	21	84.13	17.06	50.0	83.33	100.0	20	7.50	21.27	-33.3	0.00	66.7
Cycle 20 Day 1	19	85.09	19.16	50.0	100.00	100.0	18	8.33	24.42	-50.0	0.00	66.7
Cycle 21 Day 1	18	82.41	23.20	33.3	100.00	100.0	17	4.90	26.85	-33.3	0.00	66.7
Cycle 22 Day 1	15	87.78	20.38	33.3	100.00	100.0	14	9.52	25.91	-33.3	0.00	66.7
Cycle 23 Day 1	15	87.78	20.38	33.3	100.00	100.0	14	4.76	32.96	-66.7	0.00	66.7
Cycle 24 Day 1	14	91.67	14.25	66.7	100.00	100.0	13	6.41	27.67	-33.3	0.00	66.7
Cycle 25 Day 1	14	89.29	14.03	66.7	100.00	100.0	13	3.85	27.35	-33.3	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.10.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Social Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	90.28	15.01	66.7	100.00	100.0	11	4.55	28.95	-33.3	0.00	66.7
Cycle 27 Day 1	13	87.18	20.59	33.3	100.00	100.0	12	0.00	34.08	-66.7	0.00	66.7
Cycle 28 Day 1	11	84.85	22.92	33.3	100.00	100.0	10	5.00	37.72	-66.7	8.33	66.7
Cycle 29 Day 1	11	80.30	22.13	33.3	83.33	100.0	10	0.00	36.85	-66.7	0.00	66.7
Cycle 30 Day 1	10	83.33	23.57	33.3	100.00	100.0	9	1.85	42.04	-66.7	0.00	66.7
Cycle 31 Day 1	10	80.00	24.60	33.3	91.67	100.0	9	-1.85	37.68	-66.7	0.00	66.7
Cycle 32 Day 1	10	83.33	23.57	33.3	100.00	100.0	9	1.85	38.59	-66.7	0.00	66.7
Study Disc 1	48	69.10	33.15	0.0	75.00	100.0	48	-4.51	28.71	-100.0	0.00	33.3
30 D SFU Z/P	22	75.00	27.58	0.0	75.00	100.0	22	0.76	28.86	-66.7	0.00	33.3
90 D SFU Z/P	23	83.33	23.57	33.3	100.00	100.0	23	2.90	23.92	-66.7	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	81	80.86	24.74	0.0	83.33	100.0						
Cycle 2 Day 1	73	78.77	26.97	0.0	83.33	100.0	70	-2.62	21.16	-66.7	0.00	50.0
Cycle 3 Day 1	64	80.21	23.55	0.0	91.67	100.0	63	0.00	22.40	-66.7	0.00	66.7
Cycle 4 Day 1	56	80.36	22.94	0.0	83.33	100.0	56	0.30	21.90	-50.0	0.00	50.0
Cycle 5 Day 1	57	78.95	23.04	33.3	83.33	100.0	57	-2.34	23.24	-66.7	0.00	66.7
Cycle 6 Day 1	48	80.21	25.42	0.0	100.00	100.0	48	-1.74	20.98	-66.7	0.00	50.0
Cycle 7 Day 1	42	81.35	23.05	0.0	91.67	100.0	42	-1.59	24.08	-66.7	0.00	66.7
Cycle 8 Day 1	37	77.48	28.66	0.0	100.00	100.0	37	-4.05	25.58	-100.0	0.00	50.0
Cycle 9 Day 1	35	77.14	25.91	0.0	83.33	100.0	35	-5.24	24.84	-100.0	0.00	33.3
Cycle 10 Day 1	30	78.89	26.96	0.0	83.33	100.0	29	-5.75	26.46	-100.0	0.00	50.0
Cycle 11 Day 1	27	80.25	25.33	0.0	83.33	100.0	27	-1.23	26.92	-100.0	0.00	33.3
Cycle 12 Day 1	26	74.36	29.90	0.0	75.00	100.0	25	-8.00	26.40	-100.0	0.00	33.3
Cycle 13 Day 1	22	77.27	28.89	0.0	83.33	100.0	21	-7.14	28.17	-100.0	0.00	33.3
Cycle 14 Day 1	21	76.98	29.57	0.0	83.33	100.0	20	-6.67	27.25	-100.0	0.00	33.3
Cycle 15 Day 1	18	75.00	28.73	0.0	75.00	100.0	17	-12.75	26.70	-100.0	0.00	16.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.10.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Social Functioning
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	79.41	22.46	16.7	83.33	100.0	16	-6.25	19.12	-33.3	0.00	33.3
Cycle 17 Day 1	13	80.77	21.35	33.3	83.33	100.0	11	-4.55	13.10	-33.3	0.00	16.7
Cycle 18 Day 1	10	86.67	15.32	66.7	91.67	100.0	9	-3.70	16.20	-33.3	0.00	16.7
Study Disc 1	52	67.31	31.48	0.0	66.67	100.0	47	-14.89	29.12	-100.0	0.00	33.3
30 D SFU Z/P	29	66.67	31.81	0.0	66.67	100.0	27	-15.43	31.67	-100.0	0.00	33.3
90 D SFU Z/P	30	77.78	30.74	0.0	100.00	100.0	29	-2.30	23.03	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.11.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Fatigue
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	30.63	21.28	0.0	33.33	88.9						
Cycle 2 Day 1	69	33.17	19.76	0.0	33.33	77.8	68	3.27	17.28	-44.4	0.00	44.4
Cycle 3 Day 1	61	34.06	20.87	0.0	33.33	100.0	60	4.26	17.61	-33.3	0.00	66.7
Cycle 4 Day 1	57	30.80	23.38	0.0	33.33	88.9	57	2.53	18.43	-33.3	0.00	55.6
Cycle 5 Day 1	55	29.90	23.51	0.0	33.33	100.0	54	1.03	20.39	-33.3	0.00	88.9
Cycle 6 Day 1	55	33.13	23.18	0.0	33.33	88.9	55	3.84	18.17	-44.4	0.00	44.4
Cycle 7 Day 1	44	31.06	24.03	0.0	33.33	100.0	44	2.53	20.17	-44.4	0.00	66.7
Cycle 8 Day 1	41	33.33	22.91	0.0	33.33	100.0	39	5.98	16.88	-55.6	11.11	33.3
Cycle 9 Day 1	38	31.87	24.39	0.0	33.33	100.0	37	2.40	20.14	-55.6	0.00	44.4
Cycle 10 Day 1	34	31.37	26.30	0.0	33.33	100.0	33	2.36	27.04	-66.7	0.00	66.7
Cycle 11 Day 1	32	25.35	18.98	0.0	33.33	66.7	31	-2.51	23.26	-66.7	0.00	33.3
Cycle 12 Day 1	31	24.73	19.18	0.0	33.33	66.7	30	-3.33	22.25	-66.7	0.00	33.3
Cycle 13 Day 1	26	21.79	16.17	0.0	27.78	44.4	25	-4.89	25.47	-66.7	0.00	33.3
Cycle 14 Day 1	22	22.73	19.24	0.0	22.22	66.7	21	-2.65	21.92	-66.7	0.00	33.3
Cycle 15 Day 1	23	21.74	17.24	0.0	33.33	55.6	22	-4.04	21.56	-66.7	0.00	33.3
Cycle 16 Day 1	24	19.91	16.70	0.0	22.22	55.6	23	-5.80	22.19	-66.7	-11.11	33.3
Cycle 17 Day 1	21	22.22	18.59	0.0	22.22	55.6	20	-3.89	19.84	-55.6	0.00	33.3
Cycle 18 Day 1	21	21.69	18.08	0.0	22.22	55.6	20	-2.22	14.69	-33.3	0.00	33.3
Cycle 19 Day 1	21	20.11	19.76	0.0	22.22	66.7	20	-3.89	19.50	-55.6	0.00	33.3
Cycle 20 Day 1	19	22.22	19.95	0.0	22.22	66.7	18	-0.62	15.93	-22.2	0.00	33.3
Cycle 21 Day 1	18	23.46	21.52	0.0	27.78	66.7	17	1.31	16.14	-22.2	0.00	33.3
Cycle 22 Day 1	15	18.52	18.62	0.0	22.22	66.7	14	-2.38	19.09	-33.3	0.00	22.2
Cycle 23 Day 1	15	16.30	18.24	0.0	11.11	44.4	14	-1.59	18.42	-33.3	0.00	22.2
Cycle 24 Day 1	14	16.67	16.16	0.0	11.11	44.4	13	0.85	18.40	-33.3	0.00	33.3
Cycle 25 Day 1	14	11.90	15.39	0.0	0.00	33.3	13	-4.27	20.05	-44.4	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.11.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Fatigue
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	13.89	15.80	0.0	5.56	33.3	11	-3.03	24.39	-44.4	0.00	33.3
Cycle 27 Day 1	13	17.09	16.11	0.0	22.22	44.4	12	0.00	11.61	-22.2	0.00	22.2
Cycle 28 Day 1	11	26.26	19.42	0.0	33.33	55.6	10	2.22	16.40	-22.2	0.00	33.3
Cycle 29 Day 1	11	26.26	18.77	0.0	33.33	66.7	10	1.11	17.72	-22.2	-5.56	33.3
Cycle 30 Day 1	10	23.33	19.91	0.0	27.78	55.6	9	1.23	12.96	-22.2	0.00	22.2
Cycle 31 Day 1	10	22.22	20.95	0.0	27.78	55.6	9	0.00	13.61	-22.2	0.00	22.2
Cycle 32 Day 1	10	17.78	17.53	0.0	16.67	55.6	9	-4.94	22.30	-44.4	0.00	22.2
Study Disc 1	48	38.19	29.16	0.0	33.33	100.0	48	10.19	24.77	-66.7	11.11	100.0
30 D SFU Z/P	22	33.84	23.63	0.0	33.33	88.9	22	8.08	17.55	-22.2	0.00	55.6
90 D SFU Z/P	23	30.92	20.09	0.0	33.33	77.8	23	9.66	16.52	-22.2	11.11	55.6
Placebo + CAPOX (N= 88)												
Baseline	81	29.08	24.76	0.0	33.33	100.0						
Cycle 2 Day 1	73	31.20	21.88	0.0	33.33	100.0	70	1.90	19.66	-33.3	0.00	44.4
Cycle 3 Day 1	64	28.30	21.04	0.0	33.33	100.0	63	-0.18	21.45	-55.6	0.00	44.4
Cycle 4 Day 1	56	29.56	19.91	0.0	33.33	100.0	56	1.59	24.38	-55.6	0.00	77.8
Cycle 5 Day 1	57	31.19	20.62	0.0	33.33	100.0	57	3.31	25.28	-55.6	0.00	66.7
Cycle 6 Day 1	48	28.01	24.68	0.0	22.22	100.0	48	0.93	25.09	-44.4	0.00	66.7
Cycle 7 Day 1	42	28.57	19.03	0.0	33.33	100.0	42	2.65	24.39	-66.7	0.00	44.4
Cycle 8 Day 1	37	29.73	22.38	0.0	22.22	100.0	37	2.10	22.35	-33.3	0.00	44.4
Cycle 9 Day 1	35	27.94	20.23	0.0	33.33	88.9	35	1.59	24.12	-44.4	0.00	55.6
Cycle 10 Day 1	30	32.22	20.29	0.0	33.33	88.9	29	9.20	23.21	-33.3	11.11	55.6
Cycle 11 Day 1	27	29.22	26.89	0.0	33.33	100.0	27	3.29	28.88	-55.6	0.00	77.8
Cycle 12 Day 1	26	27.35	23.36	0.0	27.78	77.8	25	1.78	28.27	-44.4	0.00	66.7
Cycle 13 Day 1	22	29.80	22.32	0.0	33.33	88.9	21	4.76	25.72	-44.4	0.00	44.4
Cycle 14 Day 1	21	30.69	25.80	0.0	33.33	100.0	20	6.11	24.04	-33.3	0.00	66.7
Cycle 15 Day 1	18	27.16	24.76	0.0	22.22	100.0	17	3.92	20.01	-33.3	0.00	44.4

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.11.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Fatigue
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	21.57	22.04	0.0	11.11	88.9	16	-0.69	19.23	-33.3	0.00	33.3
Cycle 17 Day 1	13	20.51	17.48	0.0	22.22	66.7	11	-2.02	17.08	-33.3	0.00	22.2
Cycle 18 Day 1	10	13.33	11.48	0.0	11.11	33.3	9	-7.41	19.25	-33.3	-11.11	22.2
Study Disc 1	52	42.09	29.38	0.0	33.33	100.0	47	14.18	28.63	-33.3	11.11	100.0
30 D SFU Z/P	29	36.40	26.38	0.0	33.33	100.0	27	9.47	29.51	-44.4	0.00	77.8
90 D SFU Z/P	30	31.11	25.67	0.0	33.33	100.0	29	1.53	21.56	-33.3	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.12.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Nausea and Vomiting
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	12.82	19.36	0.0	0.00	83.3						
Cycle 2 Day 1	69	20.29	22.48	0.0	16.67	83.3	68	7.84	23.83	-33.3	0.00	83.3
Cycle 3 Day 1	61	18.85	19.36	0.0	16.67	66.7	60	7.50	21.35	-50.0	16.67	66.7
Cycle 4 Day 1	57	16.08	18.08	0.0	16.67	66.7	57	5.56	23.43	-66.7	0.00	66.7
Cycle 5 Day 1	55	17.88	21.00	0.0	16.67	100.0	54	7.10	25.00	-50.0	0.00	66.7
Cycle 6 Day 1	55	14.55	17.29	0.0	16.67	66.7	55	4.24	21.81	-66.7	0.00	50.0
Cycle 7 Day 1	44	10.23	11.49	0.0	8.33	33.3	44	0.00	21.26	-83.3	0.00	33.3
Cycle 8 Day 1	41	11.79	15.02	0.0	16.67	66.7	39	1.28	21.42	-83.3	0.00	50.0
Cycle 9 Day 1	38	11.40	11.03	0.0	16.67	33.3	37	1.35	22.35	-83.3	0.00	33.3
Cycle 10 Day 1	34	7.84	13.13	0.0	0.00	50.0	33	-0.51	24.47	-83.3	0.00	50.0
Cycle 11 Day 1	32	5.21	9.87	0.0	0.00	33.3	31	-3.76	22.24	-83.3	0.00	33.3
Cycle 12 Day 1	31	9.14	12.05	0.0	0.00	33.3	30	0.00	24.37	-83.3	0.00	33.3
Cycle 13 Day 1	26	6.41	14.20	0.0	0.00	66.7	25	-2.67	25.77	-83.3	0.00	66.7
Cycle 14 Day 1	22	6.06	12.11	0.0	0.00	50.0	21	-0.79	23.85	-83.3	0.00	50.0
Cycle 15 Day 1	23	4.35	10.32	0.0	0.00	33.3	22	-2.27	22.59	-83.3	0.00	33.3
Cycle 16 Day 1	24	9.03	13.88	0.0	0.00	33.3	23	1.45	24.05	-83.3	0.00	33.3
Cycle 17 Day 1	21	5.56	8.05	0.0	0.00	16.7	20	-1.67	21.56	-83.3	0.00	16.7
Cycle 18 Day 1	21	9.52	14.50	0.0	0.00	33.3	20	2.50	24.35	-83.3	0.00	33.3
Cycle 19 Day 1	21	8.73	13.56	0.0	0.00	33.3	20	1.67	24.72	-83.3	0.00	33.3
Cycle 20 Day 1	19	7.89	12.87	0.0	0.00	33.3	18	0.00	23.57	-83.3	0.00	33.3
Cycle 21 Day 1	18	10.19	14.16	0.0	0.00	33.3	17	2.94	25.16	-83.3	0.00	33.3
Cycle 22 Day 1	15	6.67	12.28	0.0	0.00	33.3	14	-1.19	25.71	-83.3	0.00	33.3
Cycle 23 Day 1	15	3.33	9.34	0.0	0.00	33.3	14	-2.38	25.20	-83.3	0.00	33.3
Cycle 24 Day 1	14	4.76	7.81	0.0	0.00	16.7	13	-1.28	25.88	-83.3	0.00	16.7
Cycle 25 Day 1	14	4.76	10.19	0.0	0.00	33.3	13	-1.28	26.75	-83.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.12.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Nausea and Vomiting
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	1.39	4.81	0.0	0.00	16.7	11	-6.06	26.11	-83.3	0.00	16.7
Cycle 27 Day 1	13	1.28	4.62	0.0	0.00	16.7	12	-5.56	24.96	-83.3	0.00	16.7
Cycle 28 Day 1	11	6.06	13.48	0.0	0.00	33.3	10	-1.67	31.87	-83.3	0.00	33.3
Cycle 29 Day 1	11	4.55	15.08	0.0	0.00	50.0	10	-3.33	32.20	-83.3	0.00	50.0
Cycle 30 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	-5.56	31.18	-83.3	0.00	33.3
Cycle 31 Day 1	10	5.00	15.81	0.0	0.00	50.0	9	-3.70	34.13	-83.3	0.00	50.0
Cycle 32 Day 1	10	8.33	16.20	0.0	0.00	50.0	9	0.00	35.36	-83.3	0.00	50.0
Study Disc 1	48	21.53	30.36	0.0	16.67	100.0	48	12.15	29.92	-50.0	0.00	100.0
30 D SFU Z/P	22	15.15	24.07	0.0	0.00	100.0	22	6.06	20.28	-33.3	0.00	50.0
90 D SFU Z/P	23	17.39	24.86	0.0	16.67	100.0	23	11.59	25.84	-33.3	0.00	100.0
Placebo + CAPOX (N= 88)												
Baseline	81	18.93	26.19	0.0	16.67	100.0						
Cycle 2 Day 1	73	15.53	19.90	0.0	16.67	100.0	70	-0.48	20.26	-66.7	0.00	83.3
Cycle 3 Day 1	64	13.80	17.95	0.0	0.00	83.3	63	-1.06	25.02	-100.0	0.00	83.3
Cycle 4 Day 1	56	12.20	15.73	0.0	0.00	66.7	56	-1.49	22.76	-83.3	0.00	50.0
Cycle 5 Day 1	57	11.40	15.80	0.0	0.00	66.7	57	-3.22	26.81	-100.0	0.00	50.0
Cycle 6 Day 1	48	13.19	18.18	0.0	0.00	66.7	48	-2.43	27.50	-100.0	0.00	33.3
Cycle 7 Day 1	42	10.32	13.25	0.0	0.00	50.0	42	-5.56	24.88	-83.3	0.00	33.3
Cycle 8 Day 1	37	4.50	9.34	0.0	0.00	33.3	37	-11.71	28.02	-100.0	0.00	16.7
Cycle 9 Day 1	35	7.62	11.68	0.0	0.00	33.3	35	-9.52	24.01	-100.0	0.00	16.7
Cycle 10 Day 1	30	6.11	16.66	0.0	0.00	83.3	29	-9.20	30.40	-100.0	0.00	50.0
Cycle 11 Day 1	27	4.32	9.91	0.0	0.00	33.3	27	-12.35	27.19	-100.0	0.00	0.0
Cycle 12 Day 1	26	8.97	20.67	0.0	0.00	66.7	25	-5.33	30.32	-100.0	0.00	66.7
Cycle 13 Day 1	22	5.30	13.00	0.0	0.00	50.0	21	-12.70	30.69	-100.0	0.00	16.7
Cycle 14 Day 1	21	11.90	21.82	0.0	0.00	66.7	20	-3.33	23.32	-66.7	0.00	33.3
Cycle 15 Day 1	18	12.04	27.30	0.0	0.00	100.0	17	-2.94	23.74	-50.0	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.12.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Nausea and Vomiting
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	4.90	11.43	0.0	0.00	33.3	16	-9.38	24.32	-66.7	0.00	16.7
Cycle 17 Day 1	13	2.56	9.25	0.0	0.00	33.3	11	0.00	0.00	0.0	0.00	0.0
Cycle 18 Day 1	10	0.00	0.00	0.0	0.00	0.0	9	-3.70	11.11	-33.3	0.00	0.0
Study Disc 1	52	20.51	29.26	0.0	0.00	100.0	47	10.28	30.41	-66.7	0.00	100.0
30 D SFU Z/P	29	18.39	24.13	0.0	16.67	83.3	27	1.23	27.71	-83.3	0.00	66.7
90 D SFU Z/P	30	13.89	24.40	0.0	0.00	100.0	29	-1.72	27.58	-100.0	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.13.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Pain
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	25.00	21.28	0.0	33.33	66.7						
Cycle 2 Day 1	69	20.29	21.17	0.0	16.67	66.7	68	-3.92	23.94	-66.7	0.00	66.7
Cycle 3 Day 1	61	19.95	23.53	0.0	16.67	83.3	60	-5.00	21.76	-66.7	0.00	33.3
Cycle 4 Day 1	57	15.50	20.86	0.0	0.00	66.7	57	-8.77	18.66	-50.0	0.00	50.0
Cycle 5 Day 1	55	16.36	22.10	0.0	0.00	100.0	54	-6.48	21.33	-33.3	0.00	83.3
Cycle 6 Day 1	55	19.09	21.14	0.0	16.67	83.3	55	-4.85	21.68	-66.7	0.00	50.0
Cycle 7 Day 1	44	17.42	18.66	0.0	16.67	66.7	44	-6.44	23.63	-50.0	0.00	50.0
Cycle 8 Day 1	41	19.51	22.02	0.0	16.67	83.3	39	-5.56	23.05	-66.7	0.00	50.0
Cycle 9 Day 1	38	18.42	16.34	0.0	16.67	50.0	37	-7.21	20.99	-50.0	-16.67	33.3
Cycle 10 Day 1	34	19.12	18.41	0.0	16.67	66.7	33	-6.06	24.23	-66.7	0.00	33.3
Cycle 11 Day 1	32	16.15	16.66	0.0	16.67	50.0	31	-9.14	21.87	-50.0	-16.67	33.3
Cycle 12 Day 1	31	18.82	22.67	0.0	16.67	100.0	30	-6.11	26.07	-66.7	0.00	50.0
Cycle 13 Day 1	26	14.10	20.38	0.0	0.00	66.7	25	-10.67	27.59	-66.7	-16.67	33.3
Cycle 14 Day 1	22	11.36	15.76	0.0	0.00	50.0	21	-11.90	24.23	-50.0	-16.67	33.3
Cycle 15 Day 1	23	10.87	13.86	0.0	0.00	33.3	22	-12.88	23.53	-66.7	-16.67	33.3
Cycle 16 Day 1	24	11.81	15.91	0.0	0.00	50.0	23	-12.32	23.15	-66.7	-16.67	33.3
Cycle 17 Day 1	21	11.90	15.04	0.0	0.00	50.0	20	-12.50	21.54	-66.7	-16.67	16.7
Cycle 18 Day 1	21	18.25	16.59	0.0	16.67	50.0	20	-3.33	20.66	-50.0	0.00	33.3
Cycle 19 Day 1	21	15.87	19.35	0.0	0.00	66.7	20	-5.83	22.47	-66.7	0.00	33.3
Cycle 20 Day 1	19	14.04	18.64	0.0	0.00	66.7	18	-6.48	19.08	-66.7	0.00	33.3
Cycle 21 Day 1	18	12.96	16.72	0.0	0.00	50.0	17	-6.86	23.61	-66.7	0.00	33.3
Cycle 22 Day 1	15	8.89	19.79	0.0	0.00	66.7	14	-10.71	20.26	-66.7	0.00	16.7
Cycle 23 Day 1	15	5.56	10.29	0.0	0.00	33.3	14	-10.71	21.29	-66.7	-8.33	16.7
Cycle 24 Day 1	14	5.95	10.56	0.0	0.00	33.3	13	-8.97	22.17	-66.7	0.00	16.7
Cycle 25 Day 1	14	8.33	15.68	0.0	0.00	50.0	13	-6.41	25.04	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.13.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Pain
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	4.17	10.36	0.0	0.00	33.3	11	-12.12	23.68	-66.7	-16.67	16.7
Cycle 27 Day 1	13	7.69	12.94	0.0	0.00	33.3	12	-8.33	26.11	-66.7	-8.33	33.3
Cycle 28 Day 1	11	12.12	18.40	0.0	0.00	50.0	10	-10.00	28.54	-66.7	-16.67	33.3
Cycle 29 Day 1	11	13.64	17.98	0.0	0.00	50.0	10	-6.67	28.54	-66.7	0.00	33.3
Cycle 30 Day 1	10	10.00	17.92	0.0	0.00	50.0	9	-12.96	26.06	-66.7	-16.67	16.7
Cycle 31 Day 1	10	8.33	18.00	0.0	0.00	50.0	9	-14.81	25.61	-66.7	-16.67	16.7
Cycle 32 Day 1	10	10.00	17.92	0.0	0.00	50.0	9	-12.96	27.36	-66.7	-16.67	16.7
Study Disc 1	48	29.51	30.80	0.0	33.33	100.0	48	6.25	27.42	-50.0	0.00	100.0
30 D SFU Z/P	22	26.52	23.38	0.0	25.00	83.3	22	5.30	21.45	-16.7	0.00	66.7
90 D SFU Z/P	23	23.91	19.35	0.0	16.67	66.7	23	3.62	21.29	-33.3	0.00	50.0
Placebo + CAPOX (N= 88)												
Baseline	81	25.72	25.83	0.0	16.67	100.0						
Cycle 2 Day 1	73	22.37	20.07	0.0	16.67	100.0	70	-2.86	22.16	-66.7	0.00	50.0
Cycle 3 Day 1	64	19.01	21.18	0.0	16.67	100.0	63	-5.29	26.91	-66.7	0.00	83.3
Cycle 4 Day 1	56	18.75	17.71	0.0	16.67	66.7	56	-5.36	22.50	-66.7	0.00	50.0
Cycle 5 Day 1	57	19.59	23.81	0.0	16.67	100.0	57	-3.80	25.98	-66.7	0.00	83.3
Cycle 6 Day 1	48	16.67	24.07	0.0	8.33	100.0	48	-6.60	28.30	-66.7	0.00	66.7
Cycle 7 Day 1	42	13.49	16.15	0.0	0.00	50.0	42	-9.52	24.18	-66.7	0.00	33.3
Cycle 8 Day 1	37	17.12	23.40	0.0	0.00	100.0	37	-6.76	22.03	-66.7	0.00	66.7
Cycle 9 Day 1	35	18.57	25.17	0.0	0.00	83.3	35	-4.76	25.10	-66.7	0.00	66.7
Cycle 10 Day 1	30	17.78	23.13	0.0	8.33	66.7	29	-3.45	26.12	-66.7	0.00	66.7
Cycle 11 Day 1	27	16.67	20.15	0.0	16.67	66.7	27	-8.02	31.14	-66.7	0.00	66.7
Cycle 12 Day 1	26	14.74	22.27	0.0	0.00	66.7	25	-8.67	29.31	-66.7	0.00	66.7
Cycle 13 Day 1	22	16.67	23.57	0.0	0.00	83.3	21	-7.94	26.15	-66.7	0.00	66.7
Cycle 14 Day 1	21	23.02	27.63	0.0	16.67	100.0	20	-1.67	26.98	-50.0	0.00	66.7
Cycle 15 Day 1	18	19.44	29.29	0.0	8.33	100.0	17	-2.94	21.44	-50.0	0.00	50.0

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.13.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Pain
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	14.71	17.56	0.0	0.00	50.0	16	-7.29	22.75	-50.0	0.00	33.3
Cycle 17 Day 1	13	10.26	19.88	0.0	0.00	66.7	11	-7.58	17.26	-50.0	0.00	16.7
Cycle 18 Day 1	10	5.00	8.05	0.0	0.00	16.7	9	-11.11	18.63	-50.0	0.00	0.0
Study Disc 1	52	35.58	28.59	0.0	33.33	100.0	47	11.70	27.57	-33.3	0.00	66.7
30 D SFU Z/P	29	28.74	30.50	0.0	16.67	100.0	27	6.17	31.06	-66.7	0.00	66.7
90 D SFU Z/P	30	19.44	25.92	0.0	8.33	83.3	29	-5.17	25.63	-50.0	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.14.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Dyspnoea
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	8.55	16.50	0.0	0.00	66.7						
Cycle 2 Day 1	69	13.04	17.36	0.0	0.00	66.7	68	4.41	17.19	-33.3	0.00	33.3
Cycle 3 Day 1	61	11.48	20.08	0.0	0.00	100.0	60	3.33	19.11	-33.3	0.00	66.7
Cycle 4 Day 1	57	7.02	13.71	0.0	0.00	33.3	57	1.75	15.96	-33.3	0.00	33.3
Cycle 5 Day 1	55	11.52	18.39	0.0	0.00	66.7	54	3.09	19.71	-33.3	0.00	66.7
Cycle 6 Day 1	55	7.88	16.93	0.0	0.00	66.7	55	1.82	19.69	-33.3	0.00	66.7
Cycle 7 Day 1	44	9.09	16.65	0.0	0.00	66.7	44	3.79	20.61	-33.3	0.00	66.7
Cycle 8 Day 1	41	8.94	19.75	0.0	0.00	100.0	39	4.27	23.17	-33.3	0.00	100.0
Cycle 9 Day 1	38	8.77	14.88	0.0	0.00	33.3	37	2.70	18.22	-33.3	0.00	33.3
Cycle 10 Day 1	34	10.78	15.83	0.0	0.00	33.3	33	4.04	21.66	-33.3	0.00	33.3
Cycle 11 Day 1	32	9.37	17.42	0.0	0.00	66.7	31	3.23	19.92	-33.3	0.00	66.7
Cycle 12 Day 1	31	8.60	17.14	0.0	0.00	66.7	30	2.22	23.05	-33.3	0.00	66.7
Cycle 13 Day 1	26	11.54	20.96	0.0	0.00	66.7	25	4.00	27.76	-33.3	0.00	66.7
Cycle 14 Day 1	22	10.61	18.93	0.0	0.00	66.7	21	4.76	21.82	-33.3	0.00	66.7
Cycle 15 Day 1	23	11.59	16.23	0.0	0.00	33.3	22	6.06	16.70	-33.3	0.00	33.3
Cycle 16 Day 1	24	9.72	15.48	0.0	0.00	33.3	23	4.35	18.27	-33.3	0.00	33.3
Cycle 17 Day 1	21	9.52	15.43	0.0	0.00	33.3	20	5.00	16.31	-33.3	0.00	33.3
Cycle 18 Day 1	21	9.52	15.43	0.0	0.00	33.3	20	5.00	16.31	-33.3	0.00	33.3
Cycle 19 Day 1	21	4.76	11.95	0.0	0.00	33.3	20	0.00	15.29	-33.3	0.00	33.3
Cycle 20 Day 1	19	8.77	15.08	0.0	0.00	33.3	18	3.70	19.43	-33.3	0.00	33.3
Cycle 21 Day 1	18	9.26	15.36	0.0	0.00	33.3	17	3.92	16.17	-33.3	0.00	33.3
Cycle 22 Day 1	15	4.44	11.73	0.0	0.00	33.3	14	0.00	18.49	-33.3	0.00	33.3
Cycle 23 Day 1	15	4.44	11.73	0.0	0.00	33.3	14	0.00	13.07	-33.3	0.00	33.3
Cycle 24 Day 1	14	2.38	8.91	0.0	0.00	33.3	13	-2.56	16.45	-33.3	0.00	33.3
Cycle 25 Day 1	14	4.76	12.10	0.0	0.00	33.3	13	0.00	19.25	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.14.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Dyspnoea
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	2.78	9.62	0.0	0.00	33.3	11	-3.03	17.98	-33.3	0.00	33.3
Cycle 27 Day 1	13	5.13	12.52	0.0	0.00	33.3	12	0.00	14.21	-33.3	0.00	33.3
Cycle 28 Day 1	11	6.06	13.48	0.0	0.00	33.3	10	0.00	15.71	-33.3	0.00	33.3
Cycle 29 Day 1	11	18.18	31.14	0.0	0.00	100.0	10	13.33	35.83	-33.3	0.00	100.0
Cycle 30 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	0.00	16.67	-33.3	0.00	33.3
Cycle 31 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	-3.70	20.03	-33.3	0.00	33.3
Cycle 32 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	0.00	23.57	-33.3	0.00	33.3
Study Disc 1	48	13.19	19.13	0.0	0.00	66.7	48	6.25	20.23	-33.3	0.00	66.7
30 D SFU Z/P	22	9.09	18.35	0.0	0.00	66.7	22	4.55	15.59	-33.3	0.00	33.3
90 D SFU Z/P	23	10.14	15.68	0.0	0.00	33.3	23	5.80	19.21	-33.3	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	81	11.93	22.55	0.0	0.00	100.0						
Cycle 2 Day 1	73	11.87	21.06	0.0	0.00	100.0	70	-0.48	20.06	-66.7	0.00	33.3
Cycle 3 Day 1	64	11.46	18.03	0.0	0.00	66.7	63	-0.53	26.43	-100.0	0.00	66.7
Cycle 4 Day 1	56	11.90	18.45	0.0	0.00	66.7	56	0.60	25.81	-66.7	0.00	66.7
Cycle 5 Day 1	57	11.70	19.41	0.0	0.00	66.7	57	1.17	26.70	-100.0	0.00	66.7
Cycle 6 Day 1	48	11.11	18.62	0.0	0.00	66.7	48	2.78	24.63	-66.7	0.00	66.7
Cycle 7 Day 1	42	11.11	15.90	0.0	0.00	33.3	42	0.00	24.42	-66.7	0.00	33.3
Cycle 8 Day 1	37	18.02	27.88	0.0	0.00	100.0	37	5.41	27.79	-66.7	0.00	100.0
Cycle 9 Day 1	35	12.38	21.52	0.0	0.00	66.7	35	0.00	24.25	-66.7	0.00	66.7
Cycle 10 Day 1	30	10.00	15.54	0.0	0.00	33.3	29	0.00	21.82	-66.7	0.00	33.3
Cycle 11 Day 1	27	11.11	18.49	0.0	0.00	66.7	27	-2.47	22.51	-66.7	0.00	33.3
Cycle 12 Day 1	26	10.26	18.30	0.0	0.00	66.7	25	-4.00	22.19	-33.3	0.00	66.7
Cycle 13 Day 1	22	9.09	18.35	0.0	0.00	66.7	21	-3.17	25.61	-66.7	0.00	66.7
Cycle 14 Day 1	21	9.52	18.69	0.0	0.00	66.7	20	-6.67	23.20	-66.7	0.00	33.3
Cycle 15 Day 1	18	14.81	20.52	0.0	0.00	66.7	17	-1.96	18.52	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.14.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Dyspnoea
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	13.73	26.51	0.0	0.00	100.0	16	-2.08	25.73	-66.7	0.00	33.3
Cycle 17 Day 1	13	5.13	12.52	0.0	0.00	33.3	11	-12.12	22.47	-66.7	0.00	0.0
Cycle 18 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	-14.81	17.57	-33.3	0.00	0.0
Study Disc 1	52	23.08	27.64	0.0	16.67	100.0	47	14.18	27.58	-66.7	0.00	100.0
30 D SFU Z/P	29	12.64	16.46	0.0	0.00	33.3	27	4.94	23.94	-66.7	0.00	33.3
90 D SFU Z/P	30	16.67	22.74	0.0	0.00	66.7	29	3.45	27.23	-100.0	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.15.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Insomnia
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	23.93	26.26	0.0	33.33	100.0						
Cycle 2 Day 1	69	24.64	32.16	0.0	0.00	100.0	68	-0.98	28.78	-66.7	0.00	100.0
Cycle 3 Day 1	61	24.04	25.91	0.0	33.33	100.0	60	2.22	31.21	-66.7	0.00	100.0
Cycle 4 Day 1	57	18.13	24.45	0.0	0.00	100.0	57	-4.68	27.77	-66.7	0.00	66.7
Cycle 5 Day 1	55	19.39	23.74	0.0	0.00	100.0	54	-2.47	25.78	-66.7	0.00	66.7
Cycle 6 Day 1	55	17.58	23.00	0.0	0.00	100.0	55	-5.45	25.47	-66.7	0.00	33.3
Cycle 7 Day 1	44	15.91	23.28	0.0	0.00	100.0	44	-6.06	29.00	-66.7	0.00	66.7
Cycle 8 Day 1	41	21.14	20.76	0.0	33.33	66.7	39	0.00	24.18	-33.3	0.00	33.3
Cycle 9 Day 1	38	16.67	18.58	0.0	0.00	66.7	37	-7.21	28.47	-66.7	0.00	33.3
Cycle 10 Day 1	34	13.73	18.56	0.0	0.00	66.7	33	-12.12	32.08	-66.7	0.00	33.3
Cycle 11 Day 1	32	19.79	20.49	0.0	33.33	66.7	31	-5.38	33.44	-100.0	0.00	33.3
Cycle 12 Day 1	31	18.28	22.51	0.0	0.00	100.0	30	-5.56	32.85	-66.7	0.00	66.7
Cycle 13 Day 1	26	14.10	21.44	0.0	0.00	66.7	25	-5.33	29.94	-66.7	0.00	66.7
Cycle 14 Day 1	22	12.12	19.37	0.0	0.00	66.7	21	-4.76	28.45	-66.7	0.00	33.3
Cycle 15 Day 1	23	14.49	16.90	0.0	0.00	33.3	22	-3.03	27.04	-66.7	0.00	33.3
Cycle 16 Day 1	24	13.89	23.91	0.0	0.00	100.0	23	-4.35	30.66	-66.7	0.00	66.7
Cycle 17 Day 1	21	19.05	24.88	0.0	0.00	100.0	20	1.67	31.48	-66.7	0.00	66.7
Cycle 18 Day 1	21	14.29	24.88	0.0	0.00	100.0	20	-3.33	28.41	-33.3	0.00	66.7
Cycle 19 Day 1	21	11.11	16.10	0.0	0.00	33.3	20	-6.67	20.52	-33.3	0.00	33.3
Cycle 20 Day 1	19	14.04	20.23	0.0	0.00	66.7	18	-1.85	21.30	-33.3	0.00	33.3
Cycle 21 Day 1	18	11.11	16.17	0.0	0.00	33.3	17	-5.88	21.20	-33.3	0.00	33.3
Cycle 22 Day 1	15	4.44	11.73	0.0	0.00	33.3	14	-11.90	16.57	-33.3	0.00	0.0
Cycle 23 Day 1	15	4.44	11.73	0.0	0.00	33.3	14	-9.52	15.63	-33.3	0.00	0.0
Cycle 24 Day 1	14	7.14	14.19	0.0	0.00	33.3	13	-5.13	22.96	-33.3	0.00	33.3
Cycle 25 Day 1	14	2.38	8.91	0.0	0.00	33.3	13	-10.26	21.01	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.15.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Insomnia
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	5.56	12.97	0.0	0.00	33.3	11	-6.06	25.03	-33.3	0.00	33.3
Cycle 27 Day 1	13	5.13	12.52	0.0	0.00	33.3	12	-8.33	20.72	-33.3	0.00	33.3
Cycle 28 Day 1	11	15.15	22.92	0.0	0.00	66.7	10	-3.33	29.19	-33.3	0.00	33.3
Cycle 29 Day 1	11	15.15	22.92	0.0	0.00	66.7	10	0.00	31.43	-33.3	0.00	33.3
Cycle 30 Day 1	10	10.00	16.10	0.0	0.00	33.3	9	-3.70	20.03	-33.3	0.00	33.3
Cycle 31 Day 1	10	13.33	17.21	0.0	0.00	33.3	9	0.00	23.57	-33.3	0.00	33.3
Cycle 32 Day 1	10	10.00	16.10	0.0	0.00	33.3	9	-3.70	26.06	-33.3	0.00	33.3
Study Disc 1	48	27.08	27.21	0.0	33.33	100.0	48	4.17	33.42	-66.7	0.00	100.0
30 D SFU Z/P	22	21.21	26.32	0.0	0.00	66.7	22	0.00	27.22	-66.7	0.00	33.3
90 D SFU Z/P	23	20.29	21.88	0.0	33.33	66.7	23	4.35	18.27	-33.3	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	81	29.22	29.99	0.0	33.33	100.0						
Cycle 2 Day 1	73	22.37	24.25	0.0	33.33	100.0	70	-4.29	25.96	-66.7	0.00	66.7
Cycle 3 Day 1	64	21.35	22.51	0.0	33.33	66.7	63	-5.82	28.42	-66.7	0.00	66.7
Cycle 4 Day 1	56	23.21	25.36	0.0	33.33	100.0	56	-4.17	30.53	-66.7	0.00	66.7
Cycle 5 Day 1	57	22.22	23.85	0.0	33.33	66.7	57	-3.51	33.14	-66.7	0.00	66.7
Cycle 6 Day 1	48	21.53	23.31	0.0	33.33	66.7	48	-4.86	32.24	-66.7	0.00	66.7
Cycle 7 Day 1	42	23.81	25.80	0.0	33.33	100.0	42	-1.59	38.22	-100.0	0.00	100.0
Cycle 8 Day 1	37	21.62	23.85	0.0	33.33	66.7	37	-6.31	24.64	-66.7	0.00	33.3
Cycle 9 Day 1	35	23.81	27.50	0.0	33.33	100.0	35	-1.90	37.00	-66.7	0.00	66.7
Cycle 10 Day 1	30	24.44	23.05	0.0	33.33	66.7	29	0.00	30.86	-66.7	0.00	66.7
Cycle 11 Day 1	27	28.40	27.27	0.0	33.33	100.0	27	3.70	36.20	-66.7	0.00	100.0
Cycle 12 Day 1	26	20.51	21.24	0.0	33.33	66.7	25	-2.67	34.59	-66.7	0.00	66.7
Cycle 13 Day 1	22	21.21	28.26	0.0	0.00	100.0	21	-1.59	42.79	-66.7	0.00	66.7
Cycle 14 Day 1	21	22.22	24.34	0.0	33.33	66.7	20	1.67	39.70	-66.7	0.00	66.7
Cycle 15 Day 1	18	24.07	22.30	0.0	33.33	66.7	17	5.88	39.50	-66.7	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.15.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Insomnia
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	25.49	22.14	0.0	33.33	66.7	16	10.42	29.11	-33.3	0.00	66.7
Cycle 17 Day 1	13	28.21	35.61	0.0	0.00	100.0	11	21.21	37.34	-33.3	0.00	100.0
Cycle 18 Day 1	10	16.67	23.57	0.0	0.00	66.7	9	11.11	28.87	-33.3	0.00	66.7
Study Disc 1	52	32.69	29.88	0.0	33.33	100.0	47	5.67	38.27	-66.7	0.00	100.0
30 D SFU Z/P	29	29.89	32.54	0.0	33.33	100.0	27	3.70	42.70	-66.7	0.00	100.0
90 D SFU Z/P	30	25.56	31.18	0.0	16.67	100.0	29	-5.75	32.21	-66.7	0.00	100.0

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.16.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Appetite Loss
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	33.33	30.86	0.0	33.33	100.0						
Cycle 2 Day 1	69	34.78	32.05	0.0	33.33	100.0	68	2.45	34.71	-66.7	0.00	100.0
Cycle 3 Day 1	61	32.24	29.17	0.0	33.33	100.0	60	-1.67	33.29	-66.7	0.00	100.0
Cycle 4 Day 1	57	23.98	26.54	0.0	33.33	100.0	57	-7.02	39.21	-100.0	0.00	100.0
Cycle 5 Day 1	55	24.24	29.01	0.0	33.33	100.0	54	-6.79	39.06	-100.0	0.00	100.0
Cycle 6 Day 1	55	25.45	27.94	0.0	33.33	100.0	55	-7.27	36.11	-66.7	0.00	100.0
Cycle 7 Day 1	44	25.00	27.02	0.0	33.33	100.0	44	-5.30	44.86	-100.0	0.00	100.0
Cycle 8 Day 1	41	24.39	24.75	0.0	33.33	100.0	39	-4.27	33.49	-66.7	0.00	66.7
Cycle 9 Day 1	38	22.81	32.98	0.0	0.00	100.0	37	-7.21	44.54	-100.0	0.00	100.0
Cycle 10 Day 1	34	21.57	29.45	0.0	0.00	100.0	33	-8.08	32.31	-66.7	0.00	66.7
Cycle 11 Day 1	32	16.67	22.40	0.0	0.00	100.0	31	-11.83	31.68	-100.0	0.00	33.3
Cycle 12 Day 1	31	17.20	22.56	0.0	0.00	100.0	30	-12.22	32.14	-100.0	0.00	33.3
Cycle 13 Day 1	26	15.38	23.53	0.0	0.00	66.7	25	-13.33	36.00	-100.0	0.00	66.7
Cycle 14 Day 1	22	9.09	15.19	0.0	0.00	33.3	21	-17.46	29.10	-100.0	0.00	33.3
Cycle 15 Day 1	23	14.49	16.90	0.0	0.00	33.3	22	-10.61	27.96	-100.0	0.00	33.3
Cycle 16 Day 1	24	16.67	19.66	0.0	0.00	66.7	23	-7.25	36.18	-100.0	0.00	66.7
Cycle 17 Day 1	21	17.46	27.12	0.0	0.00	100.0	20	-6.67	41.32	-100.0	0.00	100.0
Cycle 18 Day 1	21	12.70	24.67	0.0	0.00	100.0	20	-13.33	41.04	-100.0	0.00	100.0
Cycle 19 Day 1	21	11.11	19.25	0.0	0.00	66.7	20	-15.00	36.63	-100.0	0.00	66.7
Cycle 20 Day 1	19	19.30	27.92	0.0	0.00	100.0	18	-5.56	41.62	-100.0	0.00	100.0
Cycle 21 Day 1	18	16.67	20.61	0.0	0.00	66.7	17	-7.84	40.02	-100.0	0.00	66.7
Cycle 22 Day 1	15	8.89	19.79	0.0	0.00	66.7	14	-14.29	36.31	-100.0	0.00	33.3
Cycle 23 Day 1	15	6.67	13.80	0.0	0.00	33.3	14	-14.29	31.25	-100.0	0.00	33.3
Cycle 24 Day 1	14	4.76	12.10	0.0	0.00	33.3	13	-15.38	32.25	-100.0	0.00	33.3
Cycle 25 Day 1	14	9.52	15.63	0.0	0.00	33.3	13	-10.26	36.98	-100.0	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.16.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Appetite Loss
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	2.78	9.62	0.0	0.00	33.3	11	-18.18	37.61	-100.0	0.00	33.3
Cycle 27 Day 1	13	12.82	21.68	0.0	0.00	66.7	12	-8.33	37.94	-100.0	0.00	33.3
Cycle 28 Day 1	11	12.12	22.47	0.0	0.00	66.7	10	-16.67	36.00	-100.0	0.00	33.3
Cycle 29 Day 1	11	6.06	13.48	0.0	0.00	33.3	10	-20.00	35.83	-100.0	-16.67	33.3
Cycle 30 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	-18.52	33.79	-100.0	0.00	0.0
Cycle 31 Day 1	10	6.67	21.08	0.0	0.00	66.7	9	-18.52	41.20	-100.0	0.00	33.3
Cycle 32 Day 1	10	10.00	22.50	0.0	0.00	66.7	9	-14.81	44.44	-100.0	0.00	33.3
Study Disc 1	48	34.03	36.05	0.0	33.33	100.0	48	4.86	37.02	-100.0	0.00	100.0
30 D SFU Z/P	22	24.24	32.82	0.0	0.00	100.0	22	-1.52	36.34	-66.7	0.00	100.0
90 D SFU Z/P	23	18.84	24.26	0.0	0.00	66.7	23	-1.45	32.53	-66.7	0.00	66.7
Placebo + CAPOX (N= 88)												
Baseline	81	28.81	28.75	0.0	33.33	100.0						
Cycle 2 Day 1	73	26.48	27.19	0.0	33.33	100.0	70	-3.33	28.46	-66.7	0.00	100.0
Cycle 3 Day 1	64	25.52	27.05	0.0	33.33	100.0	63	-2.65	31.28	-66.7	0.00	66.7
Cycle 4 Day 1	56	24.40	28.06	0.0	33.33	100.0	56	-4.76	35.63	-66.7	0.00	66.7
Cycle 5 Day 1	57	20.47	24.20	0.0	0.00	100.0	57	-8.19	35.23	-66.7	0.00	66.7
Cycle 6 Day 1	48	22.92	25.87	0.0	33.33	100.0	48	-6.25	32.73	-100.0	0.00	66.7
Cycle 7 Day 1	42	15.87	19.81	0.0	0.00	66.7	42	-11.90	29.28	-100.0	0.00	33.3
Cycle 8 Day 1	37	12.61	19.80	0.0	0.00	66.7	37	-14.41	27.82	-100.0	0.00	66.7
Cycle 9 Day 1	35	19.05	27.16	0.0	0.00	100.0	35	-8.57	35.56	-100.0	0.00	66.7
Cycle 10 Day 1	30	14.44	20.87	0.0	0.00	66.7	29	-8.05	30.41	-66.7	0.00	66.7
Cycle 11 Day 1	27	12.35	20.98	0.0	0.00	66.7	27	-14.81	38.49	-66.7	0.00	66.7
Cycle 12 Day 1	26	10.26	22.65	0.0	0.00	100.0	25	-17.33	33.50	-66.7	0.00	66.7
Cycle 13 Day 1	22	9.09	18.35	0.0	0.00	66.7	21	-15.87	30.95	-66.7	0.00	66.7
Cycle 14 Day 1	21	15.87	22.65	0.0	0.00	66.7	20	-8.33	30.35	-66.7	0.00	66.7
Cycle 15 Day 1	18	16.67	26.20	0.0	0.00	100.0	17	-3.92	28.58	-66.7	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.16.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Appetite Loss
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	11.76	20.21	0.0	0.00	66.7	16	-8.33	31.03	-66.7	0.00	66.7
Cycle 17 Day 1	13	10.26	21.01	0.0	0.00	66.7	11	-6.06	29.13	-66.7	0.00	33.3
Cycle 18 Day 1	10	13.33	17.21	0.0	0.00	33.3	9	-7.41	22.22	-33.3	0.00	33.3
Study Disc 1	52	39.74	34.95	0.0	33.33	100.0	47	11.35	34.94	-66.7	0.00	66.7
30 D SFU Z/P	29	31.03	29.45	0.0	33.33	100.0	27	0.00	34.59	-66.7	0.00	66.7
90 D SFU Z/P	30	26.67	30.83	0.0	33.33	100.0	29	-2.30	40.76	-100.0	0.00	100.0

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.17.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Constipation
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	20.94	25.26	0.0	0.00	100.0						
Cycle 2 Day 1	69	19.32	24.53	0.0	0.00	100.0	68	0.00	29.37	-33.3	0.00	100.0
Cycle 3 Day 1	61	15.30	20.70	0.0	0.00	66.7	60	-5.56	27.56	-100.0	0.00	66.7
Cycle 4 Day 1	57	14.62	24.41	0.0	0.00	100.0	57	-4.09	25.25	-66.7	0.00	66.7
Cycle 5 Day 1	55	15.15	23.85	0.0	0.00	100.0	54	-2.47	30.95	-66.7	0.00	100.0
Cycle 6 Day 1	55	15.15	22.97	0.0	0.00	100.0	55	-3.03	27.42	-66.7	0.00	100.0
Cycle 7 Day 1	44	12.88	17.92	0.0	0.00	66.7	44	-4.55	24.47	-66.7	0.00	33.3
Cycle 8 Day 1	41	16.26	19.89	0.0	0.00	66.7	39	-0.85	29.11	-100.0	0.00	33.3
Cycle 9 Day 1	38	16.67	20.13	0.0	0.00	66.7	37	-1.80	22.15	-33.3	0.00	33.3
Cycle 10 Day 1	34	13.73	18.56	0.0	0.00	66.7	33	-4.04	24.66	-66.7	0.00	33.3
Cycle 11 Day 1	32	11.46	16.09	0.0	0.00	33.3	31	-6.45	30.33	-100.0	0.00	33.3
Cycle 12 Day 1	31	11.83	16.21	0.0	0.00	33.3	30	-6.67	29.56	-100.0	0.00	33.3
Cycle 13 Day 1	26	8.97	15.08	0.0	0.00	33.3	25	-8.00	24.11	-66.7	0.00	33.3
Cycle 14 Day 1	22	10.61	15.89	0.0	0.00	33.3	21	-7.94	23.34	-66.7	0.00	33.3
Cycle 15 Day 1	23	14.49	19.66	0.0	0.00	66.7	22	-3.03	25.01	-33.3	0.00	66.7
Cycle 16 Day 1	24	15.28	19.61	0.0	0.00	66.7	23	-1.45	27.48	-33.3	0.00	66.7
Cycle 17 Day 1	21	14.29	16.90	0.0	0.00	33.3	20	-3.33	23.94	-33.3	0.00	33.3
Cycle 18 Day 1	21	9.52	15.43	0.0	0.00	33.3	20	-8.33	23.88	-33.3	0.00	33.3
Cycle 19 Day 1	21	12.70	19.65	0.0	0.00	66.7	20	-5.00	27.09	-33.3	0.00	66.7
Cycle 20 Day 1	19	17.54	25.74	0.0	0.00	100.0	18	0.00	34.30	-33.3	0.00	100.0
Cycle 21 Day 1	18	14.81	17.04	0.0	0.00	33.3	17	-1.96	24.92	-33.3	0.00	33.3
Cycle 22 Day 1	15	8.89	15.26	0.0	0.00	33.3	14	-7.14	29.75	-66.7	0.00	33.3
Cycle 23 Day 1	15	6.67	13.80	0.0	0.00	33.3	14	-7.14	23.31	-33.3	0.00	33.3
Cycle 24 Day 1	14	7.14	14.19	0.0	0.00	33.3	13	-7.69	19.97	-33.3	0.00	33.3
Cycle 25 Day 1	14	9.52	15.63	0.0	0.00	33.3	13	-5.13	22.96	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.17.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Constipation
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	5.56	12.97	0.0	0.00	33.3	11	-9.09	21.56	-33.3	0.00	33.3
Cycle 27 Day 1	13	7.69	14.62	0.0	0.00	33.3	12	-8.33	20.72	-33.3	0.00	33.3
Cycle 28 Day 1	11	9.09	15.57	0.0	0.00	33.3	10	-6.67	21.08	-33.3	0.00	33.3
Cycle 29 Day 1	11	12.12	16.82	0.0	0.00	33.3	10	0.00	27.22	-66.7	0.00	33.3
Cycle 30 Day 1	10	10.00	16.10	0.0	0.00	33.3	9	-3.70	26.06	-33.3	0.00	33.3
Cycle 31 Day 1	10	16.67	17.57	0.0	16.67	33.3	9	3.70	20.03	-33.3	0.00	33.3
Cycle 32 Day 1	10	13.33	17.21	0.0	0.00	33.3	9	0.00	23.57	-33.3	0.00	33.3
Study Disc 1	48	16.67	22.81	0.0	0.00	100.0	48	0.00	28.35	-66.7	0.00	66.7
30 D SFU Z/P	22	18.18	28.60	0.0	0.00	100.0	22	0.00	34.12	-33.3	0.00	100.0
90 D SFU Z/P	23	14.49	16.90	0.0	0.00	33.3	23	0.00	22.47	-66.7	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	81	19.34	28.80	0.0	0.00	100.0						
Cycle 2 Day 1	73	18.26	25.48	0.0	0.00	100.0	70	0.00	24.08	-66.7	0.00	66.7
Cycle 3 Day 1	64	14.06	22.85	0.0	0.00	100.0	63	-2.65	21.00	-66.7	0.00	33.3
Cycle 4 Day 1	56	14.29	21.89	0.0	0.00	100.0	56	-3.57	27.47	-66.7	0.00	66.7
Cycle 5 Day 1	57	15.20	23.63	0.0	0.00	100.0	57	-1.75	26.29	-66.7	0.00	66.7
Cycle 6 Day 1	48	19.44	28.21	0.0	0.00	100.0	48	1.39	31.48	-66.7	0.00	100.0
Cycle 7 Day 1	42	23.02	28.02	0.0	16.67	100.0	42	5.56	33.67	-66.7	0.00	100.0
Cycle 8 Day 1	37	14.41	20.09	0.0	0.00	66.7	37	-4.50	33.48	-100.0	0.00	66.7
Cycle 9 Day 1	35	17.14	23.39	0.0	0.00	66.7	35	-1.90	36.10	-100.0	0.00	66.7
Cycle 10 Day 1	30	11.11	23.71	0.0	0.00	100.0	29	-8.05	31.69	-100.0	0.00	66.7
Cycle 11 Day 1	27	19.75	26.57	0.0	0.00	100.0	27	-1.23	36.38	-100.0	0.00	100.0
Cycle 12 Day 1	26	19.23	25.25	0.0	0.00	66.7	25	1.33	26.32	-66.7	0.00	66.7
Cycle 13 Day 1	22	19.70	28.47	0.0	0.00	100.0	21	-3.17	40.70	-100.0	0.00	100.0
Cycle 14 Day 1	21	22.22	28.54	0.0	0.00	100.0	20	1.67	31.48	-66.7	0.00	66.7
Cycle 15 Day 1	18	18.52	23.49	0.0	0.00	66.7	17	0.00	37.27	-66.7	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.17.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Constipation
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	13.73	23.74	0.0	0.00	66.7	16	-2.08	39.38	-66.7	0.00	66.7
Cycle 17 Day 1	13	7.69	19.97	0.0	0.00	66.7	11	0.00	25.82	-66.7	0.00	33.3
Cycle 18 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	-3.70	26.06	-66.7	0.00	33.3
Study Disc 1	52	20.51	28.89	0.0	0.00	100.0	47	4.26	32.32	-100.0	0.00	66.7
30 D SFU Z/P	29	17.24	24.59	0.0	0.00	100.0	27	3.70	26.69	-66.7	0.00	66.7
90 D SFU Z/P	30	17.78	24.34	0.0	0.00	66.7	29	1.15	27.43	-33.3	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.18.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Diarrhoea
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	11.54	19.24	0.0	0.00	100.0						
Cycle 2 Day 1	69	13.04	18.27	0.0	0.00	66.7	68	3.92	19.56	-33.3	0.00	66.7
Cycle 3 Day 1	61	13.11	21.33	0.0	0.00	100.0	60	3.33	21.87	-33.3	0.00	66.7
Cycle 4 Day 1	57	12.28	20.54	0.0	0.00	66.7	57	2.34	23.45	-33.3	0.00	66.7
Cycle 5 Day 1	55	12.73	18.69	0.0	0.00	66.7	54	1.85	20.90	-33.3	0.00	66.7
Cycle 6 Day 1	55	13.33	21.85	0.0	0.00	100.0	55	3.03	24.24	-33.3	0.00	100.0
Cycle 7 Day 1	44	15.15	25.37	0.0	0.00	100.0	44	5.30	29.59	-33.3	0.00	100.0
Cycle 8 Day 1	41	15.45	23.68	0.0	0.00	100.0	39	5.13	29.16	-33.3	0.00	100.0
Cycle 9 Day 1	38	15.79	20.12	0.0	0.00	66.7	37	5.41	22.92	-33.3	0.00	66.7
Cycle 10 Day 1	34	12.75	23.23	0.0	0.00	100.0	33	3.03	25.50	-33.3	0.00	66.7
Cycle 11 Day 1	32	9.37	25.73	0.0	0.00	100.0	31	-1.08	27.87	-33.3	0.00	100.0
Cycle 12 Day 1	31	12.90	20.51	0.0	0.00	66.7	30	2.22	23.05	-33.3	0.00	66.7
Cycle 13 Day 1	26	8.97	17.78	0.0	0.00	66.7	25	-2.67	19.05	-33.3	0.00	33.3
Cycle 14 Day 1	22	4.55	11.71	0.0	0.00	33.3	21	-6.35	20.05	-33.3	0.00	33.3
Cycle 15 Day 1	23	14.49	24.26	0.0	0.00	100.0	22	1.52	26.18	-33.3	0.00	33.3
Cycle 16 Day 1	24	11.11	23.40	0.0	0.00	100.0	23	-1.45	21.27	-33.3	0.00	33.3
Cycle 17 Day 1	21	11.11	16.10	0.0	0.00	33.3	20	-1.67	22.88	-33.3	0.00	33.3
Cycle 18 Day 1	21	11.11	24.34	0.0	0.00	100.0	20	0.00	18.73	-33.3	0.00	33.3
Cycle 19 Day 1	21	9.52	18.69	0.0	0.00	66.7	20	-1.67	20.16	-33.3	0.00	33.3
Cycle 20 Day 1	19	12.28	22.80	0.0	0.00	66.7	18	0.00	22.87	-33.3	0.00	33.3
Cycle 21 Day 1	18	12.96	20.26	0.0	0.00	66.7	17	1.96	21.96	-33.3	0.00	33.3
Cycle 22 Day 1	15	13.33	30.34	0.0	0.00	100.0	14	2.38	15.82	-33.3	0.00	33.3
Cycle 23 Day 1	15	15.56	27.79	0.0	0.00	100.0	14	7.14	19.30	-33.3	0.00	33.3
Cycle 24 Day 1	14	7.14	14.19	0.0	0.00	33.3	13	2.56	16.45	-33.3	0.00	33.3
Cycle 25 Day 1	14	9.52	15.63	0.0	0.00	33.3	13	5.13	18.49	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.18.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Diarrhoea
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	8.33	15.08	0.0	0.00	33.3	11	3.03	10.05	0.0	0.00	33.3
Cycle 27 Day 1	13	10.26	16.01	0.0	0.00	33.3	12	5.56	19.25	-33.3	0.00	33.3
Cycle 28 Day 1	11	12.12	30.81	0.0	0.00	100.0	10	3.33	18.92	-33.3	0.00	33.3
Cycle 29 Day 1	11	18.18	31.14	0.0	0.00	100.0	10	6.67	21.08	-33.3	0.00	33.3
Cycle 30 Day 1	10	13.33	32.20	0.0	0.00	100.0	9	0.00	23.57	-33.3	0.00	33.3
Cycle 31 Day 1	10	13.33	32.20	0.0	0.00	100.0	9	0.00	16.67	-33.3	0.00	33.3
Cycle 32 Day 1	10	20.00	32.20	0.0	0.00	100.0	9	7.41	22.22	-33.3	0.00	33.3
Study Disc 1	48	11.11	18.62	0.0	0.00	66.7	48	-0.69	20.03	-33.3	0.00	66.7
30 D SFU Z/P	22	9.09	18.35	0.0	0.00	66.7	22	-1.52	21.77	-33.3	0.00	66.7
90 D SFU Z/P	23	11.59	16.23	0.0	0.00	33.3	23	5.80	19.21	-33.3	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	81	8.64	16.48	0.0	0.00	66.7						
Cycle 2 Day 1	73	15.98	24.91	0.0	0.00	100.0	70	7.62	24.85	-66.7	0.00	100.0
Cycle 3 Day 1	64	12.50	22.62	0.0	0.00	100.0	63	4.23	21.99	-66.7	0.00	100.0
Cycle 4 Day 1	56	10.71	16.95	0.0	0.00	66.7	56	2.38	18.92	-66.7	0.00	33.3
Cycle 5 Day 1	57	11.11	19.25	0.0	0.00	100.0	57	2.34	18.75	-33.3	0.00	33.3
Cycle 6 Day 1	48	6.94	13.68	0.0	0.00	33.3	48	0.00	15.38	-66.7	0.00	33.3
Cycle 7 Day 1	42	8.73	19.56	0.0	0.00	100.0	42	1.59	16.38	-33.3	0.00	33.3
Cycle 8 Day 1	37	5.41	14.73	0.0	0.00	66.7	37	-1.80	15.61	-33.3	0.00	33.3
Cycle 9 Day 1	35	8.57	18.69	0.0	0.00	66.7	35	0.00	21.39	-33.3	0.00	66.7
Cycle 10 Day 1	30	4.44	11.52	0.0	0.00	33.3	29	-3.45	16.29	-33.3	0.00	33.3
Cycle 11 Day 1	27	4.94	12.07	0.0	0.00	33.3	27	-3.70	16.88	-33.3	0.00	33.3
Cycle 12 Day 1	26	7.69	17.15	0.0	0.00	66.7	25	-1.33	22.53	-33.3	0.00	66.7
Cycle 13 Day 1	22	4.55	11.71	0.0	0.00	33.3	21	-4.76	19.11	-33.3	0.00	33.3
Cycle 14 Day 1	21	6.35	13.41	0.0	0.00	33.3	20	-3.33	18.42	-33.3	0.00	33.3
Cycle 15 Day 1	18	7.41	14.26	0.0	0.00	33.3	17	-1.96	14.29	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.18.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Diarrhoea
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	5.88	13.10	0.0	0.00	33.3	16	-2.08	14.75	-33.3	0.00	33.3
Cycle 17 Day 1	13	5.13	12.52	0.0	0.00	33.3	11	-6.06	13.48	-33.3	0.00	0.0
Cycle 18 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	0.00	16.67	-33.3	0.00	33.3
Study Disc 1	52	12.18	20.90	0.0	0.00	66.7	47	5.67	18.80	-33.3	0.00	66.7
30 D SFU Z/P	29	12.64	18.72	0.0	0.00	66.7	27	2.47	18.32	-33.3	0.00	33.3
90 D SFU Z/P	30	11.11	15.98	0.0	0.00	33.3	29	-1.15	18.86	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.19.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Financial Difficulties
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	18.80	26.09	0.0	0.00	100.0						
Cycle 2 Day 1	69	17.39	23.99	0.0	0.00	66.7	68	-0.98	24.41	-66.7	0.00	66.7
Cycle 3 Day 1	61	18.03	23.23	0.0	0.00	66.7	60	-1.11	23.74	-66.7	0.00	66.7
Cycle 4 Day 1	57	14.62	19.94	0.0	0.00	66.7	57	-2.34	17.66	-33.3	0.00	33.3
Cycle 5 Day 1	55	18.79	27.04	0.0	0.00	100.0	54	-1.23	27.44	-66.7	0.00	100.0
Cycle 6 Day 1	55	18.18	25.51	0.0	0.00	100.0	55	-1.21	26.42	-66.7	0.00	66.7
Cycle 7 Day 1	44	20.45	22.98	0.0	33.33	100.0	44	3.03	18.77	-33.3	0.00	33.3
Cycle 8 Day 1	41	18.70	24.78	0.0	0.00	100.0	39	-0.85	25.92	-66.7	0.00	66.7
Cycle 9 Day 1	38	20.18	25.16	0.0	0.00	100.0	37	1.80	23.50	-66.7	0.00	66.7
Cycle 10 Day 1	34	16.67	24.96	0.0	0.00	100.0	33	-2.02	26.27	-66.7	0.00	66.7
Cycle 11 Day 1	32	18.75	25.31	0.0	0.00	100.0	31	-1.08	26.50	-66.7	0.00	66.7
Cycle 12 Day 1	31	18.28	24.10	0.0	0.00	100.0	30	-3.33	26.77	-66.7	0.00	33.3
Cycle 13 Day 1	26	16.67	21.60	0.0	0.00	66.7	25	-8.00	24.11	-66.7	0.00	33.3
Cycle 14 Day 1	22	13.64	16.77	0.0	0.00	33.3	21	-9.52	21.46	-66.7	0.00	33.3
Cycle 15 Day 1	23	23.19	29.19	0.0	0.00	100.0	22	-3.03	27.04	-66.7	0.00	66.7
Cycle 16 Day 1	24	16.67	26.01	0.0	0.00	100.0	23	-5.80	21.68	-66.7	0.00	33.3
Cycle 17 Day 1	21	22.22	26.53	0.0	33.33	100.0	20	-3.33	26.27	-66.7	0.00	33.3
Cycle 18 Day 1	21	26.98	32.69	0.0	33.33	100.0	20	5.00	19.57	-33.3	0.00	33.3
Cycle 19 Day 1	21	17.46	27.12	0.0	0.00	100.0	20	-5.00	22.36	-66.7	0.00	33.3
Cycle 20 Day 1	19	24.56	29.06	0.0	33.33	100.0	18	1.85	26.75	-33.3	0.00	66.7
Cycle 21 Day 1	18	20.37	20.26	0.0	33.33	66.7	17	0.00	26.35	-66.7	0.00	33.3
Cycle 22 Day 1	15	11.11	20.57	0.0	0.00	66.7	14	-9.52	24.21	-66.7	0.00	33.3
Cycle 23 Day 1	15	20.00	27.60	0.0	0.00	66.7	14	2.38	27.62	-33.3	0.00	66.7
Cycle 24 Day 1	14	9.52	15.63	0.0	0.00	33.3	13	-2.56	25.32	-66.7	0.00	33.3
Cycle 25 Day 1	14	9.52	15.63	0.0	0.00	33.3	13	-2.56	25.32	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.19.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Financial Difficulties
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	5.56	12.97	0.0	0.00	33.3	11	-6.06	25.03	-66.7	0.00	33.3
Cycle 27 Day 1	13	12.82	21.68	0.0	0.00	66.7	12	2.78	17.16	-33.3	0.00	33.3
Cycle 28 Day 1	11	15.15	22.92	0.0	0.00	66.7	10	-6.67	26.29	-66.7	0.00	33.3
Cycle 29 Day 1	11	27.27	32.72	0.0	33.33	100.0	10	6.67	14.05	0.0	0.00	33.3
Cycle 30 Day 1	10	16.67	23.57	0.0	0.00	66.7	9	-7.41	22.22	-33.3	0.00	33.3
Cycle 31 Day 1	10	23.33	27.44	0.0	16.67	66.7	9	0.00	16.67	-33.3	0.00	33.3
Cycle 32 Day 1	10	16.67	28.33	0.0	0.00	66.7	9	-7.41	14.70	-33.3	0.00	0.0
Study Disc 1	48	26.39	28.32	0.0	33.33	100.0	48	7.64	26.84	-66.7	0.00	100.0
30 D SFU Z/P	22	27.27	31.93	0.0	33.33	100.0	22	7.58	25.05	-33.3	0.00	66.7
90 D SFU Z/P	23	17.39	26.34	0.0	0.00	100.0	23	1.45	15.82	-33.3	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	81	13.99	22.89	0.0	0.00	100.0						
Cycle 2 Day 1	73	12.79	20.51	0.0	0.00	100.0	70	0.00	16.05	-33.3	0.00	33.3
Cycle 3 Day 1	64	16.15	23.00	0.0	0.00	100.0	63	1.06	20.71	-33.3	0.00	66.7
Cycle 4 Day 1	56	14.88	21.00	0.0	0.00	66.7	56	-1.19	19.03	-66.7	0.00	33.3
Cycle 5 Day 1	57	16.96	25.29	0.0	0.00	100.0	57	1.75	19.34	-33.3	0.00	66.7
Cycle 6 Day 1	48	15.28	24.75	0.0	0.00	100.0	48	-0.69	22.27	-66.7	0.00	66.7
Cycle 7 Day 1	42	13.49	20.90	0.0	0.00	66.7	42	-1.59	19.41	-66.7	0.00	33.3
Cycle 8 Day 1	37	20.72	29.76	0.0	0.00	100.0	37	4.50	26.25	-33.3	0.00	66.7
Cycle 9 Day 1	35	20.00	30.46	0.0	0.00	100.0	35	2.86	20.41	-33.3	0.00	66.7
Cycle 10 Day 1	30	22.22	30.74	0.0	0.00	100.0	29	5.75	25.31	-33.3	0.00	66.7
Cycle 11 Day 1	27	24.69	30.09	0.0	33.33	100.0	27	4.94	25.66	-33.3	0.00	66.7
Cycle 12 Day 1	26	24.36	30.63	0.0	16.67	100.0	25	6.67	25.46	-33.3	0.00	66.7
Cycle 13 Day 1	22	19.70	30.27	0.0	0.00	100.0	21	4.76	28.45	-33.3	0.00	66.7
Cycle 14 Day 1	21	17.46	27.12	0.0	0.00	100.0	20	1.67	25.31	-33.3	0.00	66.7
Cycle 15 Day 1	18	24.07	31.94	0.0	0.00	100.0	17	9.80	28.30	-33.3	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.19.2: EORTC QLQ-C30 v3.0 - Observed Means and Change from Baseline of Financial Difficulties
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	19.61	23.74	0.0	0.00	66.7	16	6.25	25.00	-33.3	0.00	66.7
Cycle 17 Day 1	13	12.82	21.68	0.0	0.00	66.7	11	0.00	14.91	-33.3	0.00	33.3
Cycle 18 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	0.00	16.67	-33.3	0.00	33.3
Study Disc 1	52	23.72	32.56	0.0	0.00	100.0	47	12.06	32.17	-33.3	0.00	100.0
30 D SFU Z/P	29	25.29	34.10	0.0	0.00	100.0	27	9.88	27.45	-33.3	0.00	100.0
90 D SFU Z/P	30	13.33	25.67	0.0	0.00	100.0	29	-1.15	16.63	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Max=maximum;
Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik und Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ-C30

3. Time-to-Event-Analysen - Zeit bis zur ersten Verschlechterung

Table 302.3.3003.5.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Global Health Status (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	47 (56.0%)	46 (52.3%)	
Number of patients censored	37 (44.0%)	42 (47.7%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	6.28 [3.15, 10.61]	4.96 [3.02, 7.20]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.956 [0.617, 1.482]
Log-rank test			
Two-sided stratified log-rank p-value			0.8762

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.5.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Global Health Status by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	34 (56.7)	7.20 [2.99, 10.87]	60	31 (51.7)	4.96 [2.50, 15.67]	1.061 [0.652, 1.727]	0.7920	0.6508
>65 years	24	13 (54.2)	6.01 [1.51, 15.77]	28	15 (53.6)	5.29 [2.79, 7.20]	0.883 [0.419, 1.861]	0.7460	
Age Group 2									
<=75 years	81	45 (55.6)	6.28 [3.22, 10.61]	81	43 (53.1)	5.29 [3.02, 11.53]	0.984 [0.648, 1.496]	0.9637	0.6166
>75 years	3	2 (66.7)	0.69 [0.56, NC]	7	3 (42.9)	3.02 [2.79, NC]	1.200 [0.192, 7.503]	0.8452	
Sex									
Male	52	30 (57.7)	6.67 [3.65, 10.61]	46	25 (54.3)	4.24 [1.48, 7.20]	0.795 [0.467, 1.355]	0.4285	0.2368
Female	32	17 (53.1)	3.75 [1.71, 12.42]	42	21 (50.0)	6.47 [3.02, 19.35]	1.338 [0.705, 2.541]	0.3702	
Region									
Asia	38	23 (60.5)	9.23 [2.53, 10.94]	41	22 (53.7)	5.29 [3.02, 11.53]	1.057 [0.588, 1.899]	0.8405	0.7596
Non-Asia	46	24 (52.2)	4.99 [2.79, 7.20]	47	24 (51.1)	3.71 [1.48, 14.55]	0.934 [0.529, 1.648]	0.8237	
Number of Organs with Metastatic Sites									
0-2	64	36 (56.3)	6.28 [2.79, 10.87]	64	31 (48.4)	5.36 [3.09, 14.55]	1.097 [0.678, 1.774]	0.6797	0.4622
>=3	20	11 (55.0)	7.20 [2.99, 10.94]	24	15 (62.5)	3.02 [2.50, 5.98]	0.682 [0.305, 1.522]	0.3458	
Prior Gastrectomy (total or partial)									
Yes	24	14 (58.3)	3.02 [1.48, 11.01]	22	11 (50.0)	14.55 [3.09, NC]	1.883 [0.834, 4.250]	0.1201	0.0335
No	60	33 (55.0)	7.16 [3.65, 10.87]	66	35 (53.0)	3.55 [2.50, 5.29]	0.697 [0.427, 1.138]	0.1527	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.5.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Global Health Status (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	47 (56.0%)	46 (52.3%)
Deterioration Before Cutoff Date	47 (56.0%)	46 (52.3%)
Number of patients censored	37 (44.0%)	42 (47.7%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	5 (6.0%)	2 (2.3%)
Death	5 (6.0%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	0
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	5 (6.0%)	1 (1.1%)
Progressive Disease	15 (17.9%)	27 (30.7%)
Withdrawal By Subject	5 (6.0%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.6.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Physical Functioning (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	50 (59.5%)	42 (47.7%)	
Number of patients censored	34 (40.5%)	46 (52.3%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	3.94 [2.23, 5.52]	5.29 [2.92, 9.23]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.305 [0.853, 1.996]
Log-rank test			
Two-sided stratified log-rank p-value			0.2131

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.6.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Physical Functioning by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	35 (58.3)	4.40 [2.33, 8.08]	60	30 (50.0)	4.83 [2.50, 9.23]	1.094 [0.672, 1.783]	0.6942	0.2667
>65 years	24	15 (62.5)	2.92 [0.99, 4.67]	28	12 (42.9)	5.29 [1.51, NC]	1.907 [0.877, 4.144]	0.0979	
Age Group 2									
<=75 years	81	47 (58.0)	4.17 [2.33, 6.41]	81	39 (48.1)	5.59 [2.92, 14.09]	1.227 [0.802, 1.877]	0.3288	0.2130
>75 years	3	3 (100.0)	0.69 [0.56, NC]	7	3 (42.9)	2.30 [1.22, NC]	3.494 [0.566, 21.554]	0.1531	
Sex									
Male	52	32 (61.5)	4.40 [2.92, 7.20]	46	23 (50.0)	4.83 [1.51, 14.09]	1.068 [0.625, 1.827]	0.7949	0.3160
Female	32	18 (56.3)	2.33 [1.45, 15.67]	42	19 (45.2)	6.83 [2.66, NC]	1.656 [0.864, 3.173]	0.1156	
Region									
Asia	38	24 (63.2)	4.42 [2.20, 8.08]	41	18 (43.9)	6.67 [2.66, NC]	1.388 [0.753, 2.561]	0.2762	0.6720
Non-Asia	46	26 (56.5)	3.55 [1.71, 7.20]	47	24 (51.1)	4.83 [2.10, 6.97]	1.147 [0.657, 2.002]	0.6226	
Number of Organs with Metastatic Sites									
0-2	64	38 (59.4)	4.40 [2.33, 7.62]	64	30 (46.9)	4.83 [2.66, NC]	1.222 [0.757, 1.973]	0.3988	0.7889
>=3	20	12 (60.0)	3.07 [1.05, 4.40]	24	12 (50.0)	5.59 [1.25, 7.92]	1.446 [0.640, 3.265]	0.3666	
Prior Gastrectomy (total or partial)									
Yes	24	19 (79.2)	3.94 [2.20, 5.52]	22	11 (50.0)	14.09 [2.66, NC]	2.109 [0.994, 4.478]	0.0465	0.1221
No	60	31 (51.7)	4.17 [1.71, 9.95]	66	31 (47.0)	4.83 [2.10, 6.97]	0.998 [0.605, 1.645]	0.9888	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.6.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Physical Functioning (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	50 (59.5%)	42 (47.7%)
Deterioration Before Cutoff Date	50 (59.5%)	42 (47.7%)
Number of patients censored	34 (40.5%)	46 (52.3%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	5 (6.0%)	2 (2.3%)
Death	5 (6.0%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	6 (7.1%)	0
Progressive Disease	14 (16.7%)	31 (35.2%)
Withdrawal By Subject	2 (2.4%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.7.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Role Functioning (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	55 (65.5%)	49 (55.7%)	
Number of patients censored	29 (34.5%)	39 (44.3%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	2.20 [1.64, 4.50]	3.15 [1.51, 4.93]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.137 [0.759, 1.703]
Log-rank test			
Two-sided stratified log-rank p-value			0.5290

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.7.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Role Functioning by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	40 (66.7)	2.33 [1.64, 6.11]	60	37 (61.7)	2.79 [1.41, 5.16]	1.012 [0.646, 1.585]	0.9408	0.5652
>65 years	24	15 (62.5)	1.82 [0.92, 6.67]	28	12 (42.9)	3.68 [1.41, NC]	1.186 [0.548, 2.567]	0.6633	
Age Group 2									
<=75 years	81	53 (65.4)	2.33 [1.64, 4.50]	81	45 (55.6)	3.68 [1.51, 5.29]	1.145 [0.769, 1.705]	0.4867	0.3823
>75 years	3	2 (66.7)	1.58 [0.56, NC]	7	4 (57.1)	1.36 [0.79, NC]	0.546 [0.096, 3.094]	0.4883	
Sex									
Male	52	34 (65.4)	3.58 [1.41, 7.20]	46	28 (60.9)	2.79 [1.41, 4.93]	0.876 [0.530, 1.447]	0.6240	0.1754
Female	32	21 (65.6)	2.07 [1.58, 4.50]	42	21 (50.0)	3.88 [1.51, 8.57]	1.562 [0.849, 2.872]	0.1503	
Region									
Asia	38	26 (68.4)	2.27 [1.41, 10.35]	41	23 (56.1)	2.79 [1.41, 5.59]	1.039 [0.589, 1.831]	0.8708	0.6257
Non-Asia	46	29 (63.0)	2.20 [1.51, 6.11]	47	26 (55.3)	3.88 [1.41, 5.16]	1.220 [0.714, 2.086]	0.4591	
Number of Organs with Metastatic Sites									
0-2	64	42 (65.6)	2.33 [1.64, 6.41]	64	37 (57.8)	3.48 [1.45, 4.93]	0.982 [0.630, 1.531]	0.9481	0.2682
>=3	20	13 (65.0)	1.92 [0.76, 4.37]	24	12 (50.0)	2.56 [0.82, NC]	1.593 [0.723, 3.510]	0.2415	
Prior Gastrectomy (total or partial)									
Yes	24	15 (62.5)	3.58 [1.91, 23.03]	22	12 (54.5)	3.88 [1.12, NC]	0.999 [0.464, 2.149]	0.9851	0.8158
No	60	40 (66.7)	2.07 [1.41, 4.37]	66	37 (56.1)	2.79 [1.45, 4.83]	1.113 [0.710, 1.744]	0.6252	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.7.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Role Functioning (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	55 (65.5%)	49 (55.7%)
Deterioration Before Cutoff Date	55 (65.5%)	49 (55.7%)
Number of patients censored	29 (34.5%)	39 (44.3%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	5 (6.0%)	2 (2.3%)
Death	6 (7.1%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	2 (2.4%)	0
Other	3 (3.6%)	1 (1.1%)
Progressive Disease	9 (10.7%)	25 (28.4%)
Withdrawal By Subject	3 (3.6%)	2 (2.3%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.8.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Emotional Functioning (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	43 (51.2%)	41 (46.6%)	
Number of patients censored	41 (48.8%)	47 (53.4%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	6.80 [3.65, 10.94]	5.78 [3.15, 7.92]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.966 [0.615, 1.517]
Log-rank test			
Two-sided stratified log-rank p-value			0.8894

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.8.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Emotional Functioning by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	29 (48.3)	7.95 [3.22, 11.76]	60	30 (50.0)	4.99 [3.15, 7.23]	0.868 [0.517, 1.457]	0.5928	0.4132
>65 years	24	14 (58.3)	4.37 [1.74, NC]	28	11 (39.3)	6.51 [1.81, NC]	1.240 [0.555, 2.769]	0.5942	
Age Group 2									
<=75 years	81	41 (50.6)	7.20 [3.65, 11.73]	81	38 (46.9)	5.88 [3.15, 7.92]	0.970 [0.621, 1.515]	0.9021	0.3525
>75 years	3	2 (66.7)	0.69 [0.56, NC]	7	3 (42.9)	4.29 [1.22, NC]	1.510 [0.245, 9.309]	0.6552	
Sex									
Male	52	28 (53.8)	6.67 [3.22, 10.94]	46	23 (50.0)	4.96 [2.14, 7.23]	0.846 [0.483, 1.481]	0.5657	0.4600
Female	32	15 (46.9)	7.95 [1.45, 20.99]	42	18 (42.9)	6.34 [3.15, NC]	1.193 [0.598, 2.378]	0.6191	
Region									
Asia	38	20 (52.6)	7.95 [1.64, NC]	41	20 (48.8)	6.28 [2.96, NC]	0.997 [0.535, 1.858]	0.9976	0.9873
Non-Asia	46	23 (50.0)	6.28 [2.60, 11.76]	47	21 (44.7)	4.76 [2.14, 9.23]	0.972 [0.532, 1.775]	0.9288	
Number of Organs with Metastatic Sites									
0-2	64	32 (50.0)	7.95 [3.71, 20.99]	64	29 (45.3)	6.34 [3.15, 9.23]	0.945 [0.567, 1.576]	0.8342	0.5776
>=3	20	11 (55.0)	3.65 [0.85, NC]	24	12 (50.0)	4.96 [1.25, NC]	1.241 [0.543, 2.838]	0.5990	
Prior Gastrectomy (total or partial)									
Yes	24	14 (58.3)	5.49 [1.64, NC]	22	12 (54.5)	7.23 [2.23, NC]	1.214 [0.550, 2.680]	0.6305	0.4206
No	60	29 (48.3)	7.20 [2.10, 11.76]	66	29 (43.9)	4.96 [2.96, 6.51]	0.861 [0.509, 1.455]	0.5819	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.8.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Emotional Functioning (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	43 (51.2%)	41 (46.6%)
Deterioration Before Cutoff Date	43 (51.2%)	41 (46.6%)
Number of patients censored	41 (48.8%)	47 (53.4%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	6 (7.1%)	3 (3.4%)
Death	4 (4.8%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	4 (4.8%)	1 (1.1%)
Progressive Disease	22 (26.2%)	29 (33.0%)
Withdrawal By Subject	3 (3.6%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.9.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Cognitive Functioning (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	51 (60.7%)	42 (47.7%)	
Number of patients censored	33 (39.3%)	46 (52.3%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	3.22 [1.64, 5.85]	5.09 [4.01, 8.94]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.325 [0.864, 2.033]
Log-rank test			
Two-sided stratified log-rank p-value			0.1853

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.9.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Cognitive Functioning by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	34 (56.7)	4.17 [2.10, 8.31]	60	31 (51.7)	4.76 [1.51, 8.97]	1.016 [0.623, 1.658]	0.9321	0.0948
>65 years	24	17 (70.8)	1.64 [0.85, 6.67]	28	11 (39.3)	6.05 [2.79, NC]	2.180 [1.014, 4.686]	0.0413	
Age Group 2									
<=75 years	81	49 (60.5)	3.25 [1.64, 5.85]	81	39 (48.1)	6.05 [4.01, 8.97]	1.286 [0.843, 1.961]	0.2324	0.9871
>75 years	3	2 (66.7)	2.27 [0.56, NC]	7	3 (42.9)	4.47 [2.79, NC]	1.200 [0.192, 7.503]	0.8452	
Sex									
Male	52	32 (61.5)	3.22 [1.58, 8.31]	46	23 (50.0)	4.47 [1.48, 8.97]	1.039 [0.608, 1.776]	0.8804	0.2788
Female	32	19 (59.4)	3.25 [1.45, 5.85]	42	19 (45.2)	6.51 [4.17, NC]	1.694 [0.891, 3.221]	0.1012	
Region									
Asia	38	25 (65.8)	3.24 [1.51, 8.31]	41	22 (53.7)	4.47 [2.33, 13.83]	1.321 [0.742, 2.352]	0.3270	0.9166
Non-Asia	46	26 (56.5)	3.22 [1.58, 6.67]	47	20 (42.6)	6.51 [1.64, 8.97]	1.300 [0.720, 2.349]	0.3812	
Number of Organs with Metastatic Sites									
0-2	64	39 (60.9)	5.42 [2.07, 8.08]	64	30 (46.9)	5.09 [4.17, 13.83]	1.213 [0.753, 1.953]	0.4180	0.4897
>=3	20	12 (60.0)	2.10 [1.05, 4.17]	24	12 (50.0)	4.99 [1.45, 8.54]	1.798 [0.768, 4.208]	0.1686	
Prior Gastrectomy (total or partial)									
Yes	24	15 (62.5)	5.85 [1.58, 8.31]	22	11 (50.0)	7.92 [2.33, NC]	1.433 [0.655, 3.138]	0.3640	0.7641
No	60	36 (60.0)	2.33 [1.51, 5.85]	66	31 (47.0)	4.99 [1.48, 8.94]	1.210 [0.747, 1.961]	0.4134	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.9.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Cognitive Functioning (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	51 (60.7%)	42 (47.7%)
Deterioration Before Cutoff Date	51 (60.7%)	42 (47.7%)
Number of patients censored	33 (39.3%)	46 (52.3%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	7 (8.3%)	1 (1.1%)
Death	4 (4.8%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	1 (1.1%)
Other	4 (4.8%)	1 (1.1%)
Progressive Disease	13 (15.5%)	29 (33.0%)
Withdrawal By Subject	3 (3.6%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.10.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Social Functioning (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	47 (56.0%)	47 (53.4%)	
Number of patients censored	37 (44.0%)	41 (46.6%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	4.40 [1.51, 8.54]	4.44 [2.50, 6.01]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.913 [0.600, 1.388]
Log-rank test			
Two-sided stratified log-rank p-value			0.6771

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.10.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Social Functioning by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	32 (53.3)	5.82 [1.51, 15.44]	60	38 (63.3)	2.83 [1.45, 4.96]	0.712 [0.442, 1.147]	0.1704	0.0160
>65 years	24	15 (62.5)	1.58 [0.85, 9.23]	28	9 (32.1)	7.85 [2.33, NC]	2.351 [1.024, 5.398]	0.0382	
Age Group 2									
<=75 years	81	45 (55.6)	5.55 [1.51, 8.54]	81	45 (55.6)	4.17 [2.33, 5.85]	0.941 [0.620, 1.427]	0.7900	0.4920
>75 years	3	2 (66.7)	1.48 [0.56, NC]	7	2 (28.6)	7.85 [1.22, NC]	1.682 [0.235, 12.033]	0.6006	
Sex									
Male	52	31 (59.6)	4.40 [1.45, 12.65]	46	26 (56.5)	4.70 [1.45, 6.18]	0.896 [0.528, 1.522]	0.7016	0.6790
Female	32	16 (50.0)	5.55 [1.48, 9.23]	42	21 (50.0)	4.17 [2.27, NC]	1.044 [0.544, 2.002]	0.8967	
Region									
Asia	38	23 (60.5)	5.90 [0.95, 12.65]	41	19 (46.3)	6.01 [2.60, NC]	1.237 [0.671, 2.281]	0.4895	0.2424
Non-Asia	46	24 (52.2)	4.40 [1.48, 8.54]	47	28 (59.6)	2.89 [1.25, 5.59]	0.773 [0.445, 1.343]	0.3689	
Number of Organs with Metastatic Sites									
0-2	64	36 (56.3)	6.70 [1.48, 12.65]	64	38 (59.4)	2.89 [1.87, 5.85]	0.826 [0.521, 1.311]	0.4200	0.1165
>=3	20	11 (55.0)	4.29 [0.92, 7.85]	24	9 (37.5)	5.59 [1.41, NC]	1.761 [0.726, 4.270]	0.2009	
Prior Gastrectomy (total or partial)									
Yes	24	19 (79.2)	1.48 [1.02, 8.54]	22	13 (59.1)	5.85 [1.87, NC]	1.637 [0.793, 3.381]	0.1793	0.0809
No	60	28 (46.7)	5.55 [1.64, 15.44]	66	34 (51.5)	3.61 [1.81, 5.59]	0.741 [0.448, 1.225]	0.2477	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.10.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Social Functioning (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	47 (56.0%)	47 (53.4%)
Deterioration Before Cutoff Date	47 (56.0%)	47 (53.4%)
Number of patients censored	37 (44.0%)	41 (46.6%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	5 (6.0%)	2 (2.3%)
Death	6 (7.1%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	1 (1.1%)
Other	4 (4.8%)	0
Progressive Disease	18 (21.4%)	25 (28.4%)
Withdrawal By Subject	2 (2.4%)	3 (3.4%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.11.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Fatigue (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	58 (69.0%)	56 (63.6%)	
Number of patients censored	26 (31.0%)	32 (36.4%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	1.51 [0.95, 2.83]	1.48 [0.92, 3.45]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.021 [0.694, 1.502]
Log-rank test			
Two-sided stratified log-rank p-value			0.8847

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.11.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Fatigue by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	41 (68.3)	1.45 [0.89, 2.33]	60	43 (71.7)	1.12 [0.79, 2.60]	0.914 [0.592, 1.411]	0.6962	0.1303
>65 years	24	17 (70.8)	2.92 [0.92, 4.37]	28	13 (46.4)	4.83 [1.22, 14.09]	1.941 [0.896, 4.206]	0.0866	
Age Group 2									
<=75 years	81	55 (67.9)	1.61 [0.99, 2.83]	81	52 (64.2)	1.61 [0.89, 3.88]	1.091 [0.744, 1.599]	0.6189	0.3760
>75 years	3	3 (100.0)	0.69 [0.56, NC]	7	4 (57.1)	1.35 [0.82, NC]	2.000 [0.387, 10.333]	0.4000	
Sex									
Male	52	38 (73.1)	1.51 [0.99, 4.37]	46	29 (63.0)	1.41 [0.79, 4.96]	1.074 [0.657, 1.755]	0.7514	0.7404
Female	32	20 (62.5)	1.74 [0.76, 2.37]	42	27 (64.3)	2.50 [0.82, 3.88]	1.260 [0.698, 2.274]	0.4274	
Region									
Asia	38	29 (76.3)	0.94 [0.79, 1.61]	41	24 (58.5)	2.56 [0.82, 5.32]	1.641 [0.946, 2.847]	0.0656	0.0414
Non-Asia	46	29 (63.0)	2.37 [1.45, 4.40]	47	32 (68.1)	1.22 [0.79, 3.25]	0.786 [0.472, 1.309]	0.3684	
Number of Organs with Metastatic Sites									
0-2	64	46 (71.9)	1.51 [0.92, 2.83]	64	43 (67.2)	1.41 [0.82, 2.60]	1.050 [0.690, 1.597]	0.7647	0.7459
>=3	20	12 (60.0)	1.79 [0.72, 6.41]	24	13 (54.2)	3.25 [0.82, 7.92]	1.278 [0.579, 2.824]	0.5622	
Prior Gastrectomy (total or partial)									
Yes	24	19 (79.2)	1.45 [0.82, 3.55]	22	16 (72.7)	3.88 [0.92, 7.92]	1.765 [0.885, 3.521]	0.1007	0.1616
No	60	39 (65.0)	1.74 [0.95, 3.45]	66	40 (60.6)	1.25 [0.79, 2.56]	0.928 [0.595, 1.449]	0.7700	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.11.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Fatigue (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	58 (69.0%)	56 (63.6%)
Deterioration Before Cutoff Date	58 (69.0%)	56 (63.6%)
Number of patients censored	26 (31.0%)	32 (36.4%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	4 (4.8%)	2 (2.3%)
Death	6 (7.1%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	0
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	2 (2.4%)	0
Progressive Disease	10 (11.9%)	19 (21.6%)
Withdrawal By Subject	2 (2.4%)	2 (2.3%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.12.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Nausea and Vomiting (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	58 (69.0%)	48 (54.5%)	
Number of patients censored	26 (31.0%)	40 (45.5%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	1.48 [0.99, 1.71]	3.55 [2.27, 5.85]	
Cox proportional hazards model			
Stratified HR, 95% CI			2.018 [1.319, 3.088]
Log-rank test			
Two-sided stratified log-rank p-value			0.0008

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.12.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Nausea and Vomiting by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	42 (70.0)	1.51 [0.82, 2.04]	60	37 (61.7)	3.55 [2.27, 5.85]	1.714 [1.097, 2.679]	0.0166	0.9590
>65 years	24	16 (66.7)	1.41 [0.85, 6.67]	28	11 (39.3)	2.56 [1.45, NC]	1.693 [0.783, 3.658]	0.1731	
Age Group 2									
<=75 years	81	56 (69.1)	1.51 [0.99, 1.71]	81	46 (56.8)	3.55 [2.27, 5.85]	1.666 [1.124, 2.467]	0.0098	0.5972
>75 years	3	2 (66.7)	0.69 [0.56, NC]	7	2 (28.6)	NC [0.82, NC]	2.380 [0.322, 17.617]	0.3826	
Sex									
Male	52	34 (65.4)	2.04 [1.45, 4.40]	46	24 (52.2)	3.52 [1.45, 4.47]	1.215 [0.719, 2.053]	0.4565	0.0085
Female	32	24 (75.0)	0.89 [0.72, 1.51]	42	24 (57.1)	3.91 [2.27, 6.97]	4.238 [2.214, 8.113]	<.0001	
Region									
Asia	38	29 (76.3)	1.46 [0.72, 2.04]	41	24 (58.5)	2.83 [1.51, 5.98]	1.627 [0.945, 2.802]	0.0812	0.6921
Non-Asia	46	29 (63.0)	1.51 [0.95, 3.02]	47	24 (51.1)	3.61 [2.27, 6.97]	2.118 [1.175, 3.818]	0.0091	
Number of Organs with Metastatic Sites									
0-2	64	45 (70.3)	1.51 [1.08, 2.27]	64	35 (54.7)	3.61 [2.27, 6.93]	1.649 [1.057, 2.573]	0.0239	0.5935
>=3	20	13 (65.0)	0.95 [0.72, 2.99]	24	13 (54.2)	2.56 [1.41, 5.98]	2.574 [1.107, 5.985]	0.0234	
Prior Gastrectomy (total or partial)									
Yes	24	21 (87.5)	1.48 [0.72, 2.04]	22	15 (68.2)	3.52 [1.51, 5.85]	2.296 [1.154, 4.570]	0.0157	0.3602
No	60	37 (61.7)	1.51 [0.85, 3.02]	66	33 (50.0)	3.61 [2.23, 6.97]	1.461 [0.911, 2.342]	0.1073	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.12.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Nausea and Vomiting (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	58 (69.0%)	48 (54.5%)
Deterioration Before Cutoff Date	58 (69.0%)	48 (54.5%)
Number of patients censored	26 (31.0%)	40 (45.5%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	7 (8.3%)	1 (1.1%)
Death	6 (7.1%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	1 (1.2%)	1 (1.1%)
Progressive Disease	8 (9.5%)	24 (27.3%)
Withdrawal By Subject	2 (2.4%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.13.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Pain (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	45 (53.6%)	51 (58.0%)	
Number of patients censored	39 (46.4%)	37 (42.0%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	4.40 [3.71, 9.03]	3.52 [2.14, 5.78]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.792 [0.515, 1.220]
Log-rank test			
Two-sided stratified log-rank p-value			0.2880

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.13.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Pain by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	32 (53.3)	4.27 [3.35, 13.24]	60	37 (61.7)	4.93 [2.14, 5.78]	0.839 [0.519, 1.355]	0.4626	0.6983
>65 years	24	13 (54.2)	4.44 [2.46, 12.65]	28	14 (50.0)	3.02 [0.89, 7.92]	0.707 [0.331, 1.508]	0.3693	
Age Group 2									
<=75 years	81	42 (51.9)	4.40 [3.71, 12.65]	81	48 (59.3)	3.58 [2.27, 5.85]	0.763 [0.502, 1.158]	0.2023	0.2415
>75 years	3	3 (100.0)	0.69 [0.56, NC]	7	3 (42.9)	1.35 [0.82, NC]	2.000 [0.387, 10.333]	0.4000	
Sex									
Male	52	30 (57.7)	4.40 [3.35, 12.65]	46	27 (58.7)	3.02 [1.22, 6.01]	0.675 [0.398, 1.144]	0.1409	0.2908
Female	32	15 (46.9)	3.78 [1.64, 13.24]	42	24 (57.1)	3.52 [2.27, 6.67]	0.993 [0.516, 1.914]	0.9796	
Region									
Asia	38	23 (60.5)	5.13 [1.61, 13.63]	41	25 (61.0)	4.96 [1.45, 6.01]	0.742 [0.417, 1.320]	0.3035	0.7592
Non-Asia	46	22 (47.8)	4.27 [2.46, 7.46]	47	26 (55.3)	3.02 [1.25, 9.23]	0.831 [0.470, 1.472]	0.5222	
Number of Organs with Metastatic Sites									
0-2	64	36 (56.3)	4.40 [2.89, 9.03]	64	39 (60.9)	3.48 [1.45, 5.85]	0.746 [0.471, 1.180]	0.2081	0.6339
>=3	20	9 (45.0)	4.40 [2.23, NC]	24	12 (50.0)	4.96 [1.41, 9.82]	0.931 [0.389, 2.227]	0.8714	
Prior Gastrectomy (total or partial)									
Yes	24	17 (70.8)	3.78 [1.45, 5.49]	22	14 (63.6)	5.85 [1.48, NC]	1.539 [0.729, 3.247]	0.2524	0.0328
No	60	28 (46.7)	8.08 [3.91, 13.63]	66	37 (56.1)	3.52 [1.45, 5.72]	0.577 [0.349, 0.955]	0.0295	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.13.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Pain (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	45 (53.6%)	51 (58.0%)
Deterioration Before Cutoff Date	45 (53.6%)	51 (58.0%)
Number of patients censored	39 (46.4%)	37 (42.0%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	7 (8.3%)	2 (2.3%)
Death	6 (7.1%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	4 (4.8%)	1 (1.1%)
Progressive Disease	15 (17.9%)	22 (25.0%)
Withdrawal By Subject	5 (6.0%)	3 (3.4%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.14.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Dyspnoea (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	38 (45.2%)	40 (45.5%)	
Number of patients censored	46 (54.8%)	48 (54.5%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	6.80 [4.21, 19.65]	5.29 [4.17, 10.84]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.963 [0.608, 1.527]
Log-rank test			
Two-sided stratified log-rank p-value			0.8868

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.14.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Dyspnoea by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	31 (51.7)	6.57 [2.99, 11.99]	60	32 (53.3)	4.93 [2.37, 6.97]	0.980 [0.598, 1.606]	0.9420	0.7745
>65 years	24	7 (29.2)	23.03 [4.21, NC]	28	8 (28.6)	10.84 [4.17, NC]	0.775 [0.268, 2.241]	0.6371	
Age Group 2									
<=75 years	81	36 (44.4)	8.28 [4.40, 19.65]	81	38 (46.9)	5.45 [4.17, 10.84]	0.907 [0.575, 1.432]	0.6796	0.0184
>75 years	3	2 (66.7)	0.74 [0.69, NC]	7	2 (28.6)	NC [0.76, NC]	5.848 [0.519, 65.854]	0.1070	
Sex									
Male	52	24 (46.2)	6.80 [3.65, 23.03]	46	20 (43.5)	5.29 [2.79, NC]	0.938 [0.518, 1.700]	0.8285	0.8410
Female	32	14 (43.8)	8.28 [0.95, NC]	42	20 (47.6)	5.45 [3.65, NC]	1.012 [0.510, 2.005]	0.9514	
Region									
Asia	38	23 (60.5)	4.17 [1.45, 10.87]	41	20 (48.8)	5.29 [2.79, NC]	1.249 [0.686, 2.277]	0.4647	0.2417
Non-Asia	46	15 (32.6)	11.99 [4.40, 19.81]	47	20 (42.6)	5.45 [2.37, NC]	0.722 [0.367, 1.423]	0.3454	
Number of Organs with Metastatic Sites									
0-2	64	30 (46.9)	8.28 [4.21, 19.81]	64	26 (40.6)	9.23 [4.17, NC]	1.122 [0.663, 1.900]	0.6647	0.2585
>=3	20	8 (40.0)	4.40 [1.74, NC]	24	14 (58.3)	4.96 [0.82, 6.64]	0.602 [0.251, 1.441]	0.2517	
Prior Gastrectomy (total or partial)									
Yes	24	13 (54.2)	6.80 [2.04, 23.03]	22	8 (36.4)	28.68 [2.23, NC]	1.848 [0.764, 4.469]	0.1679	0.0799
No	60	25 (41.7)	8.28 [3.71, 19.65]	66	32 (48.5)	4.83 [2.79, 6.28]	0.726 [0.429, 1.227]	0.2327	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.14.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Dyspnoea (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	38 (45.2%)	40 (45.5%)
Deterioration Before Cutoff Date	38 (45.2%)	40 (45.5%)
Number of patients censored	46 (54.8%)	48 (54.5%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	11 (13.1%)	1 (1.1%)
Death	6 (7.1%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	2 (2.4%)	0
Other	5 (6.0%)	2 (2.3%)
Progressive Disease	16 (19.0%)	30 (34.1%)
Withdrawal By Subject	5 (6.0%)	6 (6.8%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.15.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Insomnia (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	40 (47.6%)	39 (44.3%)	
Number of patients censored	44 (52.4%)	49 (55.7%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	5.42 [2.99, 13.90]	4.21 [2.56, 7.75]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.935 [0.586, 1.492]
Log-rank test			
Two-sided stratified log-rank p-value			0.7967

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.15.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Insomnia by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	28 (46.7)	5.42 [2.99, 20.76]	60	31 (51.7)	4.17 [2.23, 7.26]	0.689 [0.406, 1.170]	0.1670	0.1379
>65 years	24	12 (50.0)	4.40 [0.99, NC]	28	8 (28.6)	NC [1.58, NC]	1.547 [0.632, 3.788]	0.3435	
Age Group 2									
<=75 years	81	40 (49.4)	5.42 [2.99, 13.90]	81	37 (45.7)	4.21 [2.56, 7.75]	0.928 [0.589, 1.460]	0.7456	0.9860
>75 years	3	0 (0.0)	NC [NC, NC]	7	2 (28.6)	NC [0.79, NC]	0.000 [0.000, NC]	0.2807	
Sex									
Male	52	29 (55.8)	4.40 [2.99, 10.87]	46	20 (43.5)	4.96 [1.58, NC]	0.995 [0.560, 1.767]	0.9860	0.3502
Female	32	11 (34.4)	20.76 [1.71, NC]	42	19 (45.2)	4.17 [2.23, NC]	0.707 [0.328, 1.522]	0.3689	
Region									
Asia	38	21 (55.3)	6.90 [2.04, 10.87]	41	20 (48.8)	4.21 [2.07, NC]	0.991 [0.537, 1.829]	0.9850	0.5398
Non-Asia	46	19 (41.3)	5.42 [2.56, NC]	47	19 (40.4)	5.13 [1.81, NC]	0.789 [0.408, 1.523]	0.4750	
Number of Organs with Metastatic Sites									
0-2	64	31 (48.4)	6.90 [2.89, 20.76]	64	25 (39.1)	7.75 [2.56, NC]	1.011 [0.591, 1.727]	0.9643	0.4866
>=3	20	9 (45.0)	4.17 [0.76, NC]	24	14 (58.3)	2.83 [1.25, 5.16]	0.726 [0.312, 1.692]	0.4475	
Prior Gastrectomy (total or partial)									
Yes	24	15 (62.5)	4.40 [1.51, 20.96]	22	10 (45.5)	11.63 [0.92, NC]	1.257 [0.555, 2.848]	0.5756	0.3410
No	60	25 (41.7)	10.87 [2.99, NC]	66	29 (43.9)	4.17 [2.23, 7.26]	0.753 [0.436, 1.302]	0.3109	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.15.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Insomnia (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	40 (47.6%)	39 (44.3%)
Deterioration Before Cutoff Date	40 (47.6%)	39 (44.3%)
Number of patients censored	44 (52.4%)	49 (55.7%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	8 (9.5%)	2 (2.3%)
Death	5 (6.0%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	2 (2.4%)	0
Other	3 (3.6%)	2 (2.3%)
Progressive Disease	22 (26.2%)	31 (35.2%)
Withdrawal By Subject	3 (3.6%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.16.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Appetite Loss (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	44 (52.4%)	48 (54.5%)	
Number of patients censored	40 (47.6%)	40 (45.5%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	3.35 [1.51, 4.99]	2.96 [2.23, 6.28]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.047 [0.681, 1.610]
Log-rank test			
Two-sided stratified log-rank p-value			0.8421

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.16.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Appetite Loss by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	31 (51.7)	3.78 [1.64, 10.71]	60	36 (60.0)	4.96 [2.23, 6.97]	0.887 [0.547, 1.437]	0.6234	0.5287
>65 years	24	13 (54.2)	1.51 [0.92, 7.62]	28	12 (42.9)	2.79 [1.41, 7.92]	1.217 [0.552, 2.683]	0.6200	
Age Group 2									
<=75 years	81	41 (50.6)	3.78 [1.64, 7.62]	81	45 (55.6)	2.96 [2.23, 6.67]	0.904 [0.591, 1.382]	0.6460	0.0013
>75 years	3	3 (100.0)	0.69 [0.56, NC]	7	3 (42.9)	4.29 [1.48, NC]	2.72E8 [0.000, NC]	0.0101	
Sex									
Male	52	30 (57.7)	3.35 [1.51, 4.40]	46	25 (54.3)	2.96 [1.45, 9.17]	0.946 [0.556, 1.610]	0.8492	0.9985
Female	32	14 (43.8)	3.78 [0.72, NC]	42	23 (54.8)	3.52 [2.27, 6.97]	0.901 [0.455, 1.786]	0.7327	
Region									
Asia	38	23 (60.5)	3.35 [0.95, 10.71]	41	24 (58.5)	2.79 [1.45, 6.28]	0.955 [0.538, 1.693]	0.8665	0.9382
Non-Asia	46	21 (45.7)	3.78 [1.45, 18.23]	47	24 (51.1)	5.06 [1.64, 9.17]	0.977 [0.542, 1.763]	0.9499	
Number of Organs with Metastatic Sites									
0-2	64	35 (54.7)	3.25 [1.38, 7.62]	64	35 (54.7)	2.96 [1.64, 9.17]	0.999 [0.625, 1.599]	0.9880	0.7015
>=3	20	9 (45.0)	4.17 [1.64, NC]	24	13 (54.2)	4.96 [1.45, 6.97]	0.882 [0.374, 2.080]	0.7659	
Prior Gastrectomy (total or partial)									
Yes	24	14 (58.3)	4.09 [1.45, 10.71]	22	11 (50.0)	14.75 [1.48, NC]	1.401 [0.632, 3.104]	0.3995	0.2567
No	60	30 (50.0)	3.25 [0.99, 10.87]	66	37 (56.1)	2.83 [1.64, 5.06]	0.838 [0.515, 1.365]	0.4776	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.16.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Appetite Loss (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	44 (52.4%)	48 (54.5%)
Deterioration Before Cutoff Date	44 (52.4%)	48 (54.5%)
Number of patients censored	40 (47.6%)	40 (45.5%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	6 (7.1%)	2 (2.3%)
Death	5 (6.0%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	3 (3.6%)	0
Other	3 (3.6%)	1 (1.1%)
Progressive Disease	18 (21.4%)	25 (28.4%)
Withdrawal By Subject	4 (4.8%)	3 (3.4%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.17.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Constipation (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	34 (40.5%)	41 (46.6%)	
Number of patients censored	50 (59.5%)	47 (53.4%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	5.49 [4.40, NC]	4.86 [3.48, 9.23]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.762 [0.469, 1.237]
Log-rank test			
Two-sided stratified log-rank p-value			0.2679

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.17.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Constipation by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	26 (43.3)	5.42 [3.48, 13.90]	60	31 (51.7)	4.70 [2.27, 9.23]	0.739 [0.436, 1.254]	0.2524	0.7541
>65 years	24	8 (33.3)	7.03 [2.46, NC]	28	10 (35.7)	7.39 [1.41, NC]	0.911 [0.358, 2.317]	0.8339	
Age Group 2									
<=75 years	81	33 (40.7)	5.49 [4.40, NC]	81	38 (46.9)	5.09 [3.48, 9.23]	0.807 [0.506, 1.290]	0.3641	0.9511
>75 years	3	1 (33.3)	NC [0.69, NC]	7	3 (42.9)	2.99 [1.22, NC]	0.859 [0.088, 8.397]	0.8957	
Sex									
Male	52	24 (46.2)	5.29 [3.48, NC]	46	22 (47.8)	4.21 [1.51, 10.78]	0.759 [0.425, 1.356]	0.3446	0.8051
Female	32	10 (31.3)	12.09 [3.25, NC]	42	19 (45.2)	6.83 [3.65, 23.26]	0.821 [0.376, 1.792]	0.6172	
Region									
Asia	38	17 (44.7)	12.09 [3.48, NC]	41	18 (43.9)	7.39 [3.65, NC]	0.922 [0.473, 1.795]	0.8047	0.5568
Non-Asia	46	17 (37.0)	5.29 [3.71, NC]	47	23 (48.9)	4.21 [1.51, 9.23]	0.682 [0.362, 1.284]	0.2300	
Number of Organs with Metastatic Sites									
0-2	64	26 (40.6)	5.49 [3.71, NC]	64	28 (43.8)	6.83 [4.21, NC]	0.899 [0.526, 1.537]	0.6891	0.3651
>=3	20	8 (40.0)	7.03 [2.14, NC]	24	13 (54.2)	2.27 [0.82, 7.39]	0.543 [0.224, 1.319]	0.1727	
Prior Gastrectomy (total or partial)									
Yes	24	12 (50.0)	5.49 [3.48, NC]	22	15 (68.2)	4.86 [1.51, 8.64]	0.746 [0.344, 1.615]	0.4566	0.7759
No	60	22 (36.7)	7.03 [3.48, NC]	66	26 (39.4)	5.09 [2.50, NC]	0.842 [0.476, 1.491]	0.5476	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.17.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Constipation (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	34 (40.5%)	41 (46.6%)
Deterioration Before Cutoff Date	34 (40.5%)	41 (46.6%)
Number of patients censored	50 (59.5%)	47 (53.4%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	11 (13.1%)	2 (2.3%)
Death	5 (6.0%)	10 (11.4%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	5 (6.0%)	0
Progressive Disease	21 (25.0%)	30 (34.1%)
Withdrawal By Subject	6 (7.1%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.18.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Diarrhoea (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	35 (41.7%)	42 (47.7%)	
Number of patients censored	49 (58.3%)	46 (52.3%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	6.67 [3.22, 27.17]	2.92 [2.27, 18.89]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.788 [0.494, 1.256]
Log-rank test			
Two-sided stratified log-rank p-value			0.3087

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.18.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Diarrhoea by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	28 (46.7)	5.29 [2.40, 17.28]	60	29 (48.3)	2.92 [2.10, NC]	0.921 [0.547, 1.551]	0.7742	0.2324
>65 years	24	7 (29.2)	NC [1.22, NC]	28	13 (46.4)	2.86 [0.92, NC]	0.496 [0.197, 1.247]	0.1285	
Age Group 2									
<=75 years	81	34 (42.0)	6.67 [3.22, 27.17]	81	39 (48.1)	2.92 [2.27, 18.89]	0.809 [0.510, 1.283]	0.3725	0.5418
>75 years	3	1 (33.3)	NC [0.56, NC]	7	3 (42.9)	3.99 [1.48, NC]	0.372 [0.036, 3.829]	0.3901	
Sex									
Male	52	20 (38.5)	27.17 [4.17, NC]	46	22 (47.8)	2.83 [1.41, NC]	0.587 [0.319, 1.078]	0.0824	0.1187
Female	32	15 (46.9)	4.44 [1.22, 17.28]	42	20 (47.6)	6.64 [2.10, NC]	1.203 [0.615, 2.355]	0.5805	
Region									
Asia	38	21 (55.3)	2.83 [1.45, NC]	41	25 (61.0)	2.60 [1.48, 6.64]	0.860 [0.480, 1.539]	0.5994	0.6903
Non-Asia	46	14 (30.4)	13.40 [4.99, NC]	47	17 (36.2)	NC [2.30, NC]	0.725 [0.356, 1.477]	0.3881	
Number of Organs with Metastatic Sites									
0-2	64	28 (43.8)	6.67 [2.40, 27.17]	64	33 (51.6)	2.92 [2.10, 11.27]	0.764 [0.460, 1.269]	0.2953	0.8659
>=3	20	7 (35.0)	5.29 [1.45, NC]	24	9 (37.5)	2.92 [0.92, NC]	0.774 [0.288, 2.080]	0.6178	
Prior Gastrectomy (total or partial)									
Yes	24	13 (54.2)	4.44 [1.22, NC]	22	11 (50.0)	18.89 [1.45, NC]	1.368 [0.610, 3.068]	0.4460	0.0648
No	60	22 (36.7)	17.28 [4.17, NC]	66	31 (47.0)	2.86 [2.10, 6.64]	0.579 [0.331, 1.012]	0.0523	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.18.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Diarrhoea (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	35 (41.7%)	42 (47.7%)
Deterioration Before Cutoff Date	35 (41.7%)	42 (47.7%)
Number of patients censored	49 (58.3%)	46 (52.3%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	11 (13.1%)	2 (2.3%)
Death	7 (8.3%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	2 (2.4%)	0
Other	5 (6.0%)	1 (1.1%)
Progressive Disease	19 (22.6%)	30 (34.1%)
Withdrawal By Subject	4 (4.8%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.19.2.1: EORTC QLQ-C30 - Summary of Time to First Deterioration of Financial Difficulties (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	31 (36.9%)	29 (33.0%)	
Number of patients censored	53 (63.1%)	59 (67.0%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	9.20 [5.42, NC]	NC [4.96, NC]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.172 [0.698, 1.969]
Log-rank test			
Two-sided stratified log-rank p-value			0.5491

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.19.2.2: EORTC QLQ-C30 - Summary of Time to First Deterioration of Financial Difficulties by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	20 (33.3)	20.30 [5.42, NC]	60	18 (30.0)	NC [4.96, NC]	1.143 [0.605, 2.162]	0.6764	0.9502
>65 years	24	11 (45.8)	7.75 [0.85, NC]	28	11 (39.3)	5.09 [1.58, NC]	1.217 [0.527, 2.811]	0.6438	
Age Group 2									
<=75 years	81	29 (35.8)	9.20 [5.42, NC]	81	25 (30.9)	NC [4.96, NC]	1.207 [0.707, 2.061]	0.4897	0.9318
>75 years	3	2 (66.7)	0.69 [0.56, NC]	7	4 (57.1)	3.86 [1.22, NC]	0.965 [0.170, 5.483]	0.9682	
Sex									
Male	52	19 (36.5)	20.30 [4.27, NC]	46	21 (45.7)	3.38 [1.58, NC]	0.613 [0.329, 1.143]	0.1201	0.0055
Female	32	12 (37.5)	7.75 [1.58, NC]	42	8 (19.0)	NC [NC, NC]	2.892 [1.179, 7.096]	0.0154	
Region									
Asia	38	15 (39.5)	20.30 [2.83, NC]	41	16 (39.0)	NC [4.21, NC]	0.959 [0.474, 1.944]	0.9112	0.5202
Non-Asia	46	16 (34.8)	7.75 [4.17, NC]	47	13 (27.7)	NC [3.38, NC]	1.366 [0.656, 2.841]	0.4057	
Number of Organs with Metastatic Sites									
0-2	64	24 (37.5)	9.20 [5.42, NC]	64	19 (29.7)	NC [4.96, NC]	1.286 [0.704, 2.350]	0.4156	0.5124
>=3	20	7 (35.0)	5.55 [1.05, NC]	24	10 (41.7)	6.05 [1.25, NC]	0.871 [0.330, 2.295]	0.7840	
Prior Gastrectomy (total or partial)									
Yes	24	10 (41.7)	9.00 [1.58, NC]	22	5 (22.7)	NC [4.47, NC]	2.039 [0.697, 5.969]	0.1842	0.2111
No	60	21 (35.0)	9.20 [4.17, NC]	66	24 (36.4)	5.09 [3.65, NC]	0.933 [0.518, 1.680]	0.8209	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.19.2.3: EORTC QLQ-C30 - Type of Events and Censoring for Time to First Deterioration of Financial Difficulties (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	31 (36.9%)	29 (33.0%)
Deterioration Before Cutoff Date	31 (36.9%)	29 (33.0%)
Number of patients censored	53 (63.1%)	59 (67.0%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	9 (10.7%)	3 (3.4%)
Death	6 (7.1%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	3 (3.6%)	1 (1.1%)
Other	5 (6.0%)	1 (1.1%)
Progressive Disease	26 (31.0%)	38 (43.2%)
Withdrawal By Subject	3 (3.6%)	6 (6.8%)


Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik und Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ-C30


4. Graphische Darstellung des Verlaufs (Mean Change from Baseline)

Figure 302.3.3002.5.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Global Health Status - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.6.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Physical Functioning - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.7.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Role Functioning - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.8.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Emotional Functioning - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.9.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Cognitive Functioning - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.10.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Social Functioning - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.11.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Fatigue - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.12.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Nausea and Vomiting - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.13.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Pain - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.14.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Dyspnoea - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.15.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Insomnia - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.16.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Appetite Loss - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.17.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Constipation - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.18.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Diarrhoea - Modified Full Analysis Set (CPS < 1)



Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.19.2: EORTC QLQ-C30 - Plot of Mean Change from Baseline of Financial Difficulties - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik und Gesundheitsbezogene Lebensqualität anhand des EORTC QLQ-C30

5. Kaplan-Meier-Plots

Figure 302.3.3003.5.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Global Health Status (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	28 (28.6)	9 (38.1)	3 (41.7)	2 (42.9)	0 (44.0)	0 (44.0)	0 (44.0)	0 (44.0)
2	88 (0.0)	25 (27.3)	8 (42.0)	3 (45.5)	2 (45.5)	0 (47.7)	0 (47.7)	0 (47.7)	0 (47.7)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.5.2.6: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Global Health Status by Prior Gastrectomy (total or partial) (MID=10) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): Yes



at Risk

1	24 (0.0)	6 (25.0)	1 (37.5)	1 (37.5)	0 (41.7)	0 (41.7)	0 (41.7)	0 (41.7)	0 (41.7)
2	22 (0.0)	11 (18.2)	5 (36.4)	3 (40.9)	2 (40.9)	0 (50.0)	0 (50.0)	0 (50.0)	0 (50.0)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.5.2.6: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Global Health Status by Prior Gastrectomy (total or partial) (MID=10) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): No



at Risk

1	60 (0.0)	22 (30.0)	8 (38.3)	2 (43.3)	2 (43.3)	0 (45.0)	0 (45.0)	0 (45.0)	0 (45.0)
2	66 (0.0)	14 (30.3)	3 (43.9)	0 (47.0)	0 (47.0)	0 (47.0)	0 (47.0)	0 (47.0)	0 (47.0)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.6.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Physical Functioning (MID=10) - Modified Full Analysis Set (CPS < 1)



	# at Risk								
1	84 (0.0)	22 (22.6)	9 (32.1)	5 (35.7)	4 (35.7)	1 (39.3)	1 (39.3)	0 (40.5)	0 (40.5)
2	88 (0.0)	27 (28.4)	9 (43.2)	4 (47.7)	4 (47.7)	0 (52.3)	0 (52.3)	0 (52.3)	0 (52.3)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.7.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Role Functioning (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	21 (22.6)	9 (28.6)	5 (32.1)	2 (32.1)	1 (33.3)	0 (34.5)	0 (34.5)	0 (34.5)
2	88 (0.0)	19 (27.3)	8 (36.4)	4 (40.9)	2 (43.2)	0 (44.3)	0 (44.3)	0 (44.3)	0 (44.3)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.8.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Emotional Functioning (MID=10) - Modified Full Analysis Set (CPS < 1)



# at Risk									
1	84 (0.0)	31 (26.2)	9 (40.5)	5 (45.2)	3 (46.4)	0 (48.8)	0 (48.8)	0 (48.8)	0 (48.8)
2	88 (0.0)	26 (33.0)	6 (47.7)	2 (52.3)	2 (52.3)	0 (53.4)	0 (53.4)	0 (53.4)	0 (53.4)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.9.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Cognitive Functioning (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	21 (23.8)	6 (34.5)	3 (35.7)	1 (38.1)	0 (39.3)	0 (39.3)	0 (39.3)	0 (39.3)
2	88 (0.0)	25 (33.0)	6 (47.7)	1 (51.1)	1 (51.1)	1 (51.1)	0 (52.3)	0 (52.3)	0 (52.3)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.10.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Social Functioning (MID=10) - Modified Full Analysis Set (CPS < 1)



	# at Risk								
1	84 (0.0)	27 (23.8)	10 (36.9)	5 (40.5)	2 (41.7)	0 (44.0)	0 (44.0)	0 (44.0)	0 (44.0)
2	88 (0.0)	22 (28.4)	7 (39.8)	3 (44.3)	3 (44.3)	1 (45.5)	0 (46.6)	0 (46.6)	0 (46.6)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.10.2.1: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Social Functioning by Age Group 1 (MID=10) - Modified Full Analysis Set (CPS < 1)

Age Group 1: <=65 years



	# at Risk								
1	60 (0.0)	21 (23.3)	8 (38.3)	5 (41.7)	2 (43.3)	0 (46.7)	0 (46.7)	0 (46.7)	0 (46.7)
2	60 (0.0)	11 (23.3)	3 (33.3)	3 (33.3)	3 (33.3)	1 (35.0)	0 (36.7)	0 (36.7)	0 (36.7)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.10.2.1: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Social Functioning by Age Group 1 (MID=10) - Modified Full Analysis Set (CPS < 1)

Age Group 1: >65 years



# at Risk									
1	24 (0.0)	6 (25.0)	2 (33.3)	0 (37.5)	0 (37.5)	0 (37.5)	0 (37.5)	0 (37.5)	0 (37.5)
2	28 (0.0)	11 (39.3)	4 (53.6)	0 (67.9)	0 (67.9)	0 (67.9)	0 (67.9)	0 (67.9)	0 (67.9)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.11.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Fatigue (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	11 (23.8)	3 (29.8)	1 (31.0)	0 (31.0)	0 (31.0)	0 (31.0)	0 (31.0)	0 (31.0)
2	88 (0.0)	18 (21.6)	3 (34.1)	0 (36.4)	0 (36.4)	0 (36.4)	0 (36.4)	0 (36.4)	0 (36.4)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.11.2.4: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Fatigue by Region (MID=10) - Modified Full Analysis Set (CPS < 1)

Region: Asia



at Risk

1	38 (0.0)	6 (15.8)	1 (23.7)	0 (23.7)	0 (23.7)	0 (23.7)	0 (23.7)	0 (23.7)	0 (23.7)
2	41 (0.0)	10 (22.0)	3 (36.6)	0 (41.5)	0 (41.5)	0 (41.5)	0 (41.5)	0 (41.5)	0 (41.5)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.11.2.4: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Fatigue by Region (MID=10) - Modified Full Analysis Set (CPS < 1)
Region: Non-Asia



	# at Risk								
1	46 (0.0)	5 (30.4)	2 (34.8)	1 (37.0)	0 (37.0)	0 (37.0)	0 (37.0)	0 (37.0)	0 (37.0)
2	47 (0.0)	8 (21.3)	0 (31.9)	0 (31.9)	0 (31.9)	0 (31.9)	0 (31.9)	0 (31.9)	0 (31.9)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.12.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Nausea and Vomiting (MID=10) - Modified Full Analysis Set (CPS < 1)



	# at Risk								
1	84 (0.0)	9 (25.0)	3 (28.6)	1 (29.8)	1 (29.8)	0 (31.0)	0 (31.0)	0 (31.0)	0 (31.0)
2	88 (0.0)	17 (34.1)	7 (39.8)	2 (45.5)	0 (45.5)	0 (45.5)	0 (45.5)	0 (45.5)	0 (45.5)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.12.2.3: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Nausea and Vomiting by Sex (MID=10) - Modified Full Analysis Set (CPS < 1)

Sex: Male



at Risk

1	52 (0.0)	9 (25.0)	3 (30.8)	1 (32.7)	1 (32.7)	0 (34.6)	0 (34.6)	0 (34.6)	0 (34.6)
2	46 (0.0)	8 (34.8)	4 (39.1)	0 (47.8)	0 (47.8)	0 (47.8)	0 (47.8)	0 (47.8)	0 (47.8)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.12.2.3: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Nausea and Vomiting by Sex (MID=10) - Modified Full Analysis Set (CPS < 1)

Sex: Female



at Risk

1	32 (0.0)	0 (25.0)	0 (25.0)	0 (25.0)	0 (25.0)	0 (25.0)	0 (25.0)	0 (25.0)	0 (25.0)
2	42 (0.0)	9 (33.3)	3 (40.5)	2 (42.9)	0 (42.9)	0 (42.9)	0 (42.9)	0 (42.9)	0 (42.9)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.13.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Pain (MID=10) - Modified Full Analysis Set (CPS < 1)



# at Risk									
1	84 (0.0)	22 (29.8)	10 (40.5)	4 (44.0)	2 (45.2)	0 (46.4)	0 (46.4)	0 (46.4)	0 (46.4)
2	88 (0.0)	19 (30.7)	6 (37.5)	3 (40.9)	1 (40.9)	0 (42.0)	0 (42.0)	0 (42.0)	0 (42.0)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.13.2.6: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Pain by Prior Gastrectomy (total or partial) (MID=10) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): Yes



# at Risk									
1	24 (0.0)	5 (16.7)	1 (25.0)	0 (29.2)	0 (29.2)	0 (29.2)	0 (29.2)	0 (29.2)	0 (29.2)
2	22 (0.0)	7 (18.2)	4 (27.3)	2 (36.4)	0 (36.4)	0 (36.4)	0 (36.4)	0 (36.4)	0 (36.4)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.13.2.6: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Pain by Prior Gastrectomy (total or partial) (MID=10) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): No



at Risk

1	60 (0.0)	17 (35.0)	9 (46.7)	4 (50.0)	2 (51.7)	0 (53.3)	0 (53.3)	0 (53.3)	0 (53.3)
2	66 (0.0)	12 (34.8)	2 (40.9)	1 (42.4)	1 (42.4)	0 (43.9)	0 (43.9)	0 (43.9)	0 (43.9)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.14.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Dyspnoea (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	28 (33.3)	8 (48.8)	7 (50.0)	3 (51.2)	1 (53.6)	0 (54.8)	0 (54.8)	0 (54.8)
2	88 (0.0)	25 (34.1)	11 (43.2)	5 (50.0)	4 (51.1)	0 (54.5)	0 (54.5)	0 (54.5)	0 (54.5)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.14.2.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Dyspnoea by Age Group 2 (MID=10) - Modified Full Analysis Set (CPS < 1)

Age Group 2: <=75 years



# at Risk									
1	81 (0.0)	28 (33.3)	8 (49.4)	7 (50.6)	3 (51.9)	1 (54.3)	0 (55.6)	0 (55.6)	0 (55.6)
2	81 (0.0)	24 (32.1)	10 (42.0)	5 (48.1)	4 (49.4)	0 (53.1)	0 (53.1)	0 (53.1)	0 (53.1)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.14.2.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Dyspnoea by Age Group 2 (MID=10) - Modified Full Analysis Set (CPS < 1)

Age Group 2: >75 years



# at Risk									
1	3 (0.0)	0 (33.3)	0 (33.3)	0 (33.3)	0 (33.3)	0 (33.3)	0 (33.3)	0 (33.3)	0 (33.3)
2	7 (0.0)	1 (57.1)	1 (57.1)	0 (71.4)	0 (71.4)	0 (71.4)	0 (71.4)	0 (71.4)	0 (71.4)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.15.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Insomnia (MID=10) - Modified Full Analysis Set (CPS < 1)



	# at Risk								
1	84 (0.0)	24 (32.1)	10 (44.0)	5 (48.8)	2 (50.0)	1 (51.2)	0 (52.4)	0 (52.4)	0 (52.4)
2	88 (0.0)	20 (36.4)	4 (51.1)	1 (54.5)	0 (55.7)	0 (55.7)	0 (55.7)	0 (55.7)	0 (55.7)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.16.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Appetite Loss (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	17 (32.1)	8 (39.3)	6 (41.7)	4 (42.9)	2 (45.2)	0 (47.6)	0 (47.6)	0 (47.6)
2	88 (0.0)	21 (31.8)	7 (39.8)	3 (43.2)	2 (44.3)	0 (45.5)	0 (45.5)	0 (45.5)	0 (45.5)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.16.2.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Appetite Loss by Age Group 2 (MID=10) - Modified Full Analysis Set (CPS < 1)

Age Group 2: <=75 years



	# at Risk								
1	81 (0.0)	17 (33.3)	8 (40.7)	6 (43.2)	4 (44.4)	2 (46.9)	0 (49.4)	0 (49.4)	0 (49.4)
2	81 (0.0)	21 (29.6)	7 (38.3)	3 (42.0)	2 (43.2)	0 (44.4)	0 (44.4)	0 (44.4)	0 (44.4)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MD=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.16.2.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Appetite Loss by Age Group 2 (MID=10) - Modified Full Analysis Set (CPS < 1)

Age Group 2: >75 years




Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.17.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Constipation (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	21 (39.3)	12 (48.8)	6 (52.4)	2 (57.1)	1 (58.3)	1 (58.3)	0 (59.5)	0 (59.5)
2	88 (0.0)	24 (33.0)	5 (48.9)	3 (51.1)	1 (52.3)	0 (53.4)	0 (53.4)	0 (53.4)	0 (53.4)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.18.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Diarrhoea (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	23 (36.9)	11 (48.8)	5 (53.6)	4 (54.8)	2 (56.0)	1 (57.1)	0 (58.3)	0 (58.3)
2	88 (0.0)	22 (30.7)	8 (44.3)	4 (48.9)	2 (50.0)	0 (52.3)	0 (52.3)	0 (52.3)	0 (52.3)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.19.2: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Financial Difficulties (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	28 (35.7)	12 (50.0)	8 (54.8)	4 (58.3)	2 (60.7)	0 (63.1)	0 (63.1)	0 (63.1)
2	88 (0.0)	30 (34.1)	10 (55.7)	6 (60.2)	5 (61.4)	1 (65.9)	0 (67.0)	0 (67.0)	0 (67.0)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.19.2.3: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Financial Difficulties by Sex (MID=10) - Modified Full Analysis Set (CPS < 1)

Sex: Male



	# at Risk								
1	52 (0.0)	19 (32.7)	9 (48.1)	6 (53.8)	3 (57.7)	1 (61.5)	0 (63.5)	0 (63.5)	0 (63.5)
2	46 (0.0)	11 (30.4)	4 (45.7)	2 (50.0)	2 (50.0)	0 (54.3)	0 (54.3)	0 (54.3)	0 (54.3)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.19.2.3: EORTC QLQ-C30 - Kaplan-Meier Plot of Time to First Deterioration of Financial Difficulties by Sex (MID=10) - Modified Full Analysis Set (CPS < 1)

Sex: Female



	# at Risk								
1	32 (0.0)	9 (40.6)	3 (53.1)	2 (56.3)	1 (59.4)	1 (59.4)	0 (62.5)	0 (62.5)	0 (62.5)
2	42 (0.0)	19 (38.1)	6 (66.7)	4 (71.4)	3 (73.8)	1 (78.6)	0 (81.0)	0 (81.0)	0 (81.0)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-C30= european organisation for research and treatment of cancer quality of life questionnaire; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte

Anhang 4-G Symptomatik anhand des EORTC QLQ-OG25

1. Rücklaufquoten

Table 302.3.3001.2.2: EORTC QLQ-OG25 - Completion Status
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.2.2: EORTC QLQ-OG25 - Completion Status
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.2.2: EORTC QLQ-OG25 - Completion Status
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.20.2: EORTC QLQ-OG25 - Completion Status of Dysphagia
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.20.2: EORTC QLQ-OG25 - Completion Status of Dysphagia
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.20.2: EORTC QLQ-OG25 - Completion Status of Dysphagia
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.21.2: EORTC QLQ-OG25 - Completion Status of Eating Restrictions
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.21.2: EORTC QLQ-OG25 - Completion Status of Eating Restrictions
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.21.2: EORTC QLQ-OG25 - Completion Status of Eating Restrictions
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.22.2: EORTC QLQ-OG25 - Completion Status of Reflux
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.22.2: EORTC QLQ-OG25 - Completion Status of Reflux
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.22.2: EORTC QLQ-OG25 - Completion Status of Reflux
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.23.2: EORTC QLQ-OG25 - Completion Status of Odynophagia
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.23.2: EORTC QLQ-OG25 - Completion Status of Odynophagia
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.23.2: EORTC QLQ-OG25 - Completion Status of Odynophagia
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.24.2: EORTC QLQ-OG25 - Completion Status of Pain and Discomfort
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.24.2: EORTC QLQ-OG25 - Completion Status of Pain and Discomfort
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.24.2: EORTC QLQ-OG25 - Completion Status of Pain and Discomfort
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.25.2: EORTC QLQ-OG25 - Completion Status of Anxiety
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.25.2: EORTC QLQ-OG25 - Completion Status of Anxiety
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.25.2: EORTC QLQ-OG25 - Completion Status of Anxiety
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.26.2: EORTC QLQ-OG25 - Completion Status of Eating in Front of Others
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.26.2: EORTC QLQ-OG25 - Completion Status of Eating in Front of Others
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.26.2: EORTC QLQ-OG25 - Completion Status of Eating in Front of Others
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.27.2: EORTC QLQ-OG25 - Completion Status of Dry Mouth
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.27.2: EORTC QLQ-OG25 - Completion Status of Dry Mouth
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.27.2: EORTC QLQ-OG25 - Completion Status of Dry Mouth
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.28.2: EORTC QLQ-OG25 - Completion Status of Trouble with Taste
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.28.2: EORTC QLQ-OG25 - Completion Status of Trouble with Taste
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.28.2: EORTC QLQ-OG25 - Completion Status of Trouble with Taste
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.29.2: EORTC QLQ-OG25 - Completion Status of Body Image
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.29.2: EORTC QLQ-OG25 - Completion Status of Body Image
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.29.2: EORTC QLQ-OG25 - Completion Status of Body Image
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.30.2: EORTC QLQ-OG25 - Completion Status of Trouble Swallowing Saliva
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.30.2: EORTC QLQ-OG25 - Completion Status of Trouble Swallowing Saliva
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.30.2: EORTC QLQ-OG25 - Completion Status of Trouble Swallowing Saliva
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.31.2: EORTC QLQ-OG25 - Completion Status of Choked when Swallowing Score
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.31.2: EORTC QLQ-OG25 - Completion Status of Choked when Swallowing Score
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.31.2: EORTC QLQ-OG25 - Completion Status of Choked when Swallowing Score
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.32.2: EORTC QLQ-OG25 - Completion Status of Trouble with Coughing
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.32.2: EORTC QLQ-OG25 - Completion Status of Trouble with Coughing
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.32.2: EORTC QLQ-OG25 - Completion Status of Trouble with Coughing
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.33.2: EORTC QLQ-OG25 - Completion Status of Trouble Talking
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.33.2: EORTC QLQ-OG25 - Completion Status of Trouble Talking
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.33.2: EORTC QLQ-OG25 - Completion Status of Trouble Talking
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.34.2: EORTC QLQ-OG25 - Completion Status of Weight Loss
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.34.2: EORTC QLQ-OG25 - Completion Status of Weight Loss
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.34.2: EORTC QLQ-OG25 - Completion Status of Weight Loss
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.35.2: EORTC QLQ-OG25 - Completion Status of Hair Loss
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	29/ 83 (34.9%)	29/ 83 (34.9%)	29/ 84 (34.5%)	19/ 87 (21.8%)	19/ 88 (21.6%)	19/ 88 (21.6%)
Cycle 2 Day 1	33/ 72 (45.8%)	33/ 78 (42.3%)	33/ 84 (39.3%)	26/ 78 (33.3%)	26/ 81 (32.1%)	26/ 88 (29.5%)
Cycle 3 Day 1	33/ 65 (50.8%)	33/ 74 (44.6%)	33/ 84 (39.3%)	22/ 70 (31.4%)	22/ 79 (27.8%)	22/ 88 (25.0%)
Cycle 4 Day 1	29/ 62 (46.8%)	29/ 73 (39.7%)	29/ 84 (34.5%)	15/ 64 (23.4%)	16/ 79 (20.3%)	16/ 88 (18.2%)
Cycle 5 Day 1	22/ 59 (37.3%)	22/ 71 (31.0%)	23/ 84 (27.4%)	18/ 61 (29.5%)	18/ 79 (22.8%)	18/ 88 (20.5%)
Cycle 6 Day 1	25/ 56 (44.6%)	26/ 70 (37.1%)	26/ 84 (31.0%)	16/ 56 (28.6%)	16/ 75 (21.3%)	16/ 88 (18.2%)
Cycle 7 Day 1	15/ 46 (32.6%)	15/ 67 (22.4%)	15/ 84 (17.9%)	15/ 48 (31.3%)	15/ 74 (20.3%)	15/ 88 (17.0%)
Cycle 8 Day 1	17/ 41 (41.5%)	17/ 65 (26.2%)	18/ 84 (21.4%)	15/ 41 (36.6%)	15/ 74 (20.3%)	15/ 88 (17.0%)
Cycle 9 Day 1	15/ 38 (39.5%)	15/ 63 (23.8%)	15/ 84 (17.9%)	14/ 38 (36.8%)	14/ 74 (18.9%)	14/ 88 (15.9%)
Cycle 10 Day 1	14/ 34 (41.2%)	15/ 63 (23.8%)	15/ 84 (17.9%)	14/ 32 (43.8%)	14/ 74 (18.9%)	14/ 88 (15.9%)
Cycle 11 Day 1	12/ 34 (35.3%)	12/ 63 (19.0%)	12/ 84 (14.3%)	13/ 29 (44.8%)	13/ 74 (17.6%)	13/ 88 (14.8%)
Cycle 12 Day 1	14/ 32 (43.8%)	14/ 63 (22.2%)	14/ 84 (16.7%)	10/ 28 (35.7%)	11/ 74 (14.9%)	11/ 88 (12.5%)
Cycle 13 Day 1	13/ 29 (44.8%)	13/ 63 (20.6%)	13/ 84 (15.5%)	7/ 25 (28.0%)	7/ 74 (9.5%)	7/ 88 (8.0%)
Cycle 14 Day 1	8/ 26 (30.8%)	8/ 63 (12.7%)	8/ 84 (9.5%)	8/ 22 (36.4%)	8/ 74 (10.8%)	8/ 88 (9.1%)
Cycle 15 Day 1	8/ 23 (34.8%)	8/ 61 (13.1%)	9/ 84 (10.7%)	6/ 20 (30.0%)	6/ 73 (8.2%)	6/ 88 (6.8%)
Cycle 16 Day 1	11/ 23 (47.8%)	11/ 61 (18.0%)	11/ 84 (13.1%)	8/ 17 (47.1%)	8/ 73 (11.0%)	8/ 88 (9.1%)
Cycle 17 Day 1	10/ 22 (45.5%)	10/ 61 (16.4%)	10/ 84 (11.9%)	6/ 13 (46.2%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 18 Day 1	8/ 21 (38.1%)	8/ 61 (13.1%)	8/ 84 (9.5%)	6/ 11 (54.5%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 19 Day 1	8/ 21 (38.1%)	8/ 61 (13.1%)	8/ 84 (9.5%)	4/ 10 (40.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 20 Day 1	6/ 20 (30.0%)	6/ 60 (10.0%)	6/ 84 (7.1%)	5/ 10 (50.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 21 Day 1	6/ 19 (31.6%)	6/ 60 (10.0%)	6/ 84 (7.1%)	4/ 9 (44.4%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 22 Day 1	4/ 16 (25.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	4/ 8 (50.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 23 Day 1	5/ 15 (33.3%)	5/ 59 (8.5%)	5/ 84 (6.0%)	3/ 7 (42.9%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 24 Day 1	5/ 15 (33.3%)	5/ 59 (8.5%)	5/ 84 (6.0%)	2/ 6 (33.3%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 25 Day 1	6/ 15 (40.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	3/ 6 (50.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 26 Day 1	4/ 14 (28.6%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0/ 5 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.35.2: EORTC QLQ-OG25 - Completion Status of Hair Loss
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	4/ 13 (30.8%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 5 (20.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 28 Day 1	4/ 12 (33.3%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 5 (20.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 29 Day 1	4/ 11 (36.4%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0/ 5 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 30 Day 1	3/ 10 (30.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	1/ 4 (25.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 31 Day 1	3/ 10 (30.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0/ 4 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 32 Day 1	3/ 10 (30.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0/ 4 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 33 Day 1	3/ 8 (37.5%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0/ 4 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 34 Day 1	2/ 7 (28.6%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0/ 4 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 35 Day 1	2/ 7 (28.6%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0/ 3 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 36 Day 1	2/ 7 (28.6%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0/ 2 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 37 Day 1	2/ 7 (28.6%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0/ 2 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 38 Day 1	2/ 6 (33.3%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0/ 2 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 39 Day 1	1/ 5 (20.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0/ 2 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 40 Day 1	1/ 5 (20.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0/ 1 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 41 Day 1	1/ 5 (20.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0/ 1 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 42 Day 1	2/ 5 (40.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0/ 1 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 43 Day 1	1/ 5 (20.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0/ 1 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 44 Day 1	1/ 5 (20.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0/ 1 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 45 Day 1	1/ 5 (20.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0/ 1 (0.0%)	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 46 Day 1	1/ 5 (20.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	2/ 4 (50.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	1/ 4 (25.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	1/ 3 (33.3%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	0/ 2 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	0/ 2 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	0/ 2 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.35.2: EORTC QLQ-OG25 - Completion Status of Hair Loss
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	0/ 2 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	0/ 2 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	0/ 1 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	0/ 1 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	0/ 1 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	0/ 1 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	0/ 1 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	0/ 1 (0.0%)	0/ 59 (0.0%)	0/ 84 (0.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	19/ 73 (26.0%)	19/ 77 (24.7%)	19/ 84 (22.6%)	16/ 75 (21.3%)	16/ 76 (21.1%)	16/ 88 (18.2%)
30 D SFU Z/P	9/ 69 (13.0%)	9/ 73 (12.3%)	9/ 84 (10.7%)	11/ 70 (15.7%)	11/ 71 (15.5%)	11/ 88 (12.5%)
90 D SFU Z/P	14/ 60 (23.3%)	14/ 66 (21.2%)	14/ 84 (16.7%)	19/ 58 (32.8%)	19/ 59 (32.2%)	19/ 88 (21.6%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EORTC QLQ-OG25

2. Verlauf über die Zeit (Observed Means and Change from Baseline)

Table 302.3.3002.20.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Dysphagia
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	14.39	19.79	0.0	11.11	66.7						
Cycle 2 Day 1	69	15.30	22.15	0.0	0.00	88.9	68	1.47	21.45	-44.4	0.00	66.7
Cycle 3 Day 1	61	12.57	18.20	0.0	0.00	77.8	60	-1.30	15.05	-44.4	0.00	33.3
Cycle 4 Day 1	56	10.12	15.17	0.0	0.00	66.7	56	-1.98	17.74	-66.7	0.00	33.3
Cycle 5 Day 1	55	11.52	18.64	0.0	0.00	100.0	54	-1.23	23.31	-66.7	0.00	100.0
Cycle 6 Day 1	55	11.11	14.97	0.0	0.00	44.4	55	-1.82	17.99	-66.7	0.00	33.3
Cycle 7 Day 1	44	8.59	12.19	0.0	0.00	44.4	44	-3.03	18.46	-55.6	0.00	33.3
Cycle 8 Day 1	41	8.40	15.07	0.0	0.00	66.7	39	-4.27	19.52	-55.6	0.00	33.3
Cycle 9 Day 1	38	7.89	13.40	0.0	0.00	66.7	37	-5.71	18.07	-55.6	0.00	33.3
Cycle 10 Day 1	34	8.50	16.20	0.0	0.00	77.8	33	-4.38	18.20	-55.6	0.00	33.3
Cycle 11 Day 1	31	7.53	13.57	0.0	0.00	44.4	30	-6.67	19.92	-66.7	0.00	33.3
Cycle 12 Day 1	31	9.68	16.42	0.0	0.00	77.8	30	-4.44	21.16	-66.7	0.00	33.3
Cycle 13 Day 1	26	3.85	8.28	0.0	0.00	33.3	25	-9.78	20.87	-66.7	0.00	33.3
Cycle 14 Day 1	22	6.06	10.69	0.0	0.00	33.3	21	-4.76	17.06	-55.6	0.00	33.3
Cycle 15 Day 1	23	7.25	12.36	0.0	0.00	44.4	22	-4.55	15.96	-44.4	0.00	33.3
Cycle 16 Day 1	24	9.26	12.97	0.0	0.00	33.3	23	-3.86	17.28	-44.4	0.00	33.3
Cycle 17 Day 1	21	8.99	13.89	0.0	0.00	44.4	20	-3.89	14.54	-44.4	0.00	22.2
Cycle 18 Day 1	21	7.41	10.14	0.0	0.00	33.3	20	-5.00	15.49	-44.4	0.00	22.2
Cycle 19 Day 1	21	5.82	9.70	0.0	0.00	33.3	20	-6.67	13.68	-44.4	0.00	11.1
Cycle 20 Day 1	19	7.60	12.31	0.0	0.00	44.4	18	-5.56	13.87	-44.4	0.00	11.1
Cycle 21 Day 1	18	8.02	13.09	0.0	0.00	33.3	17	-3.92	17.98	-44.4	0.00	33.3
Cycle 22 Day 1	15	5.19	10.17	0.0	0.00	33.3	14	-7.14	19.78	-44.4	0.00	33.3
Cycle 23 Day 1	15	4.44	8.19	0.0	0.00	22.2	14	-4.76	14.92	-44.4	0.00	22.2
Cycle 24 Day 1	14	1.59	4.03	0.0	0.00	11.1	13	-5.13	12.52	-44.4	0.00	0.0
Cycle 25 Day 1	14	1.59	4.03	0.0	0.00	11.1	13	-5.13	12.52	-44.4	0.00	0.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.20.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Dysphagia
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	0.93	3.21	0.0	0.00	11.1	11	-7.07	13.40	-44.4	0.00	0.0
Cycle 27 Day 1	13	3.42	7.00	0.0	0.00	22.2	12	-3.70	15.23	-44.4	0.00	22.2
Cycle 28 Day 1	11	8.08	11.21	0.0	0.00	33.3	10	-4.44	20.42	-44.4	0.00	33.3
Cycle 29 Day 1	11	5.05	9.11	0.0	0.00	22.2	10	-7.78	17.41	-44.4	-5.56	22.2
Cycle 30 Day 1	10	7.78	13.91	0.0	0.00	33.3	9	-4.94	20.12	-44.4	0.00	33.3
Cycle 31 Day 1	10	7.78	14.86	0.0	0.00	44.4	9	-4.94	17.67	-44.4	0.00	22.2
Cycle 32 Day 1	10	4.44	7.77	0.0	0.00	22.2	9	-9.88	19.60	-55.6	0.00	11.1
Study Disc 1	48	15.74	24.77	0.0	0.00	100.0	48	4.86	20.62	-33.3	0.00	66.7
30 D SFU Z/P	22	10.61	18.30	0.0	0.00	66.7	22	1.52	16.55	-33.3	0.00	55.6
90 D SFU Z/P	23	8.70	12.96	0.0	0.00	44.4	23	3.86	11.90	-33.3	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	80	14.17	20.54	0.0	11.11	100.0						
Cycle 2 Day 1	73	12.63	18.45	0.0	11.11	100.0	69	-1.77	18.73	-55.6	0.00	77.8
Cycle 3 Day 1	64	10.24	16.48	0.0	0.00	66.7	62	-4.48	19.76	-66.7	0.00	44.4
Cycle 4 Day 1	56	9.13	11.82	0.0	0.00	33.3	56	-3.97	17.27	-44.4	0.00	33.3
Cycle 5 Day 1	57	6.63	11.28	0.0	0.00	55.6	57	-7.02	18.14	-55.6	0.00	33.3
Cycle 6 Day 1	48	7.18	13.46	0.0	0.00	44.4	48	-5.79	18.90	-44.4	0.00	44.4
Cycle 7 Day 1	41	5.69	9.66	0.0	0.00	33.3	41	-6.50	17.74	-44.4	0.00	22.2
Cycle 8 Day 1	37	8.11	14.73	0.0	0.00	66.7	37	-5.71	17.69	-44.4	0.00	55.6
Cycle 9 Day 1	35	5.08	8.67	0.0	0.00	33.3	35	-6.35	13.55	-44.4	0.00	11.1
Cycle 10 Day 1	30	4.81	9.54	0.0	0.00	44.4	29	-7.66	14.27	-44.4	0.00	11.1
Cycle 11 Day 1	27	3.29	8.04	0.0	0.00	33.3	27	-9.88	19.08	-44.4	0.00	33.3
Cycle 12 Day 1	26	4.70	8.42	0.0	0.00	22.2	25	-6.22	17.00	-44.4	0.00	22.2
Cycle 13 Day 1	22	4.55	8.85	0.0	0.00	33.3	21	-4.23	12.41	-44.4	0.00	11.1
Cycle 14 Day 1	21	7.41	13.30	0.0	0.00	44.4	20	1.11	13.92	-22.2	0.00	44.4
Cycle 15 Day 1	18	8.02	15.15	0.0	0.00	55.6	17	1.31	15.66	-22.2	0.00	55.6

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.20.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Dysphagia
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	9.15	13.74	0.0	0.00	44.4	16	3.47	10.52	-11.1	0.00	33.3
Cycle 17 Day 1	13	4.27	10.68	0.0	0.00	33.3	11	0.00	7.03	-11.1	0.00	11.1
Cycle 18 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	-1.23	6.68	-11.1	0.00	11.1
Study Disc 1	51	19.61	24.60	0.0	11.11	100.0	46	6.52	25.93	-66.7	0.00	66.7
30 D SFU Z/P	27	17.28	23.13	0.0	0.00	66.7	25	0.89	29.73	-55.6	0.00	66.7
90 D SFU Z/P	30	11.48	18.10	0.0	0.00	66.7	29	-4.21	22.89	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.21.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Eating Restrictions
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	27.14	25.88	0.0	25.00	91.7						
Cycle 2 Day 1	69	25.72	25.71	0.0	25.00	100.0	68	-0.12	24.54	-58.3	0.00	83.3
Cycle 3 Day 1	61	22.40	22.08	0.0	16.67	83.3	60	-3.06	18.66	-50.0	0.00	50.0
Cycle 4 Day 1	56	18.75	20.30	0.0	16.67	66.7	56	-3.57	18.79	-50.0	0.00	58.3
Cycle 5 Day 1	55	18.94	21.18	0.0	8.33	100.0	54	-5.56	27.14	-83.3	-8.33	100.0
Cycle 6 Day 1	55	20.76	20.09	0.0	16.67	75.0	55	-3.33	20.82	-50.0	0.00	41.7
Cycle 7 Day 1	44	19.89	18.43	0.0	16.67	75.0	44	-2.65	24.30	-50.0	0.00	50.0
Cycle 8 Day 1	41	18.09	18.81	0.0	8.33	66.7	39	-3.85	22.77	-50.0	0.00	41.7
Cycle 9 Day 1	38	19.30	19.77	0.0	16.67	75.0	37	-4.50	23.62	-50.0	0.00	41.7
Cycle 10 Day 1	34	19.12	20.87	0.0	16.67	83.3	33	-4.55	24.21	-58.3	0.00	50.0
Cycle 11 Day 1	31	17.20	20.63	0.0	16.67	100.0	30	-6.11	26.62	-50.0	-8.33	66.7
Cycle 12 Day 1	31	16.40	20.80	0.0	8.33	100.0	30	-6.94	26.54	-66.7	-8.33	66.7
Cycle 13 Day 1	26	14.74	16.55	0.0	8.33	50.0	25	-8.67	28.00	-75.0	-8.33	41.7
Cycle 14 Day 1	22	13.26	13.77	0.0	12.50	41.7	21	-8.73	22.43	-58.3	-8.33	25.0
Cycle 15 Day 1	23	14.86	15.27	0.0	16.67	41.7	22	-7.95	22.64	-58.3	0.00	33.3
Cycle 16 Day 1	24	14.24	15.44	0.0	8.33	41.7	23	-8.33	21.61	-58.3	-8.33	33.3
Cycle 17 Day 1	21	16.27	15.47	0.0	16.67	50.0	20	-7.50	19.85	-50.0	-8.33	25.0
Cycle 18 Day 1	21	17.86	16.52	0.0	16.67	41.7	20	-4.17	19.78	-50.0	-4.17	33.3
Cycle 19 Day 1	21	14.68	16.01	0.0	8.33	41.7	20	-7.50	21.10	-50.0	-8.33	33.3
Cycle 20 Day 1	19	19.30	20.80	0.0	16.67	58.3	18	-3.70	24.79	-41.7	-8.33	50.0
Cycle 21 Day 1	18	16.67	17.39	0.0	12.50	41.7	17	-4.41	20.01	-50.0	0.00	33.3
Cycle 22 Day 1	15	11.67	15.69	0.0	0.00	41.7	14	-5.95	21.29	-58.3	0.00	25.0
Cycle 23 Day 1	15	7.78	12.78	0.0	0.00	33.3	14	-5.95	12.42	-41.7	-4.17	8.3
Cycle 24 Day 1	14	10.12	14.68	0.0	8.33	50.0	13	-1.28	20.08	-58.3	0.00	25.0
Cycle 25 Day 1	14	8.93	12.85	0.0	4.17	41.7	13	-2.56	24.62	-66.7	0.00	25.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.21.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Eating Restrictions
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	4.86	8.30	0.0	0.00	25.0	11	-7.58	22.19	-58.3	-8.33	25.0
Cycle 27 Day 1	13	8.97	17.17	0.0	0.00	50.0	12	-3.47	23.15	-66.7	0.00	33.3
Cycle 28 Day 1	11	16.67	19.72	0.0	8.33	58.3	10	-0.83	28.72	-66.7	-4.17	41.7
Cycle 29 Day 1	11	6.82	11.07	0.0	0.00	33.3	10	-10.83	18.86	-58.3	-8.33	8.3
Cycle 30 Day 1	10	13.33	14.80	0.0	8.33	33.3	9	-5.56	19.98	-50.0	-8.33	25.0
Cycle 31 Day 1	10	11.67	15.32	0.0	4.17	41.7	9	-7.41	20.17	-50.0	-8.33	25.0
Cycle 32 Day 1	10	10.83	20.81	0.0	0.00	66.7	9	-8.33	25.34	-66.7	-8.33	25.0
Study Disc 1	48	28.12	30.59	0.0	20.83	100.0	48	4.34	27.45	-50.0	0.00	75.0
30 D SFU Z/P	22	19.70	23.08	0.0	12.50	91.7	22	-3.03	24.47	-58.3	0.00	50.0
90 D SFU Z/P	23	17.39	21.01	0.0	8.33	91.7	23	0.72	25.49	-50.0	0.00	75.0
Placebo + CAPOX (N= 88)												
Baseline	80	26.98	25.31	0.0	25.00	100.0						
Cycle 2 Day 1	73	23.29	23.57	0.0	16.67	100.0	69	-5.19	23.75	-66.7	0.00	83.3
Cycle 3 Day 1	64	19.79	20.65	0.0	16.67	75.0	62	-7.12	23.61	-83.3	0.00	41.7
Cycle 4 Day 1	56	20.39	20.10	0.0	16.67	83.3	56	-6.25	22.49	-66.7	0.00	41.7
Cycle 5 Day 1	57	18.27	18.53	0.0	16.67	75.0	57	-8.92	23.72	-75.0	0.00	33.3
Cycle 6 Day 1	48	19.44	21.22	0.0	16.67	75.0	48	-7.81	24.09	-58.3	-8.33	50.0
Cycle 7 Day 1	41	16.06	19.13	0.0	8.33	75.0	41	-7.93	22.12	-66.7	0.00	33.3
Cycle 8 Day 1	37	16.67	19.84	0.0	8.33	91.7	37	-10.36	21.55	-75.0	-8.33	33.3
Cycle 9 Day 1	35	15.48	14.02	0.0	16.67	41.7	35	-9.52	19.40	-41.7	-8.33	25.0
Cycle 10 Day 1	30	13.89	16.43	0.0	8.33	58.3	29	-10.34	22.89	-75.0	0.00	25.0
Cycle 11 Day 1	27	8.64	12.55	0.0	0.00	50.0	27	-17.90	25.29	-75.0	-8.33	16.7
Cycle 12 Day 1	26	11.54	18.12	0.0	8.33	83.3	25	-13.33	24.77	-75.0	-8.33	41.7
Cycle 13 Day 1	22	13.64	18.28	0.0	8.33	58.3	21	-11.11	23.02	-75.0	0.00	16.7
Cycle 14 Day 1	21	17.46	26.34	0.0	8.33	100.0	20	-5.42	22.50	-41.7	0.00	58.3
Cycle 15 Day 1	18	16.67	24.75	0.0	8.33	91.7	17	-4.90	18.88	-41.7	0.00	50.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.21.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Eating Restrictions
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	12.75	14.17	0.0	8.33	33.3	16	-7.81	15.66	-33.3	-4.17	25.0
Cycle 17 Day 1	13	12.82	17.55	0.0	8.33	58.3	11	-3.03	15.49	-33.3	0.00	16.7
Cycle 18 Day 1	10	5.83	10.43	0.0	0.00	33.3	9	-12.04	15.09	-33.3	0.00	0.0
Study Disc 1	51	32.35	29.84	0.0	25.00	100.0	46	7.25	29.17	-58.3	0.00	100.0
30 D SFU Z/P	27	26.85	29.08	0.0	16.67	100.0	25	-2.33	26.41	-75.0	0.00	50.0
90 D SFU Z/P	30	21.67	24.72	0.0	16.67	75.0	29	-4.60	23.31	-66.7	-8.33	50.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.22.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Reflux
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	18.38	21.75	0.0	16.67	66.7						
Cycle 2 Day 1	69	16.67	23.91	0.0	0.00	100.0	68	-1.96	27.85	-66.7	0.00	100.0
Cycle 3 Day 1	61	16.67	23.77	0.0	0.00	100.0	60	-0.83	26.11	-66.7	0.00	66.7
Cycle 4 Day 1	56	14.88	20.02	0.0	0.00	100.0	56	-1.49	24.05	-66.7	0.00	100.0
Cycle 5 Day 1	55	12.12	16.81	0.0	0.00	66.7	54	-4.63	22.99	-66.7	0.00	50.0
Cycle 6 Day 1	55	14.24	18.26	0.0	0.00	83.3	55	-3.03	22.24	-66.7	0.00	50.0
Cycle 7 Day 1	44	10.98	19.00	0.0	0.00	100.0	44	-4.17	23.33	-66.7	0.00	50.0
Cycle 8 Day 1	41	13.01	17.68	0.0	0.00	66.7	39	-3.85	24.02	-66.7	0.00	66.7
Cycle 9 Day 1	38	14.91	22.86	0.0	0.00	100.0	37	-2.70	29.53	-66.7	0.00	100.0
Cycle 10 Day 1	34	15.20	26.71	0.0	0.00	100.0	33	0.00	29.46	-66.7	0.00	66.7
Cycle 11 Day 1	31	11.29	20.81	0.0	0.00	100.0	30	-3.89	24.24	-33.3	0.00	66.7
Cycle 12 Day 1	31	11.29	15.75	0.0	0.00	50.0	30	-4.44	25.87	-66.7	0.00	33.3
Cycle 13 Day 1	26	8.33	19.58	0.0	0.00	83.3	25	-7.33	30.46	-66.7	0.00	83.3
Cycle 14 Day 1	22	9.09	16.04	0.0	0.00	50.0	21	-2.38	21.27	-50.0	0.00	50.0
Cycle 15 Day 1	23	6.52	12.04	0.0	0.00	33.3	22	-6.06	17.48	-33.3	0.00	33.3
Cycle 16 Day 1	24	7.64	12.02	0.0	0.00	33.3	23	-6.52	22.88	-50.0	0.00	33.3
Cycle 17 Day 1	21	3.17	10.03	0.0	0.00	33.3	20	-11.67	20.30	-50.0	0.00	33.3
Cycle 18 Day 1	21	9.52	17.14	0.0	0.00	50.0	20	-4.17	23.49	-50.0	0.00	50.0
Cycle 19 Day 1	21	7.14	16.31	0.0	0.00	66.7	20	-6.67	22.56	-33.3	0.00	66.7
Cycle 20 Day 1	19	14.04	20.23	0.0	0.00	66.7	18	1.85	22.79	-33.3	0.00	50.0
Cycle 21 Day 1	18	14.81	27.94	0.0	0.00	100.0	17	3.92	31.47	-50.0	0.00	100.0
Cycle 22 Day 1	15	4.44	13.31	0.0	0.00	50.0	14	-7.14	12.60	-33.3	0.00	0.0
Cycle 23 Day 1	15	8.89	21.70	0.0	0.00	83.3	14	-2.38	18.32	-33.3	0.00	33.3
Cycle 24 Day 1	14	4.76	10.19	0.0	0.00	33.3	13	-3.85	16.88	-50.0	0.00	16.7
Cycle 25 Day 1	14	7.14	14.19	0.0	0.00	50.0	13	-1.28	18.59	-50.0	0.00	16.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.22.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Reflux
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	2.78	9.62	0.0	0.00	33.3	11	-4.55	19.85	-50.0	0.00	33.3
Cycle 27 Day 1	13	5.13	14.25	0.0	0.00	50.0	12	-4.17	17.59	-50.0	0.00	16.7
Cycle 28 Day 1	11	12.12	30.81	0.0	0.00	100.0	10	-3.33	24.60	-50.0	0.00	50.0
Cycle 29 Day 1	11	4.55	10.78	0.0	0.00	33.3	10	-8.33	18.00	-50.0	0.00	16.7
Cycle 30 Day 1	10	6.67	16.10	0.0	0.00	50.0	9	-7.41	12.11	-33.3	0.00	0.0
Cycle 31 Day 1	10	6.67	16.10	0.0	0.00	50.0	9	-7.41	18.84	-50.0	0.00	16.7
Cycle 32 Day 1	10	10.00	17.92	0.0	0.00	50.0	9	-3.70	23.24	-50.0	0.00	33.3
Study Disc 1	48	14.93	26.24	0.0	0.00	100.0	48	1.39	26.59	-50.0	0.00	100.0
30 D SFU Z/P	22	12.12	27.78	0.0	0.00	100.0	22	-3.79	24.63	-33.3	0.00	66.7
90 D SFU Z/P	23	18.12	27.94	0.0	0.00	100.0	23	5.80	25.92	-33.3	0.00	66.7
Placebo + CAPOX (N= 88)												
Baseline	80	17.92	24.70	0.0	16.67	100.0						
Cycle 2 Day 1	73	12.79	19.15	0.0	0.00	100.0	69	-2.90	21.57	-83.3	0.00	66.7
Cycle 3 Day 1	64	12.50	19.47	0.0	0.00	100.0	62	-1.88	19.11	-66.7	0.00	50.0
Cycle 4 Day 1	56	9.82	17.05	0.0	0.00	66.7	56	-3.87	22.02	-83.3	0.00	33.3
Cycle 5 Day 1	57	8.48	16.10	0.0	0.00	66.7	57	-6.14	19.32	-83.3	0.00	33.3
Cycle 6 Day 1	48	9.38	15.72	0.0	0.00	66.7	48	-6.94	21.70	-66.7	0.00	33.3
Cycle 7 Day 1	41	6.50	11.10	0.0	0.00	33.3	41	-9.35	20.43	-66.7	0.00	33.3
Cycle 8 Day 1	37	5.41	14.19	0.0	0.00	66.7	37	-11.26	21.89	-83.3	0.00	33.3
Cycle 9 Day 1	35	5.24	10.52	0.0	0.00	33.3	35	-11.43	19.29	-83.3	0.00	16.7
Cycle 10 Day 1	30	7.78	13.66	0.0	0.00	50.0	29	-8.05	23.41	-83.3	0.00	33.3
Cycle 11 Day 1	27	4.32	10.93	0.0	0.00	33.3	27	-13.58	24.48	-83.3	0.00	33.3
Cycle 12 Day 1	26	6.41	14.20	0.0	0.00	50.0	25	-11.33	27.52	-100.0	0.00	33.3
Cycle 13 Day 1	22	8.33	16.06	0.0	0.00	50.0	21	-9.52	23.90	-83.3	0.00	50.0
Cycle 14 Day 1	21	5.56	12.17	0.0	0.00	33.3	20	-6.67	12.57	-50.0	0.00	0.0
Cycle 15 Day 1	18	6.48	12.96	0.0	0.00	33.3	17	-3.92	17.21	-50.0	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.22.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Reflux
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	6.86	15.66	0.0	0.00	50.0	16	-5.21	19.92	-50.0	0.00	50.0
Cycle 17 Day 1	13	1.28	4.62	0.0	0.00	16.7	11	-4.55	7.78	-16.7	0.00	0.0
Cycle 18 Day 1	10	6.67	16.10	0.0	0.00	50.0	9	1.85	19.44	-16.7	0.00	50.0
Study Disc 1	51	22.22	29.00	0.0	16.67	100.0	46	10.51	30.09	-50.0	0.00	100.0
30 D SFU Z/P	27	18.52	27.09	0.0	0.00	100.0	25	-0.67	30.99	-100.0	0.00	66.7
90 D SFU Z/P	30	13.89	25.55	0.0	0.00	100.0	29	-2.87	26.38	-66.7	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.23.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Odynophagia
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	20.94	23.64	0.0	16.67	100.0						
Cycle 2 Day 1	69	15.46	23.10	0.0	0.00	100.0	68	-5.15	23.62	-66.7	0.00	66.7
Cycle 3 Day 1	61	13.39	17.96	0.0	0.00	66.7	60	-6.39	16.26	-50.0	0.00	33.3
Cycle 4 Day 1	56	11.31	18.83	0.0	0.00	66.7	56	-5.95	17.82	-50.0	0.00	33.3
Cycle 5 Day 1	55	12.73	19.24	0.0	0.00	100.0	54	-6.79	23.69	-66.7	0.00	100.0
Cycle 6 Day 1	55	12.73	21.75	0.0	0.00	100.0	55	-6.06	20.12	-50.0	0.00	66.7
Cycle 7 Day 1	44	10.23	14.91	0.0	0.00	66.7	44	-6.44	21.33	-50.0	0.00	33.3
Cycle 8 Day 1	41	8.13	12.98	0.0	0.00	50.0	39	-10.26	17.78	-50.0	0.00	33.3
Cycle 9 Day 1	38	11.40	14.03	0.0	0.00	33.3	37	-9.01	17.39	-50.0	0.00	33.3
Cycle 10 Day 1	34	9.80	13.05	0.0	0.00	33.3	33	-10.61	21.17	-50.0	0.00	33.3
Cycle 11 Day 1	31	13.44	21.70	0.0	0.00	100.0	30	-7.78	23.05	-50.0	0.00	66.7
Cycle 12 Day 1	31	10.22	14.06	0.0	0.00	33.3	30	-10.56	21.21	-50.0	0.00	33.3
Cycle 13 Day 1	26	7.05	10.72	0.0	0.00	33.3	25	-15.33	24.49	-83.3	0.00	16.7
Cycle 14 Day 1	22	6.82	11.10	0.0	0.00	33.3	21	-13.49	18.72	-50.0	-16.67	16.7
Cycle 15 Day 1	23	6.52	10.94	0.0	0.00	33.3	22	-15.15	18.48	-50.0	-16.67	16.7
Cycle 16 Day 1	24	8.33	13.00	0.0	0.00	33.3	23	-15.22	17.34	-50.0	-16.67	16.7
Cycle 17 Day 1	21	7.94	13.56	0.0	0.00	33.3	20	-17.50	18.32	-50.0	-16.67	16.7
Cycle 18 Day 1	21	10.32	14.41	0.0	0.00	33.3	20	-13.33	18.42	-50.0	-16.67	16.7
Cycle 19 Day 1	21	10.32	18.62	0.0	0.00	66.7	20	-13.33	15.86	-50.0	-8.33	0.0
Cycle 20 Day 1	19	9.65	17.84	0.0	0.00	66.7	18	-13.89	17.39	-50.0	-16.67	16.7
Cycle 21 Day 1	18	12.96	20.26	0.0	0.00	66.7	17	-8.82	11.96	-33.3	0.00	0.0
Cycle 22 Day 1	15	11.11	20.57	0.0	0.00	66.7	14	-9.52	12.60	-33.3	0.00	0.0
Cycle 23 Day 1	15	5.56	12.06	0.0	0.00	33.3	14	-11.90	15.23	-33.3	0.00	0.0
Cycle 24 Day 1	14	5.95	12.42	0.0	0.00	33.3	13	-7.69	16.12	-33.3	0.00	16.7
Cycle 25 Day 1	14	3.57	9.65	0.0	0.00	33.3	13	-10.26	17.40	-50.0	0.00	0.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.23.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Odynophagia
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	0.00	0.00	0.0	0.00	0.0	11	-13.64	17.98	-50.0	0.00	0.0
Cycle 27 Day 1	13	7.69	12.94	0.0	0.00	33.3	12	-6.94	13.22	-33.3	0.00	0.0
Cycle 28 Day 1	11	13.64	20.84	0.0	0.00	66.7	10	-10.00	11.65	-33.3	-8.33	0.0
Cycle 29 Day 1	11	7.58	20.23	0.0	0.00	66.7	10	-13.33	15.32	-33.3	-8.33	0.0
Cycle 30 Day 1	10	10.00	16.10	0.0	0.00	50.0	9	-12.96	13.89	-33.3	-16.67	0.0
Cycle 31 Day 1	10	8.33	21.15	0.0	0.00	66.7	9	-14.81	15.47	-33.3	-16.67	0.0
Cycle 32 Day 1	10	6.67	21.08	0.0	0.00	66.7	9	-16.67	18.63	-50.0	-16.67	0.0
Study Disc 1	48	21.18	29.32	0.0	0.00	100.0	48	4.17	26.07	-50.0	0.00	83.3
30 D SFU Z/P	22	13.64	24.47	0.0	0.00	83.3	22	-5.30	18.82	-50.0	0.00	50.0
90 D SFU Z/P	23	13.04	15.86	0.0	0.00	50.0	23	0.72	14.63	-50.0	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	80	19.58	25.95	0.0	16.67	100.0						
Cycle 2 Day 1	73	17.35	20.50	0.0	16.67	100.0	69	-2.66	24.69	-83.3	0.00	50.0
Cycle 3 Day 1	64	13.28	17.86	0.0	0.00	66.7	62	-6.18	24.37	-83.3	0.00	50.0
Cycle 4 Day 1	56	12.80	14.56	0.0	8.33	50.0	56	-5.36	20.62	-66.7	0.00	33.3
Cycle 5 Day 1	57	11.11	16.77	0.0	0.00	83.3	57	-7.31	25.59	-83.3	0.00	50.0
Cycle 6 Day 1	48	13.54	19.34	0.0	0.00	66.7	48	-5.21	24.10	-66.7	0.00	50.0
Cycle 7 Day 1	41	10.98	13.75	0.0	0.00	33.3	41	-5.28	22.50	-83.3	0.00	33.3
Cycle 8 Day 1	37	13.51	18.77	0.0	0.00	66.7	37	-4.50	21.03	-66.7	0.00	50.0
Cycle 9 Day 1	35	10.00	12.26	0.0	0.00	33.3	35	-6.19	23.60	-100.0	0.00	33.3
Cycle 10 Day 1	30	11.11	17.14	0.0	0.00	66.7	29	-5.75	25.31	-100.0	0.00	33.3
Cycle 11 Day 1	27	4.94	10.14	0.0	0.00	33.3	27	-13.58	24.48	-100.0	0.00	33.3
Cycle 12 Day 1	26	7.69	10.78	0.0	0.00	33.3	25	-12.00	23.33	-83.3	0.00	33.3
Cycle 13 Day 1	22	12.12	15.59	0.0	0.00	50.0	21	-4.76	27.46	-83.3	0.00	50.0
Cycle 14 Day 1	21	13.49	21.49	0.0	0.00	66.7	20	1.67	20.16	-33.3	0.00	33.3
Cycle 15 Day 1	18	14.81	26.75	0.0	0.00	100.0	17	6.86	23.61	-33.3	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.23.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Odynophagia
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	13.73	16.91	0.0	0.00	50.0	16	7.29	19.21	-16.7	0.00	50.0
Cycle 17 Day 1	13	7.69	11.00	0.0	0.00	33.3	11	4.55	10.78	-16.7	0.00	16.7
Cycle 18 Day 1	10	5.00	11.25	0.0	0.00	33.3	9	0.00	8.33	-16.7	0.00	16.7
Study Disc 1	51	24.84	30.07	0.0	16.67	100.0	46	9.78	29.93	-50.0	0.00	83.3
30 D SFU Z/P	27	25.31	32.15	0.0	16.67	100.0	25	5.33	36.23	-100.0	0.00	66.7
90 D SFU Z/P	30	17.22	26.44	0.0	0.00	100.0	29	-0.57	26.16	-83.3	0.00	50.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.24.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Pain and Discomfort
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	27.14	24.93	0.0	33.33	100.0						
Cycle 2 Day 1	69	22.46	24.06	0.0	16.67	100.0	68	-3.19	25.47	-100.0	0.00	66.7
Cycle 3 Day 1	61	18.31	21.67	0.0	16.67	66.7	60	-8.61	20.24	-66.7	0.00	33.3
Cycle 4 Day 1	56	16.67	21.08	0.0	0.00	83.3	56	-7.14	20.31	-66.7	0.00	33.3
Cycle 5 Day 1	55	16.67	19.77	0.0	16.67	83.3	54	-7.72	16.73	-50.0	0.00	33.3
Cycle 6 Day 1	55	17.58	23.00	0.0	0.00	100.0	55	-6.97	26.78	-100.0	0.00	66.7
Cycle 7 Day 1	44	15.91	18.66	0.0	16.67	66.7	44	-8.33	24.77	-100.0	0.00	33.3
Cycle 8 Day 1	41	15.45	18.02	0.0	16.67	66.7	39	-9.40	20.52	-66.7	0.00	33.3
Cycle 9 Day 1	38	23.25	22.77	0.0	25.00	100.0	37	-4.95	24.49	-66.7	0.00	66.7
Cycle 10 Day 1	34	19.61	22.65	0.0	16.67	100.0	33	-7.07	27.01	-83.3	0.00	66.7
Cycle 11 Day 1	31	17.20	23.37	0.0	16.67	100.0	30	-8.33	28.28	-100.0	0.00	66.7
Cycle 12 Day 1	31	19.35	23.21	0.0	16.67	100.0	30	-6.11	29.52	-66.7	0.00	66.7
Cycle 13 Day 1	26	10.90	17.60	0.0	0.00	66.7	25	-13.33	26.79	-100.0	-16.67	33.3
Cycle 14 Day 1	22	9.85	13.27	0.0	0.00	33.3	21	-11.11	21.94	-66.7	-16.67	33.3
Cycle 15 Day 1	23	12.32	13.50	0.0	16.67	33.3	22	-10.61	20.28	-66.7	0.00	16.7
Cycle 16 Day 1	24	9.72	13.83	0.0	0.00	33.3	23	-13.77	18.57	-66.7	-16.67	16.7
Cycle 17 Day 1	21	11.90	15.94	0.0	0.00	33.3	20	-12.50	21.54	-66.7	0.00	33.3
Cycle 18 Day 1	21	13.49	18.72	0.0	0.00	66.7	20	-9.17	16.64	-33.3	0.00	33.3
Cycle 19 Day 1	21	15.08	18.18	0.0	16.67	66.7	20	-7.50	22.60	-66.7	0.00	33.3
Cycle 20 Day 1	19	18.42	21.44	0.0	16.67	66.7	18	-4.63	16.96	-33.3	0.00	33.3
Cycle 21 Day 1	18	16.67	22.87	0.0	0.00	66.7	17	-5.88	15.52	-33.3	0.00	33.3
Cycle 22 Day 1	15	13.33	29.68	0.0	0.00	100.0	14	-9.52	18.16	-33.3	-8.33	33.3
Cycle 23 Day 1	15	10.00	20.70	0.0	0.00	66.7	14	-8.33	14.25	-33.3	0.00	16.7
Cycle 24 Day 1	14	8.33	12.66	0.0	0.00	33.3	13	-6.41	10.84	-33.3	0.00	0.0
Cycle 25 Day 1	14	5.95	12.42	0.0	0.00	33.3	13	-8.97	18.78	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.24.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Pain and Discomfort
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	8.33	19.46	0.0	0.00	66.7	11	-6.06	29.13	-33.3	-16.67	66.7
Cycle 27 Day 1	13	7.69	12.94	0.0	0.00	33.3	12	-8.33	20.72	-33.3	-8.33	33.3
Cycle 28 Day 1	11	16.67	25.82	0.0	0.00	66.7	10	-8.33	18.00	-33.3	-16.67	33.3
Cycle 29 Day 1	11	10.61	20.10	0.0	0.00	66.7	10	-11.67	11.25	-33.3	-16.67	0.0
Cycle 30 Day 1	10	8.33	21.15	0.0	0.00	66.7	9	-16.67	14.43	-33.3	-16.67	0.0
Cycle 31 Day 1	10	10.00	21.08	0.0	0.00	66.7	9	-14.81	13.03	-33.3	-16.67	0.0
Cycle 32 Day 1	10	8.33	21.15	0.0	0.00	66.7	9	-16.67	14.43	-33.3	-16.67	0.0
Study Disc 1	48	26.39	30.14	0.0	16.67	100.0	48	5.56	24.63	-50.0	0.00	66.7
30 D SFU Z/P	22	22.73	26.50	0.0	16.67	83.3	22	2.27	23.17	-33.3	0.00	50.0
90 D SFU Z/P	23	21.01	24.73	0.0	0.00	66.7	23	4.35	20.24	-33.3	0.00	50.0
Placebo + CAPOX (N= 88)												
Baseline	80	26.46	27.52	0.0	33.33	100.0						
Cycle 2 Day 1	73	23.29	21.47	0.0	33.33	100.0	69	-2.17	24.90	-83.3	0.00	33.3
Cycle 3 Day 1	64	16.41	18.90	0.0	16.67	66.7	62	-8.33	22.93	-100.0	0.00	33.3
Cycle 4 Day 1	56	15.77	21.18	0.0	0.00	100.0	56	-9.23	24.60	-83.3	0.00	66.7
Cycle 5 Day 1	57	16.08	21.59	0.0	0.00	83.3	57	-8.19	27.30	-100.0	0.00	50.0
Cycle 6 Day 1	48	17.01	19.90	0.0	16.67	66.7	48	-7.64	27.92	-66.7	0.00	33.3
Cycle 7 Day 1	41	15.04	17.00	0.0	16.67	66.7	41	-6.10	23.50	-66.7	0.00	33.3
Cycle 8 Day 1	37	13.51	19.18	0.0	0.00	66.7	37	-10.81	21.59	-66.7	0.00	33.3
Cycle 9 Day 1	35	15.71	20.59	0.0	0.00	66.7	35	-7.14	25.34	-66.7	0.00	50.0
Cycle 10 Day 1	30	18.33	23.30	0.0	8.33	83.3	29	-4.60	26.31	-66.7	0.00	50.0
Cycle 11 Day 1	27	14.20	18.32	0.0	0.00	66.7	27	-9.88	25.43	-66.7	0.00	33.3
Cycle 12 Day 1	26	17.31	20.81	0.0	16.67	66.7	25	-5.33	26.23	-83.3	0.00	33.3
Cycle 13 Day 1	22	16.67	18.54	0.0	16.67	66.7	21	-9.52	30.99	-83.3	0.00	33.3
Cycle 14 Day 1	21	20.63	27.84	0.0	16.67	100.0	20	-0.83	29.85	-50.0	0.00	66.7
Cycle 15 Day 1	18	19.44	29.84	0.0	0.00	100.0	17	-1.96	26.93	-33.3	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.24.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Pain and Discomfort
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	11.76	19.33	0.0	0.00	50.0	16	-7.29	19.21	-33.3	0.00	33.3
Cycle 17 Day 1	13	5.13	10.51	0.0	0.00	33.3	11	-6.06	13.48	-33.3	0.00	0.0
Cycle 18 Day 1	10	8.33	14.16	0.0	0.00	33.3	9	-1.85	17.57	-33.3	0.00	33.3
Study Disc 1	51	32.68	29.62	0.0	33.33	100.0	46	8.33	30.98	-50.0	0.00	83.3
30 D SFU Z/P	27	30.25	29.97	0.0	33.33	100.0	25	2.00	35.46	-66.7	0.00	66.7
90 D SFU Z/P	30	20.00	27.12	0.0	0.00	100.0	29	-5.17	21.87	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.25.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Anxiety
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	45.51	29.51	0.0	33.33	100.0						
Cycle 2 Day 1	69	39.61	29.99	0.0	33.33	100.0	68	-3.19	28.98	-66.7	0.00	66.7
Cycle 3 Day 1	61	39.07	25.98	0.0	33.33	100.0	60	-1.94	26.41	-66.7	0.00	66.7
Cycle 4 Day 1	56	31.55	24.76	0.0	33.33	100.0	56	-7.14	21.05	-66.7	0.00	33.3
Cycle 5 Day 1	55	35.45	28.88	0.0	33.33	100.0	54	-4.32	29.53	-50.0	0.00	83.3
Cycle 6 Day 1	55	33.33	23.79	0.0	33.33	83.3	55	-6.97	25.40	-100.0	0.00	50.0
Cycle 7 Day 1	44	34.09	29.19	0.0	33.33	100.0	44	-3.03	23.92	-50.0	0.00	66.7
Cycle 8 Day 1	41	33.74	28.74	0.0	33.33	100.0	39	-6.41	25.54	-66.7	0.00	33.3
Cycle 9 Day 1	38	32.89	25.85	0.0	33.33	100.0	37	-6.76	23.39	-66.7	0.00	33.3
Cycle 10 Day 1	34	27.45	18.30	0.0	33.33	66.7	33	-11.11	24.53	-66.7	-16.67	33.3
Cycle 11 Day 1	31	24.19	16.58	0.0	33.33	66.7	30	-14.44	26.89	-66.7	-16.67	33.3
Cycle 12 Day 1	31	24.19	21.87	0.0	33.33	83.3	30	-13.33	26.77	-66.7	-16.67	33.3
Cycle 13 Day 1	26	23.08	23.61	0.0	33.33	100.0	25	-14.00	27.50	-66.7	-16.67	33.3
Cycle 14 Day 1	22	21.21	21.32	0.0	33.33	83.3	21	-15.08	28.34	-66.7	0.00	33.3
Cycle 15 Day 1	23	23.91	18.00	0.0	33.33	66.7	22	-14.39	26.38	-66.7	-16.67	33.3
Cycle 16 Day 1	24	15.97	15.91	0.0	16.67	33.3	23	-21.74	22.15	-66.7	-16.67	16.7
Cycle 17 Day 1	21	30.16	22.12	0.0	33.33	66.7	20	-8.33	23.88	-66.7	0.00	33.3
Cycle 18 Day 1	21	28.57	19.82	0.0	33.33	66.7	20	-9.17	24.47	-66.7	0.00	33.3
Cycle 19 Day 1	21	28.57	19.11	0.0	33.33	66.7	20	-9.17	21.27	-66.7	0.00	16.7
Cycle 20 Day 1	19	25.44	21.06	0.0	33.33	66.7	18	-13.89	25.72	-66.7	0.00	33.3
Cycle 21 Day 1	18	24.07	19.99	0.0	33.33	66.7	17	-16.67	25.69	-66.7	-16.67	33.3
Cycle 22 Day 1	15	28.89	33.61	0.0	33.33	100.0	14	-7.14	30.46	-66.7	0.00	33.3
Cycle 23 Day 1	15	25.56	22.60	0.0	33.33	66.7	14	-9.52	22.37	-50.0	0.00	33.3
Cycle 24 Day 1	14	22.62	20.26	0.0	33.33	66.7	13	-7.69	19.97	-50.0	0.00	33.3
Cycle 25 Day 1	14	17.86	19.02	0.0	16.67	50.0	13	-12.82	16.88	-50.0	0.00	0.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.25.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Anxiety
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	19.44	17.16	0.0	33.33	33.3	11	-9.09	20.23	-50.0	0.00	16.7
Cycle 27 Day 1	13	26.92	30.08	0.0	33.33	100.0	12	-5.56	25.95	-50.0	0.00	33.3
Cycle 28 Day 1	11	34.85	28.34	0.0	33.33	66.7	10	-6.67	30.63	-50.0	-8.33	33.3
Cycle 29 Day 1	11	36.36	16.36	16.7	33.33	83.3	10	0.00	26.06	-33.3	0.00	33.3
Cycle 30 Day 1	10	26.67	19.56	0.0	33.33	66.7	9	-9.26	23.73	-33.3	-16.67	33.3
Cycle 31 Day 1	10	30.00	17.21	0.0	33.33	66.7	9	-5.56	20.41	-33.3	0.00	33.3
Cycle 32 Day 1	10	30.00	17.21	0.0	33.33	66.7	9	-5.56	30.05	-50.0	0.00	33.3
Study Disc 1	48	40.28	31.85	0.0	33.33	100.0	48	-1.39	33.66	-66.7	0.00	100.0
30 D SFU Z/P	22	37.88	26.32	0.0	33.33	100.0	22	1.52	29.51	-66.7	0.00	50.0
90 D SFU Z/P	23	32.61	25.37	0.0	33.33	100.0	23	5.80	25.43	-50.0	0.00	50.0
Placebo + CAPOX (N= 88)												
Baseline	80	46.46	31.12	0.0	33.33	100.0						
Cycle 2 Day 1	73	42.01	30.95	0.0	33.33	100.0	69	-7.00	23.64	-66.7	0.00	66.7
Cycle 3 Day 1	64	40.36	29.52	0.0	33.33	100.0	62	-8.87	27.28	-83.3	0.00	66.7
Cycle 4 Day 1	56	45.54	28.34	0.0	33.33	100.0	56	-1.49	27.57	-66.7	0.00	66.7
Cycle 5 Day 1	57	42.11	30.23	0.0	33.33	100.0	57	-5.56	30.10	-66.7	0.00	66.7
Cycle 6 Day 1	48	38.54	28.38	0.0	33.33	100.0	48	-7.99	30.17	-66.7	0.00	66.7
Cycle 7 Day 1	41	36.59	30.33	0.0	33.33	100.0	41	-6.10	28.81	-66.7	0.00	66.7
Cycle 8 Day 1	37	44.59	28.88	0.0	33.33	100.0	37	-7.66	32.77	-66.7	-16.67	66.7
Cycle 9 Day 1	35	41.90	28.97	0.0	33.33	100.0	35	-5.71	27.99	-66.7	0.00	66.7
Cycle 10 Day 1	30	38.89	29.79	0.0	33.33	100.0	29	-8.05	34.97	-100.0	0.00	66.7
Cycle 11 Day 1	27	37.04	28.24	0.0	33.33	100.0	27	-6.79	34.98	-100.0	0.00	66.7
Cycle 12 Day 1	26	37.18	27.21	0.0	33.33	100.0	25	-4.67	38.04	-100.0	0.00	66.7
Cycle 13 Day 1	22	40.91	26.59	0.0	33.33	100.0	21	0.79	34.35	-66.7	0.00	66.7
Cycle 14 Day 1	21	38.10	29.41	0.0	33.33	100.0	20	0.00	35.46	-66.7	0.00	66.7
Cycle 15 Day 1	18	40.74	26.95	0.0	33.33	100.0	17	4.90	28.11	-33.3	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.25.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Anxiety
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	31.37	24.92	0.0	33.33	66.7	16	2.08	36.96	-66.7	0.00	66.7
Cycle 17 Day 1	13	29.49	21.68	0.0	33.33	66.7	11	-1.52	36.10	-83.3	0.00	66.7
Cycle 18 Day 1	10	26.67	17.92	0.0	33.33	50.0	9	-5.56	30.05	-50.0	0.00	50.0
Study Disc 1	51	54.90	28.73	0.0	66.67	100.0	46	8.70	33.47	-66.7	0.00	66.7
30 D SFU Z/P	27	51.23	32.00	0.0	50.00	100.0	25	-4.67	26.14	-50.0	0.00	50.0
90 D SFU Z/P	30	43.89	28.53	0.0	33.33	100.0	29	-9.20	34.67	-100.0	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.26.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Eating in Front of Others
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	15.81	24.46	0.0	0.00	100.0						
Cycle 2 Day 1	69	10.63	20.21	0.0	0.00	66.7	68	-4.90	20.98	-66.7	0.00	66.7
Cycle 3 Day 1	61	8.74	15.99	0.0	0.00	66.7	60	-3.89	19.50	-66.7	0.00	33.3
Cycle 4 Day 1	56	7.14	15.19	0.0	0.00	66.7	56	-3.57	16.43	-66.7	0.00	33.3
Cycle 5 Day 1	55	8.48	14.65	0.0	0.00	33.3	54	-3.70	16.72	-66.7	0.00	33.3
Cycle 6 Day 1	55	10.30	16.82	0.0	0.00	66.7	55	-2.42	16.80	-33.3	0.00	33.3
Cycle 7 Day 1	44	8.33	14.60	0.0	0.00	33.3	44	-3.03	22.53	-66.7	0.00	33.3
Cycle 8 Day 1	41	8.13	14.49	0.0	0.00	33.3	39	-4.27	23.17	-66.7	0.00	33.3
Cycle 9 Day 1	38	9.65	20.37	0.0	0.00	100.0	37	-4.50	26.25	-66.7	0.00	66.7
Cycle 10 Day 1	34	10.78	21.27	0.0	0.00	100.0	33	-2.02	24.92	-66.7	0.00	66.7
Cycle 11 Day 1	31	11.83	22.02	0.0	0.00	100.0	30	-2.22	27.59	-66.7	0.00	66.7
Cycle 12 Day 1	31	10.75	18.03	0.0	0.00	66.7	30	-3.33	23.73	-66.7	0.00	33.3
Cycle 13 Day 1	26	6.41	13.40	0.0	0.00	33.3	25	-8.00	25.96	-66.7	0.00	33.3
Cycle 14 Day 1	22	4.55	11.71	0.0	0.00	33.3	21	-7.94	20.83	-66.7	0.00	33.3
Cycle 15 Day 1	23	2.90	9.60	0.0	0.00	33.3	22	-12.12	26.32	-66.7	0.00	33.3
Cycle 16 Day 1	24	5.56	12.69	0.0	0.00	33.3	23	-8.70	22.96	-66.7	0.00	33.3
Cycle 17 Day 1	21	6.35	13.41	0.0	0.00	33.3	20	-10.00	24.42	-66.7	0.00	33.3
Cycle 18 Day 1	21	6.35	13.41	0.0	0.00	33.3	20	-10.00	24.42	-66.7	0.00	33.3
Cycle 19 Day 1	21	1.59	7.27	0.0	0.00	33.3	20	-15.00	27.52	-66.7	0.00	33.3
Cycle 20 Day 1	19	5.26	12.49	0.0	0.00	33.3	18	-12.96	25.92	-66.7	0.00	33.3
Cycle 21 Day 1	18	7.41	14.26	0.0	0.00	33.3	17	-9.80	25.72	-66.7	0.00	33.3
Cycle 22 Day 1	15	8.89	15.26	0.0	0.00	33.3	14	-7.14	23.31	-66.7	0.00	33.3
Cycle 23 Day 1	15	2.22	8.61	0.0	0.00	33.3	14	-9.52	24.21	-66.7	0.00	0.0
Cycle 24 Day 1	14	7.14	19.30	0.0	0.00	66.7	13	0.00	23.57	-66.7	0.00	33.3
Cycle 25 Day 1	14	7.14	14.19	0.0	0.00	33.3	13	0.00	27.22	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values;
Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.26.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Eating in Front of Others
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	2.78	9.62	0.0	0.00	33.3	11	-6.06	25.03	-66.7	0.00	33.3
Cycle 27 Day 1	13	7.69	14.62	0.0	0.00	33.3	12	0.00	24.62	-66.7	0.00	33.3
Cycle 28 Day 1	11	12.12	22.47	0.0	0.00	66.7	10	-3.33	36.68	-66.7	0.00	66.7
Cycle 29 Day 1	11	3.03	10.05	0.0	0.00	33.3	10	-13.33	28.11	-66.7	0.00	0.0
Cycle 30 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	-11.11	33.33	-66.7	0.00	33.3
Cycle 31 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	-11.11	28.87	-66.7	0.00	33.3
Cycle 32 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	-11.11	28.87	-66.7	0.00	33.3
Study Disc 1	48	13.89	29.04	0.0	0.00	100.0	48	2.78	26.48	-66.7	0.00	66.7
30 D SFU Z/P	22	10.61	23.87	0.0	0.00	100.0	22	-1.52	16.19	-33.3	0.00	33.3
90 D SFU Z/P	23	7.25	17.28	0.0	0.00	66.7	23	2.90	17.15	-33.3	0.00	66.7
Placebo + CAPOX (N= 88)												
Baseline	80	12.92	25.15	0.0	0.00	100.0						
Cycle 2 Day 1	73	11.42	20.20	0.0	0.00	100.0	69	-0.48	19.38	-66.7	0.00	33.3
Cycle 3 Day 1	64	11.98	20.89	0.0	0.00	66.7	62	-1.61	24.46	-66.7	0.00	66.7
Cycle 4 Day 1	56	5.95	12.88	0.0	0.00	33.3	56	-5.95	23.87	-100.0	0.00	33.3
Cycle 5 Day 1	57	8.19	14.48	0.0	0.00	33.3	57	-4.09	25.25	-100.0	0.00	33.3
Cycle 6 Day 1	48	6.94	15.31	0.0	0.00	66.7	48	-6.25	25.41	-100.0	0.00	33.3
Cycle 7 Day 1	41	7.32	19.02	0.0	0.00	100.0	41	-4.07	22.60	-66.7	0.00	66.7
Cycle 8 Day 1	37	7.21	15.98	0.0	0.00	66.7	37	-6.31	22.00	-66.7	0.00	33.3
Cycle 9 Day 1	35	6.67	15.76	0.0	0.00	66.7	35	-3.81	22.54	-66.7	0.00	66.7
Cycle 10 Day 1	30	5.56	12.63	0.0	0.00	33.3	29	-3.45	18.57	-33.3	0.00	33.3
Cycle 11 Day 1	27	3.70	10.68	0.0	0.00	33.3	27	-4.94	17.79	-33.3	0.00	33.3
Cycle 12 Day 1	26	3.85	10.86	0.0	0.00	33.3	25	-4.00	17.53	-33.3	0.00	33.3
Cycle 13 Day 1	22	10.61	18.93	0.0	0.00	66.7	21	3.17	23.34	-33.3	0.00	66.7
Cycle 14 Day 1	21	3.17	10.03	0.0	0.00	33.3	20	-3.33	10.26	-33.3	0.00	0.0
Cycle 15 Day 1	18	5.56	12.78	0.0	0.00	33.3	17	1.96	8.08	0.0	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.26.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Eating in Front of Others
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	5.88	13.10	0.0	0.00	33.3	16	0.00	0.00	0.0	0.00	0.0
Cycle 17 Day 1	13	5.13	12.52	0.0	0.00	33.3	11	3.03	10.05	0.0	0.00	33.3
Cycle 18 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	0.00	0.00	0.0	0.00	0.0
Study Disc 1	51	18.95	30.74	0.0	0.00	100.0	46	5.80	30.88	-66.7	0.00	100.0
30 D SFU Z/P	27	12.35	26.39	0.0	0.00	100.0	25	-1.33	20.37	-33.3	0.00	66.7
90 D SFU Z/P	30	13.33	24.13	0.0	0.00	100.0	29	2.30	15.25	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values;
Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.27.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Dry Mouth
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	24.79	24.87	0.0	33.33	100.0						
Cycle 2 Day 1	69	27.54	27.39	0.0	33.33	100.0	68	0.49	25.43	-66.7	0.00	100.0
Cycle 3 Day 1	61	28.42	27.10	0.0	33.33	100.0	60	2.78	25.52	-66.7	0.00	100.0
Cycle 4 Day 1	56	22.62	27.05	0.0	33.33	100.0	56	-0.60	23.35	-66.7	0.00	66.7
Cycle 5 Day 1	55	20.00	26.91	0.0	0.00	100.0	54	-3.70	25.63	-66.7	0.00	66.7
Cycle 6 Day 1	55	26.06	30.56	0.0	33.33	100.0	55	3.64	27.72	-66.7	0.00	100.0
Cycle 7 Day 1	44	25.00	31.44	0.0	16.67	100.0	44	0.76	28.29	-66.7	0.00	66.7
Cycle 8 Day 1	41	20.33	25.69	0.0	0.00	100.0	39	-0.85	19.48	-33.3	0.00	33.3
Cycle 9 Day 1	38	21.93	28.24	0.0	0.00	100.0	37	0.00	26.06	-33.3	0.00	66.7
Cycle 10 Day 1	34	14.71	27.45	0.0	0.00	100.0	33	-5.05	25.17	-66.7	0.00	66.7
Cycle 11 Day 1	31	13.98	24.00	0.0	0.00	100.0	30	-5.56	24.89	-33.3	0.00	66.7
Cycle 12 Day 1	31	10.75	21.75	0.0	0.00	100.0	30	-5.56	23.30	-33.3	0.00	66.7
Cycle 13 Day 1	26	8.97	15.08	0.0	0.00	33.3	25	-6.67	21.52	-33.3	0.00	33.3
Cycle 14 Day 1	22	9.09	15.19	0.0	0.00	33.3	21	-7.94	20.83	-33.3	0.00	33.3
Cycle 15 Day 1	23	13.04	19.43	0.0	0.00	66.7	22	-7.58	20.40	-33.3	0.00	33.3
Cycle 16 Day 1	24	13.89	23.91	0.0	0.00	100.0	23	-5.80	19.21	-33.3	0.00	33.3
Cycle 17 Day 1	21	15.87	24.99	0.0	0.00	100.0	20	-5.00	19.57	-33.3	0.00	33.3
Cycle 18 Day 1	21	14.29	24.88	0.0	0.00	100.0	20	-5.00	19.57	-33.3	0.00	33.3
Cycle 19 Day 1	21	7.94	23.34	0.0	0.00	100.0	20	-11.67	22.36	-66.7	0.00	33.3
Cycle 20 Day 1	19	10.53	24.98	0.0	0.00	100.0	18	-9.26	19.15	-33.3	0.00	33.3
Cycle 21 Day 1	18	12.96	25.92	0.0	0.00	100.0	17	-5.88	21.20	-33.3	0.00	33.3
Cycle 22 Day 1	15	2.22	8.61	0.0	0.00	33.3	14	-9.52	24.21	-66.7	0.00	33.3
Cycle 23 Day 1	15	8.89	15.26	0.0	0.00	33.3	14	-2.38	24.33	-33.3	0.00	33.3
Cycle 24 Day 1	14	14.29	17.12	0.0	0.00	33.3	13	2.56	21.35	-33.3	0.00	33.3
Cycle 25 Day 1	14	4.76	12.10	0.0	0.00	33.3	13	-7.69	19.97	-66.7	0.00	0.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values;
Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.27.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Dry Mouth
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	5.56	12.97	0.0	0.00	33.3	11	-6.06	29.13	-66.7	0.00	33.3
Cycle 27 Day 1	13	5.13	12.52	0.0	0.00	33.3	12	-8.33	20.72	-33.3	0.00	33.3
Cycle 28 Day 1	11	15.15	17.41	0.0	0.00	33.3	10	3.33	24.60	-33.3	0.00	33.3
Cycle 29 Day 1	11	12.12	16.82	0.0	0.00	33.3	10	0.00	35.14	-66.7	0.00	33.3
Cycle 30 Day 1	10	16.67	17.57	0.0	16.67	33.3	9	3.70	26.06	-33.3	0.00	33.3
Cycle 31 Day 1	10	10.00	16.10	0.0	0.00	33.3	9	-3.70	30.93	-66.7	0.00	33.3
Cycle 32 Day 1	10	10.00	16.10	0.0	0.00	33.3	9	-3.70	35.14	-66.7	0.00	33.3
Study Disc 1	48	25.69	33.85	0.0	0.00	100.0	48	0.00	29.17	-66.7	0.00	100.0
30 D SFU Z/P	22	16.67	32.12	0.0	0.00	100.0	22	-3.03	25.01	-33.3	0.00	66.7
90 D SFU Z/P	23	15.94	31.57	0.0	0.00	100.0	23	-1.45	21.27	-33.3	0.00	66.7
Placebo + CAPOX (N= 88)												
Baseline	80	18.33	26.47	0.0	0.00	100.0						
Cycle 2 Day 1	73	20.55	25.84	0.0	0.00	100.0	69	3.38	20.73	-66.7	0.00	66.7
Cycle 3 Day 1	64	20.83	24.12	0.0	16.67	100.0	62	5.38	25.03	-33.3	0.00	66.7
Cycle 4 Day 1	56	20.24	22.63	0.0	33.33	100.0	56	5.36	26.04	-66.7	0.00	66.7
Cycle 5 Day 1	57	18.71	22.73	0.0	0.00	66.7	57	2.34	29.45	-66.7	0.00	66.7
Cycle 6 Day 1	48	22.92	26.77	0.0	16.67	100.0	48	5.56	28.63	-66.7	0.00	66.7
Cycle 7 Day 1	41	16.26	21.24	0.0	0.00	66.7	41	0.00	30.73	-100.0	0.00	66.7
Cycle 8 Day 1	37	20.72	24.03	0.0	0.00	66.7	37	2.70	28.74	-66.7	0.00	66.7
Cycle 9 Day 1	35	17.14	23.39	0.0	0.00	66.7	35	1.90	27.94	-100.0	0.00	66.7
Cycle 10 Day 1	30	10.00	15.54	0.0	0.00	33.3	29	-5.75	23.69	-66.7	0.00	33.3
Cycle 11 Day 1	27	12.35	16.40	0.0	0.00	33.3	27	-3.70	23.27	-66.7	0.00	33.3
Cycle 12 Day 1	26	17.95	21.56	0.0	0.00	66.7	25	2.67	27.08	-66.7	0.00	66.7
Cycle 13 Day 1	22	16.67	19.92	0.0	0.00	66.7	21	0.00	33.33	-100.0	0.00	66.7
Cycle 14 Day 1	21	19.05	29.00	0.0	0.00	100.0	20	6.67	25.59	-33.3	0.00	66.7
Cycle 15 Day 1	18	20.37	28.33	0.0	0.00	100.0	17	7.84	18.74	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.27.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Dry Mouth
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	17.65	20.81	0.0	0.00	66.7	16	4.17	20.64	-33.3	0.00	33.3
Cycle 17 Day 1	13	10.26	16.01	0.0	0.00	33.3	11	3.03	17.98	-33.3	0.00	33.3
Cycle 18 Day 1	10	10.00	16.10	0.0	0.00	33.3	9	3.70	11.11	0.0	0.00	33.3
Study Disc 1	51	20.92	26.63	0.0	0.00	100.0	46	5.07	28.95	-100.0	0.00	66.7
30 D SFU Z/P	27	25.93	25.04	0.0	33.33	66.7	25	5.33	26.67	-66.7	0.00	66.7
90 D SFU Z/P	30	24.44	27.59	0.0	33.33	100.0	29	6.90	30.05	-66.7	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.28.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble with Taste
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	12.39	22.86	0.0	0.00	100.0						
Cycle 2 Day 1	69	19.81	28.19	0.0	0.00	100.0	68	7.35	28.71	-66.7	0.00	100.0
Cycle 3 Day 1	61	20.22	27.41	0.0	0.00	100.0	60	7.22	23.84	-33.3	0.00	100.0
Cycle 4 Day 1	56	20.83	26.64	0.0	0.00	100.0	56	8.93	23.35	-33.3	0.00	66.7
Cycle 5 Day 1	55	21.21	26.73	0.0	0.00	100.0	54	9.88	26.41	-33.3	0.00	66.7
Cycle 6 Day 1	55	26.06	28.47	0.0	33.33	100.0	55	13.94	26.98	-33.3	0.00	100.0
Cycle 7 Day 1	44	24.24	29.96	0.0	16.67	100.0	44	12.12	27.93	-33.3	0.00	100.0
Cycle 8 Day 1	41	25.20	33.98	0.0	0.00	100.0	39	11.11	24.58	-33.3	0.00	66.7
Cycle 9 Day 1	38	21.93	30.29	0.0	0.00	100.0	37	8.11	27.67	-33.3	0.00	66.7
Cycle 10 Day 1	34	17.65	26.25	0.0	0.00	100.0	33	3.03	29.30	-66.7	0.00	66.7
Cycle 11 Day 1	31	16.13	24.15	0.0	0.00	100.0	30	4.44	28.68	-66.7	0.00	66.7
Cycle 12 Day 1	31	13.98	22.40	0.0	0.00	100.0	30	3.33	25.30	-66.7	0.00	66.7
Cycle 13 Day 1	26	7.69	14.32	0.0	0.00	33.3	25	-4.00	27.76	-66.7	0.00	33.3
Cycle 14 Day 1	22	10.61	18.93	0.0	0.00	66.7	21	0.00	29.81	-66.7	0.00	66.7
Cycle 15 Day 1	23	7.25	17.28	0.0	0.00	66.7	22	-6.06	22.15	-66.7	0.00	33.3
Cycle 16 Day 1	24	12.50	23.70	0.0	0.00	100.0	23	0.00	26.59	-66.7	0.00	33.3
Cycle 17 Day 1	21	11.11	19.25	0.0	0.00	66.7	20	-3.33	26.27	-66.7	0.00	33.3
Cycle 18 Day 1	21	11.11	19.25	0.0	0.00	66.7	20	-3.33	26.27	-66.7	0.00	33.3
Cycle 19 Day 1	21	7.94	17.97	0.0	0.00	66.7	20	-6.67	23.20	-66.7	0.00	33.3
Cycle 20 Day 1	19	10.53	22.37	0.0	0.00	66.7	18	-3.70	19.43	-66.7	0.00	33.3
Cycle 21 Day 1	18	9.26	15.36	0.0	0.00	33.3	17	-5.88	24.25	-66.7	0.00	33.3
Cycle 22 Day 1	15	4.44	11.73	0.0	0.00	33.3	14	-4.76	28.81	-66.7	0.00	33.3
Cycle 23 Day 1	15	6.67	13.80	0.0	0.00	33.3	14	2.38	24.33	-66.7	0.00	33.3
Cycle 24 Day 1	14	4.76	12.10	0.0	0.00	33.3	13	0.00	23.57	-66.7	0.00	33.3
Cycle 25 Day 1	14	4.76	12.10	0.0	0.00	33.3	13	0.00	23.57	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.28.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble with Taste
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	0.00	0.00	0.0	0.00	0.0	11	-6.06	20.10	-66.7	0.00	0.0
Cycle 27 Day 1	13	2.56	9.25	0.0	0.00	33.3	12	-2.78	22.29	-66.7	0.00	33.3
Cycle 28 Day 1	11	6.06	13.48	0.0	0.00	33.3	10	0.00	27.22	-66.7	0.00	33.3
Cycle 29 Day 1	11	9.09	15.57	0.0	0.00	33.3	10	3.33	29.19	-66.7	0.00	33.3
Cycle 30 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	-3.70	26.06	-66.7	0.00	33.3
Cycle 31 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	0.00	28.87	-66.7	0.00	33.3
Cycle 32 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	0.00	28.87	-66.7	0.00	33.3
Study Disc 1	48	21.53	31.88	0.0	0.00	100.0	48	7.64	26.84	-66.7	0.00	100.0
30 D SFU Z/P	22	16.67	24.67	0.0	0.00	100.0	22	3.03	25.01	-66.7	0.00	33.3
90 D SFU Z/P	23	11.59	25.84	0.0	0.00	100.0	23	5.80	31.22	-66.7	0.00	100.0
Placebo + CAPOX (N= 88)												
Baseline	80	8.75	21.70	0.0	0.00	100.0						
Cycle 2 Day 1	73	15.98	25.53	0.0	0.00	100.0	69	6.76	23.28	-66.7	0.00	100.0
Cycle 3 Day 1	64	14.06	22.07	0.0	0.00	100.0	62	8.06	20.63	-66.7	0.00	66.7
Cycle 4 Day 1	56	14.88	22.85	0.0	0.00	100.0	56	8.33	23.99	-66.7	0.00	66.7
Cycle 5 Day 1	57	18.71	25.21	0.0	0.00	66.7	57	11.70	25.58	-66.7	0.00	66.7
Cycle 6 Day 1	48	24.31	30.55	0.0	0.00	100.0	48	15.97	32.24	-66.7	0.00	100.0
Cycle 7 Day 1	41	17.07	27.00	0.0	0.00	100.0	41	8.94	26.90	-66.7	0.00	100.0
Cycle 8 Day 1	37	17.12	25.61	0.0	0.00	100.0	37	9.01	27.94	-66.7	0.00	100.0
Cycle 9 Day 1	35	9.52	17.29	0.0	0.00	66.7	35	3.81	23.94	-66.7	0.00	66.7
Cycle 10 Day 1	30	6.67	16.14	0.0	0.00	66.7	29	2.30	23.45	-66.7	0.00	66.7
Cycle 11 Day 1	27	3.70	10.68	0.0	0.00	33.3	27	-3.70	23.27	-66.7	0.00	33.3
Cycle 12 Day 1	26	5.13	12.26	0.0	0.00	33.3	25	-1.33	24.49	-66.7	0.00	33.3
Cycle 13 Day 1	22	7.58	14.30	0.0	0.00	33.3	21	1.59	16.59	-33.3	0.00	33.3
Cycle 14 Day 1	21	7.94	17.97	0.0	0.00	66.7	20	3.33	26.27	-66.7	0.00	66.7
Cycle 15 Day 1	18	7.41	14.26	0.0	0.00	33.3	17	1.96	24.92	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.28.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble with Taste
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	5.88	13.10	0.0	0.00	33.3	16	0.00	17.21	-33.3	0.00	33.3
Cycle 17 Day 1	13	5.13	12.52	0.0	0.00	33.3	11	6.06	13.48	0.0	0.00	33.3
Cycle 18 Day 1	10	0.00	0.00	0.0	0.00	0.0	9	0.00	0.00	0.0	0.00	0.0
Study Disc 1	51	18.95	30.00	0.0	0.00	100.0	46	13.04	29.38	-66.7	0.00	100.0
30 D SFU Z/P	27	16.05	25.10	0.0	0.00	66.7	25	6.67	27.22	-66.7	0.00	66.7
90 D SFU Z/P	30	14.44	18.94	0.0	0.00	66.7	29	8.05	24.65	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.29.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Body Image
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	21.79	29.34	0.0	0.00	100.0						
Cycle 2 Day 1	69	19.81	25.13	0.0	0.00	100.0	68	-0.98	25.08	-66.7	0.00	66.7
Cycle 3 Day 1	61	19.13	28.19	0.0	0.00	100.0	60	-0.56	27.10	-66.7	0.00	66.7
Cycle 4 Day 1	56	19.05	26.10	0.0	0.00	100.0	56	2.38	25.31	-66.7	0.00	100.0
Cycle 5 Day 1	55	23.03	31.99	0.0	0.00	100.0	54	4.32	31.09	-66.7	0.00	100.0
Cycle 6 Day 1	55	24.24	32.37	0.0	0.00	100.0	55	4.85	26.77	-66.7	0.00	100.0
Cycle 7 Day 1	44	21.21	29.72	0.0	0.00	100.0	44	0.00	27.84	-66.7	0.00	66.7
Cycle 8 Day 1	41	26.02	32.92	0.0	0.00	100.0	39	2.56	27.98	-33.3	0.00	100.0
Cycle 9 Day 1	38	23.68	28.90	0.0	0.00	100.0	37	-0.90	22.89	-66.7	0.00	66.7
Cycle 10 Day 1	34	21.57	25.80	0.0	16.67	100.0	33	-1.01	28.24	-66.7	0.00	100.0
Cycle 11 Day 1	31	17.20	20.85	0.0	0.00	66.7	30	-6.67	22.15	-66.7	0.00	33.3
Cycle 12 Day 1	31	20.43	22.24	0.0	33.33	66.7	30	-3.33	25.30	-66.7	0.00	33.3
Cycle 13 Day 1	26	14.10	21.44	0.0	0.00	66.7	25	-9.33	24.57	-66.7	0.00	33.3
Cycle 14 Day 1	22	13.64	19.68	0.0	0.00	66.7	21	-7.94	25.61	-66.7	0.00	33.3
Cycle 15 Day 1	23	17.39	22.18	0.0	0.00	66.7	22	-6.06	26.50	-66.7	0.00	33.3
Cycle 16 Day 1	24	18.06	21.93	0.0	0.00	66.7	23	-5.80	23.89	-66.7	0.00	33.3
Cycle 17 Day 1	21	19.05	24.88	0.0	0.00	66.7	20	-8.33	23.88	-66.7	0.00	33.3
Cycle 18 Day 1	21	17.46	22.65	0.0	0.00	66.7	20	-8.33	21.29	-66.7	0.00	33.3
Cycle 19 Day 1	21	15.87	20.05	0.0	0.00	66.7	20	-10.00	26.71	-66.7	0.00	33.3
Cycle 20 Day 1	19	22.81	29.51	0.0	0.00	100.0	18	-3.70	22.55	-33.3	0.00	66.7
Cycle 21 Day 1	18	14.81	20.52	0.0	0.00	66.7	17	-11.76	20.21	-66.7	0.00	0.0
Cycle 22 Day 1	15	20.00	30.34	0.0	0.00	100.0	14	-7.14	23.31	-66.7	0.00	33.3
Cycle 23 Day 1	15	13.33	24.56	0.0	0.00	66.7	14	-7.14	19.30	-66.7	0.00	0.0
Cycle 24 Day 1	14	11.90	21.11	0.0	0.00	66.7	13	-5.13	12.52	-33.3	0.00	0.0
Cycle 25 Day 1	14	9.52	15.63	0.0	0.00	33.3	13	-7.69	24.17	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values;
Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.29.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Body Image
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	11.11	16.41	0.0	0.00	33.3	11	-9.09	21.56	-33.3	0.00	33.3
Cycle 27 Day 1	13	15.38	29.24	0.0	0.00	100.0	12	-2.78	17.16	-33.3	0.00	33.3
Cycle 28 Day 1	11	18.18	27.34	0.0	0.00	66.7	10	-10.00	22.50	-66.7	0.00	0.0
Cycle 29 Day 1	11	18.18	34.52	0.0	0.00	100.0	10	-10.00	27.44	-66.7	0.00	33.3
Cycle 30 Day 1	10	26.67	34.43	0.0	16.67	100.0	9	-3.70	20.03	-33.3	0.00	33.3
Cycle 31 Day 1	10	20.00	28.11	0.0	0.00	66.7	9	-11.11	16.67	-33.3	0.00	0.0
Cycle 32 Day 1	10	13.33	23.31	0.0	0.00	66.7	9	-18.52	24.22	-66.7	0.00	0.0
Study Disc 1	48	23.61	31.48	0.0	0.00	100.0	48	4.86	35.05	-100.0	0.00	100.0
30 D SFU Z/P	22	16.67	26.73	0.0	0.00	100.0	22	-1.52	24.07	-66.7	0.00	33.3
90 D SFU Z/P	23	13.04	16.63	0.0	0.00	33.3	23	2.90	17.15	-33.3	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	80	18.33	26.47	0.0	0.00	100.0						
Cycle 2 Day 1	73	19.18	27.17	0.0	0.00	100.0	69	1.45	21.72	-33.3	0.00	66.7
Cycle 3 Day 1	64	18.23	28.44	0.0	0.00	100.0	62	0.54	26.65	-66.7	0.00	66.7
Cycle 4 Day 1	56	18.45	23.72	0.0	0.00	100.0	56	1.79	22.40	-66.7	0.00	66.7
Cycle 5 Day 1	57	14.62	20.91	0.0	0.00	66.7	57	-0.58	21.35	-66.7	0.00	33.3
Cycle 6 Day 1	48	19.44	28.21	0.0	0.00	100.0	48	3.47	29.37	-66.7	0.00	100.0
Cycle 7 Day 1	41	14.63	23.63	0.0	0.00	100.0	41	2.44	21.59	-66.7	0.00	66.7
Cycle 8 Day 1	37	17.12	26.78	0.0	0.00	100.0	37	2.70	25.31	-33.3	0.00	66.7
Cycle 9 Day 1	35	19.05	24.64	0.0	0.00	66.7	35	5.71	18.94	-33.3	0.00	33.3
Cycle 10 Day 1	30	18.89	24.26	0.0	0.00	100.0	29	6.90	22.50	-33.3	0.00	66.7
Cycle 11 Day 1	27	17.28	19.33	0.0	0.00	66.7	27	2.47	22.51	-33.3	0.00	66.7
Cycle 12 Day 1	26	15.38	21.56	0.0	0.00	66.7	25	1.33	26.32	-66.7	0.00	66.7
Cycle 13 Day 1	22	19.70	22.20	0.0	16.67	66.7	21	6.35	22.65	-33.3	0.00	66.7
Cycle 14 Day 1	21	14.29	24.88	0.0	0.00	66.7	20	3.33	26.27	-33.3	0.00	66.7
Cycle 15 Day 1	18	16.67	26.20	0.0	0.00	100.0	17	5.88	29.43	-33.3	0.00	100.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.29.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Body Image
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	13.73	20.61	0.0	0.00	66.7	16	4.17	20.64	-33.3	0.00	33.3
Cycle 17 Day 1	13	5.13	12.52	0.0	0.00	33.3	11	-3.03	10.05	-33.3	0.00	0.0
Cycle 18 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	-3.70	11.11	-33.3	0.00	0.0
Study Disc 1	51	26.14	32.19	0.0	33.33	100.0	46	7.25	26.21	-33.3	0.00	100.0
30 D SFU Z/P	27	25.93	33.76	0.0	0.00	100.0	25	8.00	27.69	-33.3	0.00	100.0
90 D SFU Z/P	30	25.56	29.92	0.0	16.67	100.0	29	4.60	29.17	-66.7	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.30.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble Swallowing Saliva
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	5.13	14.29	0.0	0.00	66.7						
Cycle 2 Day 1	69	3.86	10.75	0.0	0.00	33.3	68	-1.47	17.69	-66.7	0.00	33.3
Cycle 3 Day 1	61	6.01	15.53	0.0	0.00	66.7	60	0.56	14.38	-66.7	0.00	33.3
Cycle 4 Day 1	56	5.36	16.55	0.0	0.00	100.0	56	0.60	14.90	-66.7	0.00	33.3
Cycle 5 Day 1	55	4.24	11.21	0.0	0.00	33.3	54	0.62	15.17	-66.7	0.00	33.3
Cycle 6 Day 1	55	10.30	22.10	0.0	0.00	100.0	55	5.45	22.00	-66.7	0.00	100.0
Cycle 7 Day 1	44	9.09	20.79	0.0	0.00	100.0	44	3.03	27.67	-66.7	0.00	100.0
Cycle 8 Day 1	41	2.44	8.79	0.0	0.00	33.3	39	-4.27	17.40	-66.7	0.00	33.3
Cycle 9 Day 1	38	7.02	15.80	0.0	0.00	66.7	37	0.90	20.01	-66.7	0.00	66.7
Cycle 10 Day 1	34	3.92	13.64	0.0	0.00	66.7	33	-3.03	15.28	-66.7	0.00	33.3
Cycle 11 Day 1	31	7.53	20.57	0.0	0.00	100.0	30	0.00	17.51	-66.7	0.00	33.3
Cycle 12 Day 1	31	5.38	15.15	0.0	0.00	66.7	30	0.00	12.38	-33.3	0.00	33.3
Cycle 13 Day 1	26	2.56	9.06	0.0	0.00	33.3	25	-1.33	11.71	-33.3	0.00	33.3
Cycle 14 Day 1	22	3.03	9.81	0.0	0.00	33.3	21	-1.59	12.81	-33.3	0.00	33.3
Cycle 15 Day 1	23	1.45	6.95	0.0	0.00	33.3	22	-6.06	16.70	-66.7	0.00	0.0
Cycle 16 Day 1	24	5.56	12.69	0.0	0.00	33.3	23	-1.45	21.27	-66.7	0.00	33.3
Cycle 17 Day 1	21	3.17	10.03	0.0	0.00	33.3	20	-5.00	16.31	-66.7	0.00	0.0
Cycle 18 Day 1	21	3.17	10.03	0.0	0.00	33.3	20	-5.00	16.31	-66.7	0.00	0.0
Cycle 19 Day 1	21	6.35	13.41	0.0	0.00	33.3	20	-1.67	20.16	-66.7	0.00	33.3
Cycle 20 Day 1	19	1.75	7.65	0.0	0.00	33.3	18	-7.41	21.56	-66.7	0.00	33.3
Cycle 21 Day 1	18	7.41	14.26	0.0	0.00	33.3	17	0.00	23.57	-66.7	0.00	33.3
Cycle 22 Day 1	15	2.22	8.61	0.0	0.00	33.3	14	0.00	13.07	-33.3	0.00	33.3
Cycle 23 Day 1	15	2.22	8.61	0.0	0.00	33.3	14	0.00	13.07	-33.3	0.00	33.3
Cycle 24 Day 1	14	2.38	8.91	0.0	0.00	33.3	13	0.00	13.61	-33.3	0.00	33.3
Cycle 25 Day 1	14	2.38	8.91	0.0	0.00	33.3	13	0.00	13.61	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values;
Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.30.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble Swallowing Saliva
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	0.00	0.00	0.0	0.00	0.0	11	-3.03	10.05	-33.3	0.00	0.0
Cycle 27 Day 1	13	5.13	12.52	0.0	0.00	33.3	12	2.78	17.16	-33.3	0.00	33.3
Cycle 28 Day 1	11	3.03	10.05	0.0	0.00	33.3	10	0.00	15.71	-33.3	0.00	33.3
Cycle 29 Day 1	11	6.06	13.48	0.0	0.00	33.3	10	3.33	18.92	-33.3	0.00	33.3
Cycle 30 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	0.00	16.67	-33.3	0.00	33.3
Cycle 31 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	0.00	16.67	-33.3	0.00	33.3
Cycle 32 Day 1	10	0.00	0.00	0.0	0.00	0.0	9	-3.70	11.11	-33.3	0.00	0.0
Study Disc 1	48	9.03	20.33	0.0	0.00	100.0	48	3.47	20.90	-66.7	0.00	66.7
30 D SFU Z/P	22	4.55	15.59	0.0	0.00	66.7	22	-3.03	17.55	-66.7	0.00	33.3
90 D SFU Z/P	23	8.70	18.03	0.0	0.00	66.7	23	2.90	22.28	-66.7	0.00	66.7
Placebo + CAPOX (N= 88)												
Baseline	80	8.33	20.20	0.0	0.00	100.0						
Cycle 2 Day 1	73	5.48	15.73	0.0	0.00	100.0	69	-1.93	16.05	-66.7	0.00	33.3
Cycle 3 Day 1	64	3.65	10.49	0.0	0.00	33.3	62	-4.84	19.88	-100.0	0.00	33.3
Cycle 4 Day 1	56	4.76	16.12	0.0	0.00	100.0	56	-2.38	19.96	-66.7	0.00	100.0
Cycle 5 Day 1	57	3.51	12.09	0.0	0.00	66.7	57	-3.51	19.60	-66.7	0.00	66.7
Cycle 6 Day 1	48	7.64	15.74	0.0	0.00	66.7	48	1.39	20.58	-33.3	0.00	66.7
Cycle 7 Day 1	41	2.44	8.79	0.0	0.00	33.3	41	-4.88	17.58	-66.7	0.00	33.3
Cycle 8 Day 1	37	4.50	11.55	0.0	0.00	33.3	37	-2.70	14.44	-33.3	0.00	33.3
Cycle 9 Day 1	35	4.76	14.33	0.0	0.00	66.7	35	-3.81	21.04	-66.7	0.00	66.7
Cycle 10 Day 1	30	3.33	18.26	0.0	0.00	100.0	29	-3.45	24.14	-33.3	0.00	100.0
Cycle 11 Day 1	27	2.47	8.90	0.0	0.00	33.3	27	-7.41	21.35	-66.7	0.00	33.3
Cycle 12 Day 1	26	2.56	13.07	0.0	0.00	66.7	25	-6.67	23.57	-66.7	0.00	66.7
Cycle 13 Day 1	22	6.06	16.70	0.0	0.00	66.7	21	1.59	19.65	-33.3	0.00	66.7
Cycle 14 Day 1	21	6.35	22.65	0.0	0.00	100.0	20	0.00	30.59	-66.7	0.00	100.0
Cycle 15 Day 1	18	3.70	15.71	0.0	0.00	66.7	17	-3.92	26.04	-66.7	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.30.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble Swallowing Saliva
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	3.92	11.07	0.0	0.00	33.3	16	-4.17	23.96	-66.7	0.00	33.3
Cycle 17 Day 1	13	0.00	0.00	0.0	0.00	0.0	11	-9.09	21.56	-66.7	0.00	0.0
Cycle 18 Day 1	10	0.00	0.00	0.0	0.00	0.0	9	-11.11	23.57	-66.7	0.00	0.0
Study Disc 1	51	14.38	23.34	0.0	0.00	100.0	46	5.80	31.67	-100.0	0.00	100.0
30 D SFU Z/P	27	6.17	13.19	0.0	0.00	33.3	25	-5.33	22.93	-66.7	0.00	33.3
90 D SFU Z/P	30	3.33	13.42	0.0	0.00	66.7	29	-9.20	29.41	-100.0	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.31.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Choked when Swallowing Score
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	6.41	13.22	0.0	0.00	33.3						
Cycle 2 Day 1	69	3.86	12.18	0.0	0.00	66.7	68	-2.94	14.95	-33.3	0.00	33.3
Cycle 3 Day 1	61	6.01	14.28	0.0	0.00	66.7	60	-1.11	12.22	-33.3	0.00	33.3
Cycle 4 Day 1	56	5.36	16.55	0.0	0.00	100.0	56	-1.19	17.94	-33.3	0.00	66.7
Cycle 5 Day 1	55	5.45	14.00	0.0	0.00	66.7	54	-0.62	18.87	-33.3	0.00	66.7
Cycle 6 Day 1	55	4.85	17.47	0.0	0.00	100.0	55	-1.82	20.71	-33.3	0.00	66.7
Cycle 7 Day 1	44	10.61	24.67	0.0	0.00	100.0	44	3.03	25.74	-33.3	0.00	100.0
Cycle 8 Day 1	41	4.07	11.04	0.0	0.00	33.3	39	-2.56	14.07	-33.3	0.00	33.3
Cycle 9 Day 1	38	7.02	15.80	0.0	0.00	66.7	37	0.00	17.57	-33.3	0.00	33.3
Cycle 10 Day 1	34	3.92	13.64	0.0	0.00	66.7	33	-3.03	15.28	-33.3	0.00	33.3
Cycle 11 Day 1	31	6.45	20.04	0.0	0.00	100.0	30	-1.11	20.50	-33.3	0.00	66.7
Cycle 12 Day 1	31	5.38	15.15	0.0	0.00	66.7	30	-2.22	19.44	-33.3	0.00	33.3
Cycle 13 Day 1	26	2.56	9.06	0.0	0.00	33.3	25	-5.33	18.46	-33.3	0.00	33.3
Cycle 14 Day 1	22	6.06	13.16	0.0	0.00	33.3	21	-3.17	14.55	-33.3	0.00	33.3
Cycle 15 Day 1	23	1.45	6.95	0.0	0.00	33.3	22	-7.58	17.61	-33.3	0.00	33.3
Cycle 16 Day 1	24	6.94	13.83	0.0	0.00	33.3	23	-1.45	15.82	-33.3	0.00	33.3
Cycle 17 Day 1	21	6.35	13.41	0.0	0.00	33.3	20	-1.67	7.45	-33.3	0.00	0.0
Cycle 18 Day 1	21	7.94	14.55	0.0	0.00	33.3	20	0.00	15.29	-33.3	0.00	33.3
Cycle 19 Day 1	21	6.35	13.41	0.0	0.00	33.3	20	-1.67	13.13	-33.3	0.00	33.3
Cycle 20 Day 1	19	5.26	12.49	0.0	0.00	33.3	18	-1.85	13.87	-33.3	0.00	33.3
Cycle 21 Day 1	18	9.26	15.36	0.0	0.00	33.3	17	3.92	16.17	-33.3	0.00	33.3
Cycle 22 Day 1	15	4.44	11.73	0.0	0.00	33.3	14	0.00	13.07	-33.3	0.00	33.3
Cycle 23 Day 1	15	4.44	11.73	0.0	0.00	33.3	14	2.38	15.82	-33.3	0.00	33.3
Cycle 24 Day 1	14	2.38	8.91	0.0	0.00	33.3	13	0.00	13.61	-33.3	0.00	33.3
Cycle 25 Day 1	14	2.38	8.91	0.0	0.00	33.3	13	0.00	13.61	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values;
Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.31.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Choked when Swallowing Score
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	2.78	9.62	0.0	0.00	33.3	11	0.00	14.91	-33.3	0.00	33.3
Cycle 27 Day 1	13	5.13	18.49	0.0	0.00	66.7	12	2.78	22.29	-33.3	0.00	66.7
Cycle 28 Day 1	11	9.09	15.57	0.0	0.00	33.3	10	6.67	21.08	-33.3	0.00	33.3
Cycle 29 Day 1	11	9.09	15.57	0.0	0.00	33.3	10	6.67	21.08	-33.3	0.00	33.3
Cycle 30 Day 1	10	10.00	16.10	0.0	0.00	33.3	9	7.41	22.22	-33.3	0.00	33.3
Cycle 31 Day 1	10	10.00	16.10	0.0	0.00	33.3	9	7.41	22.22	-33.3	0.00	33.3
Cycle 32 Day 1	10	10.00	16.10	0.0	0.00	33.3	9	7.41	22.22	-33.3	0.00	33.3
Study Disc 1	48	7.64	19.74	0.0	0.00	100.0	48	0.69	17.52	-33.3	0.00	66.7
30 D SFU Z/P	22	10.61	26.00	0.0	0.00	100.0	22	1.52	21.77	-33.3	0.00	66.7
90 D SFU Z/P	23	2.90	9.60	0.0	0.00	33.3	23	-4.35	15.26	-33.3	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	80	7.50	19.83	0.0	0.00	100.0						
Cycle 2 Day 1	73	6.85	17.53	0.0	0.00	100.0	69	0.00	18.08	-66.7	0.00	66.7
Cycle 3 Day 1	64	4.17	12.60	0.0	0.00	66.7	62	-2.15	20.80	-100.0	0.00	66.7
Cycle 4 Day 1	56	5.36	12.35	0.0	0.00	33.3	56	0.00	16.82	-33.3	0.00	33.3
Cycle 5 Day 1	57	2.92	9.51	0.0	0.00	33.3	57	-2.92	17.00	-66.7	0.00	33.3
Cycle 6 Day 1	48	4.17	13.09	0.0	0.00	66.7	48	-2.08	21.09	-66.7	0.00	66.7
Cycle 7 Day 1	41	4.88	14.07	0.0	0.00	66.7	41	-1.63	21.02	-66.7	0.00	66.7
Cycle 8 Day 1	37	5.41	12.46	0.0	0.00	33.3	37	-0.90	18.40	-66.7	0.00	33.3
Cycle 9 Day 1	35	5.71	12.75	0.0	0.00	33.3	35	0.00	18.08	-66.7	0.00	33.3
Cycle 10 Day 1	30	4.44	11.52	0.0	0.00	33.3	29	0.00	19.92	-66.7	0.00	33.3
Cycle 11 Day 1	27	3.70	10.68	0.0	0.00	33.3	27	-1.23	17.25	-66.7	0.00	33.3
Cycle 12 Day 1	26	5.13	12.26	0.0	0.00	33.3	25	0.00	19.25	-66.7	0.00	33.3
Cycle 13 Day 1	22	6.06	13.16	0.0	0.00	33.3	21	1.59	19.65	-66.7	0.00	33.3
Cycle 14 Day 1	21	6.35	22.65	0.0	0.00	100.0	20	5.00	24.84	-33.3	0.00	100.0
Cycle 15 Day 1	18	9.26	25.06	0.0	0.00	100.0	17	9.80	25.72	0.0	0.00	100.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.31.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Choked when Swallowing Score
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	9.80	19.60	0.0	0.00	66.7	16	10.42	20.07	0.0	0.00	66.7
Cycle 17 Day 1	13	5.13	12.52	0.0	0.00	33.3	11	6.06	13.48	0.0	0.00	33.3
Cycle 18 Day 1	10	0.00	0.00	0.0	0.00	0.0	9	0.00	0.00	0.0	0.00	0.0
Study Disc 1	51	6.54	14.94	0.0	0.00	66.7	46	-0.72	22.76	-100.0	0.00	33.3
30 D SFU Z/P	27	3.70	10.68	0.0	0.00	33.3	25	-6.67	23.57	-66.7	0.00	33.3
90 D SFU Z/P	30	4.44	14.47	0.0	0.00	66.7	29	-4.60	29.17	-100.0	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.32.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble with Coughing
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	11.54	16.84	0.0	0.00	66.7						
Cycle 2 Day 1	69	12.56	19.05	0.0	0.00	66.7	68	2.45	17.58	-33.3	0.00	66.7
Cycle 3 Day 1	61	12.02	18.29	0.0	0.00	66.7	60	2.22	17.21	-33.3	0.00	66.7
Cycle 4 Day 1	56	11.90	20.53	0.0	0.00	100.0	56	1.79	18.44	-33.3	0.00	100.0
Cycle 5 Day 1	55	9.09	16.30	0.0	0.00	66.7	54	-1.23	17.09	-33.3	0.00	66.7
Cycle 6 Day 1	55	12.73	21.75	0.0	0.00	100.0	55	3.03	23.37	-33.3	0.00	100.0
Cycle 7 Day 1	44	10.61	20.04	0.0	0.00	100.0	44	1.52	17.54	-33.3	0.00	66.7
Cycle 8 Day 1	41	8.13	16.30	0.0	0.00	66.7	39	0.00	20.23	-33.3	0.00	66.7
Cycle 9 Day 1	38	7.89	16.32	0.0	0.00	66.7	37	-2.70	21.34	-33.3	0.00	66.7
Cycle 10 Day 1	34	7.84	14.35	0.0	0.00	33.3	33	-3.03	17.41	-33.3	0.00	33.3
Cycle 11 Day 1	31	11.83	22.02	0.0	0.00	100.0	30	0.00	24.76	-33.3	0.00	100.0
Cycle 12 Day 1	31	12.90	18.61	0.0	0.00	66.7	30	2.22	23.05	-33.3	0.00	66.7
Cycle 13 Day 1	26	3.85	10.86	0.0	0.00	33.3	25	-6.67	16.67	-33.3	0.00	33.3
Cycle 14 Day 1	22	4.55	11.71	0.0	0.00	33.3	21	-1.59	16.59	-33.3	0.00	33.3
Cycle 15 Day 1	23	5.80	16.37	0.0	0.00	66.7	22	-3.03	17.55	-33.3	0.00	33.3
Cycle 16 Day 1	24	8.33	14.74	0.0	0.00	33.3	23	0.00	17.41	-33.3	0.00	33.3
Cycle 17 Day 1	21	4.76	11.95	0.0	0.00	33.3	20	-5.00	16.31	-33.3	0.00	33.3
Cycle 18 Day 1	21	4.76	11.95	0.0	0.00	33.3	20	-5.00	19.57	-33.3	0.00	33.3
Cycle 19 Day 1	21	6.35	13.41	0.0	0.00	33.3	20	-3.33	18.42	-33.3	0.00	33.3
Cycle 20 Day 1	19	8.77	15.08	0.0	0.00	33.3	18	0.00	19.80	-33.3	0.00	33.3
Cycle 21 Day 1	18	7.41	14.26	0.0	0.00	33.3	17	0.00	20.41	-33.3	0.00	33.3
Cycle 22 Day 1	15	6.67	18.69	0.0	0.00	66.7	14	2.38	15.82	-33.3	0.00	33.3
Cycle 23 Day 1	15	4.44	11.73	0.0	0.00	33.3	14	0.00	13.07	-33.3	0.00	33.3
Cycle 24 Day 1	14	4.76	12.10	0.0	0.00	33.3	13	2.56	16.45	-33.3	0.00	33.3
Cycle 25 Day 1	14	4.76	12.10	0.0	0.00	33.3	13	2.56	16.45	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.32.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble with Coughing
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	5.56	12.97	0.0	0.00	33.3	11	3.03	17.98	-33.3	0.00	33.3
Cycle 27 Day 1	13	5.13	12.52	0.0	0.00	33.3	12	2.78	17.16	-33.3	0.00	33.3
Cycle 28 Day 1	11	6.06	13.48	0.0	0.00	33.3	10	0.00	15.71	-33.3	0.00	33.3
Cycle 29 Day 1	11	15.15	31.14	0.0	0.00	100.0	10	10.00	27.44	-33.3	0.00	66.7
Cycle 30 Day 1	10	10.00	22.50	0.0	0.00	66.7	9	3.70	20.03	-33.3	0.00	33.3
Cycle 31 Day 1	10	13.33	32.20	0.0	0.00	100.0	9	7.41	27.78	-33.3	0.00	66.7
Cycle 32 Day 1	10	6.67	21.08	0.0	0.00	66.7	9	0.00	16.67	-33.3	0.00	33.3
Study Disc 1	48	10.42	21.91	0.0	0.00	100.0	48	1.39	22.76	-33.3	0.00	66.7
30 D SFU Z/P	22	7.58	14.30	0.0	0.00	33.3	22	-1.52	21.77	-33.3	0.00	33.3
90 D SFU Z/P	23	10.14	15.68	0.0	0.00	33.3	23	2.90	17.15	-33.3	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	80	13.75	24.70	0.0	0.00	100.0						
Cycle 2 Day 1	73	8.68	20.05	0.0	0.00	100.0	69	-4.35	17.07	-66.7	0.00	33.3
Cycle 3 Day 1	64	9.90	18.48	0.0	0.00	100.0	62	-3.76	21.00	-100.0	0.00	33.3
Cycle 4 Day 1	56	10.12	22.85	0.0	0.00	100.0	56	-2.98	25.64	-100.0	0.00	100.0
Cycle 5 Day 1	57	7.60	15.45	0.0	0.00	66.7	57	-5.85	22.82	-100.0	0.00	33.3
Cycle 6 Day 1	48	8.33	16.13	0.0	0.00	66.7	48	-3.47	18.50	-66.7	0.00	33.3
Cycle 7 Day 1	41	8.13	16.30	0.0	0.00	66.7	41	-4.07	22.60	-66.7	0.00	33.3
Cycle 8 Day 1	37	8.11	14.50	0.0	0.00	33.3	37	-5.41	21.54	-66.7	0.00	33.3
Cycle 9 Day 1	35	4.76	11.83	0.0	0.00	33.3	35	-8.57	21.91	-100.0	0.00	33.3
Cycle 10 Day 1	30	4.44	11.52	0.0	0.00	33.3	29	-9.20	23.40	-100.0	0.00	33.3
Cycle 11 Day 1	27	2.47	8.90	0.0	0.00	33.3	27	-13.58	24.91	-100.0	0.00	33.3
Cycle 12 Day 1	26	2.56	9.06	0.0	0.00	33.3	25	-13.33	25.46	-100.0	0.00	33.3
Cycle 13 Day 1	22	4.55	11.71	0.0	0.00	33.3	21	-12.70	19.65	-66.7	0.00	0.0
Cycle 14 Day 1	21	4.76	11.95	0.0	0.00	33.3	20	-13.33	27.36	-100.0	0.00	33.3
Cycle 15 Day 1	18	9.26	15.36	0.0	0.00	33.3	17	-11.76	20.21	-66.7	0.00	0.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.32.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble with Coughing
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	7.84	14.57	0.0	0.00	33.3	16	-10.42	20.07	-66.7	0.00	0.0
Cycle 17 Day 1	13	7.69	14.62	0.0	0.00	33.3	11	-3.03	17.98	-33.3	0.00	33.3
Cycle 18 Day 1	10	0.00	0.00	0.0	0.00	0.0	9	-11.11	16.67	-33.3	0.00	0.0
Study Disc 1	51	6.54	14.94	0.0	0.00	66.7	46	-3.62	27.42	-100.0	0.00	66.7
30 D SFU Z/P	27	13.58	21.20	0.0	0.00	66.7	25	2.67	30.31	-66.7	0.00	66.7
90 D SFU Z/P	30	12.22	22.29	0.0	0.00	66.7	29	1.15	28.84	-66.7	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.33.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble Talking
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	5.56	17.34	0.0	0.00	100.0						
Cycle 2 Day 1	69	6.28	13.13	0.0	0.00	33.3	68	2.45	15.58	-66.7	0.00	33.3
Cycle 3 Day 1	61	2.73	9.22	0.0	0.00	33.3	60	-0.56	9.69	-33.3	0.00	33.3
Cycle 4 Day 1	56	3.57	10.40	0.0	0.00	33.3	56	0.60	13.47	-66.7	0.00	33.3
Cycle 5 Day 1	55	6.06	14.47	0.0	0.00	66.7	54	3.70	13.99	-33.3	0.00	33.3
Cycle 6 Day 1	55	5.45	15.40	0.0	0.00	66.7	55	2.42	16.80	-33.3	0.00	66.7
Cycle 7 Day 1	44	6.06	18.00	0.0	0.00	100.0	44	2.27	22.04	-66.7	0.00	100.0
Cycle 8 Day 1	41	4.07	11.04	0.0	0.00	33.3	39	0.00	15.29	-66.7	0.00	33.3
Cycle 9 Day 1	38	5.26	12.32	0.0	0.00	33.3	37	0.90	18.40	-66.7	0.00	33.3
Cycle 10 Day 1	34	3.92	10.90	0.0	0.00	33.3	33	0.00	16.67	-66.7	0.00	33.3
Cycle 11 Day 1	31	5.38	12.46	0.0	0.00	33.3	30	1.11	18.54	-66.7	0.00	33.3
Cycle 12 Day 1	31	3.23	10.02	0.0	0.00	33.3	30	-1.11	16.34	-66.7	0.00	33.3
Cycle 13 Day 1	26	0.00	0.00	0.0	0.00	0.0	25	-5.33	15.75	-66.7	0.00	0.0
Cycle 14 Day 1	22	0.00	0.00	0.0	0.00	0.0	21	-6.35	17.06	-66.7	0.00	0.0
Cycle 15 Day 1	23	1.45	6.95	0.0	0.00	33.3	22	-4.55	18.67	-66.7	0.00	33.3
Cycle 16 Day 1	24	5.56	12.69	0.0	0.00	33.3	23	0.00	22.47	-66.7	0.00	33.3
Cycle 17 Day 1	21	0.00	0.00	0.0	0.00	0.0	20	-6.67	17.44	-66.7	0.00	0.0
Cycle 18 Day 1	21	3.17	10.03	0.0	0.00	33.3	20	-3.33	14.91	-33.3	0.00	33.3
Cycle 19 Day 1	21	6.35	13.41	0.0	0.00	33.3	20	0.00	18.73	-33.3	0.00	33.3
Cycle 20 Day 1	19	3.51	10.51	0.0	0.00	33.3	18	-3.70	19.43	-66.7	0.00	33.3
Cycle 21 Day 1	18	5.56	12.78	0.0	0.00	33.3	17	-1.96	24.92	-66.7	0.00	33.3
Cycle 22 Day 1	15	2.22	8.61	0.0	0.00	33.3	14	-4.76	17.82	-66.7	0.00	0.0
Cycle 23 Day 1	15	0.00	0.00	0.0	0.00	0.0	14	-4.76	17.82	-66.7	0.00	0.0
Cycle 24 Day 1	14	0.00	0.00	0.0	0.00	0.0	13	-5.13	18.49	-66.7	0.00	0.0
Cycle 25 Day 1	14	2.38	8.91	0.0	0.00	33.3	13	-2.56	21.35	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values;
Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.33.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble Talking
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	0.00	0.00	0.0	0.00	0.0	11	-6.06	20.10	-66.7	0.00	0.0
Cycle 27 Day 1	13	0.00	0.00	0.0	0.00	0.0	12	-5.56	19.25	-66.7	0.00	0.0
Cycle 28 Day 1	11	0.00	0.00	0.0	0.00	0.0	10	-6.67	21.08	-66.7	0.00	0.0
Cycle 29 Day 1	11	0.00	0.00	0.0	0.00	0.0	10	-6.67	21.08	-66.7	0.00	0.0
Cycle 30 Day 1	10	0.00	0.00	0.0	0.00	0.0	9	-7.41	22.22	-66.7	0.00	0.0
Cycle 31 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	-3.70	26.06	-66.7	0.00	33.3
Cycle 32 Day 1	10	0.00	0.00	0.0	0.00	0.0	9	-7.41	22.22	-66.7	0.00	0.0
Study Disc 1	48	9.72	20.58	0.0	0.00	100.0	48	3.47	23.05	-66.7	0.00	66.7
30 D SFU Z/P	22	7.58	22.84	0.0	0.00	100.0	22	3.03	17.55	-33.3	0.00	66.7
90 D SFU Z/P	23	2.90	9.60	0.0	0.00	33.3	23	2.90	9.60	0.0	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	80	5.83	16.58	0.0	0.00	100.0						
Cycle 2 Day 1	73	4.11	14.64	0.0	0.00	100.0	69	-1.45	6.85	-33.3	0.00	0.0
Cycle 3 Day 1	64	2.60	9.02	0.0	0.00	33.3	62	-2.15	15.82	-100.0	0.00	33.3
Cycle 4 Day 1	56	5.36	13.89	0.0	0.00	66.7	56	2.38	16.65	-33.3	0.00	66.7
Cycle 5 Day 1	57	2.34	8.59	0.0	0.00	33.3	57	-1.17	12.54	-33.3	0.00	33.3
Cycle 6 Day 1	48	4.17	11.14	0.0	0.00	33.3	48	0.69	12.84	-33.3	0.00	33.3
Cycle 7 Day 1	41	3.25	10.01	0.0	0.00	33.3	41	0.00	12.91	-33.3	0.00	33.3
Cycle 8 Day 1	37	3.60	10.49	0.0	0.00	33.3	37	-0.90	12.39	-33.3	0.00	33.3
Cycle 9 Day 1	35	5.71	15.09	0.0	0.00	66.7	35	1.90	16.05	-33.3	0.00	33.3
Cycle 10 Day 1	30	4.44	14.47	0.0	0.00	66.7	29	0.00	17.82	-33.3	0.00	66.7
Cycle 11 Day 1	27	2.47	8.90	0.0	0.00	33.3	27	-1.23	11.25	-33.3	0.00	33.3
Cycle 12 Day 1	26	3.85	10.86	0.0	0.00	33.3	25	1.33	11.71	-33.3	0.00	33.3
Cycle 13 Day 1	22	3.03	9.81	0.0	0.00	33.3	21	-1.59	16.59	-33.3	0.00	33.3
Cycle 14 Day 1	21	6.35	17.06	0.0	0.00	66.7	20	3.33	18.42	-33.3	0.00	66.7
Cycle 15 Day 1	18	3.70	10.78	0.0	0.00	33.3	17	0.00	11.79	-33.3	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.33.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Trouble Talking
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	5.88	13.10	0.0	0.00	33.3	16	2.08	14.75	-33.3	0.00	33.3
Cycle 17 Day 1	13	2.56	9.25	0.0	0.00	33.3	11	3.03	10.05	0.0	0.00	33.3
Cycle 18 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	3.70	11.11	0.0	0.00	33.3
Study Disc 1	51	10.46	22.60	0.0	0.00	100.0	46	6.52	25.93	-66.7	0.00	100.0
30 D SFU Z/P	27	7.41	19.25	0.0	0.00	66.7	25	1.33	20.37	-33.3	0.00	66.7
90 D SFU Z/P	30	6.67	18.36	0.0	0.00	66.7	29	2.30	28.07	-100.0	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.34.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Weight Loss
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	24.79	28.14	0.0	33.33	100.0						
Cycle 2 Day 1	69	21.26	24.23	0.0	0.00	66.7	68	-2.94	21.34	-66.7	0.00	33.3
Cycle 3 Day 1	61	21.31	27.91	0.0	0.00	100.0	60	-0.56	22.54	-33.3	0.00	66.7
Cycle 4 Day 1	56	21.43	24.14	0.0	33.33	100.0	56	0.00	29.13	-66.7	0.00	66.7
Cycle 5 Day 1	55	21.82	29.55	0.0	0.00	100.0	54	-1.23	32.35	-66.7	0.00	100.0
Cycle 6 Day 1	55	21.21	26.73	0.0	0.00	100.0	55	-2.42	27.86	-33.3	0.00	66.7
Cycle 7 Day 1	44	21.97	31.29	0.0	0.00	100.0	44	0.76	31.74	-66.7	0.00	100.0
Cycle 8 Day 1	41	20.33	26.75	0.0	0.00	100.0	39	-2.56	30.95	-66.7	0.00	66.7
Cycle 9 Day 1	38	15.79	22.91	0.0	0.00	100.0	37	-9.01	31.08	-66.7	0.00	100.0
Cycle 10 Day 1	34	18.63	28.65	0.0	0.00	100.0	33	-4.04	34.11	-66.7	0.00	100.0
Cycle 11 Day 1	31	11.83	20.27	0.0	0.00	66.7	30	-12.22	30.93	-66.7	0.00	66.7
Cycle 12 Day 1	31	13.98	25.49	0.0	0.00	100.0	30	-11.11	34.28	-66.7	0.00	100.0
Cycle 13 Day 1	26	15.38	21.56	0.0	0.00	66.7	25	-12.00	27.01	-66.7	0.00	33.3
Cycle 14 Day 1	22	12.12	19.37	0.0	0.00	66.7	21	-14.29	24.88	-66.7	0.00	33.3
Cycle 15 Day 1	23	11.59	16.23	0.0	0.00	33.3	22	-13.64	28.47	-66.7	0.00	33.3
Cycle 16 Day 1	24	9.72	15.48	0.0	0.00	33.3	23	-14.49	26.26	-66.7	0.00	33.3
Cycle 17 Day 1	21	9.52	21.46	0.0	0.00	66.7	20	-16.67	22.94	-66.7	0.00	0.0
Cycle 18 Day 1	21	17.46	24.99	0.0	0.00	66.7	20	-10.00	28.82	-66.7	0.00	33.3
Cycle 19 Day 1	21	9.52	15.43	0.0	0.00	33.3	20	-18.33	25.31	-66.7	-16.67	33.3
Cycle 20 Day 1	19	17.54	20.39	0.0	0.00	66.7	18	-9.26	22.30	-33.3	0.00	33.3
Cycle 21 Day 1	18	11.11	16.17	0.0	0.00	33.3	17	-13.73	29.01	-66.7	0.00	33.3
Cycle 22 Day 1	15	11.11	27.22	0.0	0.00	100.0	14	-11.90	28.06	-66.7	0.00	33.3
Cycle 23 Day 1	15	11.11	24.12	0.0	0.00	66.7	14	-9.52	24.21	-66.7	0.00	33.3
Cycle 24 Day 1	14	16.67	31.35	0.0	0.00	100.0	13	-2.56	28.74	-66.7	0.00	33.3
Cycle 25 Day 1	14	11.90	21.11	0.0	0.00	66.7	13	-7.69	24.17	-66.7	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.34.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Weight Loss
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	0.00	0.00	0.0	0.00	0.0	11	-21.21	26.97	-66.7	0.00	0.0
Cycle 27 Day 1	13	10.26	28.50	0.0	0.00	100.0	12	-11.11	25.95	-66.7	0.00	33.3
Cycle 28 Day 1	11	15.15	22.92	0.0	0.00	66.7	10	-13.33	23.31	-66.7	0.00	0.0
Cycle 29 Day 1	11	9.09	21.56	0.0	0.00	66.7	10	-16.67	23.57	-66.7	0.00	0.0
Cycle 30 Day 1	10	6.67	21.08	0.0	0.00	66.7	9	-18.52	24.22	-66.7	0.00	0.0
Cycle 31 Day 1	10	13.33	23.31	0.0	0.00	66.7	9	-11.11	23.57	-66.7	0.00	0.0
Cycle 32 Day 1	10	3.33	10.54	0.0	0.00	33.3	9	-22.22	23.57	-66.7	-33.33	0.0
Study Disc 1	48	27.08	29.70	0.0	33.33	100.0	48	4.86	27.50	-66.7	0.00	66.7
30 D SFU Z/P	22	19.70	26.55	0.0	0.00	100.0	22	-9.09	23.42	-66.7	0.00	33.3
90 D SFU Z/P	23	18.84	24.26	0.0	0.00	66.7	23	0.00	24.62	-33.3	0.00	66.7
Placebo + CAPOX (N= 88)												
Baseline	80	23.33	29.72	0.0	0.00	100.0						
Cycle 2 Day 1	73	25.11	28.75	0.0	33.33	100.0	69	1.45	29.94	-100.0	0.00	100.0
Cycle 3 Day 1	64	25.00	29.10	0.0	33.33	100.0	62	2.69	31.54	-66.7	0.00	100.0
Cycle 4 Day 1	56	24.40	28.06	0.0	33.33	100.0	56	1.19	30.46	-66.7	0.00	100.0
Cycle 5 Day 1	57	19.30	24.35	0.0	0.00	100.0	57	-2.92	25.42	-66.7	0.00	66.7
Cycle 6 Day 1	48	18.75	26.55	0.0	0.00	100.0	48	-5.56	30.23	-66.7	0.00	100.0
Cycle 7 Day 1	41	17.07	22.51	0.0	0.00	66.7	41	-0.81	26.34	-66.7	0.00	66.7
Cycle 8 Day 1	37	16.22	25.61	0.0	0.00	100.0	37	-1.80	29.34	-66.7	0.00	66.7
Cycle 9 Day 1	35	14.29	20.27	0.0	0.00	66.7	35	-4.76	28.17	-66.7	0.00	33.3
Cycle 10 Day 1	30	16.67	20.99	0.0	0.00	66.7	29	0.00	21.82	-66.7	0.00	33.3
Cycle 11 Day 1	27	13.58	23.13	0.0	0.00	66.7	27	-6.17	29.29	-66.7	0.00	66.7
Cycle 12 Day 1	26	15.38	21.56	0.0	0.00	66.7	25	-4.00	27.76	-66.7	0.00	33.3
Cycle 13 Day 1	22	16.67	24.67	0.0	0.00	66.7	21	-3.17	29.64	-66.7	0.00	66.7
Cycle 14 Day 1	21	19.05	24.88	0.0	0.00	66.7	20	1.67	22.88	-33.3	0.00	66.7
Cycle 15 Day 1	18	22.22	34.30	0.0	0.00	100.0	17	1.96	34.30	-33.3	0.00	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.34.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Weight Loss
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	17.65	20.81	0.0	0.00	66.7	16	0.00	21.08	-33.3	0.00	33.3
Cycle 17 Day 1	13	7.69	14.62	0.0	0.00	33.3	11	-9.09	15.57	-33.3	0.00	0.0
Cycle 18 Day 1	10	6.67	14.05	0.0	0.00	33.3	9	-11.11	16.67	-33.3	0.00	0.0
Study Disc 1	51	24.18	32.03	0.0	0.00	100.0	46	0.00	31.43	-66.7	0.00	100.0
30 D SFU Z/P	27	25.93	31.12	0.0	33.33	100.0	25	-5.33	28.35	-66.7	0.00	66.7
90 D SFU Z/P	30	22.22	31.96	0.0	0.00	100.0	29	-1.15	31.48	-66.7	0.00	100.0

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.35.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Hair Loss
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	29	10.34	18.05	0.0	0.00	66.7						
Cycle 2 Day 1	33	11.11	15.96	0.0	0.00	33.3	20	-3.33	14.91	-33.3	0.00	33.3
Cycle 3 Day 1	33	11.11	15.96	0.0	0.00	33.3	18	-1.85	17.98	-33.3	0.00	33.3
Cycle 4 Day 1	29	9.20	15.16	0.0	0.00	33.3	17	0.00	11.79	-33.3	0.00	33.3
Cycle 5 Day 1	23	10.14	15.68	0.0	0.00	33.3	15	0.00	17.82	-33.3	0.00	33.3
Cycle 6 Day 1	26	15.38	23.53	0.0	0.00	66.7	15	6.67	22.54	-33.3	0.00	66.7
Cycle 7 Day 1	15	11.11	16.27	0.0	0.00	33.3	11	-3.03	17.98	-33.3	0.00	33.3
Cycle 8 Day 1	18	11.11	16.17	0.0	0.00	33.3	12	-2.78	17.16	-33.3	0.00	33.3
Cycle 9 Day 1	15	11.11	16.27	0.0	0.00	33.3	10	6.67	14.05	0.0	0.00	33.3
Cycle 10 Day 1	15	11.11	16.27	0.0	0.00	33.3	9	3.70	11.11	0.0	0.00	33.3
Cycle 11 Day 1	12	11.11	16.41	0.0	0.00	33.3	7	4.76	12.60	0.0	0.00	33.3
Cycle 12 Day 1	14	11.90	21.11	0.0	0.00	66.7	10	3.33	18.92	-33.3	0.00	33.3
Cycle 13 Day 1	13	2.56	9.25	0.0	0.00	33.3	8	-4.17	21.36	-33.3	0.00	33.3
Cycle 16 Day 1	11	3.03	10.05	0.0	0.00	33.3	6	-5.56	13.61	-33.3	0.00	0.0
Cycle 17 Day 1	10	13.33	23.31	0.0	0.00	66.7	6	0.00	21.08	-33.3	0.00	33.3
Study Disc 1	19	26.32	28.50	0.0	33.33	100.0	12	16.67	33.33	-33.3	0.00	100.0
90 D SFU Z/P	14	26.19	35.03	0.0	16.67	100.0	10	23.33	44.58	-33.3	0.00	100.0
Placebo + CAPOX (N= 88)												
Baseline	19	7.02	17.84	0.0	0.00	66.7						
Cycle 2 Day 1	26	6.41	16.38	0.0	0.00	66.7	12	0.00	14.21	-33.3	0.00	33.3
Cycle 3 Day 1	22	13.64	19.68	0.0	0.00	66.7	10	13.33	17.21	0.0	0.00	33.3
Cycle 4 Day 1	16	14.58	20.97	0.0	0.00	66.7	9	3.70	11.11	0.0	0.00	33.3
Cycle 5 Day 1	18	16.67	20.61	0.0	0.00	66.7	8	8.33	23.57	-33.3	0.00	33.3
Cycle 6 Day 1	16	12.50	16.67	0.0	0.00	33.3	7	0.00	19.25	-33.3	0.00	33.3
Cycle 7 Day 1	15	13.33	24.56	0.0	0.00	66.7	7	4.76	12.60	0.0	0.00	33.3

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.35.2: EORTC QLQ-OG25 - Observed Means and Change from Baseline of Hair Loss
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 8 Day 1	15	15.56	21.33	0.0	0.00	66.7	4	8.33	16.67	0.0	0.00	33.3
Cycle 9 Day 1	14	19.05	21.54	0.0	16.67	66.7	4	8.33	16.67	0.0	0.00	33.3
Cycle 10 Day 1	14	16.67	28.50	0.0	0.00	100.0	3	11.11	19.25	0.0	0.00	33.3
Cycle 11 Day 1	13	15.38	25.88	0.0	0.00	66.7	3	0.00	0.00	0.0	0.00	0.0
Cycle 12 Day 1	11	21.21	30.81	0.0	0.00	100.0	2	33.33	0.00	33.3	33.33	33.3
Study Disc 1	14	9.52	15.63	0.0	0.00	33.3	4	8.33	16.67	0.0	0.00	33.3
30 D SFU Z/P	11	21.21	26.97	0.0	0.00	66.7	4	16.67	33.33	0.0	0.00	66.7
90 D SFU Z/P	19	38.60	37.29	0.0	33.33	100.0	4	25.00	31.91	0.0	16.67	66.7

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EORTC QLQ-OG25

3. Time-to-Event-Analysen - Zeit bis zur ersten Verschlechterung

Table 302.3.3003.20.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Dysphagia (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	46 (54.8%)	40 (45.5%)	
Number of patients censored	38 (45.2%)	48 (54.5%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	3.94 [1.61, 8.02]	6.44 [3.52, 11.73]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.166 [0.746, 1.823]
Log-rank test			
Two-sided stratified log-rank p-value			0.4942

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.20.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Dysphagia by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	34 (56.7)	3.94 [1.61, 9.33]	60	30 (50.0)	6.44 [1.54, 11.73]	1.004 [0.606, 1.664]	0.9941	0.6156
>65 years	24	12 (50.0)	6.67 [0.99, NC]	28	10 (35.7)	14.09 [1.64, NC]	1.332 [0.574, 3.089]	0.5009	
Age Group 2									
<=75 years	81	43 (53.1)	5.52 [2.14, 9.33]	81	38 (46.9)	6.44 [3.48, 14.09]	1.042 [0.669, 1.624]	0.8549	0.1218
>75 years	3	3 (100.0)	1.48 [0.56, NC]	7	2 (28.6)	4.40 [2.40, NC]	2.72E8 [0.000, NC]	0.0101	
Sex									
Male	52	30 (57.7)	3.22 [1.41, 10.87]	46	23 (50.0)	4.83 [1.25, 11.73]	0.899 [0.517, 1.564]	0.7250	0.3445
Female	32	16 (50.0)	5.52 [1.45, 9.33]	42	17 (40.5)	10.81 [3.48, NC]	1.367 [0.686, 2.725]	0.3678	
Region									
Asia	38	26 (68.4)	2.17 [1.31, 7.62]	41	21 (51.2)	4.21 [1.41, NC]	1.290 [0.723, 2.302]	0.3772	0.6363
Non-Asia	46	20 (43.5)	6.67 [1.58, 21.29]	47	19 (40.4)	8.34 [3.52, NC]	0.970 [0.506, 1.860]	0.9182	
Number of Organs with Metastatic Sites									
0-2	64	37 (57.8)	4.40 [1.48, 9.33]	64	28 (43.8)	6.51 [4.01, 14.09]	1.216 [0.737, 2.004]	0.4428	0.5640
>=3	20	9 (45.0)	3.48 [1.45, NC]	24	12 (50.0)	2.58 [1.25, NC]	0.894 [0.370, 2.164]	0.7997	
Prior Gastrectomy (total or partial)									
Yes	24	18 (75.0)	2.60 [1.31, 8.02]	22	10 (45.5)	14.09 [1.54, NC]	1.792 [0.820, 3.917]	0.1421	0.1388
No	60	28 (46.7)	6.67 [1.58, 18.92]	66	30 (45.5)	4.96 [3.48, 10.81]	0.855 [0.504, 1.453]	0.5707	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.20.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Dysphagia (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	46 (54.8%)	40 (45.5%)
Deterioration Before Cutoff Date	46 (54.8%)	40 (45.5%)
Number of patients censored	38 (45.2%)	48 (54.5%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	7 (8.3%)	2 (2.3%)
Death	5 (6.0%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	2 (2.4%)	0
Other	3 (3.6%)	2 (2.3%)
Progressive Disease	17 (20.2%)	31 (35.2%)
Withdrawal By Subject	3 (3.6%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.21.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Eating Restrictions (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	38 (45.2%)	36 (40.9%)	
Number of patients censored	46 (54.8%)	52 (59.1%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	7.62 [3.38, 22.70]	7.92 [4.96, 27.20]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.029 [0.636, 1.665]
Log-rank test			
Two-sided stratified log-rank p-value			0.9020

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.21.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Eating Restrictions by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	28 (46.7)	9.69 [1.51, 22.70]	60	26 (43.3)	8.34 [4.96, 27.20]	1.151 [0.674, 1.966]	0.6073	0.6350
>65 years	24	10 (41.7)	7.62 [1.48, NC]	28	10 (35.7)	7.92 [1.48, NC]	0.929 [0.386, 2.234]	0.8685	
Age Group 2									
<=75 years	81	35 (43.2)	9.69 [3.48, 22.70]	81	32 (39.5)	8.34 [6.44, NC]	1.081 [0.669, 1.748]	0.7447	0.3203
>75 years	3	3 (100.0)	0.69 [0.56, NC]	7	4 (57.1)	1.35 [0.82, NC]	2.818 [0.449, 17.675]	0.2708	
Sex									
Male	52	25 (48.1)	7.62 [2.99, NC]	46	22 (47.8)	6.44 [2.10, 11.73]	0.884 [0.498, 1.569]	0.6783	0.3676
Female	32	13 (40.6)	17.28 [1.38, NC]	42	14 (33.3)	9.23 [5.06, NC]	1.322 [0.615, 2.844]	0.4803	
Region									
Asia	38	21 (55.3)	6.57 [1.45, NC]	41	15 (36.6)	9.23 [2.79, NC]	1.466 [0.756, 2.846]	0.2510	0.1959
Non-Asia	46	17 (37.0)	17.28 [3.38, NC]	47	21 (44.7)	7.43 [2.33, 11.73]	0.802 [0.422, 1.525]	0.4922	
Number of Organs with Metastatic Sites									
0-2	64	31 (48.4)	7.62 [1.51, 22.70]	64	26 (40.6)	9.23 [6.44, 27.20]	1.146 [0.679, 1.934]	0.6018	0.5177
>=3	20	7 (35.0)	NC [1.45, NC]	24	10 (41.7)	5.06 [1.38, NC]	0.772 [0.293, 2.034]	0.5913	
Prior Gastrectomy (total or partial)									
Yes	24	15 (62.5)	3.63 [1.38, 9.69]	22	10 (45.5)	27.20 [2.33, NC]	2.028 [0.884, 4.654]	0.0886	0.0725
No	60	23 (38.3)	17.28 [3.48, NC]	66	26 (39.4)	6.67 [3.48, 11.73]	0.772 [0.434, 1.371]	0.3708	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.21.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Eating Restrictions (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	38 (45.2%)	36 (40.9%)
Deterioration Before Cutoff Date	38 (45.2%)	36 (40.9%)
Number of patients censored	46 (54.8%)	52 (59.1%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	9 (10.7%)	1 (1.1%)
Death	5 (6.0%)	10 (11.4%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	3 (3.6%)	0
Progressive Disease	22 (26.2%)	37 (42.0%)
Withdrawal By Subject	5 (6.0%)	3 (3.4%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.22.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Reflux (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	45 (53.6%)	40 (45.5%)	
Number of patients censored	39 (46.4%)	48 (54.5%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	3.61 [2.04, 6.54]	4.83 [3.42, 9.23]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.161 [0.732, 1.839]
Log-rank test			
Two-sided stratified log-rank p-value			0.5024

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.22.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Reflux by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	31 (51.7)	4.17 [1.91, 13.80]	60	28 (46.7)	5.03 [3.48, NC]	1.120 [0.667, 1.880]	0.6651	0.8910
>65 years	24	14 (58.3)	3.61 [1.08, 6.54]	28	12 (42.9)	4.47 [0.92, 14.09]	1.090 [0.503, 2.361]	0.8225	
Age Group 2									
<=75 years	81	43 (53.1)	3.61 [2.04, 9.26]	81	38 (46.9)	5.03 [3.42, 9.23]	1.076 [0.693, 1.671]	0.7362	0.3580
>75 years	3	2 (66.7)	0.69 [0.56, NC]	7	2 (28.6)	4.47 [0.76, NC]	2.143 [0.291, 15.794]	0.4444	
Sex									
Male	52	29 (55.8)	3.61 [1.61, 6.11]	46	24 (52.2)	3.42 [1.41, 8.34]	0.806 [0.466, 1.392]	0.4505	0.1014
Female	32	16 (50.0)	3.45 [1.08, 13.80]	42	16 (38.1)	5.98 [4.21, NC]	1.572 [0.778, 3.175]	0.2038	
Region									
Asia	38	21 (55.3)	3.14 [1.45, NC]	41	21 (51.2)	4.83 [2.10, 14.09]	0.983 [0.531, 1.818]	0.9626	0.6045
Non-Asia	46	24 (52.2)	4.27 [1.58, 9.26]	47	19 (40.4)	5.06 [3.06, NC]	1.203 [0.655, 2.210]	0.5396	
Number of Organs with Metastatic Sites									
0-2	64	37 (57.8)	3.25 [1.58, 6.54]	64	27 (42.2)	5.88 [3.84, NC]	1.368 [0.826, 2.264]	0.2177	0.1142
>=3	20	8 (40.0)	4.17 [1.18, NC]	24	13 (54.2)	2.50 [1.25, 5.98]	0.623 [0.254, 1.527]	0.3001	
Prior Gastrectomy (total or partial)									
Yes	24	18 (75.0)	2.04 [0.89, 4.27]	22	12 (54.5)	4.57 [2.10, NC]	2.052 [0.985, 4.276]	0.0502	0.0909
No	60	27 (45.0)	4.86 [2.10, 18.69]	66	28 (42.4)	5.03 [2.27, NC]	0.856 [0.501, 1.464]	0.5876	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.22.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Reflux (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	45 (53.6%)	40 (45.5%)
Deterioration Before Cutoff Date	45 (53.6%)	40 (45.5%)
Number of patients censored	39 (46.4%)	48 (54.5%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	6 (7.1%)	3 (3.4%)
Death	5 (6.0%)	10 (11.4%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	5 (6.0%)	2 (2.3%)
Progressive Disease	18 (21.4%)	27 (30.7%)
Withdrawal By Subject	3 (3.6%)	5 (5.7%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.23.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Odynophagia (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	Placebo + CAPOX (N= 88)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	31 (36.9%)	42 (47.7%)	
Number of patients censored	53 (63.1%)	46 (52.3%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	7.36 [4.73, NC]	5.06 [2.60, 9.23]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.661 [0.404, 1.079]
Log-rank test			
Two-sided stratified log-rank p-value			0.0917

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.23.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Odynophagia by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	24 (40.0)	6.57 [3.48, NC]	60	32 (53.3)	5.06 [2.27, 9.23]	0.701 [0.412, 1.192]	0.1848	0.4011
>65 years	24	7 (29.2)	NC [5.68, NC]	28	10 (35.7)	3.48 [0.89, NC]	0.465 [0.175, 1.234]	0.1168	
Age Group 2									
<=75 years	81	30 (37.0)	7.36 [4.60, NC]	81	39 (48.1)	5.16 [2.60, 9.59]	0.637 [0.395, 1.028]	0.0627	0.4559
>75 years	3	1 (33.3)	NC [0.56, NC]	7	3 (42.9)	2.12 [0.79, NC]	0.464 [0.048, 4.521]	0.4987	
Sex									
Male	52	20 (38.5)	7.36 [4.60, NC]	46	24 (52.2)	4.96 [1.61, 9.23]	0.586 [0.323, 1.061]	0.0739	0.8052
Female	32	11 (34.4)	6.57 [2.10, NC]	42	18 (42.9)	5.06 [1.12, NC]	0.656 [0.307, 1.400]	0.2731	
Region									
Asia	38	22 (57.9)	4.19 [1.31, 7.62]	41	18 (43.9)	4.96 [1.41, NC]	1.130 [0.605, 2.111]	0.7032	0.0078
Non-Asia	46	9 (19.6)	NC [6.67, NC]	47	24 (51.1)	5.16 [1.61, 9.23]	0.279 [0.129, 0.603]	0.0005	
Number of Organs with Metastatic Sites									
0-2	64	24 (37.5)	7.62 [4.73, NC]	64	31 (48.4)	7.43 [1.61, 11.73]	0.639 [0.374, 1.091]	0.0989	0.9581
>=3	20	7 (35.0)	6.41 [2.99, NC]	24	11 (45.8)	4.96 [2.14, NC]	0.587 [0.221, 1.554]	0.2780	
Prior Gastrectomy (total or partial)									
Yes	24	13 (54.2)	6.57 [2.07, NC]	22	13 (59.1)	2.79 [0.92, 27.20]	0.777 [0.357, 1.691]	0.5275	0.3719
No	60	18 (30.0)	NC [4.60, NC]	66	29 (43.9)	5.16 [2.83, 9.59]	0.524 [0.289, 0.950]	0.0303	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.23.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Odynophagia (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	31 (36.9%)	42 (47.7%)
Deterioration Before Cutoff Date	31 (36.9%)	42 (47.7%)
Number of patients censored	53 (63.1%)	46 (52.3%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	12 (14.3%)	1 (1.1%)
Death	6 (7.1%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	3 (3.6%)	0
Other	2 (2.4%)	1 (1.1%)
Progressive Disease	25 (29.8%)	29 (33.0%)
Withdrawal By Subject	4 (4.8%)	5 (5.7%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.24.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Pain and Discomfort (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	39 (46.4%)	44 (50.0%)	
Number of patients censored	45 (53.6%)	44 (50.0%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	7.33 [4.27, 15.67]	4.57 [2.60, 6.67]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.691 [0.437, 1.093]
Log-rank test			
Two-sided stratified log-rank p-value			0.1110

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.24.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Pain and Discomfort by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	30 (50.0)	7.20 [3.91, 17.05]	60	35 (58.3)	4.21 [2.37, 6.64]	0.666 [0.405, 1.094]	0.1046	0.6731
>65 years	24	9 (37.5)	15.67 [1.05, NC]	28	9 (32.1)	16.36 [0.89, NC]	0.928 [0.367, 2.348]	0.8852	
Age Group 2									
<=75 years	81	37 (45.7)	7.33 [4.40, 15.67]	81	42 (51.9)	4.57 [2.50, 6.67]	0.683 [0.437, 1.068]	0.0928	0.1563
>75 years	3	2 (66.7)	0.69 [0.56, NC]	7	2 (28.6)	NC [2.20, NC]	2.380 [0.322, 17.617]	0.3826	
Sex									
Male	52	25 (48.1)	15.44 [4.27, 17.05]	46	22 (47.8)	4.21 [1.41, 9.76]	0.667 [0.373, 1.193]	0.1729	0.5730
Female	32	14 (43.8)	7.33 [2.07, 18.92]	42	22 (52.4)	5.06 [2.60, 6.67]	0.854 [0.435, 1.678]	0.6475	
Region									
Asia	38	22 (57.9)	7.20 [2.20, 17.05]	41	21 (51.2)	5.59 [2.20, 9.76]	0.841 [0.458, 1.543]	0.5759	0.4693
Non-Asia	46	17 (37.0)	9.23 [4.27, 18.92]	47	23 (48.9)	3.75 [1.41, 9.23]	0.620 [0.329, 1.168]	0.1334	
Number of Organs with Metastatic Sites									
0-2	64	33 (51.6)	7.33 [4.21, 15.67]	64	33 (51.6)	5.45 [2.60, 9.23]	0.761 [0.464, 1.248]	0.2755	0.5103
>=3	20	6 (30.0)	NC [3.48, NC]	24	11 (45.8)	3.68 [0.76, NC]	0.464 [0.171, 1.258]	0.1265	
Prior Gastrectomy (total or partial)									
Yes	24	15 (62.5)	6.08 [1.61, 17.05]	22	12 (54.5)	4.57 [0.82, NC]	1.073 [0.500, 2.302]	0.8603	0.2836
No	60	24 (40.0)	15.18 [4.40, 18.69]	66	32 (48.5)	4.21 [2.60, 6.67]	0.578 [0.336, 0.996]	0.0461	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.24.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Pain and Discomfort (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	39 (46.4%)	44 (50.0%)
Deterioration Before Cutoff Date	39 (46.4%)	44 (50.0%)
Number of patients censored	45 (53.6%)	44 (50.0%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	9 (10.7%)	1 (1.1%)
Death	6 (7.1%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	3 (3.6%)	0
Other	3 (3.6%)	1 (1.1%)
Progressive Disease	19 (22.6%)	29 (33.0%)
Withdrawal By Subject	4 (4.8%)	3 (3.4%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.25.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Anxiety (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	44 (52.4%)	40 (45.5%)	
Number of patients censored	40 (47.6%)	48 (54.5%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	3.25 [1.51, 5.13]	3.38 [2.14, 6.28]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.115 [0.703, 1.767]
Log-rank test			
Two-sided stratified log-rank p-value			0.6464

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.25.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Anxiety by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	30 (50.0)	3.22 [1.41, 12.55]	60	28 (46.7)	3.15 [1.45, 5.06]	0.884 [0.526, 1.485]	0.6458	0.2606
>65 years	24	14 (58.3)	3.25 [0.76, 12.65]	28	12 (42.9)	4.83 [2.14, NC]	1.464 [0.673, 3.184]	0.3354	
Age Group 2									
<=75 years	81	41 (50.6)	3.25 [1.51, 5.42]	81	37 (45.7)	3.48 [2.14, 6.28]	1.036 [0.663, 1.619]	0.8744	0.9363
>75 years	3	3 (100.0)	0.79 [0.56, NC]	7	3 (42.9)	1.71 [0.79, NC]	1.375 [0.222, 8.518]	0.7491	
Sex									
Male	52	30 (57.7)	3.22 [1.38, 5.13]	46	22 (47.8)	2.33 [1.45, 6.28]	1.032 [0.594, 1.793]	0.9097	0.9091
Female	32	14 (43.8)	3.48 [0.76, 15.84]	42	18 (42.9)	3.91 [2.96, 10.38]	0.983 [0.483, 1.998]	0.9607	
Region									
Asia	38	23 (60.5)	2.33 [0.85, 5.13]	41	21 (51.2)	2.96 [2.07, 8.31]	1.127 [0.623, 2.038]	0.6899	0.7225
Non-Asia	46	21 (45.7)	4.21 [1.45, 15.18]	47	19 (40.4)	3.38 [1.61, 10.38]	0.866 [0.454, 1.653]	0.6557	
Number of Organs with Metastatic Sites									
0-2	64	36 (56.3)	3.22 [1.02, 5.42]	64	28 (43.8)	3.02 [2.07, 8.31]	1.131 [0.688, 1.861]	0.6377	0.4328
>=3	20	8 (40.0)	4.17 [0.95, NC]	24	12 (50.0)	5.06 [0.72, 10.38]	0.798 [0.324, 1.967]	0.6472	
Prior Gastrectomy (total or partial)									
Yes	24	18 (75.0)	0.95 [0.76, 3.25]	22	12 (54.5)	7.92 [1.45, NC]	2.256 [1.069, 4.763]	0.0294	0.0158
No	60	26 (43.3)	5.13 [2.33, 15.18]	66	28 (42.4)	3.02 [1.81, 5.06]	0.686 [0.395, 1.192]	0.1808	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.25.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Anxiety (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	44 (52.4%)	40 (45.5%)
Deterioration Before Cutoff Date	44 (52.4%)	40 (45.5%)
Number of patients censored	40 (47.6%)	48 (54.5%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	8 (9.5%)	0
Death	6 (7.1%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	4 (4.8%)	1 (1.1%)
Progressive Disease	16 (19.0%)	34 (38.6%)
Withdrawal By Subject	4 (4.8%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.26.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Eating in Front of Others (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	31 (36.9%)	28 (31.8%)	
Number of patients censored	53 (63.1%)	60 (68.2%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	15.77 [7.62, 17.74]	9.17 [6.44, NC]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.960 [0.561, 1.641]
Log-rank test			
Two-sided stratified log-rank p-value			0.8550

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.26.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Eating in Front of Others by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	23 (38.3)	17.05 [4.73, NC]	60	21 (35.0)	9.17 [4.21, NC]	0.943 [0.520, 1.710]	0.8417	0.9491
>65 years	24	8 (33.3)	12.91 [7.62, NC]	28	7 (25.0)	7.92 [3.02, NC]	0.951 [0.340, 2.662]	0.9241	
Age Group 2									
<=75 years	81	29 (35.8)	15.77 [7.62, 17.74]	81	27 (33.3)	9.17 [6.44, NC]	0.891 [0.525, 1.511]	0.6665	0.4326
>75 years	3	2 (66.7)	1.48 [0.56, NC]	7	1 (14.3)	NC [0.82, NC]	3.189 [0.287, 35.452]	0.3189	
Sex									
Male	52	18 (34.6)	15.77 [5.03, NC]	46	17 (37.0)	6.90 [3.02, NC]	0.673 [0.346, 1.311]	0.2453	0.1314
Female	32	13 (40.6)	17.05 [2.56, 17.74]	42	11 (26.2)	NC [6.93, NC]	1.449 [0.639, 3.286]	0.3718	
Region									
Asia	38	23 (60.5)	5.03 [2.79, 15.77]	41	16 (39.0)	7.92 [3.48, NC]	1.259 [0.659, 2.407]	0.4893	0.1556
Non-Asia	46	8 (17.4)	17.28 [9.23, NC]	47	12 (25.5)	NC [6.44, NC]	0.542 [0.220, 1.331]	0.1756	
Number of Organs with Metastatic Sites									
0-2	64	24 (37.5)	17.28 [7.62, NC]	64	21 (32.8)	9.17 [6.44, NC]	0.882 [0.487, 1.597]	0.6735	0.5837
>=3	20	7 (35.0)	8.21 [3.48, NC]	24	7 (29.2)	NC [3.48, NC]	1.214 [0.421, 3.503]	0.7198	
Prior Gastrectomy (total or partial)									
Yes	24	13 (54.2)	7.62 [3.22, 17.74]	22	9 (40.9)	9.17 [3.02, NC]	1.285 [0.547, 3.017]	0.5824	0.3534
No	60	18 (30.0)	15.77 [8.21, NC]	66	19 (28.8)	NC [4.96, NC]	0.799 [0.415, 1.537]	0.5037	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.26.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Eating in Front of Others (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	31 (36.9%)	28 (31.8%)
Deterioration Before Cutoff Date	31 (36.9%)	28 (31.8%)
Number of patients censored	53 (63.1%)	60 (68.2%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	13 (15.5%)	2 (2.3%)
Death	6 (7.1%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	7 (8.3%)	1 (1.1%)
Progressive Disease	20 (23.8%)	43 (48.9%)
Withdrawal By Subject	5 (6.0%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.27.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Dry Mouth (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	39 (46.4%)	44 (50.0%)	
Number of patients censored	45 (53.6%)	44 (50.0%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	4.86 [2.60, 22.64]	2.96 [2.10, 6.64]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.813 [0.517, 1.277]
Log-rank test			
Two-sided stratified log-rank p-value			0.3613

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.27.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Dry Mouth by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	26 (43.3)	10.38 [2.10, NC]	60	31 (51.7)	3.15 [2.33, 9.23]	0.796 [0.472, 1.343]	0.3891	0.7876
>65 years	24	13 (54.2)	3.52 [0.85, 8.51]	28	13 (46.4)	2.53 [1.22, 14.09]	0.902 [0.417, 1.953]	0.7946	
Age Group 2									
<=75 years	81	38 (46.9)	4.86 [2.60, 22.64]	81	41 (50.6)	3.15 [2.33, 7.92]	0.831 [0.534, 1.294]	0.4131	0.9392
>75 years	3	1 (33.3)	NC [0.56, NC]	7	3 (42.9)	1.35 [0.82, NC]	0.859 [0.088, 8.397]	0.8957	
Sex									
Male	52	24 (46.2)	6.11 [1.61, NC]	46	24 (52.2)	2.79 [1.48, 9.23]	0.700 [0.396, 1.235]	0.2146	0.3486
Female	32	15 (46.9)	4.14 [1.38, NC]	42	20 (47.6)	4.17 [1.41, NC]	1.079 [0.551, 2.111]	0.8231	
Region									
Asia	38	19 (50.0)	6.11 [1.41, NC]	41	22 (53.7)	2.96 [1.41, 7.92]	0.733 [0.395, 1.359]	0.3236	0.5785
Non-Asia	46	20 (43.5)	4.86 [2.60, NC]	47	22 (46.8)	2.92 [2.33, 9.23]	0.937 [0.507, 1.732]	0.8348	
Number of Organs with Metastatic Sites									
0-2	64	33 (51.6)	4.53 [2.33, 18.43]	64	33 (51.6)	4.17 [2.73, 9.23]	0.931 [0.574, 1.512]	0.7675	0.2475
>=3	20	6 (30.0)	NC [1.05, NC]	24	11 (45.8)	1.48 [1.41, 7.92]	0.514 [0.190, 1.392]	0.1852	
Prior Gastrectomy (total or partial)									
Yes	24	15 (62.5)	2.60 [0.82, NC]	22	14 (63.6)	5.06 [1.41, 28.68]	1.307 [0.620, 2.757]	0.4903	0.1418
No	60	24 (40.0)	10.38 [3.52, 22.64]	66	30 (45.5)	2.92 [1.48, 6.64]	0.649 [0.378, 1.116]	0.1166	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.27.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Dry Mouth (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	39 (46.4%)	44 (50.0%)
Deterioration Before Cutoff Date	39 (46.4%)	44 (50.0%)
Number of patients censored	45 (53.6%)	44 (50.0%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	8 (9.5%)	3 (3.4%)
Death	6 (7.1%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	1 (1.1%)
Other	5 (6.0%)	0
Progressive Disease	20 (23.8%)	27 (30.7%)
Withdrawal By Subject	4 (4.8%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.28.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Trouble with Taste (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	49 (58.3%)	50 (56.8%)	
Number of patients censored	35 (41.7%)	38 (43.2%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	3.48 [2.76, 4.50]	2.96 [1.51, 5.32]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.009 [0.664, 1.534]
Log-rank test			
Two-sided stratified log-rank p-value			0.9487

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.28.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Trouble with Taste by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	35 (58.3)	3.58 [2.79, 4.57]	60	40 (66.7)	2.40 [1.41, 4.96]	0.735 [0.465, 1.161]	0.1914	0.1602
>65 years	24	14 (58.3)	2.89 [0.79, 6.01]	28	10 (35.7)	5.32 [1.64, NC]	1.513 [0.670, 3.416]	0.3107	
Age Group 2									
<=75 years	81	46 (56.8)	3.58 [2.79, 4.50]	81	47 (58.0)	2.73 [1.45, 5.06]	0.845 [0.561, 1.273]	0.4326	0.3143
>75 years	3	3 (100.0)	0.79 [0.56, NC]	7	3 (42.9)	3.02 [0.79, NC]	1.912 [0.258, 14.140]	0.5287	
Sex									
Male	52	30 (57.7)	3.58 [2.76, 5.09]	46	25 (54.3)	3.02 [1.41, 9.23]	0.822 [0.483, 1.399]	0.4827	0.5207
Female	32	19 (59.4)	2.83 [0.95, 5.32]	42	25 (59.5)	2.33 [1.41, 5.06]	0.984 [0.529, 1.830]	0.9569	
Region									
Asia	38	26 (68.4)	3.01 [1.45, 4.17]	41	27 (65.9)	2.40 [1.41, 4.96]	0.913 [0.532, 1.569]	0.7648	0.9957
Non-Asia	46	23 (50.0)	3.94 [2.79, 18.92]	47	23 (48.9)	3.88 [1.41, 9.23]	0.888 [0.497, 1.588]	0.6925	
Number of Organs with Metastatic Sites									
0-2	64	38 (59.4)	3.22 [2.17, 4.30]	64	36 (56.3)	3.52 [2.23, 9.23]	0.957 [0.605, 1.515]	0.8689	0.4533
>=3	20	11 (55.0)	4.17 [2.14, 5.55]	24	14 (58.3)	1.64 [1.25, 4.96]	0.731 [0.324, 1.650]	0.4444	
Prior Gastrectomy (total or partial)									
Yes	24	17 (70.8)	3.22 [1.45, 4.04]	22	17 (77.3)	3.88 [1.41, 14.09]	1.220 [0.610, 2.440]	0.5651	0.3686
No	60	32 (53.3)	3.94 [2.17, 5.55]	66	33 (50.0)	2.73 [1.41, 6.93]	0.793 [0.483, 1.302]	0.3688	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.28.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Trouble with Taste (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	49 (58.3%)	50 (56.8%)
Deterioration Before Cutoff Date	49 (58.3%)	50 (56.8%)
Number of patients censored	35 (41.7%)	38 (43.2%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	8 (9.5%)	1 (1.1%)
Death	5 (6.0%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	5 (6.0%)	1 (1.1%)
Progressive Disease	12 (14.3%)	22 (25.0%)
Withdrawal By Subject	3 (3.6%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.29.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Body Image (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	36 (42.9%)	40 (45.5%)	
Number of patients censored	48 (57.1%)	48 (54.5%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	6.67 [3.25, 16.36]	4.96 [2.66, 11.73]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.874 [0.544, 1.402]
Log-rank test			
Two-sided stratified log-rank p-value			0.5868

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.29.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Body Image by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	26 (43.3)	8.08 [3.22, 16.36]	60	28 (46.7)	4.96 [2.10, 11.73]	0.813 [0.476, 1.389]	0.4604	0.6955
>65 years	24	10 (41.7)	6.67 [0.92, NC]	28	12 (42.9)	6.01 [1.81, NC]	1.006 [0.433, 2.334]	0.9896	
Age Group 2									
<=75 years	81	34 (42.0)	8.08 [3.25, 16.36]	81	36 (44.4)	6.18 [3.02, 11.96]	0.882 [0.552, 1.410]	0.6102	0.0804
>75 years	3	2 (66.7)	0.74 [0.69, NC]	7	4 (57.1)	1.84 [1.22, NC]	1.69E8 [0.000, NC]	0.0177	
Sex									
Male	52	22 (42.3)	10.87 [3.61, NC]	46	19 (41.3)	6.18 [2.79, 14.09]	0.818 [0.442, 1.513]	0.5225	0.4432
Female	32	14 (43.8)	3.25 [1.74, 8.08]	42	21 (50.0)	3.48 [1.54, 11.96]	1.140 [0.574, 2.264]	0.6953	
Region									
Asia	38	17 (44.7)	10.87 [3.22, NC]	41	23 (56.1)	3.55 [2.10, 7.92]	0.675 [0.360, 1.266]	0.2223	0.2473
Non-Asia	46	19 (41.3)	5.55 [2.33, 8.74]	47	17 (36.2)	9.23 [1.81, NC]	1.156 [0.600, 2.227]	0.6540	
Number of Organs with Metastatic Sites									
0-2	64	28 (43.8)	6.67 [2.37, 16.36]	64	28 (43.8)	6.18 [3.02, 14.09]	1.043 [0.618, 1.762]	0.8772	0.1628
>=3	20	8 (40.0)	6.41 [2.99, NC]	24	12 (50.0)	2.79 [1.41, 7.92]	0.477 [0.193, 1.176]	0.1040	
Prior Gastrectomy (total or partial)									
Yes	24	14 (58.3)	3.45 [2.04, 16.36]	22	10 (45.5)	11.96 [2.66, NC]	1.623 [0.717, 3.676]	0.2405	0.0526
No	60	22 (36.7)	6.67 [3.25, NC]	66	30 (45.5)	3.48 [1.64, 9.23]	0.635 [0.364, 1.108]	0.1098	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.29.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Body Image (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	36 (42.9%)	40 (45.5%)
Deterioration Before Cutoff Date	36 (42.9%)	40 (45.5%)
Number of patients censored	48 (57.1%)	48 (54.5%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	8 (9.5%)	2 (2.3%)
Death	6 (7.1%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	2 (2.4%)	0
Other	7 (8.3%)	2 (2.3%)
Progressive Disease	21 (25.0%)	29 (33.0%)
Withdrawal By Subject	3 (3.6%)	5 (5.7%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.30.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Trouble Swallowing Saliva (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	36 (42.9%)	23 (26.1%)	
Number of patients censored	48 (57.1%)	65 (73.9%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	11.27 [4.86, 19.78]	18.89 [14.75, NC]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.691 [0.978, 2.923]
Log-rank test			
Two-sided stratified log-rank p-value			0.0564

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.30.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Trouble Swallowing Saliva by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	24 (40.0)	11.27 [5.95, 20.60]	60	16 (26.7)	28.68 [11.07, NC]	1.550 [0.821, 2.923]	0.1713	0.7085
>65 years	24	12 (50.0)	4.86 [3.48, NC]	28	7 (25.0)	18.89 [3.61, NC]	1.895 [0.743, 4.833]	0.1724	
Age Group 2									
<=75 years	81	34 (42.0)	11.27 [5.95, 19.78]	81	21 (25.9)	18.89 [14.75, NC]	1.670 [0.967, 2.882]	0.0617	0.8196
>75 years	3	2 (66.7)	4.44 [0.56, NC]	7	2 (28.6)	NC [1.22, NC]	1.414 [0.196, 10.192]	0.7297	
Sex									
Male	52	21 (40.4)	12.45 [5.95, NC]	46	13 (28.3)	28.68 [3.71, NC]	1.226 [0.613, 2.452]	0.5590	0.1497
Female	32	15 (46.9)	6.24 [2.07, 19.78]	42	10 (23.8)	18.89 [11.07, NC]	2.467 [1.105, 5.505]	0.0224	
Region									
Asia	38	20 (52.6)	11.27 [4.17, 20.60]	41	12 (29.3)	18.89 [11.07, NC]	1.661 [0.809, 3.407]	0.1619	0.9812
Non-Asia	46	16 (34.8)	14.62 [4.21, NC]	47	11 (23.4)	28.68 [6.44, NC]	1.725 [0.781, 3.811]	0.1709	
Number of Organs with Metastatic Sites									
0-2	64	30 (46.9)	11.27 [4.47, 19.78]	64	15 (23.4)	18.89 [14.75, NC]	1.942 [1.042, 3.622]	0.0329	0.3046
>=3	20	6 (30.0)	10.61 [1.41, NC]	24	8 (33.3)	11.07 [3.61, NC]	1.023 [0.353, 2.968]	0.9676	
Prior Gastrectomy (total or partial)									
Yes	24	14 (58.3)	4.44 [3.22, 20.60]	22	5 (22.7)	28.68 [14.75, NC]	4.087 [1.340, 12.466]	0.0074	0.0527
No	60	22 (36.7)	11.27 [5.95, 19.78]	66	18 (27.3)	NC [5.06, NC]	1.147 [0.612, 2.150]	0.6621	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.30.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Trouble Swallowing Saliva (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	36 (42.9%)	23 (26.1%)
Deterioration Before Cutoff Date	36 (42.9%)	23 (26.1%)
Number of patients censored	48 (57.1%)	65 (73.9%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	11 (13.1%)	1 (1.1%)
Death	5 (6.0%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	1 (1.1%)
Other	7 (8.3%)	1 (1.1%)
Progressive Disease	21 (25.0%)	48 (54.5%)
Withdrawal By Subject	2 (2.4%)	5 (5.7%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.31.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Choked when Swallowing (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	26 (31.0%)	23 (26.1%)	
Number of patients censored	58 (69.0%)	65 (73.9%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	15.47 [6.93, NC]	NC [9.17, NC]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.052 [0.588, 1.881]
Log-rank test			
Two-sided stratified log-rank p-value			0.8551

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.31.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Choked when Swallowing by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	20 (33.3)	14.32 [5.88, NC]	60	16 (26.7)	NC [9.17, NC]	1.235 [0.638, 2.392]	0.5183	0.4703
>65 years	24	6 (25.0)	NC [4.44, NC]	28	7 (25.0)	NC [3.48, NC]	0.805 [0.270, 2.405]	0.6973	
Age Group 2									
<=75 years	81	25 (30.9)	15.47 [6.93, NC]	81	21 (25.9)	NC [9.17, NC]	1.143 [0.639, 2.046]	0.6436	0.4478
>75 years	3	1 (33.3)	NC [0.56, NC]	7	2 (28.6)	5.09 [0.79, NC]	0.684 [0.061, 7.702]	0.7571	
Sex									
Male	52	15 (28.8)	NC [8.31, NC]	46	16 (34.8)	9.17 [4.83, NC]	0.559 [0.275, 1.138]	0.1068	0.0093
Female	32	11 (34.4)	6.93 [4.47, NC]	42	7 (16.7)	NC [11.07, NC]	2.744 [1.059, 7.107]	0.0302	
Region									
Asia	38	18 (47.4)	8.31 [4.17, NC]	41	13 (31.7)	NC [4.96, NC]	1.345 [0.658, 2.749]	0.4099	0.3279
Non-Asia	46	8 (17.4)	NC [15.47, NC]	47	10 (21.3)	10.94 [9.17, NC]	0.740 [0.289, 1.895]	0.5332	
Number of Organs with Metastatic Sites									
0-2	64	21 (32.8)	14.32 [6.01, NC]	64	17 (26.6)	NC [6.93, NC]	1.116 [0.587, 2.121]	0.7325	0.8413
>=3	20	5 (25.0)	NC [4.17, NC]	24	6 (25.0)	11.07 [4.96, NC]	1.002 [0.305, 3.291]	0.9996	
Prior Gastrectomy (total or partial)									
Yes	24	9 (37.5)	NC [4.40, NC]	22	7 (31.8)	NC [6.93, NC]	1.323 [0.492, 3.557]	0.5732	0.6691
No	60	17 (28.3)	15.47 [6.93, NC]	66	16 (24.2)	NC [5.09, NC]	0.964 [0.482, 1.928]	0.9226	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.31.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Choked when Swallowing (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	26 (31.0%)	23 (26.1%)
Deterioration Before Cutoff Date	26 (31.0%)	23 (26.1%)
Number of patients censored	58 (69.0%)	65 (73.9%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	14 (16.7%)	2 (2.3%)
Death	5 (6.0%)	10 (11.4%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	1 (1.1%)
Other	5 (6.0%)	2 (2.3%)
Progressive Disease	26 (31.0%)	42 (47.7%)
Withdrawal By Subject	6 (7.1%)	7 (8.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.32.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Trouble with Coughing (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	38 (45.2%)	29 (33.0%)	
Number of patients censored	46 (54.8%)	59 (67.0%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	9.46 [5.13, 13.47]	14.09 [9.99, 19.68]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.458 [0.877, 2.423]
Log-rank test			
Two-sided stratified log-rank p-value			0.1449

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.32.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Trouble with Coughing by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	26 (43.3)	10.61 [4.17, 13.47]	60	24 (40.0)	10.32 [5.06, 19.68]	1.150 [0.660, 2.004]	0.6197	0.1610
>65 years	24	12 (50.0)	7.46 [2.17, NC]	28	5 (17.9)	NC [11.56, NC]	2.605 [0.914, 7.423]	0.0636	
Age Group 2									
<=75 years	81	37 (45.7)	9.46 [5.13, 13.47]	81	28 (34.6)	14.09 [6.14, 19.68]	1.396 [0.854, 2.283]	0.1803	0.9520
>75 years	3	1 (33.3)	NC [4.44, NC]	7	1 (14.3)	NC [3.02, NC]	1.225 [0.076, 19.862]	0.8864	
Sex									
Male	52	26 (50.0)	9.46 [4.17, 15.77]	46	15 (32.6)	14.09 [3.75, NC]	1.267 [0.670, 2.395]	0.4634	0.6170
Female	32	12 (37.5)	10.38 [1.71, NC]	42	14 (33.3)	14.75 [9.99, NC]	1.706 [0.777, 3.744]	0.1817	
Region									
Asia	38	16 (42.1)	10.87 [4.44, NC]	41	16 (39.0)	14.09 [6.01, NC]	1.082 [0.540, 2.170]	0.8189	0.3476
Non-Asia	46	22 (47.8)	7.46 [2.17, 11.76]	47	13 (27.7)	17.05 [5.29, NC]	1.697 [0.853, 3.376]	0.1283	
Number of Organs with Metastatic Sites									
0-2	64	31 (48.4)	8.31 [4.44, 13.47]	64	22 (34.4)	14.09 [6.14, NC]	1.566 [0.906, 2.708]	0.1058	0.4001
>=3	20	7 (35.0)	10.61 [3.61, NC]	24	7 (29.2)	17.05 [1.45, NC]	1.078 [0.358, 3.246]	0.8939	
Prior Gastrectomy (total or partial)									
Yes	24	15 (62.5)	8.05 [2.20, 13.47]	22	8 (36.4)	19.68 [9.99, NC]	2.612 [1.088, 6.270]	0.0255	0.0754
No	60	23 (38.3)	10.87 [5.13, 18.92]	66	21 (31.8)	11.56 [5.29, NC]	1.010 [0.553, 1.844]	0.9772	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.32.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Trouble with Coughing (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	38 (45.2%)	29 (33.0%)
Deterioration Before Cutoff Date	38 (45.2%)	29 (33.0%)
Number of patients censored	46 (54.8%)	59 (67.0%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	8 (9.5%)	2 (2.3%)
Death	4 (4.8%)	10 (11.4%)
Lost To Follow-Up	1 (1.2%)	0
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	7 (8.3%)	3 (3.4%)
Progressive Disease	19 (22.6%)	39 (44.3%)
Withdrawal By Subject	6 (7.1%)	5 (5.7%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.33.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Trouble Talking (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	30 (35.7%)	26 (29.5%)	
Number of patients censored	54 (64.3%)	62 (70.5%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	12.42 [7.39, NC]	14.75 [6.44, NC]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.147 [0.670, 1.965]
Log-rank test			
Two-sided stratified log-rank p-value			0.6165

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.33.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Trouble Talking by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	26 (43.3)	8.31 [3.78, 12.88]	60	22 (36.7)	11.07 [5.13, NC]	1.288 [0.730, 2.275]	0.3802	0.7914
>65 years	24	4 (16.7)	NC [12.65, NC]	28	4 (14.3)	NC [6.05, NC]	1.045 [0.261, 4.180]	0.9501	
Age Group 2									
<=75 years	81	30 (37.0)	12.42 [7.39, NC]	81	26 (32.1)	14.75 [6.05, NC]	1.213 [0.717, 2.051]	0.4713	0.9999
>75 years	3	0 (0.0)	NC [NC, NC]	7	0 (0.0)	NC [NC, NC]	NC [NC, NC]	NC	
Sex									
Male	52	19 (36.5)	12.65 [7.39, NC]	46	16 (34.8)	9.23 [4.96, NC]	0.881 [0.452, 1.715]	0.7094	0.1326
Female	32	11 (34.4)	12.42 [3.45, NC]	42	10 (23.8)	14.75 [8.94, NC]	2.012 [0.850, 4.759]	0.1055	
Region									
Asia	38	18 (47.4)	10.35 [5.52, NC]	41	12 (29.3)	NC [6.05, NC]	1.718 [0.827, 3.570]	0.1420	0.2096
Non-Asia	46	12 (26.1)	NC [3.78, NC]	47	14 (29.8)	9.23 [5.52, NC]	0.872 [0.402, 1.890]	0.7253	
Number of Organs with Metastatic Sites									
0-2	64	24 (37.5)	12.42 [6.01, NC]	64	18 (28.1)	NC [6.44, NC]	1.365 [0.740, 2.515]	0.3174	0.5338
>=3	20	6 (30.0)	10.35 [2.99, NC]	24	8 (33.3)	11.07 [4.96, NC]	0.977 [0.338, 2.825]	0.9664	
Prior Gastrectomy (total or partial)									
Yes	24	12 (50.0)	5.52 [2.89, NC]	22	7 (31.8)	NC [3.48, NC]	1.836 [0.720, 4.681]	0.1977	0.1994
No	60	18 (30.0)	12.65 [10.35, NC]	66	19 (28.8)	11.07 [5.65, NC]	0.933 [0.488, 1.784]	0.8330	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.33.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Trouble Talking (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	30 (35.7%)	26 (29.5%)
Deterioration Before Cutoff Date	30 (35.7%)	26 (29.5%)
Number of patients censored	54 (64.3%)	62 (70.5%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	13 (15.5%)	2 (2.3%)
Death	5 (6.0%)	10 (11.4%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	1 (1.1%)
Other	6 (7.1%)	3 (3.4%)
Progressive Disease	22 (26.2%)	40 (45.5%)
Withdrawal By Subject	6 (7.1%)	5 (5.7%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.34.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Weight Loss (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	38 (45.2%)	36 (40.9%)	
Number of patients censored	46 (54.8%)	52 (59.1%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	6.93 [3.15, 17.02]	6.28 [2.23, NC]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.901 [0.562, 1.442]
Log-rank test			
Two-sided stratified log-rank p-value			0.6778

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.34.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Weight Loss by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	25 (41.7)	8.05 [5.55, NC]	60	26 (43.3)	5.09 [2.23, NC]	0.744 [0.428, 1.292]	0.2954	0.2051
>65 years	24	13 (54.2)	2.71 [1.22, NC]	28	10 (35.7)	14.09 [0.92, NC]	1.294 [0.557, 3.005]	0.5465	
Age Group 2									
<=75 years	81	36 (44.4)	7.39 [3.25, 17.02]	81	33 (40.7)	6.28 [2.33, NC]	0.912 [0.567, 1.465]	0.7169	0.5862
>75 years	3	2 (66.7)	1.53 [0.79, NC]	7	3 (42.9)	1.35 [0.82, NC]	1.419 [0.226, 8.903]	0.7073	
Sex									
Male	52	26 (50.0)	8.05 [2.10, 28.09]	46	20 (43.5)	6.28 [1.45, 14.09]	0.903 [0.503, 1.620]	0.7424	0.8809
Female	32	12 (37.5)	6.93 [3.15, NC]	42	16 (38.1)	5.09 [1.41, NC]	0.883 [0.414, 1.884]	0.7563	
Region									
Asia	38	17 (44.7)	10.87 [2.10, NC]	41	18 (43.9)	6.28 [1.48, NC]	0.816 [0.419, 1.589]	0.5512	0.6754
Non-Asia	46	21 (45.7)	5.55 [2.17, 28.09]	47	18 (38.3)	8.71 [1.41, NC]	1.046 [0.556, 1.969]	0.8828	
Number of Organs with Metastatic Sites									
0-2	64	32 (50.0)	6.93 [2.27, 16.36]	64	26 (40.6)	8.71 [2.33, NC]	1.051 [0.626, 1.767]	0.8401	0.2159
>=3	20	6 (30.0)	NC [2.10, NC]	24	10 (41.7)	5.06 [0.92, NC]	0.549 [0.199, 1.514]	0.2474	
Prior Gastrectomy (total or partial)									
Yes	24	17 (70.8)	3.25 [2.04, 8.05]	22	9 (40.9)	14.09 [1.48, NC]	2.001 [0.887, 4.515]	0.0845	0.0102
No	60	21 (35.0)	28.09 [3.45, NC]	66	27 (40.9)	5.06 [1.41, 9.23]	0.598 [0.332, 1.075]	0.0844	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.34.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Weight Loss (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	38 (45.2%)	36 (40.9%)
Deterioration Before Cutoff Date	38 (45.2%)	36 (40.9%)
Number of patients censored	46 (54.8%)	52 (59.1%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	6 (7.1%)	2 (2.3%)
Death	5 (6.0%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	2 (2.4%)	0
Other	4 (4.8%)	0
Progressive Disease	24 (28.6%)	36 (40.9%)
Withdrawal By Subject	4 (4.8%)	4 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.35.2.1: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Hair Loss (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	10 (11.9%)	8 (9.1%)	
Number of patients censored	74 (88.1%)	80 (90.9%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	23.03 [4.57, NC]	6.67 [1.54, NC]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.408 [0.132, 1.257]
Log-rank test			
Two-sided stratified log-rank p-value			0.1083

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.35.2.2: EORTC QLQ-OG25 - Summary of Time to First Deterioration of Hair Loss by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	6 (10.0)	NC [4.57, NC]	60	5 (8.3)	6.67 [1.54, NC]	0.369 [0.106, 1.289]	0.1043	0.9366
>65 years	24	4 (16.7)	23.03 [0.43, NC]	28	3 (10.7)	2.79 [1.41, NC]	0.560 [0.112, 2.799]	0.4752	
Age Group 2									
<=75 years	81	10 (12.3)	23.03 [4.57, NC]	81	8 (9.9)	6.67 [1.54, NC]	0.401 [0.148, 1.082]	0.0622	NC
>75 years	3	0 (0.0)	NC [NC, NC]	7	0 (0.0)	NC [NC, NC]	NC [NC, NC]	NC	
Sex									
Male	52	6 (11.5)	23.03 [1.38, NC]	46	5 (10.9)	1.61 [1.41, NC]	0.486 [0.138, 1.713]	0.2516	0.5184
Female	32	4 (12.5)	11.53 [3.58, NC]	42	3 (7.1)	8.54 [6.67, NC]	0.591 [0.115, 3.028]	0.5239	
Region									
Asia	38	5 (13.2)	23.03 [3.58, NC]	41	6 (14.6)	2.79 [0.72, NC]	0.197 [0.054, 0.717]	0.0066	0.0522
Non-Asia	46	5 (10.9)	5.55 [0.43, NC]	47	2 (4.3)	9.00 [1.61, NC]	1.234 [0.225, 6.774]	0.8084	
Number of Organs with Metastatic Sites									
0-2	64	8 (12.5)	23.03 [3.58, NC]	64	5 (7.8)	8.54 [1.61, NC]	0.505 [0.153, 1.674]	0.2552	0.1066
>=3	20	2 (10.0)	NC [1.41, NC]	24	3 (12.5)	1.41 [0.72, NC]	0.103 [0.010, 1.069]	0.0256	
Prior Gastrectomy (total or partial)									
Yes	24	6 (25.0)		22	3 (13.6)				
No	60	4 (6.7)		66	5 (7.6)				

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.35.2.3: EORTC QLQ-OG25 - Type of Events and Censoring for Time to First Deterioration of Hair Loss (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	10 (11.9%)	8 (9.1%)
Deterioration Before Cutoff Date	10 (11.9%)	8 (9.1%)
Number of patients censored	74 (88.1%)	80 (90.9%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	13 (15.5%)	4 (4.5%)
Death	6 (7.1%)	11 (12.5%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	4 (4.8%)	1 (1.1%)
Other	9 (10.7%)	2 (2.3%)
Progressive Disease	35 (41.7%)	55 (62.5%)
Withdrawal By Subject	6 (7.1%)	6 (6.8%)


Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EORTC QLQ-OG25


4. Graphische Darstellung des Verlaufs (Mean Change from Baseline)

Figure 302.3.3002.20.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Dysphagia - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.21.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Eating Restrictions - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.22.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Reflux - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.23.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Odynophagia - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.24.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Pain and Discomfort - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.25.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Anxiety - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.26.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Eating in Front of Others - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.27.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Dry Mouth - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.28.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Trouble with Taste - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.29.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Body Image - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.30.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Trouble Swallowing Saliva - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.31.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Choked when Swallowing Score - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.32.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Trouble with Coughing - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.33.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Trouble Talking - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.34.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Weight Loss - Modified Full Analysis Set (CPS < 1)



Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Figure 302.3.3002.35.2: EORTC QLQ-OG25 - Plot of Mean Change from Baseline of Hair Loss - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer
oesophago-gastric module 25; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EORTC QLQ-OG25

5. Kaplan-Meier-Plots

Figure 302.3.3003.20.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Dysphagia (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	25 (26.2)	10 (36.9)	9 (38.1)	4 (40.5)	1 (44.0)	0 (45.2)	0 (45.2)	0 (45.2)
2	88 (0.0)	26 (33.0)	6 (50.0)	1 (53.4)	0 (54.5)	0 (54.5)	0 (54.5)	0 (54.5)	0 (54.5)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.21.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Eating Restrictions (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	28 (31.0)	11 (46.4)	6 (50.0)	3 (52.4)	0 (54.8)	0 (54.8)	0 (54.8)	0 (54.8)
2	88 (0.0)	31 (35.2)	8 (51.1)	4 (55.7)	3 (56.8)	0 (59.1)	0 (59.1)	0 (59.1)	0 (59.1)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.22.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Reflux (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	21 (28.6)	10 (38.1)	5 (41.7)	3 (42.9)	0 (46.4)	0 (46.4)	0 (46.4)	0 (46.4)
2	88 (0.0)	22 (34.1)	4 (52.3)	1 (54.5)	0 (54.5)	0 (54.5)	0 (54.5)	0 (54.5)	0 (54.5)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.23.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Odynophagia (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	27 (36.9)	13 (47.6)	8 (53.6)	4 (58.3)	2 (60.7)	0 (63.1)	0 (63.1)	0 (63.1)
2	88 (0.0)	22 (37.5)	5 (50.0)	2 (51.1)	2 (51.1)	0 (52.3)	0 (52.3)	0 (52.3)	0 (52.3)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.23.2.4: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Odynophagia by Region (MID=10) - Modified Full Analysis Set (CPS < 1)
Region: Asia



# at Risk									
1	38 (0.0)	12 (18.4)	6 (26.3)	4 (31.6)	2 (36.8)	1 (39.5)	0 (42.1)	0 (42.1)	0 (42.1)
2	41 (0.0)	10 (36.6)	3 (51.2)	1 (53.7)	1 (53.7)	0 (56.1)	0 (56.1)	0 (56.1)	0 (56.1)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.23.2.4: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Odynophagia by Region (MID=10) - Modified Full Analysis Set (CPS < 1) Region: Non-Asia



at Risk

1	46 (0.0)	15 (52.2)	7 (65.2)	4 (71.7)	2 (76.1)	1 (78.3)	0 (80.4)	0 (80.4)	0 (80.4)
2	47 (0.0)	12 (38.3)	2 (48.9)	1 (48.9)	1 (48.9)	0 (48.9)	0 (48.9)	0 (48.9)	0 (48.9)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.24.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Pain and Discomfort (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	29 (31.0)	12 (46.4)	6 (48.8)	3 (50.0)	2 (51.2)	0 (53.6)	0 (53.6)	0 (53.6)
2	88 (0.0)	23 (31.8)	7 (44.3)	2 (47.7)	1 (48.9)	0 (50.0)	0 (50.0)	0 (50.0)	0 (50.0)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.25.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Anxiety (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	15 (34.5)	9 (41.7)	3 (44.0)	2 (45.2)	1 (46.4)	1 (46.4)	0 (47.6)	0 (47.6)
2	88 (0.0)	17 (40.9)	3 (52.3)	1 (53.4)	1 (53.4)	0 (54.5)	0 (54.5)	0 (54.5)	0 (54.5)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.25.2.6: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Anxiety by Prior Gastrectomy (total or partial) (MID=10) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): Yes



	# at Risk								
1	24 (0.0)	3 (12.5)	1 (20.8)	1 (20.8)	1 (20.8)	0 (25.0)	0 (25.0)	0 (25.0)	0 (25.0)
2	22 (0.0)	7 (27.3)	2 (40.9)	1 (40.9)	1 (40.9)	0 (45.5)	0 (45.5)	0 (45.5)	0 (45.5)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.25.2.6: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Anxiety by Prior Gastrectomy (total or partial) (MID=10) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): No



at Risk

1	60 (0.0)	12 (43.3)	8 (50.0)	2 (53.3)	1 (55.0)	1 (55.0)	1 (55.0)	0 (56.7)	0 (56.7)
2	66 (0.0)	10 (45.5)	1 (56.1)	0 (57.6)	0 (57.6)	0 (57.6)	0 (57.6)	0 (57.6)	0 (57.6)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.26.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Eating in Front of Others (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	32 (35.7)	16 (51.2)	7 (54.8)	3 (59.5)	1 (61.9)	1 (61.9)	0 (63.1)	0 (63.1)
2	88 (0.0)	30 (40.9)	7 (60.2)	3 (64.8)	3 (64.8)	0 (68.2)	0 (68.2)	0 (68.2)	0 (68.2)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.27.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Dry Mouth (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	24 (31.0)	11 (42.9)	5 (50.0)	2 (51.2)	1 (52.4)	1 (52.4)	0 (53.6)	0 (53.6)
2	88 (0.0)	20 (33.0)	7 (44.3)	3 (47.7)	3 (47.7)	1 (48.9)	0 (50.0)	0 (50.0)	0 (50.0)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.28.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Trouble with Taste (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	15 (27.4)	7 (35.7)	6 (36.9)	3 (38.1)	0 (41.7)	0 (41.7)	0 (41.7)	0 (41.7)
2	88 (0.0)	18 (30.7)	7 (39.8)	1 (43.2)	1 (43.2)	0 (43.2)	0 (43.2)	0 (43.2)	0 (43.2)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.29.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Body Image (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	26 (34.5)	8 (48.8)	5 (51.2)	3 (53.6)	1 (56.0)	0 (57.1)	0 (57.1)	0 (57.1)
2	88 (0.0)	23 (36.4)	7 (47.7)	4 (50.0)	3 (51.1)	0 (54.5)	0 (54.5)	0 (54.5)	0 (54.5)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.30.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Trouble Swallowing Saliva (MID=10) - Modified Full Analysis Set (CPS < 1)



	# at Risk								
1	84 (0.0)	33 (29.8)	14 (46.4)	9 (48.8)	4 (52.4)	1 (56.0)	1 (56.0)	0 (57.1)	0 (57.1)
2	88 (0.0)	37 (37.5)	14 (61.4)	6 (69.3)	4 (70.5)	1 (72.7)	0 (73.9)	0 (73.9)	0 (73.9)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.31.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Choked when Swallowing (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	32 (38.1)	16 (53.6)	8 (59.5)	4 (64.3)	0 (69.0)	0 (69.0)	0 (69.0)	0 (69.0)
2	88 (0.0)	33 (42.0)	8 (64.8)	4 (69.3)	3 (70.5)	1 (72.7)	0 (73.9)	0 (73.9)	0 (73.9)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.31.2.3: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Choked when Swallowing by Sex (MID=10) - Modified Full Analysis Set (CPS < 1)

Sex: Male



at Risk

1	52 (0.0)	22 (34.6)	12 (51.9)	6 (59.6)	3 (65.4)	0 (71.2)	0 (71.2)	0 (71.2)	0 (71.2)
2	46 (0.0)	12 (45.7)	3 (58.7)	1 (63.0)	0 (65.2)	0 (65.2)	0 (65.2)	0 (65.2)	0 (65.2)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.31.2.3: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Choked when Swallowing by Sex (MID=10) - Modified Full Analysis Set (CPS < 1)

Sex: Female



at Risk

1	32 (0.0)	10 (43.8)	4 (56.3)	2 (59.4)	1 (62.5)	0 (65.6)	0 (65.6)	0 (65.6)	0 (65.6)
2	42 (0.0)	21 (38.1)	5 (71.4)	3 (76.2)	3 (76.2)	1 (81.0)	0 (83.3)	0 (83.3)	0 (83.3)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.32.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Trouble with Coughing (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	35 (27.4)	11 (45.2)	5 (50.0)	3 (51.2)	0 (54.8)	0 (54.8)	0 (54.8)	0 (54.8)
2	88 (0.0)	35 (37.5)	13 (56.8)	4 (63.6)	2 (64.8)	0 (67.0)	0 (67.0)	0 (67.0)	0 (67.0)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.33.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Trouble Talking (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	34 (33.3)	13 (52.4)	6 (57.1)	3 (60.7)	0 (64.3)	0 (64.3)	0 (64.3)	0 (64.3)
2	88 (0.0)	36 (36.4)	12 (58.0)	5 (64.8)	3 (67.0)	1 (69.3)	0 (70.5)	0 (70.5)	0 (70.5)


Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.34.2: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Weight Loss (MID=10) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	29 (31.0)	13 (42.9)	7 (47.6)	3 (52.4)	1 (53.6)	0 (54.8)	0 (54.8)	0 (54.8)
2	88 (0.0)	24 (36.4)	7 (52.3)	3 (55.7)	3 (55.7)	0 (59.1)	0 (59.1)	0 (59.1)	0 (59.1)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.34.2.6: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Weight Loss by Prior Gastrectomy (total or partial) (MID=10) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): Yes



at Risk

1	24 (0.0)	9 (16.7)	3 (25.0)	1 (25.0)	0 (29.2)	0 (29.2)	0 (29.2)	0 (29.2)	0 (29.2)
2	22 (0.0)	10 (18.2)	6 (36.4)	3 (45.5)	3 (45.5)	0 (59.1)	0 (59.1)	0 (59.1)	0 (59.1)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.34.2.6: EORTC QLQ-OG25 - Kaplan-Meier Plot of Time to First Deterioration of Weight Loss by Prior Gastrectomy (total or partial) (MID=10) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): No



# at Risk									
1	60 (0.0)	20 (36.7)	10 (50.0)	6 (56.7)	3 (61.7)	1 (63.3)	0 (65.0)	0 (65.0)	0 (65.0)
2	66 (0.0)	14 (42.4)	1 (57.6)	0 (59.1)	0 (59.1)	0 (59.1)	0 (59.1)	0 (59.1)	0 (59.1)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte

Anhang 4-G Symptomatik anhand des EORTC QLQ-STO22 (Belching-Subskala)

1. Rücklaufquoten

Table 302.3.3001.36.2: EORTC QLQ-STO22 - Completion Status of Belching
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	80/ 87 (92.0%)	80/ 88 (90.9%)	80/ 88 (90.9%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	41/ 46 (89.1%)	44/ 67 (65.7%)	44/ 84 (52.4%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	39/ 41 (95.1%)	40/ 65 (61.5%)	41/ 84 (48.8%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; FAS=full analysis set; N=number of patients; PRO=patient reported outcome; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.36.2: EORTC QLQ-STO22 - Completion Status of Belching
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; FAS=full analysis set; N=number of patients; PRO=patient reported outcome; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.36.2: EORTC QLQ-STO22 - Completion Status of Belching
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; FAS=full analysis set; N=number of patients; PRO=patient reported outcome; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EORTC QLQ-STO22 (Belching-Subskala)

2. Verlauf über die Zeit (Observed Means and Change from Baseline)

Table 302.3.3002.36.2: EORTC QLQ-STO22 - Observed Means and Change from Baseline of Belching
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	14.96	20.21	0.0	0.00	66.7						
Cycle 2 Day 1	69	10.39	16.44	0.0	0.00	83.3	68	-3.43	19.44	-66.7	0.00	50.0
Cycle 3 Day 1	61	13.93	21.56	0.0	0.00	100.0	60	0.56	22.75	-66.7	0.00	100.0
Cycle 4 Day 1	56	11.61	16.49	0.0	0.00	66.7	56	0.00	17.98	-50.0	0.00	50.0
Cycle 5 Day 1	55	13.64	19.53	0.0	0.00	100.0	54	2.16	18.04	-33.3	0.00	66.7
Cycle 6 Day 1	55	12.42	17.63	0.0	0.00	50.0	55	-0.61	16.66	-33.3	0.00	33.3
Cycle 7 Day 1	44	11.74	16.31	0.0	0.00	50.0	44	0.00	17.97	-33.3	0.00	33.3
Cycle 8 Day 1	41	13.01	21.57	0.0	0.00	83.3	39	-2.14	21.69	-50.0	0.00	66.7
Cycle 9 Day 1	38	15.35	22.39	0.0	0.00	83.3	37	0.90	19.22	-50.0	0.00	33.3
Cycle 10 Day 1	34	13.24	19.58	0.0	0.00	83.3	33	0.51	18.39	-33.3	0.00	50.0
Cycle 11 Day 1	31	11.29	18.95	0.0	0.00	66.7	30	-2.78	15.21	-33.3	0.00	33.3
Cycle 12 Day 1	31	10.75	15.84	0.0	0.00	50.0	30	-1.11	14.47	-33.3	0.00	33.3
Cycle 13 Day 1	26	11.54	16.85	0.0	0.00	50.0	25	1.33	19.20	-33.3	0.00	50.0
Cycle 14 Day 1	22	9.09	15.19	0.0	0.00	50.0	21	2.38	14.23	-16.7	0.00	33.3
Cycle 15 Day 1	23	10.87	17.84	0.0	0.00	50.0	22	-1.52	13.52	-33.3	0.00	33.3
Cycle 16 Day 1	24	8.33	13.90	0.0	0.00	50.0	23	-5.07	16.23	-50.0	0.00	16.7
Cycle 17 Day 1	21	7.94	12.49	0.0	0.00	33.3	20	-5.83	17.33	-50.0	0.00	16.7
Cycle 18 Day 1	21	12.70	22.30	0.0	0.00	66.7	20	-0.83	12.65	-33.3	0.00	33.3
Cycle 19 Day 1	21	11.90	23.06	0.0	0.00	83.3	20	-1.67	14.20	-33.3	0.00	16.7
Cycle 20 Day 1	19	15.79	26.34	0.0	0.00	83.3	18	1.85	13.87	-33.3	0.00	16.7
Cycle 21 Day 1	18	13.89	26.97	0.0	0.00	83.3	17	0.98	12.46	-33.3	0.00	16.7
Cycle 22 Day 1	15	8.89	18.76	0.0	0.00	66.7	14	0.00	11.32	-33.3	0.00	16.7
Cycle 23 Day 1	15	6.67	21.64	0.0	0.00	83.3	14	-2.38	11.05	-33.3	0.00	16.7
Cycle 24 Day 1	14	2.38	8.91	0.0	0.00	33.3	13	-2.56	11.48	-33.3	0.00	16.7
Cycle 25 Day 1	14	3.57	9.65	0.0	0.00	33.3	13	-1.28	10.68	-33.3	0.00	16.7

Abbreviations: CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.36.2: EORTC QLQ-STO22 - Observed Means and Change from Baseline of Belching
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	2.78	6.49	0.0	0.00	16.7	11	-1.52	11.68	-33.3	0.00	16.7
Cycle 27 Day 1	13	5.13	10.51	0.0	0.00	33.3	12	0.00	12.31	-33.3	0.00	16.7
Cycle 28 Day 1	11	13.64	29.64	0.0	0.00	100.0	10	1.67	16.57	-33.3	0.00	33.3
Cycle 29 Day 1	11	9.09	17.26	0.0	0.00	50.0	10	-1.67	14.59	-33.3	0.00	16.7
Cycle 30 Day 1	10	10.00	21.08	0.0	0.00	66.7	9	-1.85	13.03	-33.3	0.00	16.7
Cycle 31 Day 1	10	11.67	22.29	0.0	0.00	66.7	9	0.00	14.43	-33.3	0.00	16.7
Cycle 32 Day 1	10	13.33	26.99	0.0	0.00	83.3	9	1.85	15.47	-33.3	0.00	16.7
Study Disc 1	48	12.15	23.25	0.0	0.00	83.3	48	1.04	19.27	-50.0	0.00	66.7
30 D SFU Z/P	22	14.39	22.00	0.0	0.00	83.3	22	-1.52	15.35	-33.3	0.00	33.3
90 D SFU Z/P	23	8.70	14.97	0.0	0.00	50.0	23	-3.62	18.09	-50.0	0.00	33.3
Placebo + CAPOX (N= 88)												
Baseline	80	15.42	23.54	0.0	0.00	100.0						
Cycle 2 Day 1	73	12.56	18.59	0.0	0.00	100.0	69	-3.14	15.47	-50.0	0.00	16.7
Cycle 3 Day 1	64	12.24	17.38	0.0	0.00	83.3	62	-1.88	19.58	-83.3	0.00	33.3
Cycle 4 Day 1	56	11.31	16.24	0.0	0.00	66.7	56	-2.38	20.94	-83.3	0.00	33.3
Cycle 5 Day 1	57	9.06	16.39	0.0	0.00	66.7	57	-5.26	18.68	-83.3	0.00	33.3
Cycle 6 Day 1	48	10.76	17.01	0.0	0.00	66.7	48	-5.21	22.06	-66.7	0.00	50.0
Cycle 7 Day 1	41	6.50	12.29	0.0	0.00	33.3	41	-9.76	19.71	-83.3	0.00	16.7
Cycle 8 Day 1	37	10.36	18.57	0.0	0.00	66.7	37	-7.21	21.35	-83.3	0.00	33.3
Cycle 9 Day 1	35	6.19	13.46	0.0	0.00	50.0	35	-10.95	22.49	-83.3	0.00	16.7
Cycle 10 Day 1	30	8.33	15.00	0.0	0.00	50.0	29	-6.90	17.55	-50.0	0.00	33.3
Cycle 11 Day 1	27	6.79	11.56	0.0	0.00	33.3	27	-12.35	22.92	-83.3	0.00	16.7
Cycle 12 Day 1	26	10.90	18.22	0.0	0.00	66.7	25	-7.33	23.11	-83.3	0.00	33.3
Cycle 13 Day 1	22	11.36	22.65	0.0	0.00	100.0	21	-4.76	21.82	-83.3	0.00	16.7
Cycle 14 Day 1	21	11.90	19.11	0.0	0.00	66.7	20	0.00	13.25	-16.7	0.00	33.3
Cycle 15 Day 1	18	11.11	18.08	0.0	0.00	66.7	17	-0.98	10.98	-16.7	0.00	16.7

Abbreviations: CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.36.2: EORTC QLQ-STO22 - Observed Means and Change from Baseline of Belching
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	6.86	14.50	0.0	0.00	50.0	16	-6.25	18.13	-50.0	0.00	16.7
Cycle 17 Day 1	13	1.28	4.62	0.0	0.00	16.7	11	-4.55	10.78	-33.3	0.00	0.0
Cycle 18 Day 1	10	8.33	14.16	0.0	0.00	33.3	9	1.85	21.15	-33.3	0.00	33.3
Study Disc 1	51	16.67	27.08	0.0	0.00	100.0	46	4.35	27.98	-66.7	0.00	100.0
30 D SFU Z/P	27	16.67	24.46	0.0	0.00	100.0	25	-0.67	18.31	-50.0	0.00	33.3
90 D SFU Z/P	30	11.67	22.81	0.0	0.00	100.0	29	-5.75	21.95	-66.7	0.00	50.0

Abbreviations: CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median;
Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EORTC QLQ-STO22 (Belching-Subskala)

3. Time-to-Event-Analysen - Zeit bis zur ersten Verschlechterung

Table 302.3.3003.36.2.1: EORTC QLQ-STO22 - Summary of Time to First Deterioration of Belching (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	38 (45.2%)	38 (43.2%)	
Number of patients censored	46 (54.8%)	50 (56.8%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	5.49 [2.79, 18.23]	7.52 [2.92, 23.72]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.063 [0.659, 1.712]
Log-rank test			
Two-sided stratified log-rank p-value			0.7892

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.36.2.2: EORTC QLQ-STO22 - Summary of Time to First Deterioration of Belching by Subgroups (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	28 (46.7)	5.49 [2.79, 18.23]	60	30 (50.0)	6.97 [2.23, 9.23]	0.958 [0.571, 1.606]	0.8856	0.3196
>65 years	24	10 (41.7)	NC [1.45, NC]	28	8 (28.6)	14.09 [1.48, NC]	1.435 [0.563, 3.661]	0.4419	
Age Group 2									
<=75 years	81	36 (44.4)	5.49 [2.99, 18.69]	81	35 (43.2)	8.34 [3.02, 23.72]	1.088 [0.682, 1.735]	0.7109	0.6149
>75 years	3	2 (66.7)	0.69 [0.56, NC]	7	3 (42.9)	2.14 [1.22, NC]	1.510 [0.245, 9.309]	0.6552	
Sex									
Male	52	24 (46.2)	4.83 [2.79, NC]	46	25 (54.3)	2.23 [1.48, 8.34]	0.644 [0.367, 1.128]	0.1244	0.0182
Female	32	14 (43.8)	5.49 [0.95, 18.23]	42	13 (31.0)	23.72 [6.97, NC]	2.049 [0.958, 4.383]	0.0564	
Region									
Asia	38	21 (55.3)	3.37 [1.54, NC]	41	17 (41.5)	14.09 [2.79, NC]	1.490 [0.785, 2.827]	0.2146	0.1496
Non-Asia	46	17 (37.0)	8.74 [2.99, 18.23]	47	21 (44.7)	6.97 [1.45, 9.23]	0.801 [0.420, 1.528]	0.5051	
Number of Organs with Metastatic Sites									
0-2	64	33 (51.6)	3.48 [2.07, 18.23]	64	27 (42.2)	8.34 [3.02, NC]	1.313 [0.788, 2.187]	0.2855	0.0941
>=3	20	5 (25.0)	NC [2.99, NC]	24	11 (45.8)	6.97 [1.25, NC]	0.521 [0.177, 1.530]	0.2250	
Prior Gastrectomy (total or partial)									
Yes	24	17 (70.8)	3.22 [1.45, 5.49]	22	9 (40.9)	14.09 [1.64, NC]	2.324 [1.019, 5.304]	0.0388	0.0095
No	60	21 (35.0)	18.23 [3.45, NC]	66	29 (43.9)	6.97 [2.23, 9.23]	0.693 [0.393, 1.223]	0.2076	

Abbreviations: CI=confidence interval; CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.36.2.3: EORTC QLQ-STO22 - Type of Events and Censoring for Time to First Deterioration of Belching (MID=10)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	38 (45.2%)	38 (43.2%)
Deterioration Before Cutoff Date	38 (45.2%)	38 (43.2%)
Number of patients censored	46 (54.8%)	50 (56.8%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	10 (11.9%)	2 (2.3%)
Death	6 (7.1%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	0
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	1 (1.1%)
Other	4 (4.8%)	1 (1.1%)
Progressive Disease	21 (25.0%)	32 (36.4%)
Withdrawal By Subject	3 (3.6%)	5 (5.7%)


Abbreviations: CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EORTC QLQ-STO22 (Belching-Subskala)

4. Graphische Darstellung des Verlaufs (Mean Change from Baseline)

Figure 302.3.3002.36.2: EORTC QLQ-STO22 - Plot of Mean Change from Baseline of Belching - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer
gastric cancer module; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EORTC QLQ-STO22 (Belching-Subskala)

5. Kaplan-Meier-Plots

Figure 302.3.3003.36.2: EORTC QLQ-STO22 - Kaplan-Meier Plot of Time to First Deterioration of Belching (MID=10) - Modified Full Analysis Set (CPS < 1)



# at Risk									
1	84 (0.0)	22 (33.3)	8 (48.8)	5 (51.2)	2 (52.4)	0 (54.8)	0 (54.8)	0 (54.8)	0 (54.8)
2	88 (0.0)	32 (29.5)	9 (48.9)	5 (52.3)	3 (53.4)	1 (55.7)	0 (56.8)	0 (56.8)	0 (56.8)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.36.2.3: EORTC QLQ-STO22 - Kaplan-Meier Plot of Time to First Deterioration of Belching by Sex (MID=10) - Modified Full Analysis Set (CPS < 1)

Sex: Male



at Risk

1	52 (0.0)	14 (30.8)	5 (46.2)	3 (50.0)	1 (51.9)	0 (53.8)	0 (53.8)	0 (53.8)	0 (53.8)
2	46 (0.0)	12 (28.3)	4 (39.1)	1 (43.5)	1 (43.5)	0 (45.7)	0 (45.7)	0 (45.7)	0 (45.7)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.36.2.3: EORTC QLQ-STO22 - Kaplan-Meier Plot of Time to First Deterioration of Belching by Sex (MID=10) - Modified Full Analysis Set (CPS < 1)

Sex: Female



# at Risk									
1	32 (0.0)	8 (37.5)	3 (53.1)	2 (53.1)	1 (53.1)	0 (56.3)	0 (56.3)	0 (56.3)	0 (56.3)
2	42 (0.0)	20 (31.0)	5 (59.5)	4 (61.9)	2 (64.3)	1 (66.7)	0 (69.0)	0 (69.0)	0 (69.0)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.36.2.6: EORTC QLQ-STO22 - Kaplan-Meier Plot of Time to First Deterioration of Belching by Prior Gastrectomy (total or partial) (MID=10) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): Yes



Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.36.2.6: EORTC QLQ-STO22 - Kaplan-Meier Plot of Time to First Deterioration of Belching by Prior Gastrectomy (total or partial) (MID=10) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): No



at Risk

1	60 (0.0)	18 (40.0)	7 (58.3)	4 (61.7)	1 (63.3)	0 (65.0)	0 (65.0)	0 (65.0)	0 (65.0)
2	66 (0.0)	21 (34.8)	2 (54.5)	1 (56.1)	0 (56.1)	0 (56.1)	0 (56.1)	0 (56.1)	0 (56.1)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 10 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte

Anhang 4-G Schmerzintensität anhand der NRS

1. Rücklaufquoten

Table 302.3.3001.4.2: Global Pain(GP) - Completion Status of PI01 - Pain Intensity
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	79/ 87 (90.8%)	79/ 88 (89.8%)	79/ 88 (89.8%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	58/ 65 (89.2%)	59/ 74 (79.7%)	59/ 84 (70.2%)	63/ 70 (90.0%)	63/ 79 (79.7%)	63/ 88 (71.6%)
Cycle 4 Day 1	55/ 62 (88.7%)	56/ 73 (76.7%)	56/ 84 (66.7%)	55/ 64 (85.9%)	56/ 79 (70.9%)	56/ 88 (63.6%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	39/ 46 (84.8%)	42/ 67 (62.7%)	42/ 84 (50.0%)	40/ 48 (83.3%)	41/ 74 (55.4%)	41/ 88 (46.6%)
Cycle 8 Day 1	37/ 41 (90.2%)	38/ 65 (58.5%)	39/ 84 (46.4%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	28/ 32 (87.5%)	29/ 74 (39.2%)	29/ 88 (33.0%)
Cycle 11 Day 1	31/ 34 (91.2%)	31/ 63 (49.2%)	31/ 84 (36.9%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.4.2: Global Pain(GP) - Completion Status of PI01 - Pain Intensity
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.4.2: Global Pain(GP) - Completion Status of PI01 - Pain Intensity
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	54/ 75 (72.0%)	54/ 76 (71.1%)	54/ 88 (61.4%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	27/ 70 (38.6%)	27/ 71 (38.0%)	27/ 88 (30.7%)
90 D SFU Z/P	23/ 60 (38.3%)	23/ 66 (34.8%)	23/ 84 (27.4%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Schmerzintensität anhand der NRS

2. Verlauf über die Zeit (Observed Means and Change from Baseline)

Table 302.3.3002.4.2: Global Pain(GP) - Observed Means and Change from Baseline of PI01 - Pain Intensity
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	2.68	2.26	0.0	2.00	8.0						
Cycle 2 Day 1	69	1.72	2.07	0.0	1.00	8.0	68	-0.94	2.59	-8.0	0.00	7.0
Cycle 3 Day 1	59	2.07	2.77	0.0	1.00	9.0	58	-0.59	2.90	-8.0	-1.00	8.0
Cycle 4 Day 1	56	1.98	2.61	0.0	1.00	9.0	56	-0.59	2.62	-7.0	-1.00	6.0
Cycle 5 Day 1	55	2.02	2.77	0.0	0.00	10.0	54	-0.43	2.97	-8.0	0.00	6.0
Cycle 6 Day 1	55	1.98	2.68	0.0	1.00	10.0	55	-0.62	2.90	-7.0	0.00	9.0
Cycle 7 Day 1	42	1.98	2.60	0.0	1.00	9.0	42	-0.64	3.03	-6.0	-0.50	9.0
Cycle 8 Day 1	39	1.92	2.14	0.0	1.00	7.0	37	-0.73	2.59	-7.0	0.00	6.0
Cycle 9 Day 1	38	1.50	2.01	0.0	1.00	8.0	37	-1.27	2.48	-7.0	-1.00	5.0
Cycle 10 Day 1	34	1.59	2.35	0.0	0.00	7.0	33	-1.03	2.65	-8.0	0.00	6.0
Cycle 11 Day 1	31	1.87	2.49	0.0	1.00	8.0	30	-0.73	2.98	-7.0	0.00	5.0
Cycle 12 Day 1	31	2.48	3.06	0.0	1.00	9.0	30	0.00	3.14	-5.0	0.00	6.0
Cycle 13 Day 1	26	2.42	2.96	0.0	0.50	9.0	25	0.08	3.55	-8.0	0.00	6.0
Cycle 14 Day 1	22	1.41	2.11	0.0	0.00	7.0	21	-0.90	3.10	-8.0	0.00	5.0
Cycle 15 Day 1	23	1.43	2.09	0.0	1.00	9.0	22	-1.05	2.84	-8.0	-0.50	4.0
Cycle 16 Day 1	24	2.21	2.78	0.0	1.00	9.0	23	-0.35	3.39	-8.0	0.00	5.0
Cycle 17 Day 1	21	1.86	2.31	0.0	1.00	6.0	20	-0.60	3.07	-6.0	0.00	4.0
Cycle 18 Day 1	21	2.52	2.56	0.0	2.00	8.0	20	0.30	3.37	-6.0	0.50	8.0
Cycle 19 Day 1	21	2.05	2.29	0.0	1.00	8.0	20	-0.20	3.07	-8.0	0.50	5.0
Cycle 20 Day 1	19	1.89	2.13	0.0	2.00	6.0	18	-0.44	2.99	-8.0	0.00	4.0
Cycle 21 Day 1	18	2.11	2.63	0.0	0.50	8.0	17	-0.24	3.68	-8.0	0.00	7.0
Cycle 22 Day 1	15	1.33	2.23	0.0	0.00	7.0	14	-0.71	3.27	-8.0	0.00	5.0
Cycle 23 Day 1	15	1.80	2.54	0.0	0.00	7.0	14	-0.21	2.69	-5.0	0.00	5.0
Cycle 24 Day 1	14	1.21	2.64	0.0	0.00	9.0	13	-0.77	4.09	-8.0	0.00	8.0
Cycle 25 Day 1	14	0.50	1.16	0.0	0.00	4.0	13	-1.54	2.57	-8.0	0.00	1.0

Abbreviations: CPS=combined positive score; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.4.2: Global Pain(GP) - Observed Means and Change from Baseline of PI01 - Pain Intensity
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	0.67	0.98	0.0	0.00	2.0	11	-1.36	2.11	-6.0	0.00	1.0
Cycle 27 Day 1	13	0.46	0.97	0.0	0.00	3.0	12	-1.75	2.77	-8.0	-1.50	2.0
Cycle 28 Day 1	11	2.18	3.09	0.0	0.00	8.0	10	-0.10	2.88	-3.0	-0.50	7.0
Cycle 29 Day 1	11	1.36	1.96	0.0	0.00	5.0	10	-0.60	1.96	-3.0	-0.50	2.0
Cycle 30 Day 1	10	1.30	2.58	0.0	0.00	8.0	9	-0.89	1.45	-3.0	0.00	1.0
Cycle 31 Day 1	10	1.60	2.17	0.0	0.00	5.0	9	-0.56	2.70	-5.0	0.00	3.0
Cycle 32 Day 1	10	1.10	1.91	0.0	0.00	6.0	9	-1.11	2.62	-6.0	-1.00	3.0
Study Disc 1	48	3.06	2.98	0.0	3.00	10.0	48	0.58	3.48	-8.0	0.00	10.0
30 D SFU Z/P	22	3.09	2.93	0.0	2.00	8.0	22	0.55	2.74	-3.0	0.00	7.0
90 D SFU Z/P	23	3.13	3.12	0.0	2.00	9.0	23	0.30	3.13	-5.0	0.00	8.0
Placebo + CAPOX (N= 88)												
Baseline	79	2.73	2.71	0.0	2.00	10.0						
Cycle 2 Day 1	73	2.05	2.03	0.0	2.00	8.0	68	-0.56	2.41	-7.0	0.00	6.0
Cycle 3 Day 1	63	1.78	2.35	0.0	1.00	8.0	60	-1.02	2.42	-7.0	-1.00	6.0
Cycle 4 Day 1	56	2.23	2.53	0.0	2.00	9.0	55	-0.58	3.18	-7.0	-1.00	9.0
Cycle 5 Day 1	57	1.89	2.35	0.0	1.00	9.0	56	-0.75	2.50	-7.0	0.00	9.0
Cycle 6 Day 1	48	2.23	2.85	0.0	1.00	9.0	47	-0.36	3.35	-9.0	0.00	9.0
Cycle 7 Day 1	41	1.61	2.18	0.0	1.00	10.0	40	-0.55	2.86	-8.0	0.00	10.0
Cycle 8 Day 1	37	1.92	2.51	0.0	1.00	10.0	37	-0.57	2.14	-6.0	0.00	6.0
Cycle 9 Day 1	35	2.06	2.46	0.0	1.00	8.0	35	-0.29	2.44	-6.0	0.00	8.0
Cycle 10 Day 1	29	1.69	2.14	0.0	1.00	7.0	28	-0.75	2.35	-5.0	0.00	7.0
Cycle 11 Day 1	27	1.59	2.24	0.0	0.00	8.0	27	-0.93	2.72	-6.0	0.00	8.0
Cycle 12 Day 1	26	1.65	2.40	0.0	0.50	8.0	25	-0.72	2.87	-6.0	0.00	8.0
Cycle 13 Day 1	22	1.91	2.60	0.0	0.50	8.0	21	-0.86	2.90	-6.0	0.00	8.0
Cycle 14 Day 1	21	2.57	3.04	0.0	1.00	8.0	20	0.00	2.45	-6.0	0.00	6.0
Cycle 15 Day 1	18	2.11	2.70	0.0	0.50	7.0	17	-0.18	1.67	-4.0	0.00	3.0

Abbreviations: CPS=combined positive score; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.4.2: Global Pain(GP) - Observed Means and Change from Baseline of PI01 - Pain Intensity
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	2.06	2.79	0.0	1.00	10.0	16	0.00	2.97	-3.0	0.00	10.0
Cycle 17 Day 1	13	0.54	1.20	0.0	0.00	4.0	11	-0.36	0.67	-2.0	0.00	0.0
Cycle 18 Day 1	10	0.70	1.57	0.0	0.00	5.0	9	-0.44	1.24	-3.0	0.00	1.0
Study Disc 1	51	3.57	3.01	0.0	4.00	10.0	46	1.17	3.11	-6.0	1.00	10.0
30 D SFU Z/P	27	3.15	3.08	0.0	3.00	9.0	25	0.68	2.27	-3.0	0.00	5.0
90 D SFU Z/P	30	2.50	2.85	0.0	1.00	9.0	29	0.17	2.92	-5.0	0.00	6.0

Abbreviations: CPS=combined positive score; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median; Min=minimum; SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo;
90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Schmerzintensität anhand der NRS

3. Time-to-Event-Analysen - Zeit bis zur ersten Verschlechterung

Table 302.3.3003.4.2.1: Global Pain - Summary of Time to First Deterioration of PI01 - Pain Intensity (MID=2)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	47 (56.0%)	34 (38.6%)	
Number of patients censored	37 (44.0%)	54 (61.4%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	6.41 [3.02, 9.23]	9.23 [4.17, NC]	
Cox proportional hazards model			
Stratified HR, 95% CI			1.362 [0.858, 2.161]
Log-rank test			
Two-sided stratified log-rank p-value			0.1792

Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 2 point increase. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.4.2.2: Global Pain - Summary of Time to First Deterioration of PI01 - Pain Intensity by Subgroups (MID=2)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	35 (58.3)	3.71 [2.14, 7.20]	60	25 (41.7)	9.23 [3.88, NC]	1.604 [0.957, 2.688]	0.0671	0.3275
>65 years	24	12 (50.0)	9.86 [4.24, 23.03]	28	9 (32.1)	10.87 [2.33, NC]	0.907 [0.374, 2.201]	0.8287	
Age Group 2									
<=75 years	81	44 (54.3)	6.41 [3.35, 9.23]	81	31 (38.3)	10.87 [4.40, NC]	1.441 [0.908, 2.287]	0.1150	0.4963
>75 years	3	3 (100.0)	2.92 [0.56, NC]	7	3 (42.9)	1.95 [1.22, NC]	0.754 [0.120, 4.736]	0.7622	
Sex									
Male	52	31 (59.6)	6.67 [3.35, 9.86]	46	17 (37.0)	10.87 [3.61, NC]	1.372 [0.758, 2.485]	0.2892	0.8717
Female	32	16 (50.0)	6.41 [1.71, 17.97]	42	17 (40.5)	7.92 [3.88, NC]	1.403 [0.701, 2.806]	0.3350	
Region									
Asia	38	26 (68.4)	4.04 [2.14, 9.86]	41	17 (41.5)	10.87 [2.79, NC]	1.641 [0.890, 3.028]	0.1051	0.4159
Non-Asia	46	21 (45.7)	6.67 [2.89, 17.97]	47	17 (36.2)	9.23 [3.61, NC]	1.107 [0.577, 2.123]	0.7566	
Number of Organs with Metastatic Sites									
0-2	64	37 (57.8)	6.41 [2.79, 9.23]	64	24 (37.5)	10.87 [3.84, NC]	1.467 [0.876, 2.458]	0.1370	0.7116
>=3	20	10 (50.0)	4.34 [2.99, 9.86]	24	10 (41.7)	6.54 [1.45, NC]	1.463 [0.589, 3.631]	0.4096	
Prior Gastrectomy (total or partial)									
Yes	24	17 (70.8)	3.71 [2.04, 20.11]	22	8 (36.4)	24.21 [3.84, NC]	2.634 [1.130, 6.138]	0.0201	0.0838
No	60	30 (50.0)	7.20 [3.02, 9.86]	66	26 (39.4)	6.54 [2.79, NC]	1.012 [0.591, 1.734]	0.9497	

Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 2 point increase. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.4.2.3: Global Pain - Type of Events and Censoring for Time to First Deterioration of PI01 - Pain Intensity (MID=2)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	47 (56.0%)	34 (38.6%)
Deterioration Before Cutoff Date	47 (56.0%)	34 (38.6%)
Number of patients censored	37 (44.0%)	54 (61.4%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	10 (11.9%)	2 (2.3%)
Death	6 (7.1%)	9 (10.2%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	1 (1.1%)
Other	5 (6.0%)	1 (1.1%)
Progressive Disease	12 (14.3%)	34 (38.6%)
Withdrawal By Subject	2 (2.4%)	6 (6.8%)


Abbreviations: CPS=combined positive score; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 2 point increase. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Schmerzintensität anhand der NRS

4. Graphische Darstellung des Verlaufs (Mean Change from Baseline)

Figure 302.3.3002.4.2: Global Pain(GP) - Plot of Mean Change from Baseline of PI01 - Pain Intensity - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Schmerzintensität anhand der NRS

5. Kaplan-Meier-Plots

Figure 302.3.3003.4.2: Global Pain - Kaplan-Meier Plot of Time to First Deterioration of PI01 - Pain Intensity (MID=2) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	24 (32.1)	12 (38.1)	7 (40.5)	3 (40.5)	1 (42.9)	1 (42.9)	0 (44.0)	0 (44.0)
2	88 (0.0)	30 (34.1)	9 (53.4)	4 (58.0)	3 (59.1)	1 (60.2)	0 (61.4)	0 (61.4)	0 (61.4)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 2 point increase. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte

Anhang 4-G Symptomatik anhand des EQ-5D VAS

1. Rücklaufquoten

Table 302.3.3001.3.2: EQ-5D-5L - Completion Status of Visual Analog Scale
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Baseline	78/ 83 (94.0%)	78/ 83 (94.0%)	78/ 84 (92.9%)	81/ 87 (93.1%)	81/ 88 (92.0%)	81/ 88 (92.0%)
Cycle 2 Day 1	68/ 72 (94.4%)	69/ 78 (88.5%)	69/ 84 (82.1%)	72/ 78 (92.3%)	72/ 81 (88.9%)	73/ 88 (83.0%)
Cycle 3 Day 1	60/ 65 (92.3%)	61/ 74 (82.4%)	61/ 84 (72.6%)	64/ 70 (91.4%)	64/ 79 (81.0%)	64/ 88 (72.7%)
Cycle 4 Day 1	56/ 62 (90.3%)	57/ 73 (78.1%)	57/ 84 (67.9%)	56/ 64 (87.5%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 5 Day 1	53/ 59 (89.8%)	54/ 71 (76.1%)	55/ 84 (65.5%)	57/ 61 (93.4%)	57/ 79 (72.2%)	57/ 88 (64.8%)
Cycle 6 Day 1	53/ 56 (94.6%)	55/ 70 (78.6%)	55/ 84 (65.5%)	48/ 56 (85.7%)	48/ 75 (64.0%)	48/ 88 (54.5%)
Cycle 7 Day 1	42/ 46 (91.3%)	45/ 67 (67.2%)	45/ 84 (53.6%)	41/ 48 (85.4%)	42/ 74 (56.8%)	42/ 88 (47.7%)
Cycle 8 Day 1	40/ 41 (97.6%)	41/ 65 (63.1%)	42/ 84 (50.0%)	36/ 41 (87.8%)	37/ 74 (50.0%)	37/ 88 (42.0%)
Cycle 9 Day 1	37/ 38 (97.4%)	38/ 63 (60.3%)	38/ 84 (45.2%)	34/ 38 (89.5%)	35/ 74 (47.3%)	35/ 88 (39.8%)
Cycle 10 Day 1	33/ 34 (97.1%)	34/ 63 (54.0%)	34/ 84 (40.5%)	29/ 32 (90.6%)	30/ 74 (40.5%)	30/ 88 (34.1%)
Cycle 11 Day 1	32/ 34 (94.1%)	32/ 63 (50.8%)	32/ 84 (38.1%)	27/ 29 (93.1%)	27/ 74 (36.5%)	27/ 88 (30.7%)
Cycle 12 Day 1	31/ 32 (96.9%)	31/ 63 (49.2%)	31/ 84 (36.9%)	25/ 28 (89.3%)	26/ 74 (35.1%)	26/ 88 (29.5%)
Cycle 13 Day 1	26/ 29 (89.7%)	26/ 63 (41.3%)	26/ 84 (31.0%)	22/ 25 (88.0%)	22/ 74 (29.7%)	22/ 88 (25.0%)
Cycle 14 Day 1	22/ 26 (84.6%)	22/ 63 (34.9%)	22/ 84 (26.2%)	20/ 22 (90.9%)	21/ 74 (28.4%)	21/ 88 (23.9%)
Cycle 15 Day 1	21/ 23 (91.3%)	21/ 61 (34.4%)	23/ 84 (27.4%)	17/ 20 (85.0%)	18/ 73 (24.7%)	18/ 88 (20.5%)
Cycle 16 Day 1	23/ 23 (100.0%)	23/ 61 (37.7%)	24/ 84 (28.6%)	16/ 17 (94.1%)	17/ 73 (23.3%)	17/ 88 (19.3%)
Cycle 17 Day 1	21/ 22 (95.5%)	21/ 61 (34.4%)	21/ 84 (25.0%)	13/ 13 (100.0%)	13/ 72 (18.1%)	13/ 88 (14.8%)
Cycle 18 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	10/ 11 (90.9%)	10/ 72 (13.9%)	10/ 88 (11.4%)
Cycle 19 Day 1	21/ 21 (100.0%)	21/ 61 (34.4%)	21/ 84 (25.0%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 20 Day 1	19/ 20 (95.0%)	19/ 60 (31.7%)	19/ 84 (22.6%)	9/ 10 (90.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 21 Day 1	18/ 19 (94.7%)	18/ 60 (30.0%)	18/ 84 (21.4%)	9/ 9 (100.0%)	9/ 72 (12.5%)	9/ 88 (10.2%)
Cycle 22 Day 1	15/ 16 (93.8%)	15/ 59 (25.4%)	15/ 84 (17.9%)	7/ 8 (87.5%)	7/ 72 (9.7%)	7/ 88 (8.0%)
Cycle 23 Day 1	15/ 15 (100.0%)	15/ 59 (25.4%)	15/ 84 (17.9%)	6/ 7 (85.7%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 24 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	4/ 6 (66.7%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 25 Day 1	14/ 15 (93.3%)	14/ 59 (23.7%)	14/ 84 (16.7%)	6/ 6 (100.0%)	6/ 72 (8.3%)	6/ 88 (6.8%)
Cycle 26 Day 1	12/ 14 (85.7%)	12/ 59 (20.3%)	12/ 84 (14.3%)	4/ 5 (80.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)

Abbreviations: CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo;
Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.3.2: EQ-5D-5L - Completion Status of Visual Analog Scale
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 27 Day 1	12/ 13 (92.3%)	13/ 59 (22.0%)	13/ 84 (15.5%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 28 Day 1	11/ 12 (91.7%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 29 Day 1	11/ 11 (100.0%)	11/ 59 (18.6%)	11/ 84 (13.1%)	5/ 5 (100.0%)	5/ 72 (6.9%)	5/ 88 (5.7%)
Cycle 30 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	3/ 4 (75.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 31 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 32 Day 1	10/ 10 (100.0%)	10/ 59 (16.9%)	10/ 84 (11.9%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 33 Day 1	8/ 8 (100.0%)	8/ 59 (13.6%)	8/ 84 (9.5%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 34 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	4/ 4 (100.0%)	4/ 72 (5.6%)	4/ 88 (4.5%)
Cycle 35 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	3/ 3 (100.0%)	3/ 72 (4.2%)	3/ 88 (3.4%)
Cycle 36 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 37 Day 1	7/ 7 (100.0%)	7/ 59 (11.9%)	7/ 84 (8.3%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 38 Day 1	6/ 6 (100.0%)	6/ 59 (10.2%)	6/ 84 (7.1%)	2/ 2 (100.0%)	2/ 72 (2.8%)	2/ 88 (2.3%)
Cycle 39 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 2 (50.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 40 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 41 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 42 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 43 Day 1	4/ 5 (80.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 44 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 45 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	1/ 1 (100.0%)	1/ 72 (1.4%)	1/ 88 (1.1%)
Cycle 46 Day 1	5/ 5 (100.0%)	5/ 59 (8.5%)	5/ 84 (6.0%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 47 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 48 Day 1	4/ 4 (100.0%)	4/ 59 (6.8%)	4/ 84 (4.8%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 49 Day 1	3/ 3 (100.0%)	3/ 59 (5.1%)	3/ 84 (3.6%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 50 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 51 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 52 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)

Abbreviations: CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo;
Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3001.3.2: EQ-5D-5L - Completion Status of Visual Analog Scale
Modified Full Analysis Set (CPS < 1)

Analysis Visit	Zolbetuximab + CAPOX (N= 84)			Placebo + CAPOX (N= 88)		
	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)	Compliance Rate [1] (based on expected assessments)	Compliance Rate [2] (adjusted for deaths)	Completion Rate [3] (unadjusted)
Cycle 53 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 54 Day 1	2/ 2 (100.0%)	2/ 59 (3.4%)	2/ 84 (2.4%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 55 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 56 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 57 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 58 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 59 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Cycle 60 Day 1	1/ 1 (100.0%)	1/ 59 (1.7%)	1/ 84 (1.2%)	0	0/ 72 (0.0%)	0/ 88 (0.0%)
Study Disc	51/ 73 (69.9%)	51/ 77 (66.2%)	51/ 84 (60.7%)	57/ 75 (76.0%)	57/ 76 (75.0%)	57/ 88 (64.8%)
30 D SFU Z/P	22/ 69 (31.9%)	22/ 73 (30.1%)	22/ 84 (26.2%)	29/ 70 (41.4%)	29/ 71 (40.8%)	29/ 88 (33.0%)
90 D SFU Z/P	25/ 60 (41.7%)	25/ 66 (37.9%)	25/ 84 (29.8%)	30/ 58 (51.7%)	30/ 59 (50.8%)	30/ 88 (34.1%)

Abbreviations: CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; N=number of patients; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo;
Study Disc=study drug discontinuation visit.
[1] Compliance (or adjusted completion) rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to progression, death or other reasons at respective visit. minimum requirements for scoring is defined as at least one scale with non-missing values.
[2] Compliance rate (adjusted for deaths) is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects with PRO from FAS without patients not expected due to death at respective visit.
[3] Unadjusted completion rate is calculated as the number of subjects with minimum requirements for scoring divided by the number of subjects in the FAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EQ-5D VAS

2. Verlauf über die Zeit (Observed Means and Change from Baseline)

Table 302.3.3002.3.2: EQ-5D-5L - Observed Means and Change from Baseline of Visual Analog Scale
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Zolbetuximab + CAPOX (N= 84)												
Baseline	78	69.51	17.84	22.0	73.00	100.0						
Cycle 2 Day 1	69	73.03	17.38	20.0	79.00	100.0	68	2.54	16.01	-46.0	3.00	44.0
Cycle 3 Day 1	61	74.16	14.92	38.0	75.00	100.0	60	3.87	15.20	-31.0	3.50	41.0
Cycle 4 Day 1	57	75.79	16.81	20.0	78.00	100.0	57	4.54	14.06	-30.0	4.00	50.0
Cycle 5 Day 1	55	74.49	16.39	20.0	79.00	100.0	54	3.43	16.16	-41.0	3.50	39.0
Cycle 6 Day 1	55	75.27	15.50	30.0	78.00	100.0	55	3.69	14.30	-41.0	6.00	31.0
Cycle 7 Day 1	45	76.33	13.79	39.0	77.00	100.0	45	4.73	13.10	-24.0	3.00	38.0
Cycle 8 Day 1	42	76.17	14.03	37.0	79.00	100.0	40	4.63	13.88	-15.0	0.50	37.0
Cycle 9 Day 1	38	76.76	14.32	20.0	79.00	97.0	37	5.65	16.61	-24.0	6.00	48.0
Cycle 10 Day 1	34	75.47	13.33	50.0	74.00	100.0	33	3.76	15.18	-21.0	1.00	38.0
Cycle 11 Day 1	32	75.19	13.12	50.0	74.50	100.0	31	2.65	13.66	-30.0	3.00	33.0
Cycle 12 Day 1	31	77.61	13.00	50.0	78.00	100.0	30	5.33	15.07	-29.0	4.50	40.0
Cycle 13 Day 1	26	77.62	11.71	50.0	79.00	100.0	25	5.68	19.29	-30.0	3.00	58.0
Cycle 14 Day 1	22	77.73	13.87	40.0	80.00	100.0	21	5.29	18.75	-30.0	4.00	46.0
Cycle 15 Day 1	23	79.04	11.45	51.0	81.00	100.0	22	5.91	18.49	-22.0	2.50	58.0
Cycle 16 Day 1	24	79.29	10.19	61.0	77.50	100.0	23	5.26	16.43	-19.0	6.00	51.0
Cycle 17 Day 1	21	79.05	11.50	50.0	80.00	100.0	20	5.85	18.71	-23.0	2.00	59.0
Cycle 18 Day 1	21	78.76	10.78	61.0	78.00	100.0	20	5.25	18.23	-17.0	4.50	47.0
Cycle 19 Day 1	21	74.10	21.87	0.0	80.00	100.0	20	0.35	18.61	-47.0	0.50	33.0
Cycle 20 Day 1	19	74.68	15.14	40.0	74.00	100.0	18	1.50	19.26	-25.0	-3.00	42.0
Cycle 21 Day 1	18	76.83	15.50	48.0	79.50	100.0	17	3.88	17.33	-20.0	1.00	38.0
Cycle 22 Day 1	15	78.93	16.67	37.0	79.00	100.0	14	4.29	16.23	-20.0	6.00	33.0
Cycle 23 Day 1	15	80.87	14.67	50.0	85.00	100.0	14	3.57	16.19	-20.0	2.00	34.0
Cycle 24 Day 1	14	85.07	11.61	66.0	89.50	100.0	13	8.69	17.61	-14.0	10.00	39.0
Cycle 25 Day 1	14	83.36	10.00	65.0	86.00	100.0	13	6.85	18.65	-15.0	2.00	45.0

Abbreviations: CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median; Min=minimum; SD=standard deviation;
SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.3.2: EQ-5D-5L - Observed Means and Change from Baseline of Visual Analog Scale
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 26 Day 1	12	84.67	11.48	64.0	87.50	100.0	11	7.18	16.42	-15.0	7.00	36.0
Cycle 27 Day 1	13	83.77	9.70	70.0	82.00	100.0	12	7.58	17.61	-15.0	8.00	46.0
Cycle 28 Day 1	11	81.09	12.69	61.0	76.00	100.0	10	2.70	18.44	-17.0	5.50	44.0
Cycle 29 Day 1	11	84.18	11.96	62.0	88.00	100.0	10	4.00	16.73	-16.0	2.00	41.0
Cycle 30 Day 1	10	85.60	11.14	69.0	90.50	100.0	9	6.22	17.20	-15.0	8.00	44.0
Cycle 31 Day 1	10	83.20	15.53	48.0	89.00	100.0	9	3.56	18.96	-23.0	7.00	41.0
Cycle 32 Day 1	10	84.60	13.62	60.0	90.00	100.0	9	5.11	19.09	-25.0	9.00	41.0
Study Disc 1	48	61.23	23.08	9.0	66.50	95.0	48	-9.56	21.67	-90.0	-8.00	33.0
30 D SFU Z/P	22	67.32	22.71	9.0	70.00	95.0	22	-6.50	22.90	-68.0	-1.00	29.0
90 D SFU Z/P	25	73.32	17.05	32.0	72.00	99.0	25	-2.84	15.08	-31.0	-1.00	34.0
Placebo + CAPOX (N= 88)												
Baseline	81	70.49	20.43	0.0	73.00	100.0						
Cycle 2 Day 1	73	72.66	18.76	0.0	79.00	100.0	70	0.94	16.80	-41.0	0.00	50.0
Cycle 3 Day 1	64	73.98	16.40	10.0	74.50	100.0	63	3.38	16.94	-40.0	0.00	53.0
Cycle 4 Day 1	57	74.37	17.57	11.0	75.00	100.0	57	3.47	17.89	-50.0	0.00	60.0
Cycle 5 Day 1	57	73.91	18.44	10.0	78.00	100.0	57	2.44	17.32	-32.0	0.00	60.0
Cycle 6 Day 1	48	73.33	17.64	12.0	75.00	100.0	48	2.77	16.07	-30.0	0.00	58.0
Cycle 7 Day 1	42	76.67	21.18	2.0	85.50	100.0	42	4.14	19.39	-46.0	2.00	64.0
Cycle 8 Day 1	37	73.97	20.60	1.0	80.00	100.0	37	2.62	17.02	-30.0	1.00	60.0
Cycle 9 Day 1	35	72.94	19.49	1.0	78.00	96.0	35	-0.03	17.70	-31.0	1.00	55.0
Cycle 10 Day 1	30	75.07	18.67	4.0	74.50	99.0	29	1.00	19.77	-40.0	0.00	55.0
Cycle 11 Day 1	27	77.19	15.41	40.0	80.00	100.0	27	2.30	20.23	-40.0	5.00	55.0
Cycle 12 Day 1	26	75.42	18.04	30.0	78.50	100.0	25	-0.28	23.92	-59.0	0.00	60.0
Cycle 13 Day 1	22	75.00	14.66	43.0	77.50	100.0	21	0.90	20.86	-46.0	2.00	40.0
Cycle 14 Day 1	21	75.33	16.28	29.0	80.00	100.0	20	1.15	19.41	-60.0	1.50	32.0
Cycle 15 Day 1	18	75.78	19.99	35.0	79.50	100.0	17	-1.06	15.96	-50.0	1.00	27.0

Abbreviations: CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median; Min=minimum; SD=standard deviation;
SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3002.3.2: EQ-5D-5L - Observed Means and Change from Baseline of Visual Analog Scale
Modified Full Analysis Set (CPS < 1)

Treatment Group Analysis Visit	Value						Change from Baseline					
	n	Mean	SD	Min	Med	Max	n	Mean	SD	Min	Med	Max
Cycle 16 Day 1	17	82.29	15.11	40.0	87.00	100.0	16	4.50	12.19	-13.0	4.00	30.0
Cycle 17 Day 1	13	83.54	14.59	47.0	86.00	100.0	11	2.73	11.03	-15.0	7.00	19.0
Cycle 18 Day 1	10	84.10	11.35	68.0	89.50	100.0	9	2.78	11.87	-20.0	9.00	16.0
Study Disc 1	54	59.04	22.82	1.0	62.50	100.0	49	-11.27	24.33	-62.0	-10.00	35.0
30 D SFU Z/P	29	61.69	22.01	0.0	65.00	100.0	27	-5.63	22.83	-68.0	-2.00	30.0
90 D SFU Z/P	30	70.20	20.80	32.0	73.00	100.0	29	-0.86	21.76	-60.0	0.00	50.0

Abbreviations: CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; N=number of patients; n=number of patients with non-missing values; Max=maximum; Med=median; Min=minimum; SD=standard deviation;
SD=standard deviation; 30 D SFU Z/P=30 day safety follow up visit - Zolbetuximab/Placebo; 90 D FU Z/P=90 day follow up visit Zolbetuximab/Placebo; Study Disc=study drug discontinuation visit.
Summary statistics will not be provided for the subgroup level for the treatment arm for the visit if that arm has less than 10 subjects at that visit.
Baseline is the last available measurement before the visit dose.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EQ-5D VAS

3. Time-to-Event-Analysen - Zeit bis zur ersten Verschlechterung

Table 302.3.3003.3.2.1: EQ-5D-5L - Summary of Time to First Deterioration of Visual Analog Scale (MID=15)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	84 (100.0%)	88 (100.0%)	
Number of patients with events	32 (38.1%)	35 (39.8%)	
Number of patients censored	52 (61.9%)	53 (60.2%)	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (a)			
50%	13.90 [7.20, 20.76]	6.54 [4.24, NC]	
Cox proportional hazards model			
Stratified HR, 95% CI			0.811 [0.490, 1.345]
Log-rank test			
Two-sided stratified log-rank p-value			0.4183

Abbreviations: CI=confidence interval; CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; HR=hazard ratio; MID=minimally important difference; N=number of patients; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 15 point decrease. Censoring date is date of last available assessment of the parameter.
The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
Stratified analyses are only performed if at least one event occurred in each treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.3.2.2: EQ-5D-5L - Summary of Time to First Deterioration of Visual Analog Scale by Subgroups (MID=15)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME 95% CI(a)	N	n (%)	KME 95% CI(a)	HR 95% CI(b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	60	25 (41.7)	13.90 [6.74, 20.76]	60	24 (40.0)	8.41 [5.06, NC]	0.937 [0.533, 1.646]	0.8241	0.3124
>65 years	24	7 (29.2)	12.65 [6.01, NC]	28	11 (39.3)	4.24 [2.20, NC]	0.558 [0.215, 1.448]	0.2235	
Age Group 2									
<=75 years	81	30 (37.0)	13.90 [7.20, 20.96]	81	32 (39.5)	8.41 [4.96, NC]	0.817 [0.495, 1.348]	0.4256	0.8763
>75 years	3	2 (66.7)	0.69 [0.56, NC]	7	3 (42.9)	2.50 [0.79, NC]	1.510 [0.245, 9.309]	0.6552	
Sex									
Male	52	19 (36.5)	13.90 [9.00, NC]	46	18 (39.1)	5.36 [4.21, NC]	0.613 [0.320, 1.175]	0.1359	0.1853
Female	32	13 (40.6)	6.74 [1.45, NC]	42	17 (40.5)	8.41 [3.48, NC]	1.277 [0.620, 2.631]	0.5049	
Region									
Asia	38	16 (42.1)	13.90 [9.00, NC]	41	18 (43.9)	5.72 [3.02, NC]	0.660 [0.334, 1.305]	0.2274	0.3937
Non-Asia	46	16 (34.8)	20.76 [2.99, NC]	47	17 (36.2)	6.54 [4.24, NC]	1.075 [0.537, 2.152]	0.8408	
Number of Organs with Metastatic Sites									
0-2	64	25 (39.1)	14.13 [6.28, 20.96]	64	26 (40.6)	6.44 [3.52, NC]	0.806 [0.464, 1.400]	0.4428	0.8432
>=3	20	7 (35.0)	13.90 [4.17, NC]	24	9 (37.5)	6.54 [2.79, NC]	0.849 [0.315, 2.288]	0.7462	
Prior Gastrectomy (total or partial)									
Yes	24	13 (54.2)	9.00 [2.04, 20.96]	22	8 (36.4)	28.68 [3.48, NC]	1.891 [0.751, 4.764]	0.1719	0.0406
No	60	19 (31.7)	13.90 [7.20, NC]	66	27 (40.9)	5.72 [3.52, NC]	0.562 [0.309, 1.024]	0.0569	

Abbreviations: CI=confidence interval; CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); MID=minimally important difference; N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method (b) Calculated from unstratified Cox proportional hazards model (c) Two-sided unstratified log-rank p-value (d) Two-sided Type 3 Wald test p-value from unstratified Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 15 point decrease. Censoring date is date of last available assessment of the parameter.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3003.3.2.3: EQ-5D-5L - Type of Events and Censoring for Time to First Deterioration of Visual Analog Scale (MID=15)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Number of patients at risk	84 (100.0%)	88 (100.0%)
Number of patients with events	32 (38.1%)	35 (39.8%)
Deterioration Before Cutoff Date	32 (38.1%)	35 (39.8%)
Number of patients censored	52 (61.9%)	53 (60.2%)
Reason for Censoring with regard to Zolbetuximab/Placebo		
Adverse Event	8 (9.5%)	2 (2.3%)
Death	6 (7.1%)	8 (9.1%)
Lost To Follow-Up	1 (1.2%)	1 (1.1%)
No Competing Event Or Deterioration Before Cutoff Date	1 (1.2%)	0
Other	9 (10.7%)	2 (2.3%)
Progressive Disease	23 (27.4%)	33 (37.5%)
Withdrawal By Subject	4 (4.8%)	7 (8.0%)


Abbreviations: CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; MID=minimal important difference; N=number of patients.
Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 15 point decrease. Censoring date is date of last available assessment of the parameter.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EQ-5D VAS

4. Graphische Darstellung des Verlaufs (Mean Change from Baseline)

Figure 302.3.3002.3.2: EQ-5D-5L - Plot of Mean Change from Baseline of Visual Analog Scale - Modified Full Analysis Set (CPS < 1)




Abbreviations: CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; N=number of patients; SD=standard deviation; SDV=study discontinuation visits; SFU=safety follow up.
Vertical bars indicate Mean +/- SD and are only provided for the treatment arm for the visit if that arm has at least 10 subjects at that visit. Baseline is the last available measurement before the visit dose.
SDV contains both Study Discontinuation Visit 1(left) and Visit 2 (right). SFU contains both 30 Day Safety Follow Up Visit - Zolbetuximab/Placebo (left) and 90 Day Safety Follow Up Visit - Zolbetuximab/Placebo (right).
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte
Anhang 4-G Symptomatik anhand des EQ-5D VAS

5. Kaplan-Meier-Plots

Figure 302.3.3003.3.2: EQ-5D-5L - Kaplan-Meier Plot of Time to First Deterioration of Visual Analog Scale (MID=15) - Modified Full Analysis Set (CPS < 1)



at Risk

1	84 (0.0)	39 (32.1)	15 (52.4)	6 (57.1)	3 (58.3)	1 (60.7)	1 (60.7)	0 (61.9)	0 (61.9)
2	88 (0.0)	29 (31.8)	8 (52.3)	4 (56.8)	4 (56.8)	0 (60.2)	0 (60.2)	0 (60.2)	0 (60.2)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 15 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.3.2.6: EQ-5D-5L - Kaplan-Meier Plot of Time to First Deterioration of Visual Analog Scale by Prior Gastrectomy (total or partial) (MID=15) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): Yes



at Risk

1	24 (0.0)	14 (12.5)	4 (37.5)	3 (37.5)	1 (41.7)	0 (45.8)	0 (45.8)	0 (45.8)	0 (45.8)
2	22 (0.0)	9 (27.3)	5 (45.5)	3 (54.5)	3 (54.5)	0 (63.6)	0 (63.6)	0 (63.6)	0 (63.6)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; MID=minimally important difference; N=number of patients; NC=not calculated.


Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 15 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.3003.3.2.6: EQ-5D-5L - Kaplan-Meier Plot of Time to First Deterioration of Visual Analog Scale by Prior Gastrectomy (total or partial) (MID=15) - Modified Full Analysis Set (CPS < 1)

Prior Gastrectomy (total or partial): No



	# at Risk								
1	60 (0.0)	25 (40.0)	11 (58.3)	3 (65.0)	2 (65.0)	1 (66.7)	1 (66.7)	0 (68.3)	0 (68.3)
2	66 (0.0)	20 (33.3)	3 (54.5)	1 (57.6)	1 (57.6)	0 (59.1)	0 (59.1)	0 (59.1)	0 (59.1)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; MID=minimally important difference; N=number of patients; NC=not calculated.

Note: Time to first deterioration is defined as the time from randomization to the first observation with a ≥ 15 point decrease. Censoring date is date of last available assessment of the parameter.

Number of patients at risk is defined as all patients who did not have a (censoring) event immediately before that timepoint.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Patientenberichtete Endpunkte

Anhang 4-G Zusammenfassung MMRM-Analysen

Table 302.3.3005.99: Summary of MMRM
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
lbl2	N	LS-Means	95% CI for LS-Means	N	LS-Means	95% CI for LS-Means	Difference of LS-Means	95% CI for Difference	p-value
EQ-5D-5L - Visual Analog Scale									
Overall	69	3.04	[-0.63 , 6.71]	72	0.58	[-3.02 , 4.19]	2.46	[-2.01 , 6.92]	0.2779
Hedges' g							0.16	[-0.17 , 0.49]	
Global Pain - Pain Intensity									
Overall	69	-0.39	[-0.87 , 0.10]	70	-0.43	[-0.91 , 0.06]	0.04	[-0.57 , 0.65]	0.8947
Hedges' g							0.02	[-0.31 , 0.35]	
EORTC QLQ-C30 - Global Health Status									
Overall	69	1.58	[-2.50 , 5.66]	72	1.32	[-2.73 , 5.37]	0.26	[-4.79 , 5.31]	0.9186
Hedges' g							0.02	[-0.32 , 0.35]	
EORTC QLQ-C30 - Physical Functioning									
Overall	69	-4.10	[-8.11 , -0.09]	72	-1.70	[-5.62 , 2.21]	-2.40	[-7.45 , 2.66]	0.3494
Hedges' g							-0.14	[-0.47 , 0.19]	
EORTC QLQ-C30 - Role Functioning									
Overall	69	-5.93	[-11.81 , -0.05]	72	-1.77	[-7.54 , 4.01]	-4.16	[-11.49 , 3.17]	0.2627
Hedges' g							-0.17	[-0.50 , 0.16]	
EORTC QLQ-C30 - Emotional Functioning									
Overall	69	0.94	[-3.18 , 5.06]	72	-0.73	[-4.82 , 3.36]	1.67	[-3.51 , 6.84]	0.5237
Hedges' g							0.10	[-0.24 , 0.43]	
EORTC QLQ-C30 - Cognitive Functioning									
Overall	69	-1.23	[-4.90 , 2.43]	72	-0.31	[-3.92 , 3.30]	-0.92	[-5.53 , 3.68]	0.6921
Hedges' g							-0.06	[-0.39 , 0.27]	
EORTC QLQ-C30 - Social Functioning									
Overall	69	-1.62	[-7.25 , 4.00]	72	-0.51	[-6.02 , 5.01]	-1.12	[-8.07 , 5.83]	0.7506
Hedges' g							-0.05	[-0.38 , 0.28]	

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
lbl2	N	LS-Means	95% CI for LS-Means	N	LS-Means	95% CI for LS-Means	Difference of LS-Means	95% CI for Difference	p-value
EORTC QLQ-C30 - Fatigue									
Overall	69	4.22	[-0.21 , 8.65]	72	3.63	[-0.75 , 8.00]	0.59	[-4.91 , 6.09]	0.8325
Hedges' g							0.03	[-0.30 , 0.36]	
EORTC QLQ-C30 - Nausea and Vomiting									
Overall	69	1.07	[-1.88 , 4.02]	72	-3.09	[-6.02 , -0.15]	4.15	[0.56 , 7.75]	0.0240
Hedges' g							0.33	[0.00 , 0.67]	
EORTC QLQ -C30 - Pain									
Overall	69	-4.97	[-9.51 , -0.42]	72	-4.38	[-8.89 , 0.12]	-0.58	[-6.31 , 5.15]	0.8406
Hedges' g							-0.03	[-0.36 , 0.30]	
EORTC QLQ -C30 - Dyspnoea									
Overall	69	2.73	[-1.44 , 6.90]	72	4.62	[0.46 , 8.77]	-1.88	[-7.23 , 3.46]	0.4848
Hedges' g							-0.11	[-0.44 , 0.23]	
EORTC QLQ-C30 - Insomnia									
Overall	69	-1.96	[-6.82 , 2.90]	72	0.43	[-4.41 , 5.27]	-2.39	[-8.31 , 3.53]	0.4255
Hedges' g							-0.12	[-0.45 , 0.22]	
EORTC QLQ-C30 - Appetite Loss									
Overall	69	-3.41	[-8.68 , 1.86]	72	-10.58	[-15.80 , -5.37]	7.17	[0.85 , 13.50]	0.0267
Hedges' g							0.32	[-0.01 , 0.65]	
EORTC QLQ-C30 - Constipation									
Overall	69	-3.43	[-7.62 , 0.76]	72	-1.39	[-5.58 , 2.81]	-2.04	[-7.25 , 3.16]	0.4379
Hedges' g							-0.11	[-0.45 , 0.22]	
EORTC QLQ-C30 - Diarrhoea									
Overall	69	3.77	[-0.21 , 7.74]	72	-0.12	[-4.06 , 3.81]	3.89	[-0.88 , 8.67]	0.1089
Hedges' g							0.23	[-0.10 , 0.56]	
EORTC QLQ-C30 - Financial Difficulties									
Overall	69	2.20	[-2.76 , 7.15]	72	3.37	[-1.54 , 8.28]	-1.17	[-7.52 , 5.17]	0.7148
Hedges' g							-0.06	[-0.39 , 0.28]	
EORTC QLQ-OG25 - Dysphagia									

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
lbl2	N	LS-Means	95% CI for LS-Means	N	LS-Means	95% CI for LS-Means	Difference of LS-Means	95% CI for Difference	p-value
Overall	69	-1.58	[-4.42 , 1.26]	71	-4.27	[-7.07 , -1.47]	2.69	[-0.71 , 6.10]	0.1197
Hedges' g							0.23	[-0.11 , 0.56]	
EORTC QLQ-OG25 - Eating Restrictions									
Overall	69	-2.27	[-6.66 , 2.12]	71	-6.62	[-10.97 , -2.28]	4.35	[-0.97 , 9.68]	0.1081
Hedges' g							0.23	[-0.10 , 0.57]	
EORTC QLQ-OG25 - Reflux									
Overall	69	-2.13	[-6.02 , 1.76]	71	-5.54	[-9.40 , -1.67]	3.41	[-1.32 , 8.14]	0.1555
Hedges' g							0.21	[-0.13 , 0.54]	
EORTC QLQ-OG25 - Odynophagia									
Overall	69	-7.15	[-10.30 , -4.00]	71	-6.17	[-9.29 , -3.04]	-0.98	[-4.76 , 2.79]	0.6068
Hedges' g							-0.07	[-0.41 , 0.26]	
EORTC QLQ-OG25 - Pain and Discomfort									
Overall	69	-7.03	[-11.31 , -2.76]	71	-6.55	[-10.78 , -2.31]	-0.49	[-5.75 , 4.77]	0.8545
Hedges' g							-0.03	[-0.36 , 0.31]	
EORTC QLQ-OG25 - Anxiety									
Overall	69	-6.73	[-12.26 , -1.20]	71	-2.95	[-8.38 , 2.49]	-3.78	[-10.51 , 2.95]	0.2677
Hedges' g							-0.16	[-0.50 , 0.17]	
EORTC QLQ-OG25 - Eating in Front of Others									
Overall	69	-1.97	[-5.31 , 1.37]	71	-3.28	[-6.60 , 0.04]	1.31	[-2.84 , 5.46]	0.5313
Hedges' g							0.09	[-0.24 , 0.43]	
EORTC QLQ-OG25 - Dry Mouth									
Overall	69	0.74	[-4.20 , 5.68]	71	-0.23	[-5.08 , 4.62]	0.97	[-5.18 , 7.12]	0.7554
Hedges' g							0.05	[-0.29 , 0.38]	
EORTC QLQ-OG25 - Trouble with Taste									
Overall	69	13.22	[7.91 , 18.53]	71	5.73	[0.49 , 10.97]	7.49	[1.06 , 13.92]	0.0228
Hedges' g							0.33	[0.00 , 0.67]	
EORTC QLQ-OG25 - Body Image									

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
lbl2	N	LS-Means	95% CI for LS-Means	N	LS-Means	95% CI for LS-Means	Difference of LS-Means	95% CI for Difference	p-value
Overall	69	1.38	[-4.20 , 6.96]	71	-0.75	[-6.28 , 4.77]	2.13	[-4.89 , 9.15]	0.5488
Hedges' g							0.09	[-0.24 , 0.42]	
EORTC QLQ-OG25 - Trouble Swallowing Saliva									
Overall	69	-0.17	[-2.92 , 2.58]	71	-2.79	[-5.53 , -0.05]	2.62	[-0.86 , 6.10]	0.1392
Hedges' g							0.22	[-0.11 , 0.56]	
EORTC QLQ-OG25 - Choked when Swallowing									
Overall	69	0.29	[-2.66 , 3.23]	71	-0.95	[-3.86 , 1.96]	1.24	[-2.41 , 4.88]	0.5029
Hedges' g							0.10	[-0.23 , 0.43]	
EORTC QLQ-OG25 - Trouble with Coughing									
Overall	69	0.74	[-2.92 , 4.40]	71	-4.04	[-7.67 , -0.40]	4.78	[0.29 , 9.27]	0.0373
Hedges' g							0.31	[-0.03 , 0.64]	
EORTC QLQ-OG25 - Trouble Talking									
Overall	69	1.61	[-1.26 , 4.47]	71	0.15	[-2.72 , 3.02]	1.46	[-2.32 , 5.23]	0.4425
Hedges' g							0.12	[-0.21 , 0.45]	
EORTC QLQ-OG25 - Weight Loss									
Overall	69	-1.53	[-6.89 , 3.82]	71	-1.68	[-6.99 , 3.63]	0.15	[-6.37 , 6.67]	0.9641
Hedges' g							0.01	[-0.33 , 0.34]	
EORTC QLQ-OG25 - Hair Loss									
Overall	22	-0.30	[-7.59 , 6.99]	14	4.89	[-3.73 , 13.51]	-5.19	[-15.13 , 4.75]	0.2929
Hedges' g							-0.31	[-0.99 , 0.37]	
EORTC QLQ-STO22 - Belching									
Overall	69	-1.09	[-4.32 , 2.14]	71	-4.80	[-8.00 , -1.59]	3.71	[-0.35 , 7.76]	0.0730
Hedges' g							0.27	[-0.06 , 0.61]	

Abbreviations: CI=confidence interval, EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30, EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25,
EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module,EQ-5D=EuroQOL group 5-dimension, LS=least squares, MMRM=Mixed Model Repeated Measures, N=number of subjects.
MIXED Model with factors treatment, baseline, visit, strata, baseline*visit and treatment*visit as covariate.
Separate unstructured covariance patterns are estimated for each treatment group.
ASTELLAS Data Cutoff Date: 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mSAF (CPS < 1)

Anhang 4-G Sicherheit

Anhang 4-G Unerwünschte Ereignisse

Table 302.3.2001.1.2.1: Effect Measures of Proportion of Subjects with TEAEs
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	82 (98.8%)	84 (96.6%)	
Number of patients without event	1 (1.2%)	3 (3.4%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			2.929 [0.298, 28.733]
Relative Risk (a)			
Unstratified RR, 95% CI			1.023 [0.977, 1.072]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.022 [-0.023, 0.067]
Test on Differences (c)			
Unstratified p-value			0.6209

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; RR=risk ratio; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.1.2.2: Effect Measures of Proportion of Subjects with TEAEs by Subgroups
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	58 (98.3)	59	57 (96.6)	1.018 [0.960, 1.079]	1.0000	NC
>65 years	24	24 (100.0)	28	27 (96.4)	1.037 [0.966, 1.114]	1.0000	
Age Group 2							
<=75 years	80	79 (98.8)	80	77 (96.3)	1.026 [0.976, 1.078]	0.6202	NC
>75 years	3	3 (100.0)	7	7 (100.0)	NC [NC , NC]	NC	
Sex							
Male	52	51 (98.1)	45	44 (97.8)	1.003 [0.946, 1.063]	1.0000	NC
Female	31	31 (100.0)	42	40 (95.2)	1.050 [0.981, 1.123]	0.5046	
Region							
Asia	38	38 (100.0)	40	37 (92.5)	1.081 [0.990, 1.181]	0.2408	NC
Non-Asia	45	44 (97.8)	47	47 (100.0)	0.978 [0.936, 1.022]	0.4891	
Number of Organs with Metastatic Sites							
0-2	64	63 (98.4)	63	61 (96.8)	1.017 [0.963, 1.073]	0.6190	NC
>=3	19	19 (100.0)	24	23 (95.8)	1.043 [0.960, 1.134]	1.0000	
Prior Gastrectomy (total or partial)							
Yes	24	24 (100.0)	22	22 (100.0)	NC [NC , NC]	NC	NC
No	59	58 (98.3)	65	62 (95.4)	1.031 [0.968, 1.098]	0.6206	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; RR=risk ratio; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented, (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mSAF (CPS < 1)

Anhang 4-G Sicherheit
Anhang 4-G Schwere unerwünschte Ereignisse

Table 302.3.2001.3.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	64 (77.1%)	57 (65.5%)	
Number of patients without event	19 (22.9%)	30 (34.5%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.773 [0.901, 3.487]
Relative Risk (a)			
Unstratified RR, 95% CI			1.177 [0.971, 1.426]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.116 [-0.019, 0.251]
Test on Differences (c)			
Unstratified p-value			0.0953

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; RR=risk ratio; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.3.2.2: Effect Measures of Proportion of Subjects with Severe TEAEs by Subgroups
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	45 (76.3)	59	36 (61.0)	1.250 [0.975, 1.603]	0.0741	0.3919
>65 years	24	19 (79.2)	28	21 (75.0)	1.056 [0.785, 1.420]	0.7222	
Age Group 2							
<=75 years	80	62 (77.5)	80	54 (67.5)	1.148 [0.947, 1.392]	0.1567	0.6281
>75 years	3	2 (66.7)	7	3 (42.9)	1.556 [0.482, 5.019]	1.0000	
Sex							
Male	52	40 (76.9)	45	34 (75.6)	1.018 [0.815, 1.273]	0.8745	0.1093
Female	31	24 (77.4)	42	23 (54.8)	1.414 [1.012, 1.975]	0.0457	
Region							
Asia	38	27 (71.1)	40	26 (65.0)	1.093 [0.806, 1.483]	0.5670	0.5111
Non-Asia	45	37 (82.2)	47	31 (66.0)	1.247 [0.974, 1.595]	0.0757	
Number of Organs with Metastatic Sites							
0-2	64	48 (75.0)	63	37 (58.7)	1.277 [0.994, 1.641]	0.0513	0.2065
>=3	19	16 (84.2)	24	20 (83.3)	1.011 [0.776, 1.316]	1.0000	
Prior Gastrectomy (total or partial)							
Yes	24	17 (70.8)	22	15 (68.2)	1.039 [0.708, 1.525]	0.8452	0.4541
No	59	47 (79.7)	65	42 (64.6)	1.233 [0.988, 1.538]	0.0630	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; RR=risk ratio; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented, (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mSAF (CPS < 1)

Anhang 4-G Sicherheit

Anhang 4-G Schwerwiegende unerwünschte Ereignisse

Table 302.3.2001.4.2.1: Effect Measures of Proportion of Subjects with TESAEs
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	45 (54.2%)	45 (51.7%)	
Number of patients without event	38 (45.8%)	42 (48.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.105 [0.605, 2.019]
Relative Risk (a)			
Unstratified RR, 95% CI			1.048 [0.790, 1.392]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.025 [-0.125, 0.175]
Test on Differences (c)			
Unstratified p-value			0.7448

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; RR=risk ratio; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.4.2.2: Effect Measures of Proportion of Subjects with TESAEs by Subgroups
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	29 (49.2)	59	32 (54.2)	0.906 [0.639, 1.286]	0.5805	0.1291
>65 years	24	16 (66.7)	28	13 (46.4)	1.436 [0.881, 2.340]	0.1430	
Age Group 2							
<=75 years	80	44 (55.0)	80	43 (53.8)	1.023 [0.770, 1.359]	0.8739	0.8993
>75 years	3	1 (33.3)	7	2 (28.6)	1.167 [0.161, 8.477]	1.0000	
Sex							
Male	52	30 (57.7)	45	24 (53.3)	1.082 [0.755, 1.549]	0.6665	0.7120
Female	31	15 (48.4)	42	21 (50.0)	0.968 [0.603, 1.553]	0.8916	
Region							
Asia	38	19 (50.0)	40	20 (50.0)	1.000 [0.641, 1.559]	1.0000	0.7782
Non-Asia	45	26 (57.8)	47	25 (53.2)	1.086 [0.753, 1.567]	0.6582	
Number of Organs with Metastatic Sites							
0-2	64	30 (46.9)	63	31 (49.2)	0.953 [0.663, 1.368]	0.7926	0.2055
>=3	19	15 (78.9)	24	14 (58.3)	1.353 [0.898, 2.040]	0.1991	
Prior Gastrectomy (total or partial)							
Yes	24	12 (50.0)	22	8 (36.4)	1.375 [0.695, 2.721]	0.3514	0.3718
No	59	33 (55.9)	65	37 (56.9)	0.983 [0.721, 1.340]	0.9115	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; RR=risk ratio; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented, (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mSAF (CPS < 1)

Anhang 4-G Sicherheit

Anhang 4-G Abbruch der Studienmedikation aufgrund unerwünschter Ereignisse

Table 302.3.2001.5.2.1: Effect Measures of Proportion of Subjects with Permanent Treatment Discontinuation due to TEAEs
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	26 (31.3%)	22 (25.3%)	
Number of patients without event	57 (68.7%)	65 (74.7%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.348 [0.690, 2.634]
Relative Risk (a)			
Unstratified RR, 95% CI			1.239 [0.765, 2.005]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.060 [-0.075, 0.196]
Test on Differences (c)			
Unstratified p-value			0.3820

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; RR=risk ratio; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.5.2.2: Effect Measures of Proportion of Subjects with Permanent Treatment Discontinuation due to TEAEs by Subgroups
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	18 (30.5)	59	14 (23.7)	1.286 [0.707, 2.338]	0.4075	0.8505
>65 years	24	8 (33.3)	28	8 (28.6)	1.167 [0.517, 2.634]	0.7107	
Age Group 2							
<=75 years	80	24 (30.0)	80	20 (25.0)	1.200 [0.723, 1.990]	0.4788	0.3919
>75 years	3	2 (66.7)	7	2 (28.6)	2.333 [0.565, 9.639]	0.5000	
Sex							
Male	52	17 (32.7)	45	12 (26.7)	1.226 [0.658, 2.283]	0.5180	0.9915
Female	31	9 (29.0)	42	10 (23.8)	1.219 [0.564, 2.638]	0.6152	
Region							
Asia	38	10 (26.3)	40	13 (32.5)	0.810 [0.404, 1.622]	0.5494	0.0948
Non-Asia	45	16 (35.6)	47	9 (19.1)	1.857 [0.916, 3.765]	0.0770	
Number of Organs with Metastatic Sites							
0-2	64	20 (31.3)	63	11 (17.5)	1.790 [0.936, 3.423]	0.0705	0.0581
>=3	19	6 (31.6)	24	11 (45.8)	0.689 [0.312, 1.521]	0.3424	
Prior Gastrectomy (total or partial)							
Yes	24	5 (20.8)	22	3 (13.6)	1.528 [0.413, 5.658]	0.7021	0.7495
No	59	21 (35.6)	65	19 (29.2)	1.218 [0.731, 2.029]	0.4491	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; RR=risk ratio; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented, (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mSAF (CPS < 1)

Anhang 4-G Sicherheit
Anhang 4-G Unerwünschte Ereignisse - SOC und PT

Table 302.3.2001.6.2.1: Effect Measures of Proportion of Subjects with TEAEs - Blood and Lymphatic System Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	43 (51.8%)	36 (41.4%)	
Number of patients without event	40 (48.2%)	51 (58.6%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.523 [0.831, 2.792]
Relative Risk (a)			
Unstratified RR, 95% CI			1.252 [0.905, 1.733]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.104 [-0.045, 0.253]
Test on Differences (c)			
Unstratified p-value			0.1730

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.7.2.1: Effect Measures of Proportion of Subjects with TEAEs - Anaemia (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	22 (26.5%)	24 (27.6%)	
Number of patients without event	61 (73.5%)	63 (72.4%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.947 [0.481, 1.864]
Relative Risk (a)			
Unstratified RR, 95% CI			0.961 [0.586, 1.575]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.011 [-0.144, 0.123]
Test on Differences (c)			
Unstratified p-value			0.8741

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.8.2.1: Effect Measures of Proportion of Subjects with TEAEs - Neutropenia (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	22 (26.5%)	16 (18.4%)	
Number of patients without event	61 (73.5%)	71 (81.6%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.600 [0.772, 3.318]
Relative Risk (a)			
Unstratified RR, 95% CI			1.441 [0.816, 2.547]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.081 [-0.044, 0.206]
Test on Differences (c)			
Unstratified p-value			0.2043

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.9.2.1: Effect Measures of Proportion of Subjects with TEAEs - Thrombocytopenia (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	9 (10.8%)	14 (16.1%)	
Number of patients without event	74 (89.2%)	73 (83.9%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.634 [0.258, 1.556]
Relative Risk (a)			
Unstratified RR, 95% CI			0.674 [0.308, 1.472]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.052 [-0.155, 0.050]
Test on Differences (c)			
Unstratified p-value			0.3173

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.10.2.1: Effect Measures of Proportion of Subjects with TEAEs - Cardiac Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	5 (6.0%)	6 (6.9%)	
Number of patients without event	78 (94.0%)	81 (93.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.865 [0.254, 2.951]
Relative Risk (a)			
Unstratified RR, 95% CI			0.873 [0.277, 2.753]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.009 [-0.083, 0.065]
Test on Differences (c)			
Unstratified p-value			0.8172

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.11.2.1: Effect Measures of Proportion of Subjects with TEAEs - Gastrointestinal Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	72 (86.7%)	65 (74.7%)	
Number of patients without event	11 (13.3%)	22 (25.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			2.215 [0.998, 4.919]
Relative Risk (a)			
Unstratified RR, 95% CI			1.161 [1.001, 1.347]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.120 [0.003, 0.237]
Test on Differences (c)			
Unstratified p-value			0.0474

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.11.2.2: Effect Measures of Proportion of Subjects with TEAEs by Subgroups - Gastrointestinal Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	50 (84.7)	59	47 (79.7)	1.064 [0.899, 1.259]	0.4703	0.0825
>65 years	24	22 (91.7)	28	18 (64.3)	1.426 [1.055, 1.927]	0.0241	
Age Group 2							
<=75 years	80	69 (86.3)	80	60 (75.0)	1.150 [0.986, 1.341]	0.0718	NC
>75 years	3	3 (100.0)	7	5 (71.4)	1.400 [0.876, 2.237]	1.0000	
Sex							
Male	52	44 (84.6)	45	32 (71.1)	1.190 [0.956, 1.482]	0.1073	0.8177
Female	31	28 (90.3)	42	33 (78.6)	1.150 [0.945, 1.398]	0.2169	
Region							
Asia	38	34 (89.5)	40	29 (72.5)	1.234 [0.991, 1.538]	0.0844	0.4563
Non-Asia	45	38 (84.4)	47	36 (76.6)	1.102 [0.901, 1.349]	0.3428	
Number of Organs with Metastatic Sites							
0-2	64	54 (84.4)	63	49 (77.8)	1.085 [0.916, 1.284]	0.3424	0.1076
>=3	19	18 (94.7)	24	16 (66.7)	1.421 [1.051, 1.922]	0.0551	
Prior Gastrectomy (total or partial)							
Yes	24	21 (87.5)	22	17 (77.3)	1.132 [0.862, 1.487]	0.4513	0.8422
No	59	51 (86.4)	65	48 (73.8)	1.171 [0.981, 1.396]	0.0809	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented. (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
Only SOCs and PTs with significant treatment effect (p-value <0.05) in the modified safety analysis set are presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.12.2.1: Effect Measures of Proportion of Subjects with TEAEs - Abdominal Distension (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	2 (2.4%)	8 (9.2%)	
Number of patients without event	81 (97.6%)	79 (90.8%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.244 [0.050, 1.184]
Relative Risk (a)			
Unstratified RR, 95% CI			0.262 [0.057, 1.198]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.068 [-0.137, 0.001]
Test on Differences (c)			
Unstratified p-value			0.1000

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.13.2.1: Effect Measures of Proportion of Subjects with TEAEs - Abdominal Pain (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	12 (14.5%)	13 (14.9%)	
Number of patients without event	71 (85.5%)	74 (85.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.962 [0.411, 2.250]
Relative Risk (a)			
Unstratified RR, 95% CI			0.968 [0.469, 1.997]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.005 [-0.111, 0.102]
Test on Differences (c)			
Unstratified p-value			0.9289

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.14.2.1: Effect Measures of Proportion of Subjects with TEAEs - Abdominal Pain Upper (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	8 (9.6%)	7 (8.0%)	
Number of patients without event	75 (90.4%)	80 (92.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.219 [0.421, 3.526]
Relative Risk (a)			
Unstratified RR, 95% CI			1.198 [0.455, 3.156]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.016 [-0.070, 0.101]
Test on Differences (c)			
Unstratified p-value			0.7144

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.15.2.1: Effect Measures of Proportion of Subjects with TEAEs - Ascites (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	1 (1.2%)	9 (10.3%)	
Number of patients without event	82 (98.8%)	78 (89.7%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.106 [0.013, 0.854]
Relative Risk (a)			
Unstratified RR, 95% CI			0.116 [0.015, 0.899]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.091 [-0.160, -0.023]
Test on Differences (c)			
Unstratified p-value			0.0183

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.15.2.2: Effect Measures of Proportion of Subjects with TEAEs by Subgroups - Ascites (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	0 (0.0)	59	6 (10.2)	0.077 [0.004, 1.335]	0.0273	0.1346
>65 years	24	1 (4.2)	28	3 (10.7)	0.389 [0.043, 3.498]	0.6146	
Age Group 2							
<=75 years	80	1 (1.3)	80	9 (11.3)	0.111 [0.014, 0.857]	0.0178	NC
>75 years	3	0 (0.0)	7	0 (0.0)	NC [NC , NC]	NC	
Sex							
Male	52	1 (1.9)	45	4 (8.9)	0.216 [0.025, 1.866]	0.1795	0.2920
Female	31	0 (0.0)	42	5 (11.9)	0.122 [0.007, 2.130]	0.0679	
Region							
Asia	38	1 (2.6)	40	5 (12.5)	0.211 [0.026, 1.720]	0.2012	0.2906
Non-Asia	45	0 (0.0)	47	4 (8.5)	0.116 [0.006, 2.094]	0.1172	
Number of Organs with Metastatic Sites							
0-2	64	0 (0.0)	63	3 (4.8)	0.141 [0.007, 2.669]	0.1191	0.3329
>=3	19	1 (5.3)	24	6 (25.0)	0.211 [0.028, 1.602]	0.1119	
Prior Gastrectomy (total or partial)							
Yes	24	0 (0.0)	22	2 (9.1)	0.184 [0.009, 3.634]	0.2232	0.4550
No	59	1 (1.7)	65	7 (10.8)	0.157 [0.020, 1.242]	0.0641	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented. (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
Only SOCs and PTs with significant treatment effect (p-value <0.05) in the modified safety analysis set are presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.16.2.1: Effect Measures of Proportion of Subjects with TEAEs - Constipation (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	8 (9.6%)	20 (23.0%)	
Number of patients without event	75 (90.4%)	67 (77.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.357 [0.148, 0.865]
Relative Risk (a)			
Unstratified RR, 95% CI			0.419 [0.196, 0.899]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.133 [-0.242, -0.025]
Test on Differences (c)			
Unstratified p-value			0.0190

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.16.2.2: Effect Measures of Proportion of Subjects with TEAEs by Subgroups - Constipation (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	6 (10.2)	59	13 (22.0)	0.462 [0.188, 1.132]	0.0796	0.7068
>65 years	24	2 (8.3)	28	7 (25.0)	0.333 [0.076, 1.455]	0.1525	
Age Group 2							
<=75 years	80	7 (8.8)	80	17 (21.3)	0.412 [0.181, 0.939]	0.0268	0.5651
>75 years	3	1 (33.3)	7	3 (42.9)	0.778 [0.127, 4.774]	1.0000	
Sex							
Male	52	4 (7.7)	45	14 (31.1)	0.247 [0.088, 0.697]	0.0039	0.1082
Female	31	4 (12.9)	42	6 (14.3)	0.903 [0.278, 2.931]	1.0000	
Region							
Asia	38	5 (13.2)	40	9 (22.5)	0.585 [0.215, 1.588]	0.2825	0.3613
Non-Asia	45	3 (6.7)	47	11 (23.4)	0.285 [0.085, 0.955]	0.0401	
Number of Organs with Metastatic Sites							
0-2	64	6 (9.4)	63	16 (25.4)	0.369 [0.154, 0.882]	0.0171	0.5703
>=3	19	2 (10.5)	24	4 (16.7)	0.632 [0.129, 3.088]	0.6783	
Prior Gastrectomy (total or partial)							
Yes	24	3 (12.5)	22	3 (13.6)	0.917 [0.206, 4.076]	1.0000	0.2491
No	59	5 (8.5)	65	17 (26.2)	0.324 [0.127, 0.824]	0.0101	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented. (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
Only SOCs and PTs with significant treatment effect (p-value <0.05) in the modified safety analysis set are presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.17.2.1: Effect Measures of Proportion of Subjects with TEAEs - Diarrhoea (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	28 (33.7%)	25 (28.7%)	
Number of patients without event	55 (66.3%)	62 (71.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.263 [0.659, 2.419]
Relative Risk (a)			
Unstratified RR, 95% CI			1.174 [0.750, 1.837]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.050 [-0.089, 0.189]
Test on Differences (c)			
Unstratified p-value			0.4818

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.18.2.1: Effect Measures of Proportion of Subjects with TEAEs - Dyspepsia (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	6 (7.2%)	5 (5.7%)	
Number of patients without event	77 (92.8%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.278 [0.375, 4.359]
Relative Risk (a)			
Unstratified RR, 95% CI			1.258 [0.399, 3.965]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.015 [-0.059, 0.089]
Test on Differences (c)			
Unstratified p-value			0.6946

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.19.2.1: Effect Measures of Proportion of Subjects with TEAEs - Nausea (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	47 (56.6%)	32 (36.8%)	
Number of patients without event	36 (43.4%)	55 (63.2%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			2.244 [1.213, 4.151]
Relative Risk (a)			
Unstratified RR, 95% CI			1.540 [1.103, 2.149]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.198 [0.051, 0.346]
Test on Differences (c)			
Unstratified p-value			0.0095

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.19.2.2: Effect Measures of Proportion of Subjects with TEAEs by Subgroups - Nausea (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	33 (55.9)	59	26 (44.1)	1.269 [0.880, 1.830]	0.1975	0.0674
>65 years	24	14 (58.3)	28	6 (21.4)	2.722 [1.241, 5.973]	0.0064	
Age Group 2							
<=75 years	80	45 (56.3)	80	29 (36.3)	1.552 [1.095, 2.200]	0.0112	0.9968
>75 years	3	2 (66.7)	7	3 (42.9)	1.556 [0.482, 5.019]	1.0000	
Sex							
Male	52	28 (53.8)	45	15 (33.3)	1.615 [0.996, 2.620]	0.0426	0.8494
Female	31	19 (61.3)	42	17 (40.5)	1.514 [0.955, 2.402]	0.0787	
Region							
Asia	38	21 (55.3)	40	13 (32.5)	1.700 [1.000, 2.890]	0.0427	0.6159
Non-Asia	45	26 (57.8)	47	19 (40.4)	1.429 [0.932, 2.192]	0.0960	
Number of Organs with Metastatic Sites							
0-2	64	36 (56.3)	63	27 (42.9)	1.313 [0.918, 1.877]	0.1312	0.0973
>=3	19	11 (57.9)	24	5 (20.8)	2.779 [1.165, 6.627]	0.0125	
Prior Gastrectomy (total or partial)							
Yes	24	13 (54.2)	22	9 (40.9)	1.324 [0.710, 2.468]	0.3686	0.5860
No	59	34 (57.6)	65	23 (35.4)	1.629 [1.097, 2.417]	0.0131	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented. (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
Only SOCs and PTs with significant treatment effect (p-value <0.05) in the modified safety analysis set are presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.20.2.1: Effect Measures of Proportion of Subjects with TEAEs - Vomiting (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	51 (61.4%)	26 (29.9%)	
Number of patients without event	32 (38.6%)	61 (70.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			3.739 [1.977, 7.072]
Relative Risk (a)			
Unstratified RR, 95% CI			2.056 [1.428, 2.959]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.316 [0.173, 0.458]
Test on Differences (c)			
Unstratified p-value			<.0001

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.20.2.2: Effect Measures of Proportion of Subjects with TEAEs by Subgroups - Vomiting (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	36 (61.0)	59	17 (28.8)	2.118 [1.350, 3.321]	0.0004	0.8280
>65 years	24	15 (62.5)	28	9 (32.1)	1.944 [1.045, 3.618]	0.0286	
Age Group 2							
<=75 years	80	49 (61.3)	80	23 (28.8)	2.130 [1.447, 3.136]	<.0001	0.6166
>75 years	3	2 (66.7)	7	3 (42.9)	1.556 [0.482, 5.019]	1.0000	
Sex							
Male	52	32 (61.5)	45	13 (28.9)	2.130 [1.284, 3.534]	0.0013	0.8453
Female	31	19 (61.3)	42	13 (31.0)	1.980 [1.164, 3.369]	0.0098	
Region							
Asia	38	24 (63.2)	40	8 (20.0)	3.158 [1.623, 6.145]	0.0001	0.0720
Non-Asia	45	27 (60.0)	47	18 (38.3)	1.567 [1.015, 2.419]	0.0374	
Number of Organs with Metastatic Sites							
0-2	64	36 (56.3)	63	19 (30.2)	1.865 [1.209, 2.877]	0.0030	0.3436
>=3	19	15 (78.9)	24	7 (29.2)	2.707 [1.392, 5.265]	0.0019	
Prior Gastrectomy (total or partial)							
Yes	24	15 (62.5)	22	6 (27.3)	2.292 [1.083, 4.849]	0.0166	0.7377
No	59	36 (61.0)	65	20 (30.8)	1.983 [1.306, 3.012]	0.0007	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented. (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
Only SOCs and PTs with significant treatment effect (p-value <0.05) in the modified safety analysis set are presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.21.2.1: Effect Measures of Proportion of Subjects with TEAEs - General Disorders and Administration Site Conditions (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	49 (59.0%)	37 (42.5%)	
Number of patients without event	34 (41.0%)	50 (57.5%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.948 [1.058, 3.584]
Relative Risk (a)			
Unstratified RR, 95% CI			1.388 [1.025, 1.879]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.165 [0.017, 0.313]
Test on Differences (c)			
Unstratified p-value			0.0314

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.21.2.2: Effect Measures of Proportion of Subjects with TEAEs by Subgroups - General Disorders and Administration Site Conditions (SOC) Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	34 (57.6)	59	26 (44.1)	1.308 [0.911, 1.877]	0.1407	0.5589
>65 years	24	15 (62.5)	28	11 (39.3)	1.591 [0.913, 2.771]	0.0951	
Age Group 2							
<=75 years	80	47 (58.8)	80	35 (43.8)	1.343 [0.986, 1.829]	0.0577	0.4585
>75 years	3	2 (66.7)	7	2 (28.6)	2.333 [0.565, 9.639]	0.5000	
Sex							
Male	52	28 (53.8)	45	19 (42.2)	1.275 [0.834, 1.950]	0.2533	0.4848
Female	31	21 (67.7)	42	18 (42.9)	1.581 [1.033, 2.419]	0.0351	
Region							
Asia	38	19 (50.0)	40	17 (42.5)	1.176 [0.728, 1.902]	0.5066	0.3650
Non-Asia	45	30 (66.7)	47	20 (42.6)	1.567 [1.059, 2.317]	0.0203	
Number of Organs with Metastatic Sites							
0-2	64	36 (56.3)	63	27 (42.9)	1.313 [0.918, 1.877]	0.1312	0.5065
>=3	19	13 (68.4)	24	10 (41.7)	1.642 [0.935, 2.885]	0.0807	
Prior Gastrectomy (total or partial)							
Yes	24	16 (66.7)	22	7 (31.8)	2.095 [1.068, 4.111]	0.0182	0.1351
No	59	33 (55.9)	65	30 (46.2)	1.212 [0.857, 1.714]	0.2767	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented. (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
Only SOCs and PTs with significant treatment effect (p-value <0.05) in the modified safety analysis set are presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.22.2.1: Effect Measures of Proportion of Subjects with TEAEs - Asthenia (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	15 (18.1%)	10 (11.5%)	
Number of patients without event	68 (81.9%)	77 (88.5%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.699 [0.716, 4.030]
Relative Risk (a)			
Unstratified RR, 95% CI			1.572 [0.749, 3.300]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.066 [-0.041, 0.172]
Test on Differences (c)			
Unstratified p-value			0.2261

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.23.2.1: Effect Measures of Proportion of Subjects with TEAEs - Fatigue (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	17 (20.5%)	16 (18.4%)	
Number of patients without event	66 (79.5%)	71 (81.6%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.143 [0.534, 2.445]
Relative Risk (a)			
Unstratified RR, 95% CI			1.114 [0.603, 2.056]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.021 [-0.098, 0.140]
Test on Differences (c)			
Unstratified p-value			0.7304

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.24.2.1: Effect Measures of Proportion of Subjects with TEAEs - Pyrexia (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	11 (13.3%)	4 (4.6%)	
Number of patients without event	72 (86.7%)	83 (95.4%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			3.170 [0.967, 10.390]
Relative Risk (a)			
Unstratified RR, 95% CI			2.883 [0.956, 8.696]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.087 [0.001, 0.172]
Test on Differences (c)			
Unstratified p-value			0.0593

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.25.2.1: Effect Measures of Proportion of Subjects with TEAEs - Hepatobiliary Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	6 (7.2%)	5 (5.7%)	
Number of patients without event	77 (92.8%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.278 [0.375, 4.359]
Relative Risk (a)			
Unstratified RR, 95% CI			1.258 [0.399, 3.965]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.015 [-0.059, 0.089]
Test on Differences (c)			
Unstratified p-value			0.6946

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.26.2.1: Effect Measures of Proportion of Subjects with TEAEs - Infections and Infestations (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	26 (31.3%)	30 (34.5%)	
Number of patients without event	57 (68.7%)	57 (65.5%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.867 [0.457, 1.645]
Relative Risk (a)			
Unstratified RR, 95% CI			0.908 [0.591, 1.397]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.032 [-0.173, 0.110]
Test on Differences (c)			
Unstratified p-value			0.6615

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.27.2.1: Effect Measures of Proportion of Subjects with TEAEs - Covid-19 (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	4 (4.8%)	9 (10.3%)	
Number of patients without event	79 (95.2%)	78 (89.7%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.439 [0.130, 1.484]
Relative Risk (a)			
Unstratified RR, 95% CI			0.466 [0.149, 1.455]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.055 [-0.134, 0.024]
Test on Differences (c)			
Unstratified p-value			0.2496

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.28.2.1: Effect Measures of Proportion of Subjects with TEAEs - Injury, Poisoning and Procedural Complications (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	16 (19.3%)	3 (3.4%)	
Number of patients without event	67 (80.7%)	84 (96.6%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			6.687 [1.870, 23.911]
Relative Risk (a)			
Unstratified RR, 95% CI			5.590 [1.691, 18.484]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.158 [0.065, 0.251]
Test on Differences (c)			
Unstratified p-value			0.0012

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.28.2.2: Effect Measures of Proportion of Subjects with TEAEs by Subgroups - Injury, Poisoning and Procedural Complications (SOC) Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	8 (13.6)	59	3 (5.1)	2.667 [0.744, 9.561]	0.2040	0.0379
>65 years	24	8 (33.3)	28	0 (0.0)	19.720 [1.197, 324.79]	0.0010	
Age Group 2							
<=75 years	80	14 (17.5)	80	3 (3.8)	4.667 [1.395, 15.616]	0.0086	0.1969
>75 years	3	2 (66.7)	7	0 (0.0)	10.000 [0.615, 162.66]	0.0667	
Sex							
Male	52	11 (21.2)	45	2 (4.4)	4.760 [1.113, 20.348]	0.0182	0.7835
Female	31	5 (16.1)	42	1 (2.4)	6.774 [0.833, 55.114]	0.0771	
Region							
Asia	38	7 (18.4)	40	1 (2.5)	7.368 [0.951, 57.106]	0.0269	0.7224
Non-Asia	45	9 (20.0)	47	2 (4.3)	4.700 [1.074, 20.578]	0.0255	
Number of Organs with Metastatic Sites							
0-2	64	12 (18.8)	63	3 (4.8)	3.937 [1.167, 13.289]	0.0252	0.1596
>=3	19	4 (21.1)	24	0 (0.0)	11.250 [0.643, 196.83]	0.0314	
Prior Gastrectomy (total or partial)							
Yes	24	5 (20.8)	22	0 (0.0)	10.120 [0.592, 173.06]	0.0502	0.1780
No	59	11 (18.6)	65	3 (4.6)	4.040 [1.184, 13.779]	0.0209	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented. (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
Only SOCs and PTs with significant treatment effect (p-value <0.05) in the modified safety analysis set are presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.29.2.1: Effect Measures of Proportion of Subjects with TEAEs - Investigations (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	42 (50.6%)	43 (49.4%)	
Number of patients without event	41 (49.4%)	44 (50.6%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.048 [0.574, 1.913]
Relative Risk (a)			
Unstratified RR, 95% CI			1.024 [0.758, 1.383]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.012 [-0.139, 0.162]
Test on Differences (c)			
Unstratified p-value			0.8781

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.30.2.1: Effect Measures of Proportion of Subjects with TEAEs - Alanine Aminotransferase Increased (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	13 (15.7%)	13 (14.9%)	
Number of patients without event	70 (84.3%)	74 (85.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.057 [0.459, 2.437]
Relative Risk (a)			
Unstratified RR, 95% CI			1.048 [0.517, 2.127]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.007 [-0.101, 0.115]
Test on Differences (c)			
Unstratified p-value			0.8963

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.31.2.1: Effect Measures of Proportion of Subjects with TEAEs - Aspartate Aminotransferase Increased (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	16 (19.3%)	17 (19.5%)	
Number of patients without event	67 (80.7%)	70 (80.5%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.983 [0.460, 2.104]
Relative Risk (a)			
Unstratified RR, 95% CI			0.987 [0.534, 1.821]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.003 [-0.122, 0.116]
Test on Differences (c)			
Unstratified p-value			0.9654

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.32.2.1: Effect Measures of Proportion of Subjects with TEAEs - Blood Bilirubin Increased (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	7 (8.4%)	5 (5.7%)	
Number of patients without event	76 (91.6%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.511 [0.460, 4.962]
Relative Risk (a)			
Unstratified RR, 95% CI			1.467 [0.485, 4.442]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.027 [-0.050, 0.104]
Test on Differences (c)			
Unstratified p-value			0.4942

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.33.2.1: Effect Measures of Proportion of Subjects with TEAEs - Neutrophil Count Decreased (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	13 (15.7%)	11 (12.6%)	
Number of patients without event	70 (84.3%)	76 (87.4%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.283 [0.540, 3.051]
Relative Risk (a)			
Unstratified RR, 95% CI			1.239 [0.588, 2.608]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.030 [-0.075, 0.135]
Test on Differences (c)			
Unstratified p-value			0.5720

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.34.2.1: Effect Measures of Proportion of Subjects with TEAEs - Platelet Count Decreased (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	12 (14.5%)	13 (14.9%)	
Number of patients without event	71 (85.5%)	74 (85.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.962 [0.411, 2.250]
Relative Risk (a)			
Unstratified RR, 95% CI			0.968 [0.469, 1.997]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.005 [-0.111, 0.102]
Test on Differences (c)			
Unstratified p-value			0.9289

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.35.2.1: Effect Measures of Proportion of Subjects with TEAEs - Weight Decreased (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	8 (9.6%)	8 (9.2%)	
Number of patients without event	75 (90.4%)	79 (90.8%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.053 [0.376, 2.949]
Relative Risk (a)			
Unstratified RR, 95% CI			1.048 [0.412, 2.664]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.004 [-0.083, 0.092]
Test on Differences (c)			
Unstratified p-value			0.9212

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.36.2.1: Effect Measures of Proportion of Subjects with TEAEs - White Blood Cell Count Decreased (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	6 (7.2%)	7 (8.0%)	
Number of patients without event	77 (92.8%)	80 (92.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.891 [0.286, 2.769]
Relative Risk (a)			
Unstratified RR, 95% CI			0.898 [0.315, 2.563]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.008 [-0.088, 0.072]
Test on Differences (c)			
Unstratified p-value			0.8412

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.37.2.1: Effect Measures of Proportion of Subjects with TEAEs - Metabolism and Nutrition Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	42 (50.6%)	42 (48.3%)	
Number of patients without event	41 (49.4%)	45 (51.7%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.098 [0.601, 2.003]
Relative Risk (a)			
Unstratified RR, 95% CI			1.048 [0.773, 1.421]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.023 [-0.127, 0.174]
Test on Differences (c)			
Unstratified p-value			0.7617

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.38.2.1: Effect Measures of Proportion of Subjects with TEAEs - Decreased Appetite (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	31 (37.3%)	26 (29.9%)	
Number of patients without event	52 (62.7%)	61 (70.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.399 [0.738, 2.650]
Relative Risk (a)			
Unstratified RR, 95% CI			1.250 [0.816, 1.913]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.075 [-0.067, 0.216]
Test on Differences (c)			
Unstratified p-value			0.3028

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.39.2.1: Effect Measures of Proportion of Subjects with TEAEs - Hypoalbuminaemia (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	9 (10.8%)	4 (4.6%)	
Number of patients without event	74 (89.2%)	83 (95.4%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			2.524 [0.746, 8.538]
Relative Risk (a)			
Unstratified RR, 95% CI			2.358 [0.755, 7.365]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.062 [-0.018, 0.143]
Test on Differences (c)			
Unstratified p-value			0.1547

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.40.2.1: Effect Measures of Proportion of Subjects with TEAEs - Hypokalaemia (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	9 (10.8%)	10 (11.5%)	
Number of patients without event	74 (89.2%)	77 (88.5%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.936 [0.360, 2.435]
Relative Risk (a)			
Unstratified RR, 95% CI			0.943 [0.404, 2.205]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.007 [-0.101, 0.088]
Test on Differences (c)			
Unstratified p-value			0.8929

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.41.2.1: Effect Measures of Proportion of Subjects with TEAEs - Musculoskeletal and Connective Tissue Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	12 (14.5%)	15 (17.2%)	
Number of patients without event	71 (85.5%)	72 (82.8%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.811 [0.355, 1.855]
Relative Risk (a)			
Unstratified RR, 95% CI			0.839 [0.418, 1.684]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.028 [-0.137, 0.082]
Test on Differences (c)			
Unstratified p-value			0.6197

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.42.2.1: Effect Measures of Proportion of Subjects with TEAEs - Nervous System Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	45 (54.2%)	47 (54.0%)	
Number of patients without event	38 (45.8%)	40 (46.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.008 [0.551, 1.843]
Relative Risk (a)			
Unstratified RR, 95% CI			1.004 [0.761, 1.324]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.002 [-0.148, 0.152]
Test on Differences (c)			
Unstratified p-value			0.9798

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.43.2.1: Effect Measures of Proportion of Subjects with TEAEs - Neuropathy Peripheral (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	5 (6.0%)	5 (5.7%)	
Number of patients without event	78 (94.0%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.051 [0.293, 3.773]
Relative Risk (a)			
Unstratified RR, 95% CI			1.048 [0.315, 3.489]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.003 [-0.068, 0.074]
Test on Differences (c)			
Unstratified p-value			0.9388

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.44.2.1: Effect Measures of Proportion of Subjects with TEAEs - Neurotoxicity (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	4 (4.8%)	8 (9.2%)	
Number of patients without event	79 (95.2%)	79 (90.8%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.500 [0.145, 1.728]
Relative Risk (a)			
Unstratified RR, 95% CI			0.524 [0.164, 1.675]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.044 [-0.120, 0.032]
Test on Differences (c)			
Unstratified p-value			0.3717

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.45.2.1: Effect Measures of Proportion of Subjects with TEAEs - Peripheral Sensory Neuropathy (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	26 (31.3%)	22 (25.3%)	
Number of patients without event	57 (68.7%)	65 (74.7%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.348 [0.690, 2.634]
Relative Risk (a)			
Unstratified RR, 95% CI			1.239 [0.765, 2.005]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.060 [-0.075, 0.196]
Test on Differences (c)			
Unstratified p-value			0.3820

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.46.2.1: Effect Measures of Proportion of Subjects with TEAEs - Psychiatric Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	7 (8.4%)	8 (9.2%)	
Number of patients without event	76 (91.6%)	79 (90.8%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.910 [0.314, 2.631]
Relative Risk (a)			
Unstratified RR, 95% CI			0.917 [0.348, 2.416]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.008 [-0.093, 0.078]
Test on Differences (c)			
Unstratified p-value			0.8611

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.47.2.1: Effect Measures of Proportion of Subjects with TEAEs - Renal and Urinary Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	7 (8.4%)	5 (5.7%)	
Number of patients without event	76 (91.6%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.511 [0.460, 4.962]
Relative Risk (a)			
Unstratified RR, 95% CI			1.467 [0.485, 4.442]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.027 [-0.050, 0.104]
Test on Differences (c)			
Unstratified p-value			0.4942

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.48.2.1: Effect Measures of Proportion of Subjects with TEAEs - Respiratory, Thoracic and Mediastinal Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	19 (22.9%)	24 (27.6%)	
Number of patients without event	64 (77.1%)	63 (72.4%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.779 [0.389, 1.562]
Relative Risk (a)			
Unstratified RR, 95% CI			0.830 [0.493, 1.398]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.047 [-0.177, 0.083]
Test on Differences (c)			
Unstratified p-value			0.4815

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.49.2.1: Effect Measures of Proportion of Subjects with TEAEs - Dyspnoea (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	5 (6.0%)	6 (6.9%)	
Number of patients without event	78 (94.0%)	81 (93.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.865 [0.254, 2.951]
Relative Risk (a)			
Unstratified RR, 95% CI			0.873 [0.277, 2.753]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.009 [-0.083, 0.065]
Test on Differences (c)			
Unstratified p-value			0.8172

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.50.2.1: Effect Measures of Proportion of Subjects with TEAEs - Skin and Subcutaneous Tissue Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	31 (37.3%)	27 (31.0%)	
Number of patients without event	52 (62.7%)	60 (69.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.325 [0.702, 2.502]
Relative Risk (a)			
Unstratified RR, 95% CI			1.203 [0.791, 1.830]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.063 [-0.079, 0.206]
Test on Differences (c)			
Unstratified p-value			0.3853

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.51.2.1: Effect Measures of Proportion of Subjects with TEAEs - Palmar-Plantar Erythrodysaesthesia Syndrome (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	17 (20.5%)	16 (18.4%)	
Number of patients without event	66 (79.5%)	71 (81.6%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.143 [0.534, 2.445]
Relative Risk (a)			
Unstratified RR, 95% CI			1.114 [0.603, 2.056]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.021 [-0.098, 0.140]
Test on Differences (c)			
Unstratified p-value			0.7304

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.52.2.1: Effect Measures of Proportion of Subjects with TEAEs - Vascular Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	16 (19.3%)	11 (12.6%)	
Number of patients without event	67 (80.7%)	76 (87.4%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.650 [0.716, 3.803]
Relative Risk (a)			
Unstratified RR, 95% CI			1.525 [0.752, 3.090]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.066 [-0.044, 0.176]
Test on Differences (c)			
Unstratified p-value			0.2369

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 10% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mSAF (CPS < 1)

Anhang 4-G Sicherheit

Anhang 4-G Schwere unerwünschte Ereignisse - SOC und PT

Table 302.3.2001.53.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Blood and Lymphatic System Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	17 (20.5%)	14 (16.1%)	
Number of patients without event	66 (79.5%)	73 (83.9%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.343 [0.615, 2.935]
Relative Risk (a)			
Unstratified RR, 95% CI			1.273 [0.671, 2.414]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.044 [-0.072, 0.160]
Test on Differences (c)			
Unstratified p-value			0.4587

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.54.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Anaemia (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	10 (12.0%)	9 (10.3%)	
Number of patients without event	73 (88.0%)	78 (89.7%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.187 [0.457, 3.087]
Relative Risk (a)			
Unstratified RR, 95% CI			1.165 [0.498, 2.722]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.017 [-0.078, 0.112]
Test on Differences (c)			
Unstratified p-value			0.7246

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.55.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Neutropenia (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	8 (9.6%)	3 (3.4%)	
Number of patients without event	75 (90.4%)	84 (96.6%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			2.987 [0.764, 11.671]
Relative Risk (a)			
Unstratified RR, 95% CI			2.795 [0.768, 10.178]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.062 [-0.012, 0.136]
Test on Differences (c)			
Unstratified p-value			0.1255

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.56.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Gastrointestinal Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	29 (34.9%)	20 (23.0%)	
Number of patients without event	54 (65.1%)	67 (77.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.799 [0.918, 3.527]
Relative Risk (a)			
Unstratified RR, 95% CI			1.520 [0.937, 2.466]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.120 [-0.016, 0.255]
Test on Differences (c)			
Unstratified p-value			0.0855

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.57.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Diarrhoea (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	6 (7.2%)	5 (5.7%)	
Number of patients without event	77 (92.8%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.278 [0.375, 4.359]
Relative Risk (a)			
Unstratified RR, 95% CI			1.258 [0.399, 3.965]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.015 [-0.059, 0.089]
Test on Differences (c)			
Unstratified p-value			0.6946

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.58.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Nausea (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	9 (10.8%)	3 (3.4%)	
Number of patients without event	74 (89.2%)	84 (96.6%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			3.405 [0.889, 13.051]
Relative Risk (a)			
Unstratified RR, 95% CI			3.145 [0.882, 11.215]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.074 [-0.003, 0.151]
Test on Differences (c)			
Unstratified p-value			0.0753

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.59.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Vomiting (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	12 (14.5%)	5 (5.7%)	
Number of patients without event	71 (85.5%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			2.772 [0.931, 8.249]
Relative Risk (a)			
Unstratified RR, 95% CI			2.516 [0.926, 6.831]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.087 [-0.003, 0.177]
Test on Differences (c)			
Unstratified p-value			0.0584

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.60.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - General Disorders and Administration Site Conditions (SOC) Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	11 (13.3%)	7 (8.0%)	
Number of patients without event	72 (86.7%)	80 (92.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.746 [0.643, 4.745]
Relative Risk (a)			
Unstratified RR, 95% CI			1.647 [0.671, 4.046]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.052 [-0.041, 0.145]
Test on Differences (c)			
Unstratified p-value			0.2700

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.61.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Infections and Infestations (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	8 (9.6%)	14 (16.1%)	
Number of patients without event	75 (90.4%)	73 (83.9%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.556 [0.220, 1.405]
Relative Risk (a)			
Unstratified RR, 95% CI			0.599 [0.265, 1.353]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.065 [-0.164, 0.035]
Test on Differences (c)			
Unstratified p-value			0.2102

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.62.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Investigations (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	17 (20.5%)	15 (17.2%)	
Number of patients without event	66 (79.5%)	72 (82.8%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.236 [0.572, 2.672]
Relative Risk (a)			
Unstratified RR, 95% CI			1.188 [0.635, 2.221]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.032 [-0.085, 0.150]
Test on Differences (c)			
Unstratified p-value			0.5890

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.63.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Neutrophil Count Decreased (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	6 (7.2%)	6 (6.9%)	
Number of patients without event	77 (92.8%)	81 (93.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.052 [0.325, 3.402]
Relative Risk (a)			
Unstratified RR, 95% CI			1.048 [0.352, 3.120]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.003 [-0.074, 0.080]
Test on Differences (c)			
Unstratified p-value			0.9326

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.64.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Metabolism and Nutrition Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	11 (13.3%)	8 (9.2%)	
Number of patients without event	72 (86.7%)	79 (90.8%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.509 [0.575, 3.960]
Relative Risk (a)			
Unstratified RR, 95% CI			1.441 [0.610, 3.405]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.041 [-0.054, 0.135]
Test on Differences (c)			
Unstratified p-value			0.4013

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.65.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Decreased Appetite (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	5 (6.0%)	0 (0.0%)	
Number of patients without event	78 (94.0%)	87 (100.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			12.261 [0.667, 225.31]
Relative Risk (a)			
Unstratified RR, 95% CI			11.524 [0.647, 205.20]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.060 [0.009, 0.111]
Test on Differences (c)			
Unstratified p-value			0.0260

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.65.2.2: Effect Measures of Proportion of Subjects with Severe TEAEs by Subgroups - Decreased Appetite (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	2 (3.4)	59	0 (0.0)	5.000 [0.245, 101.97]	0.4957	NC
>65 years	24	3 (12.5)	28	0 (0.0)	8.120 [0.440, 149.73]	0.0916	
Age Group 2							
<=75 years	80	4 (5.0)	80	0 (0.0)	9.000 [0.493, 164.46]	0.1203	NC
>75 years	3	1 (33.3)	7	0 (0.0)	6.000 [0.309, 116.61]	0.3000	
Sex							
Male	52	3 (5.8)	45	0 (0.0)	6.075 [0.322, 114.55]	0.2461	NC
Female	31	2 (6.5)	42	0 (0.0)	6.719 [0.334, 135.18]	0.1769	
Region							
Asia	38	4 (10.5)	40	0 (0.0)	9.462 [0.527, 170.02]	0.0517	NC
Non-Asia	45	1 (2.2)	47	0 (0.0)	3.130 [0.131, 74.898]	0.4891	
Number of Organs with Metastatic Sites							
0-2	64	4 (6.3)	63	0 (0.0)	8.862 [0.487, 161.26]	0.1191	NC
>=3	19	1 (5.3)	24	0 (0.0)	3.750 [0.161, 87.173]	0.4419	
Prior Gastrectomy (total or partial)							
Yes	24	2 (8.3)	22	0 (0.0)	4.600 [0.233, 90.844]	0.4899	NC
No	59	3 (5.1)	65	0 (0.0)	7.700 [0.406, 146.02]	0.1048	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented. (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
Only SOCs and PTs with significant treatment effect (p-value <0.05) in the modified safety analysis set are presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.66.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Nervous System Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	5 (6.0%)	5 (5.7%)	
Number of patients without event	78 (94.0%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.051 [0.293, 3.773]
Relative Risk (a)			
Unstratified RR, 95% CI			1.048 [0.315, 3.489]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.003 [-0.068, 0.074]
Test on Differences (c)			
Unstratified p-value			0.9388

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.67.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Respiratory, Thoracic and Mediastinal Disorders (SOC) Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	7 (8.4%)	14 (16.1%)	
Number of patients without event	76 (91.6%)	73 (83.9%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.480 [0.183, 1.257]
Relative Risk (a)			
Unstratified RR, 95% CI			0.524 [0.223, 1.234]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.077 [-0.174, 0.021]
Test on Differences (c)			
Unstratified p-value			0.1293

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.68.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Pulmonary Embolism (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	3 (3.6%)	5 (5.7%)	
Number of patients without event	80 (96.4%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.615 [0.142, 2.659]
Relative Risk (a)			
Unstratified RR, 95% CI			0.629 [0.155, 2.549]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.021 [-0.085, 0.042]
Test on Differences (c)			
Unstratified p-value			0.7206

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.69.2.1: Effect Measures of Proportion of Subjects with Severe TEAEs - Vascular Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	5 (6.0%)	5 (5.7%)	
Number of patients without event	78 (94.0%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.051 [0.293, 3.773]
Relative Risk (a)			
Unstratified RR, 95% CI			1.048 [0.315, 3.489]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.003 [-0.068, 0.074]
Test on Differences (c)			
Unstratified p-value			0.9388

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mSAF (CPS < 1)

Anhang 4-G Sicherheit

Anhang 4-G Schwerwiegende unerwünschte Ereignisse - SOC und PT

Table 302.3.2001.70.2.1: Effect Measures of Proportion of Subjects with TESAEs - Blood and Lymphatic System Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	5 (6.0%)	6 (6.9%)	
Number of patients without event	78 (94.0%)	81 (93.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.865 [0.254, 2.951]
Relative Risk (a)			
Unstratified RR, 95% CI			0.873 [0.277, 2.753]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.009 [-0.083, 0.065]
Test on Differences (c)			
Unstratified p-value			0.8172

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.71.2.1: Effect Measures of Proportion of Subjects with TESAEs - Gastrointestinal Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	18 (21.7%)	17 (19.5%)	
Number of patients without event	65 (78.3%)	70 (80.5%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.140 [0.542, 2.399]
Relative Risk (a)			
Unstratified RR, 95% CI			1.110 [0.615, 2.004]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.021 [-0.100, 0.143]
Test on Differences (c)			
Unstratified p-value			0.7294

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.72.2.1: Effect Measures of Proportion of Subjects with TESAEs - Vomiting (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	4 (4.8%)	6 (6.9%)	
Number of patients without event	79 (95.2%)	81 (93.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.684 [0.186, 2.515]
Relative Risk (a)			
Unstratified RR, 95% CI			0.699 [0.204, 2.388]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.021 [-0.091, 0.050]
Test on Differences (c)			
Unstratified p-value			0.7471

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.73.2.1: Effect Measures of Proportion of Subjects with TESAEs - General Disorders and Administration Site Conditions (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	9 (10.8%)	4 (4.6%)	
Number of patients without event	74 (89.2%)	83 (95.4%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			2.524 [0.746, 8.538]
Relative Risk (a)			
Unstratified RR, 95% CI			2.358 [0.755, 7.365]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.062 [-0.018, 0.143]
Test on Differences (c)			
Unstratified p-value			0.1547

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.74.2.1: Effect Measures of Proportion of Subjects with TESAEs - Infections and Infestations (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	11 (13.3%)	12 (13.8%)	
Number of patients without event	72 (86.7%)	75 (86.2%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.955 [0.396, 2.301]
Relative Risk (a)			
Unstratified RR, 95% CI			0.961 [0.449, 2.056]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.005 [-0.108, 0.097]
Test on Differences (c)			
Unstratified p-value			0.9180

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.75.2.1: Effect Measures of Proportion of Subjects with TESAEs - Injury, Poisoning and Procedural Complications (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	5 (6.0%)	0 (0.0%)	
Number of patients without event	78 (94.0%)	87 (100.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			12.261 [0.667, 225.31]
Relative Risk (a)			
Unstratified RR, 95% CI			11.524 [0.647, 205.20]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.060 [0.009, 0.111]
Test on Differences (c)			
Unstratified p-value			0.0260

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.75.2.2: Effect Measures of Proportion of Subjects with TESAEs by Subgroups - Injury, Poisoning and Procedural Complications (SOC) Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	1 (1.7)	59	0 (0.0)	3.000 [0.125, 72.179]	1.0000	NC
>65 years	24	4 (16.7)	28	0 (0.0)	10.440 [0.591, 184.57]	0.0393	
Age Group 2							
<=75 years	80	4 (5.0)	80	0 (0.0)	9.000 [0.493, 164.46]	0.1203	NC
>75 years	3	1 (33.3)	7	0 (0.0)	6.000 [0.309, 116.61]	0.3000	
Sex							
Male	52	5 (9.6)	45	0 (0.0)	9.547 [0.542, 168.05]	0.0593	NC
Female	31	0 (0.0)	42	0 (0.0)	NC [NC , NC]	NC	
Region							
Asia	38	3 (7.9)	40	0 (0.0)	7.359 [0.393, 137.90]	0.1109	NC
Non-Asia	45	2 (4.4)	47	0 (0.0)	5.217 [0.257, 105.77]	0.2365	
Number of Organs with Metastatic Sites							
0-2	64	3 (4.7)	63	0 (0.0)	6.892 [0.363, 130.77]	0.2441	NC
>=3	19	2 (10.5)	24	0 (0.0)	6.250 [0.318, 122.91]	0.1894	
Prior Gastrectomy (total or partial)							
Yes	24	1 (4.2)	22	0 (0.0)	2.760 [0.118, 64.415]	1.0000	NC
No	59	4 (6.8)	65	0 (0.0)	9.900 [0.544, 180.06]	0.0485	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented. (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
Only SOCs and PTs with significant treatment effect (p-value <0.05) in the modified safety analysis set are presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.76.2.1: Effect Measures of Proportion of Subjects with TESAEs - Metabolism and Nutrition Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	8 (9.6%)	3 (3.4%)	
Number of patients without event	75 (90.4%)	84 (96.6%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			2.987 [0.764, 11.671]
Relative Risk (a)			
Unstratified RR, 95% CI			2.795 [0.768, 10.178]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.062 [-0.012, 0.136]
Test on Differences (c)			
Unstratified p-value			0.1255

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.77.2.1: Effect Measures of Proportion of Subjects with TESAEs - Decreased Appetite (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	5 (6.0%)	0 (0.0%)	
Number of patients without event	78 (94.0%)	87 (100.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			12.261 [0.667, 225.31]
Relative Risk (a)			
Unstratified RR, 95% CI			11.524 [0.647, 205.20]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.060 [0.009, 0.111]
Test on Differences (c)			
Unstratified p-value			0.0260

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.77.2.2: Effect Measures of Proportion of Subjects with TESAEs by Subgroups - Decreased Appetite (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	59	2 (3.4)	59	0 (0.0)	5.000 [0.245, 101.97]	0.4957	NC
>65 years	24	3 (12.5)	28	0 (0.0)	8.120 [0.440, 149.73]	0.0916	
Age Group 2							
<=75 years	80	4 (5.0)	80	0 (0.0)	9.000 [0.493, 164.46]	0.1203	NC
>75 years	3	1 (33.3)	7	0 (0.0)	6.000 [0.309, 116.61]	0.3000	
Sex							
Male	52	4 (7.7)	45	0 (0.0)	7.811 [0.432, 141.25]	0.1211	NC
Female	31	1 (3.2)	42	0 (0.0)	4.031 [0.170, 95.756]	0.4247	
Region							
Asia	38	3 (7.9)	40	0 (0.0)	7.359 [0.393, 137.90]	0.1109	NC
Non-Asia	45	2 (4.4)	47	0 (0.0)	5.217 [0.257, 105.77]	0.2365	
Number of Organs with Metastatic Sites							
0-2	64	4 (6.3)	63	0 (0.0)	8.862 [0.487, 161.26]	0.1191	NC
>=3	19	1 (5.3)	24	0 (0.0)	3.750 [0.161, 87.173]	0.4419	
Prior Gastrectomy (total or partial)							
Yes	24	2 (8.3)	22	0 (0.0)	4.600 [0.233, 90.844]	0.4899	NC
No	59	3 (5.1)	65	0 (0.0)	7.700 [0.406, 146.02]	0.1048	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented. (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
Only SOCs and PTs with significant treatment effect (p-value <0.05) in the modified safety analysis set are presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.78.2.1: Effect Measures of Proportion of Subjects with TESAEs - Neoplasms Benign, Malignant and Unspecified (Incl Cysts and Polyps) (SOC) Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	2 (2.4%)	5 (5.7%)	
Number of patients without event	81 (97.6%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.405 [0.076, 2.147]
Relative Risk (a)			
Unstratified RR, 95% CI			0.419 [0.084, 2.102]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.033 [-0.092, 0.026]
Test on Differences (c)			
Unstratified p-value			0.4442

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.79.2.1: Effect Measures of Proportion of Subjects with TESAEs - Respiratory, Thoracic and Mediastinal Disorders (SOC)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	8 (9.6%)	13 (14.9%)	
Number of patients without event	75 (90.4%)	74 (85.1%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.607 [0.238, 1.550]
Relative Risk (a)			
Unstratified RR, 95% CI			0.645 [0.282, 1.476]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.053 [-0.151, 0.045]
Test on Differences (c)			
Unstratified p-value			0.2935

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.80.2.1: Effect Measures of Proportion of Subjects with TESAEs - Pleural Effusion (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	1 (1.2%)	5 (5.7%)	
Number of patients without event	82 (98.8%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.200 [0.023, 1.749]
Relative Risk (a)			
Unstratified RR, 95% CI			0.210 [0.025, 1.757]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.045 [-0.100, 0.009]
Test on Differences (c)			
Unstratified p-value			0.2112

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.81.2.1: Effect Measures of Proportion of Subjects with TESAEs - Pulmonary Embolism (PT)
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	Placebo + CAPOX (N= 87)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	83 (100.0%)	87 (100.0%)	
Number of patients with events	2 (2.4%)	5 (5.7%)	
Number of patients without event	81 (97.6%)	82 (94.3%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.405 [0.076, 2.147]
Relative Risk (a)			
Unstratified RR, 95% CI			0.419 [0.084, 2.102]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.033 [-0.092, 0.026]
Test on Differences (c)			
Unstratified p-value			0.4442

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; PT=preferred term; RR=risk ratio; SOC=system organ class; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction. (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo. (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
Note: SOCs and PTs are reported only if events are either 1) occurring in at least 5% of subjects in at least one treatment group; OR 2) occurring in at least 10 subjects overall and at least 1% of subjects in at least one treatment group.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mSAF (CPS < 1)

Anhang 4-G Sicherheit
Anhang 4-G Abbruchgründe – SOC und PT

Table 302.3.2000.5.2: Frequency Summary of (Permanent) Treatment Discontinuation due to Treatment Emergent Adverse Event
Modified Safety Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=83)	Placebo + CAPOX (N=87)	Total (N=170)
Overall	26 (31.3%)	22 (25.3%)	48 (28.2%)
Gastrointestinal Disorders	7 (8.4%)	4 (4.6%)	11 (6.5%)
Vomiting	3 (3.6%)	2 (2.3%)	5 (2.9%)
Diarrhoea	2 (2.4%)	1 (1.1%)	3 (1.8%)
Nausea	1 (1.2%)	1 (1.1%)	2 (1.2%)
Abdominal Pain Upper	0	1 (1.1%)	1 (0.6%)
Swollen Tongue	1 (1.2%)	0	1 (0.6%)
Upper Gastrointestinal Haemorrhage	1 (1.2%)	0	1 (0.6%)
Nervous System Disorders	7 (8.4%)	2 (2.3%)	9 (5.3%)
Peripheral Sensory Neuropathy	3 (3.6%)	1 (1.1%)	4 (2.4%)
Dizziness	1 (1.2%)	1 (1.1%)	2 (1.2%)
Paraesthesia	2 (2.4%)	0	2 (1.2%)
Dysaesthesia	1 (1.2%)	0	1 (0.6%)
General Disorders And Administration Site Conditions	5 (6.0%)	2 (2.3%)	7 (4.1%)
Chest Discomfort	1 (1.2%)	1 (1.1%)	2 (1.2%)
Asthenia	1 (1.2%)	0	1 (0.6%)
Death	1 (1.2%)	0	1 (0.6%)
Malaise	1 (1.2%)	0	1 (0.6%)
Performance Status Decreased	0	1 (1.1%)	1 (0.6%)
Sudden Death	1 (1.2%)	0	1 (0.6%)
Infections And Infestations	0	5 (5.7%)	5 (2.9%)
Abdominal Infection	0	1 (1.1%)	1 (0.6%)
Escherichia Infection	0	1 (1.1%)	1 (0.6%)
Mucosal Infection	0	1 (1.1%)	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: descending by the number of subjects in total group by system organ class and preferred term.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2000.5.2: Frequency Summary of (Permanent) Treatment Discontinuation due to Treatment Emergent Adverse Event
Modified Safety Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=83)	Placebo + CAPOX (N=87)	Total (N=170)
Pneumonia	0	1 (1.1%)	1 (0.6%)
Septic Shock	0	1 (1.1%)	1 (0.6%)
Respiratory, Thoracic And Mediastinal Disorders	0	5 (5.7%)	5 (2.9%)
Dyspnoea	0	2 (2.3%)	2 (1.2%)
Pleural Effusion	0	2 (2.3%)	2 (1.2%)
Acute Respiratory Distress Syndrome	0	1 (1.1%)	1 (0.6%)
Pulmonary Oedema	0	1 (1.1%)	1 (0.6%)
Blood And Lymphatic System Disorders	2 (2.4%)	2 (2.3%)	4 (2.4%)
Neutropenia	2 (2.4%)	2 (2.3%)	4 (2.4%)
Investigations	3 (3.6%)	1 (1.1%)	4 (2.4%)
Alanine Aminotransferase Increased	2 (2.4%)	0	2 (1.2%)
Blood Bilirubin Increased	2 (2.4%)	0	2 (1.2%)
Aspartate Aminotransferase Increased	1 (1.2%)	0	1 (0.6%)
Ejection Fraction Decreased	0	1 (1.1%)	1 (0.6%)
Gamma-Glutamyltransferase Increased	1 (1.2%)	0	1 (0.6%)
Metabolism And Nutrition Disorders	2 (2.4%)	2 (2.3%)	4 (2.4%)
Decreased Appetite	1 (1.2%)	1 (1.1%)	2 (1.2%)
Acidosis	0	1 (1.1%)	1 (0.6%)
Hypokalaemia	1 (1.2%)	0	1 (0.6%)
Renal And Urinary Disorders	1 (1.2%)	3 (3.4%)	4 (2.4%)
Acute Kidney Injury	0	2 (2.3%)	2 (1.2%)
Choluria	1 (1.2%)	0	1 (0.6%)
Chronic Kidney Disease	0	1 (1.1%)	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: descending by the number of subjects in total group by system organ class and preferred term.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2000.5.2: Frequency Summary of (Permanent) Treatment Discontinuation due to Treatment Emergent Adverse Event
Modified Safety Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=83)	Placebo + CAPOX (N=87)	Total (N=170)
Skin And Subcutaneous Tissue Disorders	3 (3.6%)	1 (1.1%)	4 (2.4%)
Cold Sweat	0	1 (1.1%)	1 (0.6%)
Pruritus	1 (1.2%)	0	1 (0.6%)
Rash Erythematous	1 (1.2%)	0	1 (0.6%)
Skin Necrosis	1 (1.2%)	0	1 (0.6%)
Cardiac Disorders	1 (1.2%)	1 (1.1%)	2 (1.2%)
Cardio-Respiratory Arrest	1 (1.2%)	1 (1.1%)	2 (1.2%)
Hepatobiliary Disorders	2 (2.4%)	0	2 (1.2%)
Deficiency Of Bile Secretion	1 (1.2%)	0	1 (0.6%)
Hepatic Function Abnormal	1 (1.2%)	0	1 (0.6%)
Jaundice	1 (1.2%)	0	1 (0.6%)
Immune System Disorders	2 (2.4%)	0	2 (1.2%)
Anaphylactic Reaction	2 (2.4%)	0	2 (1.2%)
Injury, Poisoning And Procedural Complications	2 (2.4%)	0	2 (1.2%)
Fall	1 (1.2%)	0	1 (0.6%)
Head Injury	1 (1.2%)	0	1 (0.6%)
Procedural Complication	1 (1.2%)	0	1 (0.6%)
Neoplasms Benign, Malignant And Unspecified (Incl Cysts And Polyps)	0	2 (2.3%)	2 (1.2%)
Malignant Neoplasm Progression	0	2 (2.3%)	2 (1.2%)
Congenital, Familial And Genetic Disorders	1 (1.2%)	0	1 (0.6%)
Gene Mutation	1 (1.2%)	0	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: descending by the number of subjects in total group by system organ class and preferred term.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2000.5.2: Frequency Summary of (Permanent) Treatment Discontinuation due to Treatment Emergent Adverse Event
Modified Safety Analysis Set (CPS < 1)

MedDRA SOC and PT	Zolbetuximab + CAPOX (N=83)	Placebo + CAPOX (N=87)	Total (N=170)
Vascular Disorders	1 (1.2%)	0	1 (0.6%)
Flushing	1 (1.2%)	0	1 (0.6%)
Hypotension	1 (1.2%)	0	1 (0.6%)

Abbreviations: CPS=combined positive score; N=number of patients; PT=preferred term; SOC=system organ class.
Sorting order: descending by the number of subjects in total group by system organ class and preferred term.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Weitere Analysen

Anhang 4-G Beobachtungsdauern

Table 302.3.1001.2.2.1: Summary of Duration of Observation Time of Overall Survival
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Duration of observation period (months)		
n	84	88
Mean (SD)	15.0 (11.13)	12.4 (10.45)
Median	12.0	9.5
Q1-Q3	6.8 - 21.2	4.9 - 17.3
Range	0 - 46	0 - 46

Abbreviations: CPS=combined positive score; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for overall survival will include the time from randomisation until the last date endpoint data are collected for overall survival.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.2.2.2: Summary of Duration of Observation Time of Progression-Free Survival (IRC)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Duration of observation period (months)		
n	84	88
Mean (SD)	9.0 (9.36)	7.2 (6.54)
Median	6.0	6.0
Q1-Q3	3.3 - 12.2	2.2 - 9.0
Range	0 - 46	0 - 30

Abbreviations: CPS=combined positive score; IRC=independent review committee; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for progression-free survival (IRC) will include the time from randomisation until the last date endpoint data are collected for progression-free survival (IRC).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.2.2.3: Summary of Duration of Observation Time of Progression-Free Survival (INV)
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Duration of observation period (months)		
n	84	88
Mean (SD)	8.7 (8.67)	6.6 (6.16)
Median	6.1	4.4
Q1-Q3	3.5 - 12.0	1.9 - 9.7
Range	0 - 37	0 - 29

Abbreviations: CPS=combined positive score; INV=investigator; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for progression-free survival (INV) will include the time from randomisation until the last date endpoint data are collected for progression-free survival (INV).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.3000.1.2: EORTC QLQ-C30 - Summary of Duration of Observation Time
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Duration of observation period (months)		
n	82	86
Mean (SD)	10.3 (10.18)	7.9 (6.87)
Median	6.7	6.5
Q1-Q3	3.4 - 15.8	2.8 - 11.0
Range	0 - 46	0 - 30

Abbreviations: CPS=combined positive score; EORTC QLQ-C30=european organisation for research and treatment of cancer quality of life questionnaire-core 30; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for EORTC QLQ-C30 questionnaire includes the time from randomisation until the last date data were collected for EORTC QLQ-C30 questionnaire.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3000.2.2: EORTC QLQ-OG25 - Summary of Duration of Observation Time
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Duration of observation period (months)		
n	82	86
Mean (SD)	10.3 (10.19)	7.9 (6.87)
Median	6.7	6.5
Q1-Q3	3.4 - 15.8	2.8 - 11.0
Range	0 - 46	0 - 30

Abbreviations: CPS=combined positive score; EORTC QLQ-OG25=european organisation for research and treatment of cancer oesophago-gastric module 25; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for EORTC QLQ-OG25 questionnaire includes the time from randomisation until the last date data were collected for EORTC QLQ-OG25 questionnaire.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3000.3.2: EQ-5D-5L Visual Analog Scale - Summary of Duration of Observation Time
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Duration of observation period (months)		
n	82	86
Mean (SD)	10.4 (10.16)	7.9 (6.87)
Median	6.8	6.5
Q1-Q3	3.7 - 15.8	2.8 - 11.0
Range	0 - 46	0 - 30

Abbreviations: CPS=combined positive score; EQ-5D-5L=european quality of life 5 dimensions 5 level; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for EQ-5D VAS includes the time from randomisation until the last date data were collected for EQ-5D VAS.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3000.4.2: Global Pain - Summary of Duration of Observation Time
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Duration of observation period (months)		
n	82	86
Mean (SD)	10.3 (10.19)	7.9 (6.87)
Median	6.7	6.5
Q1-Q3	3.4 - 15.8	2.8 - 11.0
Range	0 - 46	0 - 30

Abbreviations: CPS=combined positive score; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for Global Pain questionnaire includes the time from randomisation until the last date data were collected for Global Pain questionnaire.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.3000.5.2: EORTC QLQ-STO22 - Summary of Duration of Observation Time
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 84)	**Placebo + CAPOX (N= 88)**
Duration of observation period (months)		
n	82	86
Mean (SD)	10.3 (10.19)	7.9 (6.87)
Median	6.7	6.5
Q1-Q3	3.4 - 15.8	2.8 - 11.0
Range	0 - 46	0 - 30

Abbreviations: CPS=combined positive score; EORTC QLQ-STO22=european organisation for research and treatment of cancer gastric cancer module; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for EORTC QLQ-STO22 questionnaire includes the time from randomisation until the last date data were collected for EORTC QLQ-STO22 questionnaire.
ASTELLAS Data Cutoff Date: 12JAN24 (GLOW 8951-CL-302)

Table 302.3.2000.6.2.1: Summary of Duration of Observation Time for Safety Endpoints
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**
Duration of observation period (months)		
n	83	87
Mean (SD)	11.9 (9.68)	9.4 (6.89)
Median	8.5	7.6
Q1-Q3	4.1 - 15.8	4.6 - 13.2
Range	1 - 46	0 - 30

Abbreviations: CPS=combined positive score; DCO=data cut-off; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Note: Observation time for safety endpoints is defined as the time from first dose until DCO, study treatment discontinuation +90 days or death, whichever occured first and stopped the collection of endpoint data.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2000.6.2.2: Summary of Duration of Observation Time for any TEAE
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**
Duration of observation period (months)		
n	83	87
Mean (SD)	10.5 (9.83)	8.1 (6.61)
Median	7.0	6.0
Q1-Q3	3.5 - 14.0	3.2 - 11.3
Range	1 - 46	0 - 30

Abbreviations: CPS=combined positive score; DCO=data cut-off; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation; TEAE=treatment-emergent adverse event.
Note: Observation time for any TEAE is defined as the time from first dose until DCO, study treatment discontinuation +30 days or death, whichever occured first and stopped the collection of endpoint data.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Weitere Analysen

Anhang 4-G Begleitmedikationen

Table 302.3.1001.5.2: Summary of Concomitant Therapies
Modified Full Analysis Set (CPS < 1)

Therapeutic Subgroup	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)
Overall	82 (97.6%)	85 (96.6%)
Agents Acting On The Renin-Angiotensin System	16 (19.0%)	12 (13.6%)
All Other Therapeutic Products	2 (2.4%)	3 (3.4%)
Analgesics	44 (52.4%)	45 (51.1%)
Anesthetics	2 (2.4%)	1 (1.1%)
Anti-Acne Preparations	0	2 (2.3%)
Anti-Parkinson Drugs	0	1 (1.1%)
Antianemic Preparations	16 (19.0%)	14 (15.9%)
Antibacterials For Systemic Use	25 (29.8%)	16 (18.2%)
Antibiotics And Chemotherapeutics For Dermatological Use	6 (7.1%)	3 (3.4%)
Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents	22 (26.2%)	25 (28.4%)
Antiemetics And Antinauseants	65 (77.4%)	59 (67.0%)
Antiepileptics	1 (1.2%)	0
Antifungals For Dermatological Use	3 (3.6%)	2 (2.3%)
Antigout Preparations	1 (1.2%)	4 (4.5%)
Antihemorrhagics	1 (1.2%)	4 (4.5%)
Antihistamines For Systemic Use	19 (22.6%)	12 (13.6%)
Antihypertensives	1 (1.2%)	2 (2.3%)
Antiinflammatory And Antirheumatic Products	13 (15.5%)	13 (14.8%)
Antimycobacterials	1 (1.2%)	0
Antimycotics For Systemic Use	0	2 (2.3%)
Antipruritics, Incl. Antihistamines, Anesthetics, Etc.	5 (6.0%)	4 (4.5%)
Antiseptics And Disinfectants	1 (1.2%)	1 (1.1%)
Antithrombotic Agents	18 (21.4%)	13 (14.8%)
Antivirals For Systemic Use	2 (2.4%)	3 (3.4%)
Appetite Stimulants	5 (6.0%)	8 (9.1%)
Beta Blocking Agents	6 (7.1%)	6 (6.8%)

Abbreviations: CPS=combined positive score; ATC=anatomical therapeutic chemical; N=number of patients.
Sorting order: alphabetical order by Therapeutic Subgroup (ATC 2nd level).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.5.2: Summary of Concomitant Therapies
Modified Full Analysis Set (CPS < 1)

Therapeutic Subgroup	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)
Bile And Liver Therapy	8 (9.5%)	4 (4.5%)
Blood Substitutes And Perfusion Solutions	19 (22.6%)	19 (21.6%)
Calcium Channel Blockers	10 (11.9%)	10 (11.4%)
Cardiac Therapy	4 (4.8%)	4 (4.5%)
Contrast Media	1 (1.2%)	0
Corticosteroids For Systemic Use	36 (42.9%)	31 (35.2%)
Corticosteroids, Dermatological Preparations	10 (11.9%)	7 (8.0%)
Cough And Cold Preparations	2 (2.4%)	5 (5.7%)
Digestives, Incl. Enzymes	3 (3.6%)	6 (6.8%)
Diuretics	17 (20.2%)	17 (19.3%)
Drugs For Acid Related Disorders	57 (67.9%)	49 (55.7%)
Drugs For Constipation	18 (21.4%)	38 (43.2%)
Drugs For Functional Gastrointestinal Disorders	20 (23.8%)	26 (29.5%)
Drugs For Obstructive Airway Diseases	4 (4.8%)	3 (3.4%)
Drugs For Treatment Of Bone Diseases	3 (3.6%)	1 (1.1%)
Drugs Used In Diabetes	15 (17.9%)	10 (11.4%)
Emollients And Protectives	15 (17.9%)	14 (15.9%)
General Nutrients	6 (7.1%)	11 (12.5%)
Gynecological Antiinfectives And Antiseptics	0	1 (1.1%)
Immune Sera And Immunoglobulins	0	1 (1.1%)
Immunostimulants	7 (8.3%)	7 (8.0%)
Lipid Modifying Agents	14 (16.7%)	8 (9.1%)
Mineral Supplements	16 (19.0%)	6 (6.8%)
Muscle Relaxants	3 (3.6%)	5 (5.7%)
Nasal Preparations	1 (1.2%)	1 (1.1%)
Ophthalmologicals	4 (4.8%)	4 (4.5%)
Other Alimentary Tract And Metabolism Products	4 (4.8%)	2 (2.3%)
Other Drugs For Disorders Of The Musculo-Skeletal System	1 (1.2%)	0

Abbreviations: CPS=combined positive score; ATC=anatomical therapeutic chemical; N=number of patients.
Sorting order: alphabetical order by Therapeutic Subgroup (ATC 2nd level).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.5.2: Summary of Concomitant Therapies
Modified Full Analysis Set (CPS < 1)

Therapeutic Subgroup	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)
Other Nervous System Drugs	5 (6.0%)	4 (4.5%)
Preparations For Treatment Of Wounds And Ulcers	3 (3.6%)	1 (1.1%)
Psychoanaleptics	6 (7.1%)	5 (5.7%)
Psycholeptics	27 (32.1%)	30 (34.1%)
Sex Hormones And Modulators Of The Genital System	1 (1.2%)	1 (1.1%)
Stomatological Preparations	5 (6.0%)	4 (4.5%)
Throat Preparations	3 (3.6%)	1 (1.1%)
Thyroid Therapy	3 (3.6%)	1 (1.1%)
Topical Products For Joint And Muscular Pain	5 (6.0%)	2 (2.3%)
Unspecified Herbal And Traditional Medicine	2 (2.4%)	2 (2.3%)
Urologicals	6 (7.1%)	6 (6.8%)
Vaccines	7 (8.3%)	7 (8.0%)
Vasoprotectives	2 (2.4%)	2 (2.3%)
Vitamins	13 (15.5%)	12 (13.6%)

Abbreviations: CPS=combined positive score; ATC=anatomical therapeutic chemical; N=number of patients.
Sorting order: alphabetical order by Therapeutic Subgroup (ATC 2nd level).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Weitere Analysen
Anhang 4-G Studienmedikation – Exposition

Table 302.3.1001.6.2: Summary of Study Drug Exposure
Modified Safety Analysis Set (CPS < 1)

	Zolbetuximab + CAPOX (N= 83)	**Placebo + CAPOX (N= 87)**
Duration of Zolbetuximab/Placebo (days)		
n	83	87
Mean (SD)	271.0 (304.4)	198.1 (198.2)
Median	146.0	132.0
Range	1 - 1395	1 - 913
Duration of Oxaliplatin (days)		
n	81	87
Mean (SD)	111.6 (59.19)	105.8 (61.92)
Median	127.0	117.0
Range	1 - 197	1 - 204
Duration of Capecitabine (days)		
n	80	87
Mean (SD)	252.0 (263.4)	192.6 (187.2)
Median	158.0	141.0
Range	1 - 1177	3 - 904

Abbreviations: CPS=combined positive score; N=number of patients; n=number of patients treated with respective study drug; SD=standard deviation.
Duration of each component is defined as (date of last infusion) - (date of first infusion) + 1.
Zolbetuximab + CAPOX components: Zolbetuximab, Oxaliplatin and Capecitabine.
Placebo + CAPOX components: Placebo, Oxaliplatin and Capecitabine.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Weitere Analysen

Anhang 4-G Patientenfluss

Table 302.3.1001.7.2: Summary of Disposition of Subjects (CPS < 1)

	Zolbetuximab + CAPOX	Placebo + CAPOX	Total
Number of Randomized Patients	84	88	172
Safety Analysis Set [1]	83 (98.8%)	87 (98.9%)	170 (98.8%)
Full Analysis Set	84 (100.0%)	88 (100.0%)	172 (100.0%)
Pharmacokinetics Analysis Set	78 (92.9%)	0	78 (45.3%)
Overall Treatment Discontinuation [2]			
Yes	75 (89.3%)	77 (87.5%)	152 (88.4%)
No	9 (10.7%)	11 (12.5%)	20 (11.6%)
Reason for Overall Treatment Discontinuation [3]			
Adverse Event	13 (15.5%)	4 (4.5%)	17 (9.9%)
Death	7 (8.3%)	11 (12.5%)	18 (10.5%)
Lost to Follow-Up	1 (1.2%)	1 (1.1%)	2 (1.2%)
Other	13 (15.5%)	4 (4.5%)	17 (9.9%)
Pregnancy	0	0	0
Progressive Disease	38 (45.2%)	50 (56.8%)	88 (51.2%)
Protocol Deviation	0	0	0
Withdrawal by Subject	7 (8.3%)	7 (8.0%)	14 (8.1%)
Post-Treatment Follow-Up Discontinuation			
Yes	77 (91.7%)	84 (95.5%)	161 (93.6%)
No	7 (8.3%)	4 (4.5%)	11 (6.4%)
Primary Post-Treatment Follow-Up Status			
Adverse Event	1 (1.2%)	0	1 (0.6%)
Death	30 (35.7%)	43 (48.9%)	73 (42.4%)
Lost to Follow-Up	3 (3.6%)	2 (2.3%)	5 (2.9%)
Other	13 (15.5%)	12 (13.6%)	25 (14.5%)
Pregnancy	0	0	0
Progressive Disease	14 (16.7%)	14 (15.9%)	28 (16.3%)
Protocol Deviation	0	0	0
Study Terminated by Sponsor	0	0	0
Withdrawal by Subject	16 (19.0%)	13 (14.8%)	29 (16.9%)

Abbreviations: CPS=combined positive score.
[1]: All subjects who received at least one dose of any study drug (Zolbetuximab/Placebo/CAPOX). If a subject received at least one dose of zolbetuximab, the subject is counted under the zolbetuximab arm.
[2]: Of both treatments.
[3]: Reason for overall treatment discontinuation is summarized using the reason of the latest discontinued compound.
If the subject discontinued from both treatments on the same day, all different reasons of discontinuation are summarized.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.7.2: Summary of Disposition of Subjects (CPS < 1)

	Zolbetuximab + CAPOX	Placebo + CAPOX	Total
Survival Follow-Up Discontinuation			
Yes	71 (84.5%)	79 (89.8%)	150 (87.2%)
No	13 (15.5%)	9 (10.2%)	22 (12.8%)
Primary Survival Follow-Up Status			
Death	51 (60.7%)	65 (73.9%)	116 (67.4%)
Lost to Follow-Up	2 (2.4%)	2 (2.3%)	4 (2.3%)
Other	1 (1.2%)	0	1 (0.6%)
Study Terminated by Sponsor	0	0	0
Withdrawal by Subject	17 (20.2%)	12 (13.6%)	29 (16.9%)

Abbreviations: CPS=combined positive score.
[1]: All subjects who received at least one dose of any study drug (Zolbetuximab/Placebo/CAPOX). If a subject received at least one dose of zolbetuximab, the subject is counted under the zolbetuximab arm.
[2]: Of both treatments.
[3]: Reason for overall treatment discontinuation is summarized using the reason of the latest discontinued compound.
If the subject discontinued from both treatments on the same day, all different reasons of discontinuation are summarized.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Weitere Analysen

Anhang 4-G Folgetherapien

1. Erste Folgetherapie

Table 302.3.1001.8.2: Summary of First Subsequent Therapy
Modified Full Analysis Set (CPS < 1)

Subsequent Therapies	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Overall	34 (40.5%)	45 (51.1%)	79 (45.9%)
All Other Therapeutic Products	3 (3.6%)	3 (3.4%)	6 (3.5%)
All Other Therapeutic Products	1 (1.2%)	2 (2.3%)	3 (1.7%)
All Other Therapeutic Products	1 (1.2%)	2 (2.3%)	3 (1.7%)
Detoxifying Agents For Antineoplastic Treatment	2 (2.4%)	1 (1.1%)	3 (1.7%)
Calcium Folinate	1 (1.2%)	1 (1.1%)	2 (1.2%)
Calcium Levofolinate Pentahydrate	1 (1.2%)	0	1 (0.6%)
Antineoplastic Agents	30 (35.7%)	38 (43.2%)	68 (39.5%)
Combinations Of Antineoplastic Agents	8 (9.5%)	11 (12.5%)	19 (11.0%)
Calcium Folinate;fluorouracil;irinotecan Hydrochloride	2 (2.4%)	6 (6.8%)	8 (4.7%)
Capecitabine;oxaliplatin	0	1 (1.1%)	1 (0.6%)
Combinations Of Antineoplastic Agents	1 (1.2%)	0	1 (0.6%)
Paclitaxel;ramucirumab	5 (6.0%)	4 (4.5%)	9 (5.2%)
Folic Acid Analogues	0	1 (1.1%)	1 (0.6%)
Methotrexate	0	1 (1.1%)	1 (0.6%)
Pd-1/Pdl-1 (Programmed Cell Death Protein 1/Death Ligand 1) Inhibitors	1 (1.2%)	1 (1.1%)	2 (1.2%)
Pembrolizumab	1 (1.2%)	1 (1.1%)	2 (1.2%)
Platinum Compounds	5 (6.0%)	2 (2.3%)	7 (4.1%)
Carboplatin	1 (1.2%)	0	1 (0.6%)
Cisplatin	2 (2.4%)	2 (2.3%)	4 (2.3%)
Oxaliplatin	2 (2.4%)	0	2 (1.2%)
Pyrimidine Analogues	6 (7.1%)	6 (6.8%)	12 (7.0%)
Capecitabine	0	1 (1.1%)	1 (0.6%)
Fluorouracil	4 (4.8%)	3 (3.4%)	7 (4.1%)
Gemcitabine	1 (1.2%)	0	1 (0.6%)
Gimeracil;oteracil Potassium;tegafur	1 (1.2%)	2 (2.3%)	3 (1.7%)
Taxanes	14 (16.7%)	20 (22.7%)	34 (19.8%)
Docetaxel	4 (4.8%)	2 (2.3%)	6 (3.5%)

Abbreviations: CPS=combined positive score; N=number of patients.
Sorting order: alphabetical order by Therapeutic Subgroup, Chemical Subgroup and Preferred WHO Name. Ingredients are the list of active ingredients for combination drugs.
Note: If a patient received more than one subsequent therapy at the first day, all components are considered.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.8.2: Summary of First Subsequent Therapy
Modified Full Analysis Set (CPS < 1)

Subsequent Therapies	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Paclitaxel	8 (9.5%)	15 (17.0%)	23 (13.4%)
Paclitaxel Nanoparticle Albumin-Bound	2 (2.4%)	3 (3.4%)	5 (2.9%)
Topoisomerase 1 (Top1) Inhibitors	3 (3.6%)	3 (3.4%)	6 (3.5%)
Irinotecan	3 (3.6%)	3 (3.4%)	6 (3.5%)
Vegf/Vegfr (Vascular Endothelial Growth Factor) Inhibitors	3 (3.6%)	8 (9.1%)	11 (6.4%)
Ramucirumab	3 (3.6%)	8 (9.1%)	11 (6.4%)
Corticosteroids For Systemic Use	0	1 (1.1%)	1 (0.6%)
Glucocorticoids	0	1 (1.1%)	1 (0.6%)
Prednisolone Sodium Succinate	0	1 (1.1%)	1 (0.6%)
Various	3 (3.6%)	5 (5.7%)	8 (4.7%)
Various	3 (3.6%)	5 (5.7%)	8 (4.7%)
Radiotherapy	3 (3.6%)	5 (5.7%)	8 (4.7%)

Abbreviations: CPS=combined positive score; N=number of patients.
Sorting order: alphabetical order by Therapeutic Subgroup, Chemical Subgroup and Preferred WHO Name. Ingredients are the list of active ingredients for combination drugs.
Note: If a patient received more than one subsequent therapy at the first day, all components are considered.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G mITT (CPS < 1)

Anhang 4-G Weitere Analysen
Anhang 4-G Folgetherapien

2. Alle Folgetherapien

Table 302.3.1001.8: Summary of Subsequent Therapies - Patients with CPS < 1

Subsequent Therapies	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Overall	34 (40.5%)	45 (51.1%)	79 (45.9%)
All Other Therapeutic Products	4 (4.8%)	4 (4.5%)	8 (4.7%)
All Other Therapeutic Products	1 (1.2%)	2 (2.3%)	3 (1.7%)
All Other Therapeutic Products	1 (1.2%)	2 (2.3%)	3 (1.7%)
Detoxifying Agents For Antineoplastic Treatment	3 (3.6%)	2 (2.3%)	5 (2.9%)
Calcium Folinate	2 (2.4%)	2 (2.3%)	4 (2.3%)
Calcium Levofolinate Pentahydrate	1 (1.2%)	0	1 (0.6%)
Antineoplastic Agents	33 (39.3%)	42 (47.7%)	75 (43.6%)
Antineoplastic Agents	1 (1.2%)	0	1 (0.6%)
Investigational Antineoplastic Drugs	1 (1.2%)	0	1 (0.6%)
Combinations Of Antineoplastic Agents	11 (13.1%)	11 (12.5%)	22 (12.8%)
Calcium Folinate;fluorouracil;irinotecan Hydrochloride	2 (2.4%)	6 (6.8%)	8 (4.7%)
Capecitabine;oxaliplatin	3 (3.6%)	1 (1.1%)	4 (2.3%)
Combinations Of Antineoplastic Agents	1 (1.2%)	0	1 (0.6%)
Paclitaxel;ramucirumab	6 (7.1%)	4 (4.5%)	10 (5.8%)
Folic Acid Analogues	0	1 (1.1%)	1 (0.6%)
Methotrexate	0	1 (1.1%)	1 (0.6%)
Other Monoclonal Antibodies And Antibody Drug Conjugates	1 (1.2%)	1 (1.1%)	2 (1.2%)
Catumaxomab	1 (1.2%)	0	1 (0.6%)
Dkn 01	0	1 (1.1%)	1 (0.6%)
Pd-1/Pdl-1 (Programmed Cell Death Protein 1/Death Ligand 1) Inhibitors	7 (8.3%)	5 (5.7%)	12 (7.0%)
Atezolizumab	0	1 (1.1%)	1 (0.6%)
Nivolumab	6 (7.1%)	2 (2.3%)	8 (4.7%)
Pembrolizumab	1 (1.2%)	2 (2.3%)	3 (1.7%)
Platinum Compounds	6 (7.1%)	4 (4.5%)	10 (5.8%)
Carboplatin	1 (1.2%)	0	1 (0.6%)
Cisplatin	3 (3.6%)	2 (2.3%)	5 (2.9%)
Oxaliplatin	2 (2.4%)	2 (2.3%)	4 (2.3%)
Pyrimidine Analogues	9 (10.7%)	12 (13.6%)	21 (12.2%)
Capecitabine	0	3 (3.4%)	3 (1.7%)
Fluorouracil	6 (7.1%)	5 (5.7%)	11 (6.4%)
Gemcitabine	1 (1.2%)	0	1 (0.6%)
Gimeracil;oteracil Potassium;tegafur	1 (1.2%)	3 (3.4%)	4 (2.3%)
Tipiracil Hydrochloride;trifluridine	1 (1.2%)	1 (1.1%)	2 (1.2%)
Taxanes	16 (19.0%)	26 (29.5%)	42 (24.4%)
Docetaxel	5 (6.0%)	3 (3.4%)	8 (4.7%)
Paclitaxel	9 (10.7%)	19 (21.6%)	28 (16.3%)
Paclitaxel Nanoparticle Albumin-Bound	2 (2.4%)	4 (4.5%)	6 (3.5%)

Subsequent Therapies	Zolbetuximab + CAPOX (N=84)	Placebo + CAPOX (N=88)	Total (N=172)
Topoisomerase 1 (Top1) Inhibitors	8 (9.5%)	8 (9.1%)	16 (9.3%)
Irinotecan	8 (9.5%)	7 (8.0%)	15 (8.7%)
Irinotecan Hydrochloride	0	1 (1.1%)	1 (0.6%)
Vegf/Vegfr (Vascular Endothelial Growth Factor) Inhibitors	4 (4.8%)	12 (13.6%)	16 (9.3%)
Ramucirumab	4 (4.8%)	12 (13.6%)	16 (9.3%)
Corticosteroids For Systemic Use	0	1 (1.1%)	1 (0.6%)
Glucocorticoids	0	1 (1.1%)	1 (0.6%)
Prednisolone Sodium Succinate	0	1 (1.1%)	1 (0.6%)
Immunostimulants	1 (1.2%)	0	1 (0.6%)
Immunostimulants	1 (1.2%)	0	1 (0.6%)
Immunotherapy	1 (1.2%)	0	1 (0.6%)
Various	4 (4.8%)	5 (5.7%)	9 (5.2%)
Various	4 (4.8%)	5 (5.7%)	9 (5.2%)
Radiotherapy	4 (4.8%)	5 (5.7%)	9 (5.2%)

Abbreviations: N=number of patients.
Sorting order: alphabetical order by Therapeutic Subgroup, Chemical Subgroup and Preferred WHO Name. Ingredients are the list of active ingredients for combination drugs.
ASTELLAS Data Cutoff Date: 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1 / unknown

Anhang 4-G Baseline Charakteristika

Table 302.3.1001.1.4: Summary of Baseline Demographics
Modified Full Analysis Set (CPS < 1 + Unknown)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N=174)	Placebo + CAPOX (N=173)
Sex		
Male	104 (59.8%)	102 (59.0%)
Female	70 (40.2%)	71 (41.0%)
Unknown	0	0
Age (years)		
n	174	173
Mean (SD)	58.18 (12.00)	56.40 (13.12)
Median	61.0	58.0
Range	22.0 - 81.0	21.0 - 83.0
Age (years)		
>=18 to <=64	117 (67.2%)	119 (68.8%)
>=65 to <85	57 (32.8%)	54 (31.2%)
Age Group 1 (years)		
<=65	123 (70.7%)	124 (71.7%)
>65	51 (29.3%)	49 (28.3%)
Age Group 2 (years)		
<=75	168 (96.6%)	164 (94.8%)
>75	6 (3.4%)	9 (5.2%)
Race		
White	52 (30.2%)	51 (30.4%)
Black or African American	0	0
Asian	120 (69.8%)	117 (69.6%)
American Indian or Alaska Native	0	0

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.1.4: Summary of Baseline Demographics
Modified Full Analysis Set (CPS < 1 + Unknown)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N=174)	Placebo + CAPOX (N=173)
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Missing	2	5
Ethnicity		
Hispanic or Latino	7 (4.1%)	4 (2.4%)
Not Hispanic or Latino	165 (95.9%)	164 (97.6%)
Missing	2	5
Country 1		
Japan	13 (7.5%)	14 (8.1%)
Non-Japan	161 (92.5%)	159 (91.9%)
Country 2		
China	76 (43.7%)	69 (39.9%)
Non-China	98 (56.3%)	104 (60.1%)
Height (cm)		
n	173	171
Mean (SD)	164.48 (8.72)	165.12 (8.42)
Median	164.0	165.0
Range	145.0 - 189.0	141.5 - 188.4
Weight (kg)		
n	173	171
Mean (SD)	60.50 (13.05)	59.53 (12.82)
Median	59.5	59.0
Range	37.4 - 111.2	29.1 - 91.3

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.1.4: Summary of Baseline Demographics
Modified Full Analysis Set (CPS < 1 + Unknown)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N=174)	Placebo + CAPOX (N=173)
BMI (kg/m^2)		
<18.5	28 (16.2%)	30 (17.5%)
>=18.5 to <25	103 (59.5%)	107 (62.6%)
>=25 to <30	37 (21.4%)	31 (18.1%)
>=30	5 (2.9%)	3 (1.8%)
Missing	1	2
BSA (m^2)		
n	173	171
Mean (SD)	1.65 (0.20)	1.64 (0.20)
Median	1.6	1.6
Range	1.2 - 2.3	1.1 - 2.2
BSA (m^2)		
<1.7	96 (55.5%)	101 (59.1%)
>=1.7	77 (44.5%)	70 (40.9%)
Missing	1	2
Tobacco History		
Never	94 (54.7%)	94 (55.6%)
Current	19 (11.0%)	16 (9.5%)
Former	59 (34.3%)	59 (34.9%)
Missing	2	4
Baseline ECOG Status		
0	69 (39.9%)	74 (43.3%)
1	104 (60.1%)	97 (56.7%)

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.1.4: Summary of Baseline Demographics
Modified Full Analysis Set (CPS < 1 + Unknown)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N=174)	Placebo + CAPOX (N=173)
Missing	1	2
Region (IRT)		
Asia	120 (69.0%)	117 (67.6%)
Non-Asia	54 (31.0%)	56 (32.4%)
Region (eCRF)		
Asia	120 (69.0%)	117 (67.6%)
Non-Asia	54 (31.0%)	56 (32.4%)
Number of Organs with Metastatic Sites (IRT)		
0-2	130 (74.7%)	128 (74.0%)
>=3	44 (25.3%)	45 (26.0%)
Number of Organs with Metastatic Sites (eCRF)		
0-2	126 (72.4%)	125 (72.3%)
>=3	48 (27.6%)	48 (27.7%)
Prior Gastrectomy (IRT)		
Yes	51 (29.3%)	52 (30.1%)
No	123 (70.7%)	121 (69.9%)
Prior Gastrectomy (eCRF)		
Yes	52 (29.9%)	47 (27.2%)
No	122 (70.1%)	126 (72.8%)

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1 / unknown

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben

Anhang 4-G Gesamtüberleben

1. Time-to-Event-Analyse

Table 302.3.1002.1.3.1: Summary of Overall Survival
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=174)	**Placebo + CAPOX (N=173)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	174 (100.0%)	173 (100.0%)	
Number of patients with events	119 (68.4%)	137 (79.2%)	
Number of patients censored	55 (31.6%)	36 (20.8%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	81.79 [75.00, 86.90]	72.00 [64.44, 78.23]	
Month 12	57.00 [48.93, 64.26]	49.52 [41.52, 57.01]	
Month 18	39.81 [32.09, 47.41]	27.73 [20.92, 34.94]	
Month 24	29.88 [22.75, 37.32]	18.84 [13.06, 25.45]	
Month 30	22.66 [15.81, 30.26]	14.00 [8.89, 20.25]	
Month 36	19.68 [12.83, 27.60]	9.38 [4.91, 15.61]	
Month 42	16.86 [9.65, 25.79]	9.38 [4.91, 15.61]	
Month 48	NC [NC, NC]	NC [NC, NC]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	14.39 [11.96, 17.18]	11.53 [9.13, 13.90]	
Difference in median			2.86
Cox proportional hazards model			
Stratified HR, 95% CI			0.719 [0.558, 0.928]
Log-rank test			
Two-sided stratified log-rank p-value			0.0112

Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.1.3.2: Type of Events and Censoring of Overall Survival
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=174)	**Placebo + CAPOX (N=173)**
Number of patients at risk	174 (100.0%)	173 (100.0%)
Number of patients with events	119 (68.4%)	137 (79.2%)
Death before analysis cutoff date	119 (68.4%)	137 (79.2%)
Number of patients censored	55 (31.6%)	36 (20.8%)
Last known alive date is before cutoff date	50 (28.7%)	34 (19.7%)
Censored at cutoff date	5 (2.9%)	2 (1.2%)

Abbreviations: CPS=combined positive score; N=number of patients.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.1.3.2a: Breakdown of Reasons for Censoring
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX	Placebo + CAPOX	Total
Number of patients censored	55	36	91
1 Censored at Cutoff Date	5	2	7
2 Last known alive date is before cutoff date	50	34	84
2.a Not in survival follow-up	25	18	43
2.a.1 Lost To Follow-Up	4	2	6
2.a.2 Withdrawal By Subject	19	16	35
2.a.3 Other	2	0	2
2.b In survival follow-up	25	16	41
Timepoint of censoring relative to cutoff date			
2.b.1 < 4 weeks	15 (60.0%)	7 (43.8%)	22 (53.7%)
2.b.2 4-8 weeks	10 (40.0%)	8 (50.0%)	18 (43.9%)
2.b.3 8-12 weeks	0 (0.0%)	1 (6.3%)	1 (2.4%)

Abbreviations: CPS = combined positive score
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.1.3.3: Summary of Overall Survival by Subgroups
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	**N**	**n (%)**	**KME [95% CI](a)**	**N**	**n (%)**	**KME [95% CI](a)**	**HR [95% CI](b)**	**Log-rank p-value(c)**	**Test for Interaction p-value(d)**
Age Group 1									
<=65 years	123	78 (63.4)	14.32 [11.96, 18.66]	124	99 (79.8)	12.55 [8.77, 14.13]	0.662 [0.492, 0.892]	0.0062	0.2730
>65 years	51	41 (80.4)	14.39 [9.07, 17.94]	49	38 (77.6)	11.10 [7.69, 15.31]	0.892 [0.573, 1.388]	0.6163	
Age Group 2									
<=75 years	168	115 (68.5)	13.73 [11.76, 16.99]	164	131 (79.9)	11.53 [8.77, 13.67]	0.729 [0.567, 0.936]	0.0131	0.7288
>75 years	6	4 (66.7)	28.48 [14.39, NC]	9	6 (66.7)	17.74 [0.69, NC]	0.592 [0.165, 2.127]	0.4444	
Sex									
Male	104	76 (73.1)	12.35 [10.22, 15.51]	102	83 (81.4)	9.76 [7.49, 13.17]	0.761 [0.557, 1.040]	0.0864	0.6031
Female	70	43 (61.4)	17.18 [12.55, 25.89]	71	54 (76.1)	13.67 [9.86, 16.56]	0.658 [0.441, 0.983]	0.0396	
Region									
Asia	120	81 (67.5)	15.74 [13.11, 18.83]	117	89 (76.1)	10.71 [7.95, 13.90]	0.678 [0.501, 0.917]	0.0112	0.3532
Non-Asia	54	38 (70.4)	11.76 [8.80, 16.00]	56	48 (85.7)	12.94 [7.75, 16.03]	0.851 [0.554, 1.308]	0.4645	
Number of Organs with Metastatic Sites									
0-2	130	84 (64.6)	15.51 [13.11, 19.29]	128	101 (78.9)	13.17 [10.58, 15.80]	0.718 [0.537, 0.959]	0.0246	0.8372
>=3	44	35 (79.5)	11.76 [8.28, 16.62]	45	36 (80.0)	9.13 [5.82, 11.10]	0.679 [0.425, 1.086]	0.1037	
Prior Gastrectomy (total or partial)									
Yes	51	35 (68.6)	18.83 [11.37, 23.69]	52	38 (73.1)	13.11 [9.13, 19.25]	0.836 [0.528, 1.325]	0.4475	0.4123
No	123	84 (68.3)	13.67 [11.33, 16.49]	121	99 (81.8)	11.10 [7.49, 13.67]	0.675 [0.504, 0.904]	0.0080	


Abbreviations: CI=confidence interval; CPS=combined positive score; GEJ=gastro-esophageal junction; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method, (b) Calculated from Cox proportional hazards model, (c) Based on 2-sided log-rank test, unadjusted for multiplicity, and (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1/ unknown

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben
Anhang 4-G Gesamtüberleben

2. Kaplan-Meier-Plots

Figure 302.3.1002.1.3: Kaplan-Meier Plot of Overall Survival - Modified Full Analysis Set (CPS < 1 + Unknown)



at Risk

1	174 (0.0)	131 (7.5)	88 (9.8)	58 (12.1)	39 (14.9)	19 (22.4)	9 (27.0)	3 (29.9)	0 (31.6)
2	173 (0.0)	114 (7.5)	76 (9.2)	42 (9.8)	26 (11.6)	15 (14.5)	5 (17.9)	1 (20.2)	0 (20.8)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; N=number of patients.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1/ unknown

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben
Anhang 4-G Progressionsfreies Überleben (IRC und INV)

1. Time-to-Event-Analysen

Table 302.3.1002.2.3.1: Summary of Progression-Free Survival (IRC)
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=174)	**Placebo + CAPOX (N=173)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	174 (100.0%)	173 (100.0%)	
Number of patients with events	103 (59.2%)	123 (71.1%)	
Number of patients censored	71 (40.8%)	50 (28.9%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	69.60 [61.23, 76.52]	60.04 [51.82, 67.32]	
Month 12	36.08 [27.55, 44.66]	21.14 [14.34, 28.84]	
Month 18	23.21 [15.80, 31.47]	11.72 [6.48, 18.65]	
Month 24	14.22 [7.98, 22.21]	7.99 [3.60, 14.65]	
Month 30	12.19 [6.17, 20.39]	6.40 [2.46, 12.99]	
Month 36	12.19 [6.17, 20.39]	4.26 [1.07, 11.14]	
Month 42	12.19 [6.17, 20.39]	NC [NC, NC]	
Month 48	NC [NC, NC]	NC [NC, NC]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	8.44 [7.13, 10.35]	6.51 [6.05, 8.11]	
Difference in median			1.94
Cox proportional hazards model			
Stratified HR, 95% CI			0.668 [0.509, 0.877]
Log-rank test			
Two-sided stratified log-rank p-value			0.0036

Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; IRC=independent review committee; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.2.3.2: Type of Events and Censoring of Progression-Free Survival (IRC)
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=174)	**Placebo + CAPOX (N=173)**
Number of patients at risk	174 (100.0%)	173 (100.0%)
Number of patients with events	103 (59.2%)	123 (71.1%)
rPD	54 (31.0%)	70 (40.5%)
No rPD, but death recorded on eCRF	49 (28.2%)	53 (30.6%)
Number of patients censored	71 (40.8%)	50 (28.9%)

Abbreviations: CPS=combined positive score; eCRF=electronic case report form; IRC=independent review committee; N=number of patients; rPD=radiological progressive disease.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.2.3.3: Summary of Progression-Free Survival (IRC) by Subgroups
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	**N**	**n (%)**	**KME [95% CI](a)**	**N**	**n (%)**	**KME [95% CI](a)**	**HR [95% CI](b)**	**Log-rank p-value(c)**	**Test for Interaction p-value(d)**
Age Group 1									
<=65 years	123	73 (59.3)	8.44 [7.82, 11.47]	124	90 (72.6)	6.44 [5.82, 8.11]	0.656 [0.480, 0.895]	0.0074	0.5696
>65 years	51	30 (58.8)	8.80 [6.08, 15.24]	49	33 (67.3)	7.69 [5.55, 8.77]	0.771 [0.469, 1.267]	0.3035	
Age Group 2									
<=75 years	168	103 (61.3)	8.44 [6.97, 9.43]	164	119 (72.6)	6.44 [6.05, 8.08]	0.695 [0.533, 0.907]	0.0072	0.9744
>75 years	6	0 (0.0)	NC [NC, NC]	9	4 (44.4)	11.22 [0.69, NC]	0.000 [0.000, NC]	0.1409	
Sex									
Male	104	67 (64.4)	8.44 [6.24, 10.35]	102	77 (75.5)	6.21 [4.96, 7.69]	0.662 [0.475, 0.920]	0.0137	0.6422
Female	70	36 (51.4)	8.84 [6.83, 13.04]	71	46 (64.8)	8.08 [6.28, 10.22]	0.744 [0.480, 1.153]	0.1840	
Region									
Asia	120	70 (58.3)	8.51 [7.82, 11.47]	117	82 (70.1)	6.41 [5.82, 8.08]	0.629 [0.456, 0.867]	0.0045	0.2619
Non-Asia	54	33 (61.1)	8.08 [6.01, 9.30]	56	41 (73.2)	7.33 [5.75, 9.23]	0.865 [0.546, 1.370]	0.5358	
Number of Organs with Metastatic Sites									
0-2	130	74 (56.9)	8.48 [6.97, 11.99]	128	91 (71.1)	6.80 [6.21, 8.25]	0.701 [0.514, 0.954]	0.0233	0.8234
>=3	44	29 (65.9)	8.31 [6.41, 10.41]	45	32 (71.1)	6.05 [3.38, 8.08]	0.640 [0.385, 1.065]	0.0843	
Prior Gastrectomy (total or partial)									
Yes	51	34 (66.7)	9.00 [6.24, 15.11]	52	36 (69.2)	6.51 [4.93, 8.51]	0.813 [0.508, 1.302]	0.3919	0.5008
No	123	69 (56.1)	8.44 [7.10, 10.35]	121	87 (71.9)	6.54 [5.82, 8.18]	0.650 [0.472, 0.895]	0.0079	

Abbreviations: CI=confidence interval; CPS=combined positive score; GEJ=gastro-esophageal junction; HR=hazard ratio; IRC=independent review committee; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method, (b) Calculated from Cox proportional hazards model, (c) Based on 2-sided log-rank test, unadjusted for multiplicity, and (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.3.3.1: Summary of Progression-Free Survival (INV)
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=174)	**Placebo + CAPOX (N=173)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	174 (100.0%)	173 (100.0%)	
Number of patients with events	116 (66.7%)	142 (82.1%)	
Number of patients censored	58 (33.3%)	31 (17.9%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	64.06 [55.51, 71.39]	51.31 [43.21, 58.81]	
Month 12	30.99 [23.15, 39.15]	18.21 [12.41, 24.90]	
Month 18	20.51 [13.84, 28.10]	9.30 [5.11, 15.02]	
Month 24	13.28 [7.74, 20.35]	5.92 [2.69, 10.98]	
Month 30	7.97 [3.57, 14.65]	3.16 [0.81, 8.39]	
Month 36	6.38 [2.44, 12.99]	NC [NC, NC]	
Month 42	6.38 [2.44, 12.99]	NC [NC, NC]	
Month 48	NC [NC, NC]	NC [NC, NC]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	8.28 [6.28, 8.51]	6.05 [4.44, 6.31]	
Difference in median			2.23
Cox proportional hazards model			
Stratified HR, 95% CI			0.666 [0.514, 0.863]
Log-rank test			
Two-sided stratified log-rank p-value			0.0020

Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; INV=investigator; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.3.3.2: Type of Events and Censoring of Progression-Free Survival (INV)
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=174)	**Placebo + CAPOX (N=173)**
Number of patients at risk	174 (100.0%)	173 (100.0%)
Number of patients with events	116 (66.7%)	142 (82.1%)
rPD	83 (47.7%)	114 (65.9%)
No rPD, but death recorded on eCRF	33 (19.0%)	28 (16.2%)
Number of patients censored	58 (33.3%)	31 (17.9%)

Abbreviations: CPS=combined positive score; eCRF= electronic case report form; INV=investigator; N=number of patients; rPD=radiological progressive disease.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.3.3.3: Summary of Progression-Free Survival (INV) by Subgroups
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME [95% CI](a)	N	n (%)	KME [95% CI](a)	HR [95% CI](b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	123	85 (69.1)	8.31 [6.28, 9.00]	124	102 (82.3)	6.05 [4.44, 6.37]	0.660 [0.493, 0.883]	0.0048	0.8983
>65 years	51	31 (60.8)	6.97 [4.17, 9.17]	49	40 (81.6)	6.05 [4.17, 6.83]	0.694 [0.433, 1.113]	0.1286	
Age Group 2									
<=75 years	168	115 (68.5)	8.15 [6.28, 8.48]	164	137 (83.5)	6.05 [4.44, 6.28]	0.669 [0.521, 0.859]	0.0015	0.6736
>75 years	6	1 (16.7)	NC [5.55, NC]	9	5 (55.6)	9.79 [0.69, NC]	0.352 [0.041, 3.035]	0.3260	
Sex									
Male	104	70 (67.3)	7.89 [6.08, 8.97]	102	87 (85.3)	6.05 [4.27, 6.41]	0.645 [0.470, 0.886]	0.0063	0.6765
Female	70	46 (65.7)	8.31 [6.24, 9.17]	71	55 (77.5)	6.05 [4.44, 7.82]	0.710 [0.477, 1.056]	0.0890	
Region									
Asia	120	80 (66.7)	8.31 [6.24, 9.00]	117	90 (76.9)	6.11 [4.60, 6.44]	0.664 [0.490, 0.900]	0.0081	0.7072
Non-Asia	54	36 (66.7)	7.79 [4.47, 9.00]	56	52 (92.9)	5.36 [4.21, 7.62]	0.714 [0.464, 1.097]	0.1227	
Number of Organs with Metastatic Sites									
0-2	130	82 (63.1)	8.31 [6.24, 9.17]	128	103 (80.5)	6.21 [4.60, 6.44]	0.680 [0.508, 0.910]	0.0091	0.8921
>=3	44	34 (77.3)	7.79 [4.34, 8.44]	45	39 (86.7)	5.39 [3.65, 6.24]	0.631 [0.394, 1.010]	0.0511	
Prior Gastrectomy (total or partial)									
Yes	51	34 (66.7)	8.57 [6.14, 11.99]	52	37 (71.2)	6.24 [4.30, 8.31]	0.726 [0.455, 1.159]	0.1784	0.7867
No	123	82 (66.7)	7.79 [6.24, 8.44]	121	105 (86.8)	5.72 [4.30, 6.28]	0.662 [0.495, 0.886]	0.0052	


Abbreviations: CI=confidence interval; CPS=combined positive score; GEJ=gastro-esophageal junction; HR=hazard ratio; INV=investigator; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method, (b) Calculated from Cox proportional hazards model, (c) Based on 2-sided log-rank test, unadjusted for multiplicity, and (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1/ unknown

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben
Anhang 4-G Progressionsfreies Überleben (IRC und INV)

2. Kaplan-Meier-Plots


Figure 302.3.1002.2.3: Kaplan-Meier Plot of Progression-Free Survival (IRC) - Modified Full Analysis Set (CPS < 1 + Unknown)



Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; IRC=independent review committee; N=number of patients.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.1002.3.3: Kaplan-Meier Plot of Progression-Free Survival (INV) - Modified Full Analysis Set (CPS < 1 + Unknown)



at Risk

1	174 (0.0)	84 (22.4)	36 (26.4)	21 (28.2)	10 (30.5)	6 (30.5)	3 (31.6)	1 (32.8)	0 (33.3)
2	173 (0.0)	77 (11.0)	24 (13.9)	11 (15.0)	5 (16.2)	1 (17.3)	0 (17.9)	0 (17.9)	0 (17.9)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; INV=investigator; N=number of patients.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1 / unknown

Anhang 4-G Sicherheit

Anhang 4-G Schwere unerwünschte Ereignisse

Table 302.3.2001.3.4.1: Effect Measures of Proportion of Subjects with Severe TEAEs
Modified Safety Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=173)	Placebo + CAPOX (N=171)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	173 (100.0%)	171 (100.0%)	
Number of patients with events	126 (72.8%)	118 (69.0%)	
Number of patients without event	47 (27.2%)	53 (31.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.204 [0.756, 1.919]
Relative Risk (a)			
Unstratified RR, 95% CI			1.055 [0.922, 1.209]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.038 [-0.058, 0.134]
Test on Differences (c)			
Unstratified p-value			0.4345

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; RR=relative risk; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction; (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo; (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.3.4.2: Effect Measures of Proportion of Subjects with Severe TEAEs by Subgroups
Modified Safety Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	122	86 (70.5)	122	79 (64.8)	1.089 [0.915, 1.296]	0.3382	0.4648
>65 years	51	40 (78.4)	49	39 (79.6)	0.985 [0.805, 1.206]	0.8867	
Age Group 2							
<=75 years	167	123 (73.7)	162	113 (69.8)	1.056 [0.922, 1.210]	0.4323	0.7498
>75 years	6	3 (50.0)	9	5 (55.6)	0.900 [0.334, 2.424]	1.0000	
Sex							
Male	104	73 (70.2)	100	73 (73.0)	0.962 [0.809, 1.143]	0.6567	0.1019
Female	69	53 (76.8)	71	45 (63.4)	1.212 [0.973, 1.509]	0.0830	
Region							
Asia	120	84 (70.0)	115	81 (70.4)	0.994 [0.841, 1.174]	0.9419	0.1950
Non-Asia	53	42 (79.2)	56	37 (66.1)	1.199 [0.950, 1.514]	0.1238	
Number of Organs with Metastatic Sites							
0-2	130	90 (69.2)	127	83 (65.4)	1.059 [0.893, 1.257]	0.5077	0.9616
>=3	43	36 (83.7)	44	35 (79.5)	1.052 [0.862, 1.285]	0.6152	
Prior Gastrectomy (total or partial)							
Yes	51	34 (66.7)	52	35 (67.3)	0.990 [0.755, 1.299]	0.9449	0.5830
No	122	92 (75.4)	119	83 (69.7)	1.081 [0.925, 1.263]	0.3244	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; RR=relative risk; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction; (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented, (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1 / unknown

Anhang 4-G Sicherheit

Anhang 4-G Schwerwiegende unerwünschte Ereignisse

Table 302.3.2001.4.4.1: Effect Measures of Proportion of Subjects with TESAEs
Modified Safety Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=173)	Placebo + CAPOX (N=171)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	173 (100.0%)	171 (100.0%)	
Number of patients with events	85 (49.1%)	89 (52.0%)	
Number of patients without event	88 (50.9%)	82 (48.0%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			0.890 [0.583, 1.358]
Relative Risk (a)			
Unstratified RR, 95% CI			0.944 [0.766, 1.163]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			-0.029 [-0.135, 0.076]
Test on Differences (c)			
Unstratified p-value			0.5889

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; RR=relative risk; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction; (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo; (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.4.4.2: Effect Measures of Proportion of Subjects with TESAEs by Subgroups
Modified Safety Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	122	53 (43.4)	122	66 (54.1)	0.803 [0.619, 1.042]	0.0959	0.0234
>65 years	51	32 (62.7)	49	23 (46.9)	1.337 [0.928, 1.926]	0.1122	
Age Group 2							
<=75 years	167	84 (50.3)	162	86 (53.1)	0.948 [0.769, 1.168]	0.6130	0.5057
>75 years	6	1 (16.7)	9	3 (33.3)	0.500 [0.067, 3.745]	0.6044	
Sex							
Male	104	56 (53.8)	100	54 (54.0)	0.997 [0.774, 1.285]	0.9824	0.4878
Female	69	29 (42.0)	71	35 (49.3)	0.853 [0.593, 1.227]	0.3882	
Region							
Asia	120	55 (45.8)	115	59 (51.3)	0.893 [0.686, 1.163]	0.4015	0.4441
Non-Asia	53	30 (56.6)	56	30 (53.6)	1.057 [0.753, 1.483]	0.7504	
Number of Organs with Metastatic Sites							
0-2	130	58 (44.6)	127	63 (49.6)	0.899 [0.694, 1.166]	0.4229	0.4420
>=3	43	27 (62.8)	44	26 (59.1)	1.063 [0.759, 1.488]	0.7236	
Prior Gastrectomy (total or partial)							
Yes	51	23 (45.1)	52	26 (50.0)	0.902 [0.600, 1.355]	0.6184	0.7966
No	122	62 (50.8)	119	63 (52.9)	0.960 [0.753, 1.224]	0.7417	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; RR=relative risk; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction; (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented, (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1 / unknown

Anhang 4-G Sicherheit

Anhang 4-G Abbruch der Studienmedikation aufgrund unerwünschter Ereignisse

Table 302.3.2001.5.4.1: Effect Measures of Proportion of Subjects with Permanent Treatment Discontinuation due to TEAEs
Modified Safety Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=173)	**Placebo + CAPOX (N=171)**	**Zolbetuximab + CAPOX vs. Placebo + CAPOX**
Number of patients at risk	173 (100.0%)	171 (100.0%)	
Number of patients with events	55 (31.8%)	40 (23.4%)	
Number of patients without event	118 (68.2%)	131 (76.6%)	
Odds Ratio (a)			
Unstratified OR, 95% CI			1.526 [0.947, 2.460]
Relative Risk (a)			
Unstratified RR, 95% CI			1.359 [0.960, 1.925]
Absolute Risk Reduction (b)			
Unstratified ARR, 95% CI			0.084 [-0.010, 0.178]
Test on Differences (c)			
Unstratified p-value			0.0815

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CMH=Cochrane-Mantel-Haenszel; CPS=combined positive score; N=number of patients; NC=not calculated; OR=odds ratio; RR=relative risk; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction; (b) ARR = absolute risk of Zolbetuximab - absolute risk of Placebo; (c) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2001.5.4.2: Effect Measures of Proportion of Subjects with Permanent Treatment Discontinuation due to TEAEs by Subgroups
Modified Safety Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX		Placebo + CAPOX		Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	N	n (%)	Unstratified RR, 95% CI (a)	Test on Differences, Unstratified p-value (b)	Treatment and Subgroup interaction LR test p-value (c)
Age Group 1							
<=65 years	122	37 (30.3)	122	26 (21.3)	1.423 [0.922, 2.197]	0.1076	0.7018
>65 years	51	18 (35.3)	49	14 (28.6)	1.235 [0.693, 2.202]	0.4713	
Age Group 2							
<=75 years	167	53 (31.7)	162	36 (22.2)	1.428 [0.992, 2.055]	0.0521	0.3422
>75 years	6	2 (33.3)	9	4 (44.4)	0.750 [0.195, 2.884]	1.0000	
Sex							
Male	104	35 (33.7)	100	24 (24.0)	1.402 [0.902, 2.179]	0.1284	0.8140
Female	69	20 (29.0)	71	16 (22.5)	1.286 [0.729, 2.269]	0.3826	
Region							
Asia	120	36 (30.0)	115	28 (24.3)	1.232 [0.808, 1.880]	0.3306	0.4197
Non-Asia	53	19 (35.8)	56	12 (21.4)	1.673 [0.902, 3.102]	0.0953	
Number of Organs with Metastatic Sites							
0-2	130	44 (33.8)	127	24 (18.9)	1.791 [1.161, 2.762]	0.0066	0.0161
>=3	43	11 (25.6)	44	16 (36.4)	0.703 [0.370, 1.337]	0.2771	
Prior Gastrectomy (total or partial)							
Yes	51	15 (29.4)	52	11 (21.2)	1.390 [0.708, 2.732]	0.3347	0.9348
No	122	40 (32.8)	119	29 (24.4)	1.345 [0.897, 2.019]	0.1484	

Abbreviations: ARR=absolute risk reduction; CI=confidence interval; CPS=combined positive score; LR=likelihood ratio; N=number of patients; n=number of patients with event; NC=not calculated; OR=odds ratio; RR=relative risk; TE(S)AE=treatment-emergent (serious) adverse event.
(a) Estimated by logit method with zero cell correction; (b) For unstratified procedure two-sided p-value based on Chi-square test or Fisher's exact test (if any cell count is <5) is presented, (c) Type 3 likelihood ratio test p-value from log-binominal regression model including treatment, subgroup, and treatment x subgroup interaction.
Note: Subgroup analyses are only performed when the total number of events is > 1 and not all patients have an event.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1 / unknown

Anhang 4-G Weitere Analysen

Anhang 4-G Beobachtungsdauern

Table 302.3.1001.2.4.1: Summary of Duration of Observation Time of Overall Survival
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=174)	**Placebo + CAPOX (N=173)**
Duration of observation period (months)		
n	174	173
Mean (SD)	14.9 (10.79)	12.6 (10.18)
Median	12.3	9.8
Q1-Q3	6.4 - 23.1	5.0 - 17.7
Range	0 - 46	0 - 46

Abbreviations: CPS=combined positive score; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for overall survival will include the time from randomisation until the last date endpoint data are collected for overall survival.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.2.4.2: Summary of Duration of Observation Time of Progression-Free Survival (IRC)
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=174)	**Placebo + CAPOX (N=173)**
Duration of observation period (months)		
n	174	173
Mean (SD)	8.4 (8.62)	6.9 (6.50)
Median	6.0	5.8
Q1-Q3	2.5 - 10.4	2.2 - 8.3
Range	0 - 46	0 - 38

Abbreviations: CPS=combined positive score; IRC=independent review committee; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for progression-free survival (IRC) will include the time from randomisation until the last date endpoint data are collected for progression-free survival (IRC).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.2.4.3: Summary of Duration of Observation Time of Progression-Free Survival (INV)
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=174)	**Placebo + CAPOX (N=173)**
Duration of observation period (months)		
n	174	173
Mean (SD)	8.0 (8.29)	6.7 (6.17)
Median	5.6	5.0
Q1-Q3	2.2 - 10.3	2.2 - 8.3
Range	0 - 43	0 - 32

Abbreviations: CPS=combined positive score; INV=investigator; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Observation period for progression-free survival (INV) will include the time from randomisation until the last date endpoint data are collected for progression-free survival (INV).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2000.6.4.1: Summary of Duration of Observation Time for Safety Endpoints
Modified Safety Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=173)	**Placebo + CAPOX (N=171)**
Duration of observation period (months)		
n	173	171
Mean (SD)	10.5 (8.25)	9.1 (6.27)
Median	8.1	7.7
Q1-Q3	4.2 - 12.7	4.9 - 11.5
Range	0 - 46	0 - 30

Abbreviations: CPS=combined positive score; DCO=data cut-off; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation.
Note: Observation time for safety endpoints is defined as the time from first dose until DCO, study treatment discontinuation +90 days or death, whichever occured first and stopped the collection of endpoint data.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.2000.6.4.2: Summary of Duration of Observation Time for any TEAE
Modified Safety Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=173)	**Placebo + CAPOX (N=171)**
Duration of observation period (months)		
n	173	171
Mean (SD)	9.0 (8.25)	7.7 (6.00)
Median	6.5	6.2
Q1-Q3	3.3 - 10.8	3.3 - 9.6
Range	0 - 46	0 - 30

Abbreviations: CPS=combined positive score; DCO=data cut-off; N=number of patients; n=number of patients with non-missing values; Q1=first quartile; Q3=third quartile; SD=standard deviation; TEAE=treatment-emergent adverse event.
Note: Observation time for any TEAE is defined as the time from first dose until DCO, study treatment discontinuation +30 days or death, whichever occured first and stopped the collection of endpoint data.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1 / unknown

Anhang 4-G Weitere Analysen
Anhang 4-G Begleitmedikationen

Table 302.3.1001.5.4: Summary of Concomitant Therapies
Modified Full Analysis Set (CPS < 1 + Unknown)

Therapeutic Subgroup	Zolbetuximab + CAPOX (N=174)	Placebo + CAPOX (N=173)
Overall	171 (98.3%)	169 (97.7%)
Agents Acting On The Renin-Angiotensin System	24 (13.8%)	15 (8.7%)
All Other Therapeutic Products	4 (2.3%)	6 (3.5%)
Analgesics	71 (40.8%)	73 (42.2%)
Anesthetics	14 (8.0%)	6 (3.5%)
Anti-Acne Preparations	0	2 (1.2%)
Anti-Parkinson Drugs	0	1 (0.6%)
Antianemic Preparations	36 (20.7%)	42 (24.3%)
Antibacterials For Systemic Use	42 (24.1%)	37 (21.4%)
Antibiotics And Chemotherapeutics For Dermatological Use	9 (5.2%)	6 (3.5%)
Antidiarrheals, Intestinal Antiinflammatory/Antiinfective Agents	40 (23.0%)	48 (27.7%)
Antiemetics And Antinauseants	143 (82.2%)	126 (72.8%)
Antiepileptics	1 (0.6%)	0
Antifungals For Dermatological Use	4 (2.3%)	4 (2.3%)
Antigout Preparations	2 (1.1%)	8 (4.6%)
Antihemorrhagics	29 (16.7%)	24 (13.9%)
Antihistamines For Systemic Use	64 (36.8%)	44 (25.4%)
Antihypertensives	1 (0.6%)	3 (1.7%)
Antiinflammatory And Antirheumatic Products	33 (19.0%)	32 (18.5%)
Antimycobacterials	1 (0.6%)	1 (0.6%)
Antimycotics For Systemic Use	0	2 (1.2%)
Antineoplastic Agents	2 (1.1%)	0
Antipruritics, Incl. Antihistamines, Anesthetics, Etc.	11 (6.3%)	6 (3.5%)
Antiseptics And Disinfectants	1 (0.6%)	1 (0.6%)
Antithrombotic Agents	30 (17.2%)	23 (13.3%)
Antivirals For Systemic Use	6 (3.4%)	4 (2.3%)
Appetite Stimulants	18 (10.3%)	22 (12.7%)

Abbreviations: CPS=combined positive score; ATC=anatomical therapeutic chemical; N=number of patients.
Sorting order: alphabetical order by Therapeutic Subgroup (ATC 2nd level).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.5.4: Summary of Concomitant Therapies
Modified Full Analysis Set (CPS < 1 + Unknown)

Therapeutic Subgroup	Zolbetuximab + CAPOX (N=174)	Placebo + CAPOX (N=173)
Beta Blocking Agents	7 (4.0%)	10 (5.8%)
Bile And Liver Therapy	50 (28.7%)	34 (19.7%)
Blood Substitutes And Perfusion Solutions	58 (33.3%)	54 (31.2%)
Calcium Channel Blockers	26 (14.9%)	22 (12.7%)
Cardiac Therapy	9 (5.2%)	14 (8.1%)
Contrast Media	2 (1.1%)	0
Corticosteroids For Systemic Use	67 (38.5%)	52 (30.1%)
Corticosteroids, Dermatological Preparations	16 (9.2%)	11 (6.4%)
Cough And Cold Preparations	8 (4.6%)	11 (6.4%)
Digestives, Incl. Enzymes	6 (3.4%)	12 (6.9%)
Diuretics	31 (17.8%)	28 (16.2%)
Drugs For Acid Related Disorders	142 (81.6%)	118 (68.2%)
Drugs For Constipation	39 (22.4%)	55 (31.8%)
Drugs For Functional Gastrointestinal Disorders	54 (31.0%)	47 (27.2%)
Drugs For Obstructive Airway Diseases	5 (2.9%)	9 (5.2%)
Drugs For Treatment Of Bone Diseases	8 (4.6%)	4 (2.3%)
Drugs Used In Diabetes	22 (12.6%)	20 (11.6%)
Emollients And Protectives	19 (10.9%)	17 (9.8%)
General Nutrients	26 (14.9%)	25 (14.5%)
Gynecological Antiinfectives And Antiseptics	1 (0.6%)	1 (0.6%)
Immune Sera And Immunoglobulins	0	1 (0.6%)
Immunostimulants	54 (31.0%)	32 (18.5%)
Lipid Modifying Agents	18 (10.3%)	14 (8.1%)
Mineral Supplements	36 (20.7%)	21 (12.1%)
Muscle Relaxants	4 (2.3%)	8 (4.6%)
Nasal Preparations	2 (1.1%)	1 (0.6%)
Ophthalmologicals	4 (2.3%)	4 (2.3%)
Other Alimentary Tract And Metabolism Products	10 (5.7%)	9 (5.2%)

Abbreviations: CPS=combined positive score; ATC=anatomical therapeutic chemical; N=number of patients.
Sorting order: alphabetical order by Therapeutic Subgroup (ATC 2nd level).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.5.4: Summary of Concomitant Therapies
Modified Full Analysis Set (CPS < 1 + Unknown)

Therapeutic Subgroup	Zolbetuximab + CAPOX (N=174)	Placebo + CAPOX (N=173)
Other Dermatological Preparations	7 (4.0%)	5 (2.9%)
Other Drugs For Disorders Of The Musculo-Skeletal System	1 (0.6%)	0
Other Gynecologicals	0	1 (0.6%)
Other Hematological Agents	1 (0.6%)	5 (2.9%)
Other Nervous System Drugs	19 (10.9%)	8 (4.6%)
Pituitary And Hypothalamic Hormones And Analogues	4 (2.3%)	2 (1.2%)
Preparations For Treatment Of Wounds And Ulcers	4 (2.3%)	2 (1.2%)
Psychoanaleptics	11 (6.3%)	6 (3.5%)
Psycholeptics	54 (31.0%)	53 (30.6%)
Sex Hormones And Modulators Of The Genital System	2 (1.1%)	2 (1.2%)
Stomatological Preparations	9 (5.2%)	8 (4.6%)
Throat Preparations	6 (3.4%)	4 (2.3%)
Thyroid Therapy	6 (3.4%)	2 (1.2%)
Topical Products For Joint And Muscular Pain	5 (2.9%)	2 (1.2%)
Unspecified Herbal And Traditional Medicine	9 (5.2%)	12 (6.9%)
Urologicals	8 (4.6%)	7 (4.0%)
Vaccines	7 (4.0%)	8 (4.6%)
Vasoprotectives	16 (9.2%)	8 (4.6%)
Vitamins	46 (26.4%)	30 (17.3%)

Abbreviations: CPS=combined positive score; ATC=anatomical therapeutic chemical; N=number of patients.
Sorting order: alphabetical order by Therapeutic Subgroup (ATC 2nd level).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1 / unknown

Anhang 4-G Weitere Analysen
Anhang 4-G Studienmedikation - Exposition

Table 302.3.1001.6.4: Summary of Study Drug Exposure
Modified Full Analysis Set (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX (N=174)	**Placebo + CAPOX (N=173)**
Duration of Zolbetuximab/Placebo (days)		
n	172	171
Mean (SD)	224.9 (253.9)	182.4 (180.4)
Median	134.0	132.0
Range	1 - 1395	1 - 913
Duration of Oxaliplatin (days)		
n	169	171
Mean (SD)	107.7 (60.52)	103.7 (61.07)
Median	119.0	113.0
Range	1 - 210	1 - 212
Duration of Capecitabine (days)		
n	169	171
Mean (SD)	212.8 (228.2)	171.4 (158.2)
Median	138.0	135.0
Range	1 - 1177	2 - 904

Abbreviations: CPS=combined positive score; N=number of patients; n=number of patients treated with respective study drug; SD=standard deviation.
Duration of each component is defined as (date of last infusion) - (date of first infusion) + 1.
Zolbetuximab + CAPOX components: Zolbetuximab, Oxaliplatin and Capecitabine.
Placebo + CAPOX components: Placebo, Oxaliplatin and Capecitabine.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS < 1 / unknown

Anhang 4-G Weitere Analysen

Anhang 4-G Patientenfluss

Table 302.3.1001.7.4: Summary of Disposition of Subjects (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX	Placebo + CAPOX	Total
Number of Randomized Patients	174	173	347
Safety Analysis Set [1]	173 (99.4%)	171 (98.8%)	344 (99.1%)
Full Analysis Set	174 (100.0%)	173 (100.0%)	347 (100.0%)
Pharmacokinetics Analysis Set	166 (95.4%)	0	166 (47.8%)
Overall Treatment Discontinuation [2]			
Yes	160 (92.0%)	157 (90.8%)	317 (91.4%)
No	14 (8.0%)	16 (9.2%)	30 (8.6%)
Reason for Overall Treatment Discontinuation [3]			
Adverse Event	22 (12.6%)	8 (4.6%)	30 (8.6%)
Death	16 (9.2%)	16 (9.2%)	32 (9.2%)
Lost to Follow-Up	1 (0.6%)	1 (0.6%)	2 (0.6%)
Other	24 (13.8%)	19 (11.0%)	43 (12.4%)
Pregnancy	0	0	0
Progressive Disease	74 (42.5%)	97 (56.1%)	171 (49.3%)
Protocol Deviation	1 (0.6%)	1 (0.6%)	2 (0.6%)
Withdrawal by Subject	29 (16.7%)	19 (11.0%)	48 (13.8%)
Post-Treatment Follow-Up Discontinuation			
Yes	162 (93.1%)	165 (95.4%)	327 (94.2%)
No	12 (6.9%)	8 (4.6%)	20 (5.8%)
Primary Post-Treatment Follow-Up Status			
Adverse Event	1 (0.6%)	0	1 (0.3%)
Death	66 (37.9%)	77 (44.5%)	143 (41.2%)
Lost to Follow-Up	4 (2.3%)	2 (1.2%)	6 (1.7%)
Other	25 (14.4%)	25 (14.5%)	50 (14.4%)
Pregnancy	0	0	0
Progressive Disease	37 (21.3%)	44 (25.4%)	81 (23.3%)
Protocol Deviation	2 (1.1%)	0	2 (0.6%)
Study Terminated by Sponsor	0	0	0
Withdrawal by Subject	27 (15.5%)	17 (9.8%)	44 (12.7%)

Abbreviations: CPS=combined positive score.
[1]: All subjects who received at least one dose of any study drug (Zolbetuximab/Placebo/CAPOX). If a subject received at least one dose of zolbetuximab, the subject is counted under the zolbetuximab arm.
[2]: Of both treatments.
[3]: Reason for overall treatment discontinuation is summarized using the reason of the latest discontinued compound.
If the subject discontinued from both treatments on the same day, all different reasons of discontinuation are summarized.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.7.4: Summary of Disposition of Subjects (CPS < 1 + Unknown)

	Zolbetuximab + CAPOX	Placebo + CAPOX	Total
Survival Follow-Up Discontinuation			
Yes	146 (83.9%)	155 (89.6%)	301 (86.7%)
No	28 (16.1%)	18 (10.4%)	46 (13.3%)
Primary Survival Follow-Up Status			
Death	118 (67.8%)	135 (78.0%)	253 (72.9%)
Lost to Follow-Up	4 (2.3%)	2 (1.2%)	6 (1.7%)
Other	2 (1.1%)	0	2 (0.6%)
Study Terminated by Sponsor	0	0	0
Withdrawal by Subject	22 (12.6%)	18 (10.4%)	40 (11.5%)

Abbreviations: CPS=combined positive score.
[1]: All subjects who received at least one dose of any study drug (Zolbetuximab/Placebo/CAPOX). If a subject received at least one dose of zolbetuximab, the subject is counted under the zolbetuximab arm.
[2]: Of both treatments.
[3]: Reason for overall treatment discontinuation is summarized using the reason of the latest discontinued compound.
If the subject discontinued from both treatments on the same day, all different reasons of discontinuation are summarized.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G ITT

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben

Anhang 4-G Gesamtüberleben

1. Time-to-Event-Analyse

Table 302.3.1002.1.1.1: Summary of Overall Survival
Full Analysis Set

	Zolbetuximab + CAPOX (N=254)	Placebo + CAPOX (N=253)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	254 (100.0%)	253 (100.0%)	
Number of patients with events	180 (70.9%)	207 (81.8%)	
Number of patients censored	74 (29.1%)	46 (18.2%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	82.10 [76.64, 86.40]	76.28 [70.42, 81.13]	
Month 12	56.68 [50.08, 62.75]	50.44 [43.89, 56.61]	
Month 18	39.32 [32.98, 45.58]	30.14 [24.34, 36.13]	
Month 24	29.02 [23.21, 35.06]	18.81 [14.01, 24.16]	
Month 30	22.25 [16.75, 28.24]	13.00 [8.88, 17.92]	
Month 36	18.30 [12.95, 24.39]	7.88 [4.41, 12.63]	
Month 42	16.77 [11.28, 23.20]	7.88 [4.41, 12.63]	
Month 48	16.77 [11.28, 23.20]	7.88 [4.41, 12.63]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	14.32 [12.09, 16.39]	12.16 [10.28, 13.67]	
Difference in median			2.17
Cox proportional hazards model			
Stratified HR, 95% CI			0.763 [0.622, 0.936]
Log-rank test			
Two-sided stratified log-rank p-value			0.0094

Abbreviations: CI=confidence interval; HR=hazard ratio; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.1.1.2: Type of Events and Censoring of Overall Survival
Full Analysis Set

	Zolbetuximab + CAPOX (N=254)	**Placebo + CAPOX (N=253)**
Number of patients at risk	254 (100.0%)	253 (100.0%)
Number of patients with events	180 (70.9%)	207 (81.8%)
Death before analysis cutoff date	180 (70.9%)	207 (81.8%)
Number of patients censored	74 (29.1%)	46 (18.2%)
Last known alive date is before cutoff date	65 (25.6%)	44 (17.4%)
Censored at cutoff date	9 (3.5%)	2 (0.8%)

Abbreviations: N=number of patients.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.1.1.2a: Breakdown of Reasons for Censoring
Full Analysis Set

	Zolbetuximab + CAPOX	Placebo + CAPOX	Total
Number of patients censored	74	46	120
1 Censored at Cutoff Date	9	2	11
2 Last known alive date is before cutoff date	65	44	109
2.a Not in survival follow-up	32	22	54
2.a.1 Lost To Follow-Up	4	2	6
2.a.2 Withdrawal By Subject	26	20	46
2.a.3 Other	2	0	2
2.b In survival follow-up	33	22	55
Timepoint of censoring relative to cutoff date			
2.b.1 < 4 weeks	18 (54.5%)	9 (40.9%)	27 (49.1%)
2.b.2 4-8 weeks	15 (45.5%)	12 (54.5%)	27 (49.1%)
2.b.3 8-12 weeks	0 (0.0%)	1 (4.5%)	1 (1.8%)

Abbreviations: CPS=combined positive score; eCRF= electronic case report form; INV=investigator; N=number of patients; rPD=radiological progressive disease.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.1.1.3: Summary of Overall Survival by Subgroups
Full Analysis Set

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	**N**	**n (%)**	**KME [95% CI](a)**	**N**	**n (%)**	**KME [95% CI](a)**	**HR [95% CI](b)**	**Log-rank p-value(c)**	**Test for Interaction p-value(d)**
Age Group 1									
<=65 years	176	115 (65.3)	14.32 [12.09, 17.18]	180	149 (82.8)	11.93 [9.69, 13.67]	0.650 [0.509, 0.830]	0.0005	0.0314
>65 years	78	65 (83.3)	13.90 [9.07, 17.41]	73	58 (79.5)	12.29 [9.40, 16.56]	1.044 [0.732, 1.490]	0.8066	
Age Group 2									
<=75 years	242	172 (71.1)	13.67 [11.93, 16.36]	239	196 (82.0)	11.93 [9.89, 13.21]	0.749 [0.610, 0.920]	0.0057	0.8699
>75 years	12	8 (66.7)	25.49 [2.73, NC]	14	11 (78.6)	17.45 [5.09, 18.86]	0.653 [0.259, 1.642]	0.3738	
Sex									
Male	159	119 (74.8)	12.52 [10.32, 15.51]	156	133 (85.3)	11.53 [9.23, 13.17]	0.772 [0.602, 0.989]	0.0400	0.6537
Female	95	61 (64.2)	16.49 [12.55, 19.45]	97	74 (76.3)	13.17 [10.51, 15.41]	0.698 [0.497, 0.981]	0.0376	
Region									
Asia	157	111 (70.7)	14.98 [12.52, 17.84]	158	124 (78.5)	11.24 [9.40, 13.17]	0.706 [0.546, 0.913]	0.0076	0.4194
Non-Asia	97	69 (71.1)	12.29 [10.32, 16.00]	95	83 (87.4)	13.17 [9.89, 17.12]	0.814 [0.591, 1.122]	0.2076	
Number of Organs with Metastatic Sites									
0-2	189	129 (68.3)	15.74 [13.60, 18.66]	188	153 (81.4)	12.94 [10.71, 14.85]	0.705 [0.558, 0.892]	0.0034	0.3477
>=3	65	51 (78.5)	10.84 [8.08, 12.52]	65	54 (83.1)	9.76 [7.49, 13.21]	0.881 [0.601, 1.292]	0.5174	
Prior Gastrectomy (total or partial)									
Yes	75	51 (68.0)	15.51 [11.07, 22.57]	75	58 (77.3)	12.94 [9.13, 17.28]	0.760 [0.521, 1.109]	0.1535	0.8765
No	179	129 (72.1)	13.63 [11.76, 16.36]	178	149 (83.7)	11.83 [9.76, 13.67]	0.737 [0.582, 0.933]	0.0111	


Abbreviations: CI=confidence interval; GEJ=gastro-esophageal junction; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method, (b) Calculated from Cox proportional hazards model, (c) Based on 2-sided log-rank test, unadjusted for multiplicity, and (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G ITT

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben
Anhang 4-G Gesamtüberleben

2. Kaplan-Meier-Plots

Figure 302.3.1002.1.1: Kaplan-Meier Plot of Overall Survival - Full Analysis Set




at Risk

1	254 (0.0)	193 (7.1)	129 (9.1)	86 (10.6)	58 (13.0)	32 (18.9)	14 (24.0)	5 (27.2)	1 (28.7)
2	253 (0.0)	181 (5.5)	116 (7.5)	68 (8.3)	39 (9.9)	21 (12.6)	6 (15.8)	2 (17.4)	1 (17.8)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; N=number of patients.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24


Figure 302.3.1002.1.1.1: Kaplan-Meier Plot of Overall Survival by Age Group 1 - Full Analysis Set
Age Group 1: <=65 years



	# at Risk								
1	176 (0.0)	136 (8.0)	92 (9.7)	61 (11.9)	41 (14.2)	25 (20.5)	12 (27.8)	5 (31.8)	1 (34.1)
2	180 (0.0)	128 (6.1)	80 (8.3)	48 (8.9)	25 (10.0)	13 (13.3)	3 (15.6)	1 (16.7)	1 (16.7)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; N=number of patients.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.1002.1.1.1: Kaplan-Meier Plot of Overall Survival by Age Group 1 - Full Analysis Set
Age Group 1: >65 years



	# at Risk								
1	78 (0.0)	57 (5.1)	37 (7.7)	25 (7.7)	17 (10.3)	7 (15.4)	2 (15.4)	0 (16.7)	0 (16.7)
2	73 (0.0)	53 (4.1)	36 (5.5)	20 (6.8)	14 (9.6)	8 (11.0)	3 (16.4)	1 (19.2)	0 (20.5)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; N=number of patients.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G ITT

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben
Anhang 4-G Progressionsfreies Überleben (IRC und INV)

1. Time-to-Event-Analysen

Table 302.3.1002.2.1.1: Summary of Progression-Free Survival (IRC)
Full Analysis Set

	Zolbetuximab + CAPOX (N=254)	Placebo + CAPOX (N=253)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	254 (100.0%)	253 (100.0%)	
Number of patients with events	153 (60.2%)	182 (71.9%)	
Number of patients censored	101 (39.8%)	71 (28.1%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	69.72 [62.92, 75.51]	61.30 [54.63, 67.30]	
Month 12	34.05 [27.14, 41.06]	19.49 [13.96, 25.71]	
Month 18	23.25 [17.09, 29.98]	12.05 [7.50, 17.75]	
Month 24	16.19 [10.63, 22.80]	7.25 [3.69, 12.40]	
Month 30	12.79 [7.60, 19.38]	6.04 [2.73, 11.22]	
Month 36	11.63 [6.62, 18.17]	4.53 [1.60, 9.89]	
Month 42	11.63 [6.62, 18.17]	NC [NC, NC]	
Month 48	NC [NC, NC]	NC [NC, NC]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	8.21 [7.26, 8.84]	6.80 [6.14, 8.08]	
Difference in median			1.41
Cox proportional hazards model			
Stratified HR, 95% CI			0.689 [0.552, 0.860]
Log-rank test			
Two-sided stratified log-rank p-value			0.0009

Abbreviations: CI=confidence interval; HR=hazard ratio; IRC=independent review committee; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.2.1.2: Type of Events and Censoring of Progression-Free Survival (IRC)
Full Analysis Set

	Zolbetuximab + CAPOX (N=254)	**Placebo + CAPOX (N=253)**
Number of patients at risk	254 (100.0%)	253 (100.0%)
Number of patients with events	153 (60.2%)	182 (71.9%)
rPD	85 (33.5%)	108 (42.7%)
No rPD, but death recorded on eCRF	68 (26.8%)	74 (29.2%)
Number of patients censored	101 (39.8%)	71 (28.1%)

Abbreviations: eCRF=electronic case report form; IRC=independent review committee; N=number of patients; rPD=radiological progressive disease.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.2.1.3: Summary of Progression-Free Survival (IRC) by Subgroups
Full Analysis Set

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	**N**	**n (%)**	**KME [95% CI](a)**	**N**	**n (%)**	**KME [95% CI](a)**	**HR [95% CI](b)**	**Log-rank p-value(c)**	**Test for Interaction p-value(d)**
Age Group 1									
<=65 years	176	106 (60.2)	8.31 [7.85, 9.43]	180	136 (75.6)	6.44 [6.05, 8.08]	0.621 [0.480, 0.803]	0.0003	0.0611
>65 years	78	47 (60.3)	7.13 [6.08, 9.30]	73	46 (63.0)	8.21 [6.05, 10.25]	0.984 [0.655, 1.479]	0.9363	
Age Group 2									
<=75 years	242	149 (61.6)	8.18 [7.13, 8.80]	239	175 (73.2)	6.51 [6.11, 8.08]	0.703 [0.564, 0.877]	0.0016	0.9119
>75 years	12	4 (33.3)	17.84 [1.05, NC]	14	7 (50.0)	10.25 [4.14, 14.23]	0.692 [0.202, 2.373]	0.5625	
Sex									
Male	159	104 (65.4)	8.18 [6.70, 8.80]	156	116 (74.4)	6.24 [5.82, 7.69]	0.686 [0.525, 0.896]	0.0054	0.8428
Female	95	49 (51.6)	8.31 [6.41, 12.68]	97	66 (68.0)	8.08 [6.54, 8.54]	0.735 [0.507, 1.067]	0.1037	
Region									
Asia	157	91 (58.0)	8.48 [7.26, 10.41]	158	115 (72.8)	6.31 [6.01, 7.95]	0.612 [0.464, 0.809]	0.0005	0.0658
Non-Asia	97	62 (63.9)	7.95 [6.24, 8.38]	95	67 (70.5)	8.11 [6.24, 8.67]	0.900 [0.635, 1.275]	0.5464	
Number of Organs with Metastatic Sites									
0-2	189	111 (58.7)	8.31 [7.82, 9.43]	188	134 (71.3)	7.69 [6.28, 8.25]	0.707 [0.548, 0.911]	0.0070	0.9490
>=3	65	42 (64.6)	7.89 [6.14, 8.84]	65	48 (73.8)	6.05 [4.14, 7.95]	0.676 [0.444, 1.029]	0.0667	
Prior Gastrectomy (total or partial)									
Yes	75	49 (65.3)	8.18 [6.24, 13.04]	75	53 (70.7)	7.75 [6.05, 8.31]	0.794 [0.537, 1.173]	0.2441	0.5342
No	179	104 (58.1)	8.21 [7.26, 8.84]	178	129 (72.5)	6.54 [6.05, 8.15]	0.680 [0.524, 0.883]	0.0036	

Abbreviations: CI=confidence interval; GEJ=gastro-esophageal junction; HR=hazard ratio; IRC=independent review committee; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method, (b) Calculated from Cox proportional hazards model, (c) Based on 2-sided log-rank test, unadjusted for multiplicity, and (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.3.1.1: Summary of Progression-Free Survival (INV)
Full Analysis Set

	Zolbetuximab + CAPOX (N=254)	Placebo + CAPOX (N=253)	Zolbetuximab + CAPOX vs. Placebo + CAPOX
Number of patients at risk	254 (100.0%)	253 (100.0%)	
Number of patients with events	173 (68.1%)	210 (83.0%)	
Number of patients censored	81 (31.9%)	43 (17.0%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	63.89 [56.97, 70.01]	52.56 [45.93, 58.76]	
Month 12	29.18 [22.87, 35.76]	16.80 [12.10, 22.16]	
Month 18	20.32 [14.81, 26.46]	9.53 [5.90, 14.19]	
Month 24	14.35 [9.56, 20.07]	4.76 [2.29, 8.60]	
Month 30	8.77 [4.90, 14.02]	2.98 [1.02, 6.78]	
Month 36	7.79 [4.11, 12.99]	NC [NC, NC]	
Month 42	7.79 [4.11, 12.99]	NC [NC, NC]	
Month 48	NC [NC, NC]	NC [NC, NC]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	7.79 [6.34, 8.31]	6.05 [5.32, 6.28]	
Difference in median			1.74
Cox proportional hazards model			
Stratified HR, 95% CI			0.671 [0.544, 0.828]
Log-rank test			
Two-sided stratified log-rank p-value			0.0002

Abbreviations: CI=confidence interval; HR=hazard ratio; INV=investigator; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.3.1.2: Type of Events and Censoring of Progression-Free Survival (INV)
Full Analysis Set

	Zolbetuximab + CAPOX (N=254)	**Placebo + CAPOX (N=253)**
Number of patients at risk	254 (100.0%)	253 (100.0%)
Number of patients with events	173 (68.1%)	210 (83.0%)
rPD	126 (49.6%)	173 (68.4%)
No rPD, but death recorded on eCRF	47 (18.5%)	37 (14.6%)
Number of patients censored	81 (31.9%)	43 (17.0%)

Abbreviations: eCRF= electronic case report form; INV=investigator; N=number of patients; rPD=radiological progressive disease.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1002.3.1.3: Summary of Progression-Free Survival (INV) by Subgroups
Full Analysis Set

	Zolbetuximab + CAPOX			Placebo + CAPOX			Zolbetuximab + CAPOX vs. Placebo + CAPOX		
Subgroup	N	n (%)	KME [95% CI](a)	N	n (%)	KME [95% CI](a)	HR [95% CI](b)	Log-rank p-value(c)	Test for Interaction p-value(d)
Age Group 1									
<=65 years	176	124 (70.5)	7.98 [6.34, 8.44]	180	152 (84.4)	6.08 [5.19, 6.37]	0.631 [0.496, 0.804]	0.0002	0.2741
>65 years	78	49 (62.8)	6.37 [4.86, 8.44]	73	58 (79.5)	6.05 [4.27, 6.83]	0.824 [0.563, 1.206]	0.3195	
Age Group 2									
<=75 years	242	168 (69.4)	7.79 [6.31, 8.31]	239	203 (84.9)	6.05 [5.32, 6.28]	0.669 [0.544, 0.823]	0.0001	0.4314
>75 years	12	5 (41.7)	10.38 [1.05, NC]	14	7 (50.0)	9.79 [2.56, NC]	0.946 [0.299, 2.996]	0.9337	
Sex									
Male	159	114 (71.7)	7.26 [6.24, 8.28]	156	132 (84.6)	6.08 [5.19, 6.37]	0.681 [0.528, 0.877]	0.0028	0.9129
Female	95	59 (62.1)	8.15 [6.24, 9.17]	97	78 (80.4)	6.05 [4.44, 7.20]	0.681 [0.483, 0.959]	0.0265	
Region									
Asia	157	105 (66.9)	8.15 [6.24, 8.57]	158	126 (79.7)	6.05 [5.19, 6.31]	0.650 [0.500, 0.845]	0.0012	0.3649
Non-Asia	97	68 (70.1)	7.26 [6.24, 8.18]	95	84 (88.4)	6.11 [4.44, 8.11]	0.742 [0.536, 1.027]	0.0710	
Number of Organs with Metastatic Sites									
0-2	189	124 (65.6)	7.85 [6.28, 8.57]	188	154 (81.9)	6.11 [5.32, 6.37]	0.679 [0.535, 0.862]	0.0014	0.7772
>=3	65	49 (75.4)	7.10 [4.47, 8.28]	65	56 (86.2)	6.05 [4.21, 6.41]	0.688 [0.465, 1.017]	0.0580	
Prior Gastrectomy (total or partial)									
Yes	75	50 (66.7)	7.26 [6.14, 9.00]	75	55 (73.3)	6.24 [5.36, 7.95]	0.732 [0.498, 1.077]	0.1125	0.8382
No	179	123 (68.7)	7.79 [6.31, 8.31]	178	155 (87.1)	5.98 [4.44, 6.31]	0.670 [0.527, 0.851]	0.0010	


Abbreviations: CI=confidence interval; GEJ=gastro-esophageal junction; HR=hazard ratio; INV=investigator; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method, (b) Calculated from Cox proportional hazards model, (c) Based on 2-sided log-rank test, unadjusted for multiplicity, and (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G ITT

Anhang 4-G Gesamtüberleben und Progressionsfreies Überleben
Anhang 4-G Progressionsfreies Überleben (IRC und INV)

2. Kaplan-Meier-Plots

Figure 302.3.1002.2.1: Kaplan-Meier Plot of Progression-Free Survival (IRC) - Full Analysis Set




	# at Risk								
1	254 (0.0)	131 (23.6)	52 (30.3)	31 (32.3)	16 (35.0)	11 (35.8)	5 (37.8)	2 (39.0)	0 (39.8)
2	253 (0.0)	127 (14.6)	28 (24.1)	16 (24.9)	7 (26.1)	4 (26.9)	1 (27.7)	0 (28.1)	0 (28.1)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; IRC=independent review committee; N=number of patients.

ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Figure 302.3.1002.3.1: Kaplan-Meier Plot of Progression-Free Survival (INV) - Full Analysis Set



# at Risk									
1	254 (0.0)	126 (20.5)	50 (24.8)	32 (26.0)	18 (28.0)	10 (28.3)	4 (30.3)	1 (31.5)	0 (31.9)
2	253 (0.0)	117 (9.9)	32 (13.4)	16 (14.6)	6 (15.4)	2 (16.2)	0 (17.0)	0 (17.0)	0 (17.0)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; INV=investigator; N=number of patients.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G ITT

Anhang 4-G Weitere Analysen: Patientenfluss

Table 302.3.1001.7.1: Summary of Disposition of Subjects

	Zolbetuximab + CAPOX	Placebo + CAPOX	Total
Number of Subjects with Informed Consent			2333
Discontinued Before Randomization to Treatment			1826 (78.3%)
Randomized to Treatment			507 (21.7%)
Number of Randomized Patients	254	253	507
Safety Analysis Set [1]	254 (100.0%)	249 (98.4%)	503 (99.2%)
Full Analysis Set	254 (100.0%)	253 (100.0%)	507 (100.0%)
Pharmacokinetics Analysis Set	245 (96.5%)	0	245 (48.3%)
Overall Treatment Discontinuation [2]			
Yes	230 (90.6%)	231 (91.3%)	461 (90.9%)
No	24 (9.4%)	22 (8.7%)	46 (9.1%)
Reason for Overall Treatment Discontinuation [3]			
Adverse Event	30 (11.8%)	16 (6.3%)	46 (9.1%)
Death	24 (9.4%)	20 (7.9%)	44 (8.7%)
Lost to Follow-Up	1 (0.4%)	1 (0.4%)	2 (0.4%)
Other	32 (12.6%)	23 (9.1%)	55 (10.8%)
Pregnancy	0	0	0
Progressive Disease	111 (43.7%)	154 (60.9%)	265 (52.3%)
Protocol Deviation	2 (0.8%)	1 (0.4%)	3 (0.6%)
Withdrawal by Subject	39 (15.4%)	23 (9.1%)	62 (12.2%)
Post-Treatment Follow-Up Discontinuation			
Yes	234 (92.1%)	243 (96.0%)	477 (94.1%)
No	20 (7.9%)	10 (4.0%)	30 (5.9%)
Primary Post-Treatment Follow-Up Status			
Adverse Event	1 (0.4%)	2 (0.8%)	3 (0.6%)
Death	99 (39.0%)	111 (43.9%)	210 (41.4%)
Lost to Follow-Up	4 (1.6%)	2 (0.8%)	6 (1.2%)
Other	34 (13.4%)	37 (14.6%)	71 (14.0%)
Pregnancy	0	0	0

[1]: All subjects who received at least one dose of any study drug (Zolbetuximab/Placebo/CAPOX). If a subject received at least one dose of zolbetuximab, the subject is counted under the zolbetuximab arm.
[2]: Of both treatments.
[3]: Reason for overall treatment discontinuation is summarized using the reason of the latest discontinued compound.
If the subject discontinued from both treatments on the same day, all different reasons of discontinuation are summarized.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.7.1: Summary of Disposition of Subjects

	Zolbetuximab + CAPOX	Placebo + CAPOX	Total
Progressive Disease	55 (21.7%)	67 (26.5%)	122 (24.1%)
Protocol Deviation	2 (0.8%)	0	2 (0.4%)
Study Terminated by Sponsor	0	0	0
Withdrawal by Subject	39 (15.4%)	24 (9.5%)	63 (12.4%)
Survival Follow-Up Discontinuation			
Yes	214 (84.3%)	229 (90.5%)	443 (87.4%)
No	40 (15.7%)	24 (9.5%)	64 (12.6%)
Primary Survival Follow-Up Status			
Death	178 (70.1%)	201 (79.4%)	379 (74.8%)
Lost to Follow-Up	4 (1.6%)	2 (0.8%)	6 (1.2%)
Other	2 (0.8%)	1 (0.4%)	3 (0.6%)
Study Terminated by Sponsor	0	0	0
Withdrawal by Subject	30 (11.8%)	25 (9.9%)	55 (10.8%)

[1]: All subjects who received at least one dose of any study drug (Zolbetuximab/Placebo/CAPOX). If a subject received at least one dose of zolbetuximab, the subject is counted under the zolbetuximab arm.
[2]: Of both treatments.
[3]: Reason for overall treatment discontinuation is summarized using the reason of the latest discontinued compound.
If the subject discontinued from both treatments on the same day, all different reasons of discontinuation are summarized.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G *Post hoc* Analysen für die Studie GLOW, finaler Datenschnitt 12.01.2024
Anhang 4-G CPS unknown

Anhang 4-G Baseline Charakteristika

Table 302.3.1001.1.6: Summary of Baseline Demographics
Modified Full Analysis Set (unknown CPS status)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N= 90)	Placebo + CAPOX (N= 85)
Sex		
Male	52 (57.8%)	56 (65.9%)
Female	38 (42.2%)	29 (34.1%)
Unknown	0	0
Age (years)		
n	90	85
Mean (SD)	58.99 (11.78)	55.91 (13.38)
Median	61.5	58.0
Range	26.0 - 80.0	21.0 - 83.0
Age (years)		
>=18 to <=64	61 (67.8%)	62 (72.9%)
>=65 to <85	29 (32.2%)	23 (27.1%)
Age Group 1 (years)		
<=65	63 (70.0%)	64 (75.3%)
>65	27 (30.0%)	21 (24.7%)
Age Group 2 (years)		
<=75	87 (96.7%)	83 (97.6%)
>75	3 (3.3%)	2 (2.4%)
Race		
White	8 (8.9%)	8 (9.5%)
Black or African American	0	0
Asian	82 (91.1%)	76 (90.5%)
American Indian or Alaska Native	0	0

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.1.6: Summary of Baseline Demographics
Modified Full Analysis Set (unknown CPS status)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N= 90)	Placebo + CAPOX (N= 85)
Native Hawaiian or Other Pacific Islander	0	0
Other	0	0
Missing	0	1
Ethnicity		
Hispanic or Latino	1 (1.1%)	1 (1.2%)
Not Hispanic or Latino	89 (98.9%)	83 (98.8%)
Missing	0	1
Country 1		
Japan	1 (1.1%)	1 (1.2%)
Non-Japan	89 (98.9%)	84 (98.8%)
Country 2		
China	76 (84.4%)	69 (81.2%)
Non-China	14 (15.6%)	16 (18.8%)
Height (cm)		
n	90	84
Mean (SD)	163.34 (8.07)	165.44 (7.72)
Median	163.5	166.0
Range	147.0 - 180.0	147.0 - 184.3
Weight (kg)		
n	90	84
Mean (SD)	57.72 (10.61)	57.43 (12.19)
Median	57.2	55.0
Range	37.4 - 82.0	30.0 - 86.6

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.1.6: Summary of Baseline Demographics
Modified Full Analysis Set (unknown CPS status)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N= 90)	Placebo + CAPOX (N= 85)
BMI (kg/m^2)		
<18.5	17 (18.9%)	21 (25.0%)
>=18.5 to <25	56 (62.2%)	54 (64.3%)
>=25 to <30	16 (17.8%)	8 (9.5%)
>=30	1 (1.1%)	1 (1.2%)
Missing	0	1
BSA (m^2)		
n	90	84
Mean (SD)	1.61 (0.17)	1.62 (0.19)
Median	1.6	1.6
Range	1.2 - 2.0	1.1 - 2.1
BSA (m^2)		
<1.7	55 (61.1%)	51 (60.7%)
>=1.7	35 (38.9%)	33 (39.3%)
Missing	0	1
Tobacco History		
Never	62 (68.9%)	50 (59.5%)
Current	4 (4.4%)	8 (9.5%)
Former	24 (26.7%)	26 (31.0%)
Missing	0	1
Baseline ECOG Status		
0	32 (35.6%)	35 (41.7%)
1	58 (64.4%)	49 (58.3%)

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Table 302.3.1001.1.6: Summary of Baseline Demographics
Modified Full Analysis Set (unknown CPS status)

Parameter and Category/Statistic	Zolbetuximab + CAPOX (N= 90)	Placebo + CAPOX (N= 85)
Missing	0	1
Region (IRT)		
Asia	82 (91.1%)	76 (89.4%)
Non-Asia	8 (8.9%)	9 (10.6%)
Region (eCRF)		
Asia	82 (91.1%)	76 (89.4%)
Non-Asia	8 (8.9%)	9 (10.6%)
Number of Organs with Metastatic Sites (IRT)		
0-2	66 (73.3%)	64 (75.3%)
>=3	24 (26.7%)	21 (24.7%)
Number of Organs with Metastatic Sites (eCRF)		
0-2	66 (73.3%)	62 (72.9%)
>=3	24 (26.7%)	23 (27.1%)
Prior Gastrectomy (IRT)		
Yes	27 (30.0%)	30 (35.3%)
No	63 (70.0%)	55 (64.7%)
Prior Gastrectomy (eCRF)		
Yes	27 (30.0%)	28 (32.9%)
No	63 (70.0%)	57 (67.1%)

Abbreviations: BMI=body mass index; BSA=body surface area; CPS=combined positive score; ECOG=eastern cooperative oncology group; eCRF=electronic case report form; IRT=interactive response technology; N=number of patients; n=number of patients with non-missing values; SD=standard deviation.
ASTELLAS Data Cutoff Date (GLOW 8951-CL-302): 12JAN24

Anhang 4-G Ergänzende Analysen zur Studie GLOW - Gesamtüberleben
Anhang 4-G mITT (CPS < 1)

Anhang 4-G *Post hoc* Meta-Analyse aus den beiden Studien GLOW (finaler Datenschnitt 12.01.2024) und SPOTLIGHT (finaler Datenschnitt 08.09.2023)

1. Time-to-Event-Analyse

Table IPD.2MA.3.1002.1.2.1: Summary of Overall Survival
Modified Full Analysis Set (CPS < 1) - SPOTLIGHT + GLOW

	Zolbetuximab + chemotherapy (N=201)	**Placebo + chemotherapy (N=212)**	**Zolbetuximab + chemotherapy vs. Placebo + chemotherapy**
Number of patients at risk	201 (100.0%)	212 (100.0%)	
Number of patients with events	132 (65.7%)	165 (77.8%)	
Number of patients censored	69 (34.3%)	47 (22.2%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	85.77 [79.93, 90.01]	81.79 [75.75, 86.46]	
Month 12	63.50 [56.06, 70.03]	58.22 [51.01, 64.74]	
Month 18	47.82 [40.29, 54.94]	33.73 [27.12, 40.45]	
Month 24	35.67 [28.50, 42.89]	25.82 [19.77, 32.26]	
Month 30	28.05 [21.20, 35.27]	16.87 [11.71, 22.84]	
Month 36	23.29 [16.66, 30.58]	12.16 [7.60, 17.86]	
Month 42	18.81 [12.17, 26.57]	10.81 [6.30, 16.69]	
Month 48	18.81 [12.17, 26.57]	10.81 [6.30, 16.69]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	17.25 [15.51, 19.78]	14.13 [12.06, 15.84]	
Difference in median			3.12
Cox proportional hazards model			
Stratified HR, 95% CI			0.709 [0.559, 0.900]
Log-rank test			
Two-sided stratified log-rank p-value			0.0047

Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are study ID, region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. >= 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date: 08SEP23 (SPOTLIGHT) and 12JAN24 (GLOW)

Table IPD.2MA.3.1002.1.2.2: Type of Events and Censoring of Overall Survival
Modified Full Analysis Set (CPS < 1) - SPOTLIGHT + GLOW

	Zolbetuximab + chemotherapy (N=201)	**Placebo + chemotherapy (N=212)**
Number of patients at risk	201 (100.0%)	212 (100.0%)
Number of patients with events	132 (65.7%)	165 (77.8%)
Death before analysis cutoff date	132 (65.7%)	165 (77.8%)
Number of patients censored	69 (34.3%)	47 (22.2%)
Last known alive date is before cutoff date	65 (32.3%)	38 (17.9%)
Censored at cutoff date	4 (2.0%)	9 (4.2%)

Abbreviations: CPS=combined positive score; N=number of patients.
ASTELLAS Data Cutoff Date: 08SEP23 (SPOTLIGHT) and 12JAN24 (GLOW)

Table IPD.2MA.3.1002.1.2.2a: Breakdown of Reasons for Censoring
Modified Full Analysis Set (CPS < 1) - SPOTLIGHT + GLOW

	Zolbetuximab + chemotherapy	Placebo + chemotherapy	Total
Number of patients censored	69	47	116
1 Censored at Cutoff Date	4	9	13
2 Last known alive date is before cutoff date	65	38	103
2.a Not in survival follow-up	33	21	54
2.a.1 Lost To Follow-Up	3	3	6
2.a.2 Withdrawal By Subject	28	18	46
2.a.3 Other	2	0	2
2.b In survival follow-up	32	17	49
Timepoint of censoring relative to cutoff date			
2.b.1 < 4 weeks	26 (81.3%)	14 (82.4%)	40 (81.6%)
2.b.2 4-8 weeks	6 (18.8%)	2 (11.8%)	8 (16.3%)
2.b.3 8-12 weeks	0 (0.0%)	1 (5.9%)	1 (2.0%)

Abbreviations: CPS = combined positive score
ASTELLAS Data Cutoff Date: 08SEP23 (SPOTLIGHT) and 12JAN24 (GLOW)

Table IPD.2MA.3.1002.1.2.3: Summary of Overall Survival by Subgroups
Modified Full Analysis Set (CPS < 1) - SPOTLIGHT + GLOW

	Zolbetuximab + chemotherapy			Placebo + chemotherapy			Zolbetuximab + chemotherapy vs. Placebo + chemotherapy		
Subgroup	**N**	**n (%)**	**KME [95% CI](a)**	**N**	**n (%)**	**KME [95% CI](a)**	**HR [95% CI](b)**	**Log-rank p-value(c)**	**Test for Interaction p-value(d)**
Age Group 1									
<=65 years	133	80 (60.2)	19.09 [16.39, 23.33]	140	105 (75.0)	15.41 [13.60, 17.12]	0.617 [0.452, 0.842]	0.0022	0.2413
>65 years	68	52 (76.5)	13.21 [9.69, 16.49]	72	60 (83.3)	12.02 [8.97, 15.80]	0.800 [0.530, 1.207]	0.3012	
Age Group 2									
<=75 years	192	124 (64.6)	17.58 [15.51, 20.17]	193	149 (77.2)	13.90 [12.02, 16.13]	0.711 [0.555, 0.911]	0.0069	0.4195
>75 years	9	8 (88.9)	9.69 [2.63, 30.13]	19	16 (84.2)	15.64 [9.07, 17.74]	1.064 [0.338, 3.353]	0.8302	
Sex									
Male	119	81 (68.1)	15.93 [12.35, 18.63]	124	103 (83.1)	13.70 [11.27, 15.80]	0.666 [0.483, 0.918]	0.0132	0.8447
Female	82	51 (62.2)	19.45 [14.26, 26.35]	88	62 (70.5)	15.80 [11.56, 19.29]	0.741 [0.497, 1.104]	0.1401	
Region									
Asia	71	38 (53.5)	23.06 [17.58, 31.01]	81	54 (66.7)	15.80 [13.14, 19.02]	0.561 [0.362, 0.869]	0.0092	0.2330
Non-Asia	130	94 (72.3)	15.21 [10.84, 17.87]	131	111 (84.7)	13.63 [11.24, 15.64]	0.785 [0.591, 1.042]	0.0951	
Number of Organs with Metastatic Sites									
0-2	158	98 (62.0)	18.86 [16.00, 23.06]	163	122 (74.8)	14.59 [13.14, 17.12]	0.671 [0.511, 0.880]	0.0040	0.7835
>=3	43	34 (79.1)	11.10 [8.28, 16.43]	49	43 (87.8)	11.24 [7.36, 16.39]	0.852 [0.521, 1.392]	0.5255	
Prior Gastrectomy (total or partial)									
Yes	62	36 (58.1)	22.28 [16.43, 27.04]	60	38 (63.3)	19.29 [15.54, 26.58]	0.848 [0.527, 1.363]	0.4988	0.4457
No	139	96 (69.1)	15.93 [11.99, 18.53]	152	127 (83.6)	13.60 [10.68, 14.32]	0.668 [0.507, 0.880]	0.0041	

Abbreviations: CI=confidence interval; CPS=combined positive score; GEJ=gastro-esophageal junction; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method, (b) Calculated from Cox proportional hazards model, (c) Based on 2-sided log-rank test, unadjusted for multiplicity, and (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date: 08SEP23 (SPOTLIGHT) and 12JAN24 (GLOW)


Anhang 4-G Ergänzende Anaylsen zur Studie GLOW – Gesamtüberleben
Anhang 4-G mITT (CPS < 1)

Anhang 4-G *Post hoc* Meta-Analyse aus den beiden Studien GLOW (finaler Datenschnitt 12.01.2024) und SPOTLIGHT (finaler Datenschnitt 08.09.2023)

2. Forest-Plot

A-MA.3.1002.1.2.1: Forest Plot for Hazard Ratio of Overall Survival - Modified Full Analysis Set (CPS < 1)

Study	Zolbetuximab Events / Total	Placebo Events / Total	Weights (%)	Hazard Ratio (fixed effect) 95%CI
301 − SPOTLIGHT	78 / 117	98 / 124	59.8	0.730 [0.536, 0.992]
302 − GLOW	54 / 84	67 / 88	40.2	0.680 [0.467, 0.990]
Total	**132 / 201**	**165 / 212**	**100**	**0.709 [0.559, 0.900]**
Heterogeneity	Q = 0.08 (df = 1)	p = 0.7746	I² = 0.0%	p(Effect) = 0.0047



Anhang 4-G Ergänzende Anaylsen zur Studie GLOW – Gesamtüberleben
Anhang 4-G mITT (CPS < 1)

Anhang 4-G *Post hoc* Analysen für die Studie SPOTLIGHT, finaler Datenschnitt 08.09.2023)
Anhang 4-G Gesamtüberleben

1. Time-to-Event-Analyse

Table 301.3.1002.1.2.1: Summary of Overall Survival
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + mFOLFOX6 (N=117)	**Placebo + mFOLFOX6 (N=124)**	**Zolbetuximab + mFOLFOX6 vs. Placebo + mFOLFOX6**
Number of patients at risk	117 (100.0%)	124 (100.0%)	
Number of patients with events	78 (66.7%)	98 (79.0%)	
Number of patients censored	39 (33.3%)	26 (21.0%)	
Probability of being event-free (a) [95% CI] (b) at			
Month 6	85.67 [77.68, 90.97]	88.29 [81.02, 92.89]	
Month 12	67.89 [58.21, 75.79]	63.58 [54.20, 71.54]	
Month 18	53.29 [43.35, 62.26]	38.96 [30.08, 47.74]	
Month 24	38.49 [29.00, 47.88]	29.61 [21.46, 38.19]	
Month 30	29.85 [20.90, 39.30]	17.60 [10.89, 25.64]	
Month 36	23.68 [15.19, 33.24]	12.32 [6.55, 20.02]	
Month 42	19.53 [11.32, 29.40]	10.78 [5.34, 18.40]	
Month 48	19.53 [11.32, 29.40]	10.78 [5.34, 18.40]	
Kaplan-Meier estimates of time to event (months)			
Quartiles, 95% CI (c)			
50%	18.86 [15.87, 23.33]	15.64 [13.60, 17.74]	
Difference in median			3.22
Cox proportional hazards model			
Stratified HR, 95% CI			0.730 [0.536, 0.992]
Log-rank test			
Two-sided stratified log-rank p-value			0.0442

Abbreviations: CI=confidence interval; CPS=combined positive score; HR=hazard ratio; N=number of patients; NC=not calculated.
(a) Estimated from the Kaplan-Meier Method; (b) Calculated using the log-log transformation according to Kalbfleisch and Prentice and Greenwood's formula for computing the standard error of the survival estimate; (c) Based on the Brookmeyer-Crowley Method.
Note: The stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No).
ASTELLAS Data Cutoff Date (SPOTLIGHT 8951-CL-301): 08SEP23

Table 301.3.1002.1.2.2: Type of Events and Censoring of Overall Survival
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + mFOLFOX6 (N=117)	**Placebo + mFOLFOX6 (N=124)**
Number of patients at risk	117 (100.0%)	124 (100.0%)
Number of patients with events	78 (66.7%)	98 (79.0%)
Death before analysis cutoff date	78 (66.7%)	98 (79.0%)
Number of patients censored	39 (33.3%)	26 (21.0%)
Last known alive date is before cutoff date	37 (31.6%)	19 (15.3%)
Censored at cutoff date	2 (1.7%)	7 (5.6%)

Abbreviations: CPS=combined positive score; N=number of patients.
ASTELLAS Data Cutoff Date (SPOTLIGHT 8951-CL-301): 08SEP23

Table 301.3.1002.1.2.2a: Breakdown of Reasons for Censoring
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + mFOLFOX6	Placebo + mFOLFOX6	Total
Number of patients censored	39	26	65
1 Censored at Cutoff Date	2	7	9
2 Last known alive date is before cutoff date	37	19	56
2.a Not in survival follow-up	16	9	25
2.a.1 Lost To Follow-Up	1	1	2
2.a.2 Withdrawal By Subject	14	8	22
2.a.3 Other	1	0	1
2.b In survival follow-up	21	10	31
Timepoint of censoring relative to cutoff date			
2.b.1 < 4 weeks	20 (95.2%)	10 (100.0%)	30 (96.8%)
2.b.2 4-8 weeks	1 (4.8%)	0 (0.0%)	1 (3.2%)

Abbreviations: CPS = combined positive score
ASTELLAS Data Cutoff Date (SPOTLIGHT 8951-CL-301): 08SEP23
ASTELLAS Data Cutoff Date (SPOTLIGHT 8951-CL-301): 08SEP23

Table 301.3.1002.1.2.3: Summary of Overall Survival by Subgroups
Modified Full Analysis Set (CPS < 1)

	Zolbetuximab + mFOLFOX6			Placebo + mFOLFOX6			Zolbetuximab + mFOLFOX6 vs. Placebo + mFOLFOX6		
Subgroup	**N**	**n (%)**	**KME [95% CI](a)**	**N**	**n (%)**	**KME [95% CI](a)**	**HR [95% CI](b)**	**Log-rank p-value(c)**	**Test for Interaction p-value(d)**
Age Group 1									
<=65 years	73	46 (63.0)	22.41 [18.23, 26.35]	80	60 (75.0)	16.46 [13.73, 19.29]	0.681 [0.462, 1.004]	0.0512	0.5391
>65 years	44	32 (72.7)	13.21 [9.69, 19.78]	44	38 (86.4)	12.02 [8.97, 17.15]	0.829 [0.517, 1.328]	0.4322	
Age Group 2									
<=75 years	111	73 (65.8)	19.09 [16.13, 23.62]	112	88 (78.6)	16.13 [13.14, 17.77]	0.723 [0.529, 0.989]	0.0416	0.1763
>75 years	6	5 (83.3)	9.36 [2.63, NC]	12	10 (83.3)	15.64 [8.97, 26.58]	1.596 [0.534, 4.774]	0.4243	
Sex									
Male	67	45 (67.2)	16.39 [13.21, 20.24]	78	66 (84.6)	15.41 [12.02, 17.15]	0.713 [0.487, 1.043]	0.0802	0.5764
Female	50	33 (66.0)	22.41 [14.26, 30.16]	46	32 (69.6)	19.29 [11.56, 25.26]	0.846 [0.518, 1.382]	0.5035	
Region									
Asia	33	17 (51.5)	23.33 [18.23, NC]	40	28 (70.0)	18.07 [15.41, 25.13]	0.571 [0.312, 1.045]	0.0656	0.3877
Non-Asia	84	61 (72.6)	16.39 [11.66, 20.24]	84	70 (83.3)	14.29 [11.50, 17.15]	0.814 [0.576, 1.150]	0.2417	
Number of Organs with Metastatic Sites									
0-2	94	61 (64.9)	18.96 [15.93, 23.33]	99	74 (74.7)	15.64 [13.60, 19.02]	0.784 [0.558, 1.101]	0.1599	0.6756
>=3	23	17 (73.9)	16.43 [6.41, 27.86]	25	24 (96.0)	15.54 [8.57, 17.77]	0.673 [0.356, 1.271]	0.2188	
Prior Gastrectomy (total or partial)									
Yes	38	23 (60.5)	21.49 [16.43, 31.01]	38	26 (68.4)	19.45 [10.58, 27.33]	0.749 [0.427, 1.313]	0.3118	0.8924
No	79	55 (69.6)	16.39 [11.66, 23.10]	86	72 (83.7)	14.59 [12.02, 17.15]	0.787 [0.553, 1.120]	0.1827	


Abbreviations: CI=confidence interval; CPS=combined positive score; GEJ=gastro-esophageal junction; HR=hazard ratio; KME=kaplan-meier estimate of time to event (months); N=number of patients; n=number of patients with event; NC=not calculated.
(a) Based on the Brookmeyer-Crowley Method; (b) Calculated from Cox proportional hazards model; (c) Based on 2-sided log-rank test, unadjusted for multiplicity; (d) Two-sided Type 3 Wald test p-value from Cox proportional hazards model including treatment, subgroup, and treatment x subgroup interaction.
Note: Subgroup analyses are performed only when the following conditions are fulfilled 1) at least 10 subjects in each subgroup factor/level, and 2) at least 10 subjects with events occurred in at least one of the subgroup factors/levels.
ASTELLAS Data Cutoff Date (SPOTLIGHT 8951-CL-301): 08SEP23

Anhang 4-G Ergänzende Anaylsen zur Studie GLOW – Gesamtüberleben
Anhang 4-G mITT (CPS < 1)

Anhang 4-G *Post hoc* Analysen für die Studie SPOTLIGHT, finaler Datenschnitt 08.09.2023)
Anhang 4-G Gesamtüberleben

2. Kaplan-Meier-Plots

Figure 301.3.1002.1.2: Kaplan-Meier Plot of Overall Survival - Modified Full Analysis Set (CPS < 1)



	# at Risk								
1	117 (0.0)	95 (5.1)	70 (10.3)	53 (12.0)	34 (16.2)	20 (22.2)	12 (25.6)	7 (28.2)	1 (33.3)
2	124 (0.0)	104 (4.8)	74 (5.6)	44 (7.3)	29 (11.3)	15 (13.7)	8 (16.1)	6 (16.9)	2 (20.2)

Abbreviations: # at Risk=number of patients at risk; CI=confidence interval; CPS=combined positive score; N=number of patients.


ASTELLAS Data Cutoff Date (SPOTLIGHT 8951-CL-301): 08SEP23

Anhang 4-G *Post hoc* Analysen für die Studien GLOW und SPOTLIGHT

1. Übersicht zum Gesamtüberleben

Figure 301_302.3.1002.1.all.OS: Overview of Overall Survival Results from 302 - GLOW and 301 - SPOTLIGHT by (Sub-)Population

Study (Sub-)Population	Zolbetuximab + Chemo Events / Total	Placebo + Chemo Events / Total	Hazard Ratio HR, 95% CI (a)
GLOW - 302			
mFAS (CPS<1)	54 / 84	67 / 88	0.680 [0.467, 0.990]
mFAS (CPS<1+unknown)	119 / 174	137 / 173	0.719 [0.558, 0.928]
Full Analysis Set	180 / 254	207 / 253	0.763 [0.622, 0.936]
OS REI Group 1 (<75% REI, <=63 days)(b)			
mFAS (CPS<1)	48 / 84	65 / 88	0.622 [0.421, 0.920]
OS REI Group 2 (<80% REI, <=63 days)(b)			
mFAS (CPS<1)	48 / 84	65 / 88	0.622 [0.421, 0.920]
OS REI Group 3 (<75% REI, <=180 days)(b)			
mFAS (CPS<1)	48 / 84	64 / 88	0.633 [0.427, 0.938]
OS REI Group 4 (<80% REI, <=180 days)(b)			
mFAS (CPS<1)	48 / 84	64 / 88	0.633 [0.427, 0.938]
Patients receiving Corticosteroids (c)			
mFAS (CPS<1)	38 / 59	41 / 50	0.549 [0.339, 0.889]
SPOTLIGHT - 301			
mFAS (CPS<1)	78 / 117	98 / 124	0.730 [0.536, 0.992]
Full Analysis Set	197 / 283	217 / 282	0.784 [0.644, 0.954]
302 - GLOW + 301 - SPOTLIGHT			
mFAS (CPS<1)	132 / 201	165 / 212	0.709 [0.559, 0.900]
Full Analysis Set	377 / 537	424 / 535	0.774 [0.672, 0.892]



Abbreviations: CI=confidence interval; Chemo=Chemotherapy CAPOX or mFOLFOX6; CPS=combined positive score; mFAS=modified full analysis set; OS=overall survival; REI=relative exposure intensity.
(a) Stratification factors are region (Asia vs. Non-Asia), the number of organs with metastatic sites (0 to 2 vs. ≥ 3) and prior gastrectomy (Yes or No); (b) patients in the OS REI Group (<x REI,y days) were additionally censored with nausea or vomiting leading to dose interruption of any study drug with < x% REI of Zolbetuximab or nausea or vomiting leading to withdrawal of any study drug with Zolbetuximab treatment discontinued within y days; (c) patients received corticosteroids as antiemetic or concomitant medication; (d) results from aggregated meta-analysis.
ASTELLAS Data Cutoff Date: 08SEP23 (SPOTLIGHT) and 12JAN24 (GLOW)

Anhang 4-G *Post hoc* Analysen für die Studien GLOW und SPOTLIGHT

2. Übersicht zum CPS Status

Table 301.302.3.1000.99.4: Overview of Patients regarding the CPS Status
Full Analysis Set (Known CPS) - SPOTLIGHT + GLOW

Study	Number of all patients with tested CPS status	CPS < 1	CPS >= 1
GLOW	332	172 / 332 (51.8%)	160 / 332 (48.2%)
SPOTLIGHT	394	241 / 394 (61.2%)	153 / 394 (38.8%)
POOL	726	413 / 726 (56.9%)	313 / 726 (43.1%)

Abbreviations: N=number of patients.
ASTELLAS Data Cutoff Date: 08SEP23 (SPOTLIGHT) and 12JAN24 (GLOW)